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Abstract 
Myeloperoxidase (MPO) is the enzyme that is responsible for the formation of 
hypochlorous acid (HOCl), which is utilised by neutrophils and other cell types of 
the immune system to destroy invading pathogens. HOCl reacts with amine groups 
to form the secondary oxidants N-chloramines. HOCl and N-chloramines are potent 
bactericidal agents, however, under chronic inflammatory conditions, excessive 
oxidant production can lead to damage of host tissue, and is implicated in the 
initiation and progression of disease. 
Antioxidants react with oxidant species such as HOCl and N-chloramines, 
removing them from biological systems thereby limiting damage. Thiol compounds, 
including the endogenous antioxidant glutathione (GSH), have demonstrated 
efficacy as oxidant scavengers, due to their rapid rates of reaction with MPO-derived 
oxidants. Recently, selenium containing compounds have gained interest due to 
their elevated rate constants for the reaction with oxidants compared to thiol 
compounds, and the potential for them to be recycled by thiols. This thesis assesses 
the potential for selenomethionine (SeMet) and 1,4-anhydro-5-selenotalitol (SeTal), 
a novel seleno-sugar, to act as catalytic scavengers of MPO-derived oxidants. 
Previous studies have demonstrated that oxidation of SeMet by hydrogen 
peroxide (H2O2) and peroxynitrous acid (ONOOH) yields a selenoxide as the major 
product. The studies in Chapter 3 characterise the reactions of SeMet and SeTal with 
HOCl and various model N-chloramines. It is shown that SeMet and SeTal react with 
MPO-derived oxidants to form the respective selenoxides, SeMetO and SeTalO.  
These compounds are characterised using mass spectrometry and NMR 
spectroscopy, and quantification of their conversion is assessed by HPLC. In each 
case these reactions are near stoichiometric with low oxidant doses. The second-
order rate constants for the reaction with N-chloramines have been determined 
using stopped flow techniques, and are in the range k = 102 – 103 M-1 s-1. These 
represent some of the fastest biologically relevant rate constants for N-chloramines, 
suggesting that SeMet and SeTal could provide a competitive target for N-
chloramines in vivo. 
 ix 
Previous studies have demonstrated that GSH is capable of reducing SeMetO to 
reform SeMet. The studies in Chapter 4 confirm and extend this observation, and 
assess the potential for the reduction of SeTalO by GSH. The rate constants for the 
reaction of SeMetO and SeTalO with thiols have been determined, and found to be 
in the range of k = 103 – 104 M-1 s-1. This rapid reduction of selenoxides demonstrates 
the potential for a catalytic oxidant scavenging cycle, where small amounts SeMet 
and SeTal may be capable of efficiently consuming oxidants. 
Antioxidant enzymes have also been demonstrated to reduce SeMetO to SeMet. 
The initial studies reported in Chapter 5 assess the potential for a number of 
enzymes to reduce SeMetO and SeTalO. The thioredoxin reductase enzyme system 
(NADPH/TrxR) is capable of reducing SeMetO, but not SeTalO. The glutathione 
reductase enzyme system (NADPH/GSR/GSH) is capable of reducing both SeMetO 
and SeTalO, facilitated by the reaction between GSH and the selenoxides. Further 
studies assess the ability of SeMet and SeTal to remove N-chloramines in the 
presence of these enzymatic systems. The presence of SeMet and SeTal reduces the 
rate at which NADPH is consumed when N-chloramines are added to the TrxR 
system (and in the presence of other enzymes). In contrast, NADPH consumption is 
increased in the presence of SeMet when the GSR system is exposed to TauCl. 
The ability of SeMet and SeTal to rapidly react with MPO-derived oxidants, 
and subsequently be reduced by GSH and enzymes systems suggests that SeMet and 
SeTal may be able to prevent oxidative damage to cellular systems. The studies in 
Chapter 6 assess the ability of SeMet and SeTal to modulate the oxidative damage to 
J774A.1 murine macrophage-like cells resulting from exposure to HOCl and TauCl. 
However, limited protection is observed, with the presence of SeMet and SeTal 
unable to ameliorate the loss of thiols, oxidation of Met residues, or inhibit necrosis 
when the cells are exposed to either HOCl or TauCl. This lack of protection may arise 
from insufficient concentration of SeMet and SeTal, and suggest that additional 
functional cellular assays to assess cellular damage may be more informative.  
Overall, the studies presented in this Thesis demonstrate the potential for 
SeMet and SeTal to act as catalytic MPO-derived oxidant scavengers. They are 
capable of rapidly reacting with HOCl and N-chloramines to form products that are 
reduced by endogenous antioxidant systems, including GSH and TrxR. This work 
 x 
provides a detailed analysis of the potential efficacy of SeMet and SeTal as catalytic 
MPO-derived oxidant scavengers, and provides the basis for further studies to 
assess the potential of SeMet and SeTal to modulate damage in cellular and 
biological systems. 
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1 Introduction 
 2 
 Immune response and inflammation 
When bacteria and other pathogens enter the body, the innate immune system 
responds, initiating inflammation [1]. Pathogens are detected by cell-surface 
receptors on cell types such as macrophages, dendritic cells, Kupffer cells and 
mastocytes [1]. These cells then release inflammatory mediators and chemokines, 
which perform a variety of functions such as vasodilation and increased 
permeability of vessels [1]. The released chemokines attract circulating immune 
cells to the site of inflammation along a chemotactic gradient [1]. 
Neutrophils, a key effector cell of the immune response, engulf pathogens, and 
during this process of phagocytosis, a nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) complex is activated [1]. The purpose of this oxidase 
is to produce superoxide (O2•-), a strong oxidant. O2•- can dismutate either 
spontaneously or by action of superoxide dismutases (SOD), to give hydrogen 
peroxide (H2O2) [1]. Alternatively, O2•- can combine with other species, including 
nitric oxide (NO•), to form other oxidants such as peroxynitrite and radical species. 
Immune cells contain specialised enzymes, such as myeloperoxidase, whose major 
function is to catalyse the reaction of H2O2 and halide ions to form hypohalous acids 
[2]. These strongly oxidising species are then involved in the destruction of the 
invading pathogen by chemically attacking its cellular components [1].  
 Myeloperoxidase and related peroxidases 
Neutrophils are generally considered to be the major effector cells of the innate 
immune system. Their role is to seek out and destroy invading pathogens. They 
achieve this by phagocytosis, engulfing the pathogen followed by bombardment 
with strong oxidants designed to destroy the foreign body. One of the major oxidant 
producing enzymes found in neutrophils is myeloperoxidase (MPO), which makes 
up about 5% the dry cell mass [2]. MPO is stored in the azurophilic granules of 
neutrophils [3], and is released into the phagolysomal compartment after 
neutrophil activation. Eosinophils play similar roles to neutrophils, with eosinophil 
peroxidase (EPO) producing strong oxidants. 
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 Structure of peroxidases 
MPO is a dimeric protein consisting of two 73 kDa monomers linked by a 
disulfide bond at Cys153 [4]. The monomers are identical and functionally 
independent, and dimerisation appears to have no effect on the function of MPO [5]. 
The monomer has 2 major components, a large glycosylated (heavy) chain of 58.5 
kDa (red) and a shorter (light) chain of 14.5 kDa (blue) (Figure 1.1) [4]. The modified 
iron protoporphyrin IX active site [6] (green) is located in the heavy chain, and is 
surrounded by α-helices from both chains (H2, H6, H7, H9, H10 and H14), which 
hinders access to the heme for most materials except H2O2 and small anions [4, 7]. 
The heme is bound to the protein by two ether linkages and a sulfonium ion link [8]. 
Helices H2, H6 and H7 form a hydrophobic pocket at the distal heme entrance which 
allows substrates to bind and be oxidised by MPO [9]. The calcium ion (yellow) plays 
a role in the distal His orientation and interactions between monomers [9].  
 
Figure 1.1 - (A) Overall structure of mature homodimeric human myeloperoxidase. 
(B) Monomer structure of myeloperoxidase showing assignment of structural 
elements – Taken from [9] 
EPO is found in the granular compartments of eosinophils [10] whose function 
is to eliminate parasites as part of the immune system. EPO is similar in size and 
structure to MPO, being a highly cationic protein consisting of a heavy 57.9 kDa 
chain and a light 11.9 kDa chain surrounding a modified iron protoporphyrin IX 
group [9]. Lactoperoxidase (LPO) is a ca. 80 kDa single chain glycoprotein secreted 
in human tears, milk, saliva and vaginal fluid [9]. The primary role of LPO, like MPO 
and EPO, is as a first line of defense of the immune system in destroying invading 
bacteria and other pathogens. Vascular peroxidase (VPO) is a peroxidase expressed 
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in vascular cells and heart tissues, with a 42 % sequence identity with MPO [11]. 
LPO and MPO have similar heme group and binding sites [12] with an overall 51% 
sequence identity [13]. EPO and LPO have the ether linkages to the heme conserved, 
but do not contain the sulfonium ion link to the heme group characteristic of MPO, 
resulting in a more planar structure [8].  
 Function of peroxidases 
Peroxidases use H2O2 produced by enzymes such as SOD in order to produce 
strong oxidants [14]. SOD produces H2O2 from O2- generated by NADPH during the 
respiratory burst of neutrophils, which is caused by activation in response to 
invading pathogens [1]. The heme active site of peroxidases is oxidised by H2O2 
forming an oxy-ferryl heme centre and porphyrin radical known as Compound I [9]. 
Compound I can be reduced back to the native ferric enzyme by a 2-electron reaction 
with halides and pseudohalides forming hypohalous acids (Figure 1.2 - 
Halogenation cycle) [9]. Alternatively, Compound I can undergo 2 one-electron 
reductions to reform the native enzyme, via Compound II, a ferryl-oxy heme centred 
intermediate (Figure 1.2 - Peroxidase cycle) [15, 16]. Human peroxidases are 
capable of oxidising a wide variety of substances due to their high reduction 
potentials (See Table 1.1).  
H2O2 and O2- can interact with each step of the MPO catalytic cycles. Reaction 
with Compound I oxidises H2O2 to O2-and forms Compound II [9, 14, 17]. Compound 
II can also react with H2O2 to form Compound III, a ferrous enzyme with molecular 
oxygen bound to the heme centre [17]. However this reaction is relatively slow 
compared to the reaction of Compound II with O2- and other substrates, that reduce 
MPO back to the native compound [17]. Compound III can also be formed by 
reaction of O2- with the native enzyme. Compound III is then recycled to the native 
enzyme by a second reaction with O2-, producing H2O2 [17, 18]. In this way, MPO 
displays SOD activity. Compound III is capable of reacting very slowly with 
substrates, including acetaminophen and ascorbate to form radicals, and regenerate 
the native form of the enzyme [19, 20]. 
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Figure 1.2 – Catalytic cycles of myeloperoxidase a) Halogenation and peroxidase 
cycles of MPO b) Interaction of MPO with superoxide and hydrogen peroxide 
MPO has the highest reduction potential of the human peroxidases (Table 1.1). 
This is thought to be due to the sulfonium ion linkage between the heme and Met 
243 [8]. This linkage, combined with the ester bond from Glu242, has the effect of 
puckering the heme surface distorting the planar symmetry, and acts as an electron-
withdrawing moiety due to its positive charge. EPO, LPO and VPO do not contain this 
Met 243 linkage, but all three contain 2 ester links to the heme group from Asp94 
and Glu 242 [8, 11].  
a) 
b) b
) 
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Table 1.1 - Standard reduction potentials of species in the catalytic cycles of human 
peroxidases at pH 7 
 Standard reduction potentials (V) 
 MPO EPO LPO 
Compound I/native enzyme 1.16 a  1.10 a  1.09 b  
Compound I/Compound II 1.35 c   1.14 b  
Compound II/native enzyme 0.97 c  1.04 b  
a[21]; b [22]; c [23] 
 Halogenation cycle 
The major function of MPO is to oxidise halide ions Cl-, Br- and the pseudohalide 
SCN- to hypohalous acids, hypochlorous acid (HOCl), hypobromous acid (HOBr) and 
hypothiocyanous acid (HOSCN) respectively. Human peroxidases preferentially 
oxidise SCN- when compared to Cl- and Br-, with MPO recognised as the primary 
peroxidase capable of oxidising Cl- at reasonable rates (See Table 1.2). MPO 
produces primarily HOCl and HOSCN under physiological conditions, with about 45 
% and 50 % of the H2O2 consumed producing these respectively (HOBr production 
represents the final 5 %) [24]. Kinetic analysis would suggest that HOCl production 
would be preferred over HOSCN production, as Cl- is at a much higher concentration 
in vivo compared to SCN-.  However, the high levels of HOSCN produced by MPO 
reflects the specificity of MPO for SCN- over Cl-, with the relative specificity for SCN- 
being 730-fold greater than Cl- [24]. EPO produces HOSCN and HOBr [25] and LPO 
almost exclusively produces HOSCN [26]. VPO produces primarily HOBr and HOSCN, 
though 18 % of the H2O2 consumed is used to produce HOCl [27]. The preference for 
SCN- oxidation is reflected in the apparent second order rate constants for these 
processes (see Table 1.2).  The reduction potentials for the different peroxidases do 
not necessarily correlate with the rate constants (see Table 1.1 and Table 1.2), as 
halide and pseudohalide specificity is strongly affected by differences in the active 
and binding sites [9]. Hence, an increase of ca. 10 fold in the rate of Br- and SCN- 
oxidation for EPO over MPO is observed, even though MPO has a greater reduction 
potential compared to EPO. 
 7 
Table 1.2 – Apparent second order kinetics and reduction potentials for hypohalous 
acids produced by human peroxidases 
Reaction Second order rate constant (M-1s-1) Reduction 
potential of halide 
(HOX/X-) (V) MPO EPO LPO VPO 
Compound I + Cl-  Native 
enzyme + HOCl 
2.5 x 104 a  3.1 x 103 b  - 2.0 x 102 c 1.28 d  
Compound I + Br-  Native 
enzyme + HOBr 
1.1 x 106 e  1.9 x 107 f 4.1 x 104 a 7.3 x 104 c 1.13 d  
Compound I + SCN-  
Native enzyme + HOSCN 
9.6 x 106 e  1.0 x 108 g 2.0 x 108 g  1.4 x 105 c 0.56 d  
a [28]; b [29]; c [27]; d [30]; e [31]; f  [32]; g  [33] 
The relative concentrations of oxidants produced by human peroxidases are also 
drastically affected by pH [9, 30, 34]. At acidic pH, the rates of oxidation of halides 
and pseudohalides are dramatically increased [30], particularly Cl- oxidation. The 
increased affinity for Cl- at low pH is proposed to be due to the protonated distal His 
allowing direct access of the heme centre to Cl- but not the larger Br- and SCN- ions 
[35]. At pH > 7, the proportion of HOBr produced by MPO is significantly enhanced 
[34], possibly due to a lower reduction potential of MPO at high pH, inhibiting the 
oxidation of Cl- due to its higher reduction potential  [36].  
 Peroxidase cycle 
MPO is also capable of oxidising substrates, to form radicals, in 2 one-electron 
reduction steps in a process known as the peroxidase cycle. The porphyrin radical 
of compound I oxidises the substrate to give a substrate radical and forms 
Compound II, which retains the oxy-ferryl heme [15, 30]. Compound II then accepts 
a second electron from another substrate and is reduced back to the native enzyme 
[15]. Due to the lower oxidation potential of Compound II, some substrates can be 
oxidised by Compound I but not Compound II. These substrates, termed “poor” 
substrates, act as inhibitors of MPO activity as Compound II accumulates, inhibiting 
further oxidation of substrates in either the peroxidase or halogenation cycle [37]. 
However, O2- and ascorbate radicals are capable of recycling Compound II, 
reforming the native enzyme [38].  
Due to the high reduction potential of human peroxidases, a wide variety of 
substrates can be oxidised by their peroxidase cycles. MPO has the widest range of 
possible substrates due to its higher reduction potential compared to EPO and LPO 
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(Table 1.1). Major targets for the peroxidase cycle include phenolic and aromatic 
compounds such as Tyr, Trp, ascorbate and urate, the oxidation of which produces 
radical species, as well as nitrogen species such as nitrate and nitrite forming 
reactive nitrogen species. Second order rate constants for these reactions are 
summarised in Table 1.3. 
Table 1.3 - Second order rate constants for reactions between Compounds I and II 
of human peroxidases in the peroxidase cycle 
Substrate Second order rate constant (M-1s-1) 
MPO 
Compound I Compound II 
Tyr 7.7 x 105 a   1.6 x 104  a  
Dityrosine 1.12 x 105 b  7.5 x 102  b  
Trp 4.5 x 105 a  6.9 a  
Nitrite 2.0 x 106 c 5.5 x 102  c  
Substrate Second order rate constant (M-1s-1) 
LPO 
Compound I Compound II 
Tyr 1.1 x 105 a  1.0 x 104 a  
Dityrosine ND ND 
Trp 2.4 x 104 a  8.4 x 101 a  
Nitrite  2.2 x 107 c  3.5 x 105 c  
a [15]; b[37]; c[39]; ND – not determined 
Compounds I and II of MPO and LPO are capable of oxidising the amino acids Tyr 
and Trp to form radicals [15, 40-43]. The tyrosyl radicals formed can undergo 
radical-radical termination with a major product being dityrosine [44]. Radicals 
formed on Tyr residues on proteins can also react with nitrogen dioxide radicals 
(NO2) forming nitrotyrosine [45, 46]. Dityrosine is also capable of reaction with 
Compounds I and II [37], though the second order rate constant with Compound II 
is 2 orders of magnitude slower than for Tyr. Tyr radicals can promote the cross 
linking of proteins via the formation of dityrosine [40]. The oxidation of Trp residues 
is considerably faster for Compound I than Compound II for MPO and LPO [15]. 
Other phenolic and aromatic compounds are oxidised by Compound I of 
peroxidases, but not by Compound II, leading to accumulation of Compound II when 
no species capable of recycling Compound II are present [38]. 
MPO can oxidise NOto form nitrite ions (NO2-) at low levels of NO[29, 47, 
48]  though at higher levels of NOa Fe-nitrosyl complex is formed, inhibiting the 
action of MPO [49]. However, at physiological levels of SCN- and ascorbate, the 
consumption of NOby MPO is inhibited [50].  MPO can also oxidise NO2- to form 
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NO2 [39, 51]. Nitrite shows an increased binding capacity at lower pH, proposed to 
be due to the protonation of the distal His, and consequently the rate of reaction 
increases by two orders of magnitude for oxidation by Compound I [39]. The 
nitrating and chlorinating ability of neutrophils is enhanced in the presence of 
nitrite, and this is likely to be by NO2Cl, which is produced by the interaction of the 
MPO-derived oxidants HOCl and NO2 [52].  
 Production of secondary oxidants 
HOCl and HOBr are capable of reacting with nucleophilic nitrogens to form N-
chloramines and N-bromamines respectively [53-58]. Under physiological 
conditions, the major target for the formation of N-halamines are free amino acids, 
the N-termini of proteins, or amino acids with a nitrogen centre in the side chain, i.e. 
Lys, His and Arg. Taurine chloramine (TauCl) is a major product of neutrophils as 
approximately 20 mM Tau is released locally upon stimulation, which then reacts 
with the HOCl produced by MPO [59]. Rate constants for the reaction with HOCl are 
approximately 104 – 105 M-1s-1 for the α-amino groups of amino acids [60, 61]. 
Secondary amines react less rapidly, with second order rate constants for the 
reaction of HOCl with endocyclic DNA bases residues are around 103 - 104 M-1 s-1 [62, 
63], though the imidazole ring in His reacts with a rate constants of 1 x 105 M-1 s-1 
[60]. Other primary amines (i.e. not the α-amine groups of amino acids), including 
those on the Lys side chain, have rate constants of typically 5 x 103 M-1 s-1 [60, 61]. 
HOBr reacts with Lys and His residues much faster than HOCl, with rate constants 
of 2.9 x 105 and 3.0 x 106 M-1 s-1 respectively, yielding N-bromamines [61]. 
At low pH, MPO may be capable of producing Cl2, Br2 and the transhalogen BrCl 
[36, 64]. These species would be capable of halogenation reactions with biological 
substrates. The transhalogen species BrCl is produced by oxidation of Br- by HOCl 
[64]. In vitro studies have demonstrated that the MPO-H2O2-Cl-/Br- system is 
capable of bromination at acidic pH values using deoxycytidine as a bromination 
target through an interaction between HOCl and Br- [65]. However, at pH > 7 with 
physiological Br- concentrations, the MPO system showed no bromination of 
deoxycytidine [65] or Tyr residues [66], suggesting that bromination by MPO is 
unlikely to be significant pathway in vivo.  
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In addition, the formation of singlet oxygen [67-74] and ozone [75-81] by MPO, 
LPO and EPO systems has been suggested, through a reaction between HOCl or HOBr 
and H2O2 [68, 69, 74]. However, this is unlikely to be physiologically relevant due to 
the slow kinetics [17, 74], making it unable to compete with the faster reactions. 
 Reactions of MPO-derived oxidants 
 Hypohalous acids 
At physiological pH, HOCl, HOBr and HOSCN exist in equilibrium with their 
conjugate bases, OCl-, OBr- and OSCN- respectively. As the pKa of HOCl is 7.59, it 
exists as an approximately 1:1 ratio of HOCl : OCl- at pH 7.4 [82, 83]. The pKa of HOBr 
is 8.7, and so it primarily exists as the neutral HOBr species at pH 7.4 [83]. In 
contrast, the pKa of HOSCN is 5.3, and therefore exists mainly as the anion OSCN- at 
pH 7.4 [83]. In acidic conditions, with an excess of halide ions, HOCl and HOBr are 
also in equilibrium with Cl2 and Br2 [36]. In addition to HOSCN production by MPO, 
HOCl and HOBr are capable of directly oxidising SCN- to form HOSCN [84, 85].  
HOCl is capable of reacting with a wide variety of substrates [86]. Due to the high 
reactivity of HOCl, it will react with most biomolecules, and therefore proteins are 
major substrates, owing to their abundance in biological systems [87]. HOCl reacts 
most rapidly with sulfur residues, followed by amine and Trp residues, followed by 
other targets [60]. HOSCN, on the other hand, is a much more selective oxidant and 
reacts preferentially with thiols [88]. HOBr is less reactive with thiols compared to 
HOCl, however with other amino acid targets, such as amines, and aromatic residues 
such as Tyr, HOBr is more reactive [61]. The reaction of these oxidants with 
biological components can have a wide range of detrimental effects, including 
protein fragmentation or aggregation, and inactivation or modification of enzymatic 
function [2, 89].  
 Sulfur containing amino acids 
The reactions with thiols (e.g. Cys, glutathione (GSH)) and thioethers (e.g. Met) 
are some of the fastest biologically relevant reactions known for HOCl, HOBr and 
HOSCN. The reaction of HOCl and HOBr with Cys is extremely rapid with rate 
constants of 3.6 x 108 and 1.2 x 107 M-1 s-1 (at pH 7.4) respectively [61, 90]. However, 
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these rates can dramatically change with pH, and are dependent on the pKa of the 
thiol with lowered pH resulting in a lower rate of reaction observed [61, 90]. This is 
because the thiolate ion is more reactive towards the hypohalous acids than the 
protonated thiol [61, 90].  The reaction with Met is slower, but still extremely rapid 
with second order rate constants of 3.4 x 107 and 3.6 x 106 M-1 s-1 for HOCl and HOBr 
respectively [61, 90]. Rate constants for HOSCN are significantly less with Cys and 
GSH at a rate of 7.8 x 104 and 2.5 x 104 M-1 s-1 respectively [91, 92]. HOSCN reacts 
with Met slowly, with an upper limit of ~1000 M-1 s-1 [92]. 
The initial reaction product between HOCl and thiols is the sulfenyl chloride 
species (RS-Cl) [93-96] (Figure 1.3). The sulfenyl chloride species are short lived 
and can react either with H2O to yield a sulfenic acid (RSOH), or with excess thiols 
to yield a disulfide [95]. Sulfenic acids can be further oxidised to give sulfinic and 
sulfonic acids, by HOCl or other 2-electron oxidants [95]. Alternatively, RS-Cl can 
decompose via radical pathways to form thiyl radicals [97]. For HOSCN, the reaction 
with a thiol initially produces the corresponding RS-SCN species [91, 98]. RS-SCN 
groups can also react to yield sulfenic acids, but are more stable than their RS-Cl 
counterparts, and have lifetimes of a few minutes to hours depending on their 
environment [99, 100]. The formation of sulfenic acids is a key mechanism of 
antioxidants enzymes such as peroxiredoxin [101], as they can react with nearby 
cysteine residues to form disulfides that can be reduced through the action of other 
enzymes such as thioredoxin (Trx) [102]. However, over-oxidation of these residues 
can inactivate proteins, with sulfinic acid formation being reversible only through 
the action of sulfiredoxin, though this process is slow [103]. Sulfonic acid formation 
is irreversible, leading to permanent inactivation of enzymes [103-105].  
Sulfenamides are produced when RS-Cl react with a nucleophilic nitrogen [95, 
106] (Figure 1.3). Subsequent oxidation of a sulfenamide produces sulfinamides and 
sulfonamides [95]. HOCl induces the formation of glutathione sulfonamide at sub-
stoichiometric amounts of HOCl, where N-chloramines needed to be in excess of GSH 
in order to produce detectable levels of the sulfonamide [107]. The formation of 
sulfonamides can induce crosslinking in peptides, including GSH, and proteins when 
the nucleophile is a Lys or Arg side chain [95, 108]. 
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Figure 1.3 - Reaction schemes for production of sulfenic, sulfinic and sulfonic acid 
and sulfenamides, sulfinamides and sulfonamides produced from reactions of HOCl 
with thiol groups. Taken from [95] 
Oxidation of Met residues by HOCl primarily gives rise to methionine sulfoxide 
(MetSO) [106]. MetSO is a stable product, which is only reduced in vivo by 
methionine sulfoxide reductases [109, 110]. Formation of MetSO at the active site of 
proteins can lead to inactivation. A classic example of this is the inactivation of α1-
proteinase by HOCl [111, 112], which can be prevented by the presence of 
antioxidants [112-114]. Further oxidation of MetSO residues results in the 
formation of methionine sulfone, an irreversible oxidation product [88].  
Oxidation of Met by HOCl and N-chloramines can form dehydromethionine as a 
lower yield product [115]. The formation of this product can occur at N-terminal 
Met residues [116]. Thiols are capable of reducing dehydromethionine, with the 
half-life of this product in cytosol where GSH concentration is higher is predicted to 
be only a few hours [117]. Exposure of peptides containing Met and Lys residues to 
HOCl can also result in the formation of inter and intra-molecular sulfilimine 
crosslinks, though HOBr was more effective in forming these products [118]. The 
mechanism is proposed to be via a halamine intermediate reaction [118].   
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 Aromatic amino acids 
HOCl can react with the aromatic side chains of amino acids. Tyr residues are 
particularly important due to the formation of the stable 3-Cl-Tyr, which has been 
used a biomarker for HOCl, and hence MPO damage [119]. HOCl chlorinates Tyr to 
form 3-Cl-Tyr [64, 120-122] and can further chlorinate Tyr to form 3,5-dichloro-Tyr 
[122, 123]. This can occur by direct chlorination by HOCl or chlorine transfer from 
N-chloramines formed near Tyr residues [121, 124]. The reaction of HOCl with Tyr 
is much slower than other reactions mediated by HOCl, with second order rate 
constants of 71 M-1 s-1, and 238 M-1 s-1 for the reaction of 3-Cl-Tyr with HOCl [125].  
HOBr is also capable of reacting with Tyr residues to form the 3-brominated 
product, and this reaction is significantly faster than the reaction with HOCl, with a 
second order rate constant of 2.3 x 105 M-1 s-1 [61]. 3-Br-Tyr has been used a 
biomarker for MPO and EPO damage, and increased relative levels of 3-Br-Tyr to 3-
Cl-Tyr have been interpreted as HOBr being the primary oxidant present [33, 126]. 
However, based on the relative rate constants of the oxidants with Tyr, and relative 
to other targets, 3-Br-Tyr would be a more favourable product than 3-Cl-Tyr, which 
may make interpretation of relative oxidant levels based off relative halogenated 
Tyr residues more difficult [60, 61]. Tyr does not react directly with HOSCN, though 
the LPO/H2O2/SCN- system can oxidise Tyr residues, it is thought to be mediated by 
the formation of thiocyanogen, (SCN)2 or require the presence of LPO [127]. It 
should be noted the formation of these chlorinated and brominated products may 
also be mediated by the formation of Cl2 and Br2 [36, 64], though these halogen 
species are only formed at low pH, and are unfavourable under physiological 
conditions [66]. 
HOCl reacts with Trp with a second order rate constant of 7.8 x 103 [60] and can 
form a number of different products [128, 129]. Reaction of Trp with excess HOCl 
gives rise to products with chlorinated aromatic groups [128]. In the presence of 
TEMPO, a stable nitroxide capable of rapidly scavenging free radical species, a 
different chlorinated epoxide product formed at the amino acid, suggesting that 
radical interactions are important in the oxidation of Trp by HOCl [128]. Oxidation 
of Trp residues in peptides by HOCl gives rise to hydroxytryptophan and 
oxyindolyalanine products [94, 130]. Alternatively, the reaction can produce 
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kynurenine and N-formylkynurenine via reaction of nitrogen-centred radicals 
produced by N-chloramine formation and subsequent decomposition [131]. These 
reactions are protein structure dependent and Trp residues adjacent to Gly residues 
can be oxidised to a cyclic Trp-Gly species [130]. HOSCN is also capable of oxidising 
Trp to yield oxyindolamine products [132], though these reactions are favoured at 
low pH and therefore may have limited biological relevance [133].  
HOCl also reacts with His residues, with the major product being the formation 
of N-chloramines on the imidazole ring [60]. These N-chloramines are more reactive 
than those formed at the α-amino acid group, and capable of mediating 
transchlorination reactions [134-136]. It has also been suggested that the formation 
of 2-oxohistidine may occur with HOCl treatment [137]. 
 Amides 
Similar to the reaction with amines (Sections 1.2.5 and 1.3.2), HOCl can react 
with amides to form N-chloramides, though these reactions are much slower with 
rate constants in the range of < 102 [60, 138]. HOBr can also react with amides to 
form N-bromamides and this reaction is faster than that reported for HOCl at 1 x 103 
M-1 s-1 for the reaction with protein backbone amide groups [61].  N-Chloramides are 
capable of transferring chlorine and oxidising other substrates such as nicotinamide 
adenine dinucelotide (NADH), though this reaction is slow with rate constants <102 
M-1 s-1 and dependent on N-chloramide structure [138, 139]. In the presence of 
water, N-chloramides can undergo hydrolysis, which results in the cleavage of the 
amide bond [56]. One potential mechanism involves formation of a nitrogen-centred 
radical followed by hydrogen abstraction [140-144]. Protein backbone 
fragmentation can be prevented by the presence of radical scavenging antioxidants 
such as Trolox, ascorbate and GSH, indicating radical processes are occurring [145].  
 Lipids 
In addition to protein targets, HOCl can react with the unsaturated fatty acid side 
chains of lipids, forming halohydrins [9, 119, 146]. The second order rate constants 
for these reactions are in the range of 5 – 50 M-1 s-1 in aqueous solutions [63, 147]. 
However, kinetic studies have shown that the rate constant for lipids contained in 
liposome cores in vivo to be considerably (up to 10-fold) slower [148]. This is 
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attributed to the limited ability of HOCl to diffuse into the lipid environments. HOCl 
has been shown to react with cholesterol, forming halohydrin isomers, which can 
then undergo dehydrohalogenation reactions to form epoxides [119, 149, 150]. 
Plasmalogens are glycerophosphospholipids characterised by a vinyl ether 
group at the sn-1 position, and represent up to 15 – 20% of total phospholipid in the 
body. HOCl and HOBr react with plasmalogens, with the primary target of the 
reaction being the vinyl-ether bond [151-153]. HOCl reacts more slowly compared 
to HOBr, with rate constants for the HOCl and HOBr reaction with a model vinyl-
ether being 1.6 x 103 and 3.5 x 106 M-1 s-1 [151]. The reaction with HOCl cleaves the 
vinyl ether bond, and the products of the reaction depend on the fatty acid bound to 
the plasmalogen. Low levels of HOCl react with oleic fatty acids to yield chloro fatty 
aldehydes [152, 154, 155], with higher concentrations yielding chlorohydrin 
products [152]. Glycerophosphocholine products are formed upon reaction of HOCl 
with fatty acids with higher levels of unsaturation, [152, 153]. 
Reaction of HOCl with amine-containing phospholipid head groups results in the 
formation of N-chloramines [147]. Phosphatidyl-ethanolamine and phosphatidyl-
serine react with HOCl with second-order rate constants of 1.8 x 104 M-1s-1 and 3.3 x 
104 M-1s-1 [147]. In contrast, N-chloramine formation on the quarternary ammonium 
group of phosphatidyl-choline head groups is significantly slower at 0.018 M-1s-1 
[147]. HOBr also reacts with phospholipids, though faster than HOCl with rate 
constants of ca. 106 M-1 s-1 [156]. HOSCN has limited reactivity with lipids, though it 
has been shown that HOSCN and the MPO/H2O2/SCN- system can promote the 
formation of lipid peroxides upon exposure to low-density lipoproteins [157, 158].  
 RNA and DNA 
HOCl can react with DNA and RNA bases and form N-chloramines through 
reaction with amine groups, or react with the aromatic ring to form chlorinated 
products. The predominant reaction is believed to be the formation of N-
chloramines [55, 159-161]. The second order rates for monomeric endocyclic 
amines (thymidine, uridine and guanosine monophosphates) range from 103 – 104 
M-1s-1 [62, 63] and between 101 and 102 M-1s-1 [62, 63] for monomeric exocylic 
amines (adenosine and cytidine monophosphates). The N-chloramines formed are 
capable of oxidising GSH, NADH, free amino acids and peptide bonds [63], with rates 
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10-100 times slower than HOCl itself. The reaction of HOCl with polymeric bases, 
such as in DNA, is considerably slower  (~10 M-1s-1), and is attributed to base pairing 
protecting amine sites from HOCl oxidation, with heat denatured DNA reacts ~10 
times faster than native DNA [63]. 
Alternatively, HOCl and N-chloramines are capable of chlorinating DNA and RNA 
components with adenine, guanine and cytosine being major targets [162]. 5-
chloro-2’-deoxycytidine, 8-chloro-2’-deoxyadenosine and 8-chloro-2’-
deoxyguanosine are formed as in vitro products of these reactions, and 5-chloro-2’-
deoxycytidine has also been detected when cells are exposed to HOCl [162]. These 
products can also be formed by the degradation of N-chloramines formed on DNA 
bases [55, 163, 164]. HOCl is also capable of oxidising nucleosides to form other 
products including 5-hydroxy-cytosine, 5-hydroxy-uracil, and hypoxanthine [165, 
166]. HOBr is also capable of similar reaction, with exposure of guanine forming 
various oxy-guanine products as well as 8-bromoguanine [167]. In contrast, HOSCN 
has no reported reactivity with DNA [168]. 
 Carbohydrates 
HOCl reacts with the carbohydrates hyaluronan and glucosamine sugars at the 
amine site forming N-chloramines [169]. Amines are the primary target of HOCl, 
with substitution of the N decreasing reactivity [169]. HOCl reacts with amine and 
amide moieties of heparan sulfate, forming products including N-monochloramines, 
N-dichloramines, N-chlorosulfonamides, and N-chloramides [170-172], though the 
rate constants for these reaction are significantly slower (< 1 M-1 s-1) than those 
other chlorination reactions [173]. N-Monochloramines can decompose with no 
significant modifications to structure, but N-dichloramines and N-
chlorosulfonamides can cause strand breakage via radical mechanisms [172]. N-
Chloramides formed on hyaluronan and chondrotin sulfate chains cause 
fragmentation when exposed to radicals [170, 174, 175]. These reactions may be of 
particular relevance in arthritis, where oxidation of proteoglycans leads to 
degradation of cartilage [176, 177], and in atherosclerosis, where degradation of the 
matrix proteins in the arterial wall may contribute to the development of the disease 
[178]. 
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 N-Chloramines 
N-Chloramines undergo transchlorination reactions [134, 179, 180], 
demonstrated by the equilibrium between Tau, Gly and His N-chloramines [135]. As 
N-chloramines, particularly β-N-chloramines such as TauCl, are less reactive than 
HOCl, it has been hypothesised that N-chloramines may be able to propagate 
oxidative damage away from the source of HOCl, by travelling further before 
decomposition or further reaction [181]. Transfer of chlorine to imidazole or N-
acetylhistidine from monochloroamine allowed for chlorination of Tyr to occur via 
the more reactive imidazole chloramine (ImdCl) [182]. Alternatively, N-chloramines 
can undergo chlorine transfer or decomposition to radicals, transferring the damage 
to different sites [141]. 
Degradation of N-chloramines can occur in two ways, forming aldehydes or 
nitrogen-centred radicals (Figure 1.4) [86]. Aldehyde formation occurs when the N-
chloramine bond forms an imine intermediate (Figure 1.4), which is then 
hydrolysed to yield an aldehyde [183, 184]. These aldehyde products can form by 
degradation of N-chloramines formed on either free amino acids, such as Tau [183, 
184], peptides such as GSH [185], or on protein residues, as in low-density 
lipoprotein (LDL) [186, 187]. The resulting aldehydes can form advanced glycation 
end products, typically associated with diabetes and cardiovascular disease, via 
Schiff base imine intermediates [188].  
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Figure 1.4 - Reaction scheme of degradation of N-chloramines to form aldehyde and 
Schiff bases and nitrogen centred radicals and subsequent products – taken from 
[137] 
Alternatively, one-electron reduction of the N-chloramine can occur, resulting in 
the formation of nitrogen-centred radicals (Figure 1.4) [145, 189, 190]. The radicals 
form in a time dependent manner through thermal decomposition, though can be 
accelerated in the presence of one-electron reductants, such as metal ions Cu+ and 
Fe2+ [190].  These radicals can then undergo a range of intra and intermolecular 
reactions [145, 189]. In the case of proteins, hydrogen abstraction from the 
backbone carbon yields carbon-centred radicals, which can then cause protein 
cleavage [145, 189]. This cleavage can be inhibited by the presence of radical 
scavengers such as Trolox, GSH and ascorbate [145], which rapidly react with the 
nitrogen-centred radical [191]. 
N-chloramines retain the oxidising power of HOCl, though the rates of reaction 
are significantly decreased [136, 192]. N-chloramines have been shown to be 
capable of oxidising thiols and thioether groups, including Cys and Met residues and 
GSH [86, 136, 192]. Analogous to HOCl reactions, oxidation of thiols such as GSH 
primarily yields disulfides [136, 192]. Oxidation of Met by N-chloramines results in 
the formation of MetSO [192]. The rate constants for these reactions depend on the 
amino acid on which the N-chloramine is formed, particularly with side chain N-
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chloramines. N-chloramine formed on the imidazole ring of His (HisCl) react with 
sulfur residues with rate constants of 721 and 91 M-1 s-1 for GSH and Met 
respectively [136]. N-chloramines formed on the amine groups of Gly (GlyCl) and 
Tau, and those formed on the side chain amine of Lys (LysCl), are significantly less 
reactive than HisCl, with rate constants for the reaction with the thiol species Cys 
and GSH in the range of 1 – 2 x 102 M-1 s-1 [192]. Similarly, the reaction of these N-
chloramines with Met is also decreased in comparison to HOCl and HisCl with rate 
constants in the range of 0.4 – 2 x 102 M-1 s-1 [192]. 
Table 1.4 – Second order rate constants for the reaction of hypohalous acids and N-
chloramines with Cys, GSH and Met. 
 Second order rate constants / M-1 s-1 
Compound HOCla  HOBr  HOSCNb  HisClc  GlyCld  LysCld TauCld 
Cys 3.6 x 108 1.2 x 107 e 7.8 x 104 9.1 x 102 3.5 x 102  4.8 x 102 2.1 x 102 
GSH 1.2 x 108  2.5 x 104 7.2 x 102 2.3 x 102 2.6 x 102 1.2 x 102 
Met 3.4 x 107 3.6 x 106 f Slow 91 2.1 x 102 53 39 
a[90]; b[92]; d[136]; e[192]; e[61]; f[61] rate constant determined for NAc-Met-OMe 
 Cell and tissue damage 
MPO and the oxidants it produces have been demonstrated to be detrimental to 
the cellular environment and play a role in the initiation and progression of 
numerous diseases [2]. This Thesis focuses on damage caused by HOCl and N-
chloramines, as HOCl-induced damage has been thoroughly characterised and N-
chloramineshave the capacity to propagate HOCl-induced damage away from 
inflammation sites. However, the role of other MPO-derived oxidants, particularly 
HOSCN, should not be discounted in MPO related pathologies, as while the reactivity 
of this oxidant is less than and more specific compared to HOCl, damage induced by 
HOSCN may also play a role in disease [193]. The biological effects of HOSCN have 
been reviewed recently, with particular focus on the differences in reactivity and the 
extent of damage between HOSCN and HOCl [88, 89]. 
 Beneficial effects 
MPO-derived oxidants are generally believed to be important species in 
neutrophil-mediated bacterial cell killing. MPO knockout mice have been shown to 
be more susceptible to infections [194, 195], and neutrophils from MPO-deficient 
people kill some types of bacteria poorly [196]. Furthermore, the introduction of 
 20 
MPO inhibitors, such as azides, impair the ability of the cells to kill bacteria 
effectively in vitro [197]. This supports MPO-derived oxidants as an important 
source of antimicrobial activity. 
HOCl is proposed to be the major lethal oxidant produced by MPO [198, 199], 
however roles for the other oxidants, particularly HOSCN cannot be excluded. EPO 
has been shown to be effective at killing bacteria in the presence of H2O2 and Br- or 
SCN- ions [200, 201], indicating that the HOBr and HOSCN produced by this enzyme 
could play a role in pathogen killing. Secondary oxidants, including N-chloramines, 
may also play significant role as microbicidal agents, with the high flux of HOCl [17], 
and kinetic predictions that demonstrate the majority of HOCl produced will react 
with cellular constiuents [198]. TauCl, which is produced at high levels after 
neutrophil activation, has the capacity to kill numerous bacterial strains and viruses 
[202-205]. It achieves this by penetrating into the pathogen cytosol and oxidising 
proteins and thiols [202, 203]. 
TauCl can prevent host cell damage by multiple pathways, including by the 
inhibition of O2- production by activated neutrophils [206-210]. TauCl can prevent 
the phosphorylation of p47phox and subsequent translocation to the membrane, 
preventing the formation of NADPH oxidase machinery and hence O2- production 
[210]. This has been postulated as a mechanism to prevent neutrophils from self-
imposed cellular damage due to excessive oxidant production. 
 Detrimental effects 
1.4.2.1 Damage in the cellular environment 
HOCl is toxic to cells. Reagent HOCl can kill a number of cell types including red 
blood cells (from concentrations of 100 nmol HOCl per 106 cells) [211-213], 
endothelial cells (from 25 nmol per 106 cells) [214], epithelial cells (from 500 nmol 
per 106 cells) [215, 216], fibroblasts (from 5 µmol per 106 cells) [217] and T-cell 
lines (from 1.5 µmol per 106 cells) [218]. Multiple mechanisms have been suggested 
to be responsible including pore formation due to surface protein crosslinking 
[219], and inactivation of potassium channels, possibly caused by thiol inactivation 
[220]. Treatment of cells with lower concentrations induces apoptosis (< 50 nmol 
per 106 cells), though with increasing concentrations of HOCl (> 1 µmol per 106 
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cells), necrosis and cell lysis dominates the cell death pathways [221, 222]. 
However, in many cases the specific pathways have not been fully defined. N-
chloramines have also been shown to induce apoptosis via activation of caspases 
[223] and cause cell death [136, 224]. 
Treatment of cells with sub-lytic concentrations of HOCl induces the oxidation 
of thiols and as HOCl reacts very quickly with the thiol components of cells, it is likely 
that thiols are major targets. Cells exposed to HOCl have decreased levels of GSH and 
protein thiols [225, 226]. Treatment of human vein endothelial cells (HUVECs) with 
HOCl showed increases in glutathione sulfonamide, with limited disulfide products 
being detected [227]. Rapid consumption of GSH has also been observed in human 
coronary artery endothelial cells (HCAECs) [221] and human monocyte derived 
macrophages (HMDMs) [228]. 
Protein oxidation of thiols in cells may lead to enzyme inactivation and have 
further detrimental consequences for the cell. Cells treated with sub-lethal amounts 
of HOCl show modifications on a number of proteins including glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and numerous enzymes involved in protein 
folding [221, 222, 225, 229]. GAPDH has been shown to be preferentially oxidised 
compared to GSH on exposure of cells to HOCl [225]. The primary function of GAPDH 
is to catalyse the sixth step of glycolysis, though it is also involved in a number of 
other cellular processes [230]. For example, GAPDH is involved in apoptosis, and 
when exposed to oxidants, becomes nitrosylated and binds to DNA and Siah1 
leading to apoptosis pathway activation [231, 232]. GAPDH inactivation by HOCl can 
lead to ATP depletion in cells, though HOCl can affect energy production in multiple 
ways, including inhibition of mitochondrial respiration or glucose transport [220, 
233]. ATP levels are decreased when cells are treated with sub-lethal concentrations 
of HOCl [215, 220, 225, 234].  HOCl can also react directly with ATP [63].  
Peptidylprolyl isomerase A (cyclophilin A) and protein disulfide isomerase 
are affected by HOCl treatment of endothelial cells [229]. Peptidylprolyl isomerase 
A and protein disulfide isomerase are enzymes involved in protein folding [235, 
236] and inactivation of enzymes related to protein folding could potentially lead to 
the accumulation of misfolded proteins within cells. This is significant as it may 
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trigger detrimental signalling cascades, for example, the unfolded protein response, 
which ultimately leads to apoptosis of the cell [237]. 
HOCl treatment can also perturb phosphorylation via inactivation of protein 
tyrosine phosphates (PTPs) [238], and cause disruption of sulfur-metal ion clusters, 
leading to inactivation or changes in function of enzymes [239-243]. Treatment of 
enzymes containing thiol-zinc finger motifs causes the release and mobilisation of 
zinc from these enzymes [239-241]. Exposure of aconitase, an enzyme containing 
an iron-sulfur cluster, to HOCl induced a release of iron and inhibition of function, 
from both isolated aconitase and when HCAECs were treated with HOCl [244]. 
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS), 
both containing sulfur-metal clusters, when coupled produce NO•, but when treated 
with HOCl, they uncouple resulting in production of O2•- [242, 243], thereby 
increasing cellular oxidative stress. Exposure of HCAECs demonstrated an 
uncoupling of eNOS, with subsequent inhibiton of NO• formation [243].  
N-Chloramines have similar potential to oxidise intracellular thiols upon 
exposure to cells. Exposure of cells to N-chloramines causes a consumption of 
intracellular thiols and GSH [136, 229]. GAPDH, peptidylprolyl isomerase A and 
protein disulfide isomerase are also targeted by monochloramine (NH2Cl), GlyCl and 
HisCl treatment to endothelial cells [229]. While TauCl is a more potent inhibitor of 
GAPDH and creatine kinase in isolated enzymes studies [245], its inability to cross 
the cell membrane means that it cannot inactivate intracellular GAPDH [135]. 
Hence, the ability for N-chloramines to oxidise intracellular thiols is dependent upon 
structure and the potential for these species to cross the cell barrier. However, 
transchlorination reactions can occur [135, 179], transferring the N-chloramine 
group from amines unable to cross the cell membrane, such as TauCl, to more cell 
permeable molecules, such as GlyCl, which can then induce oxidative damage in the 
cytosol [135].  
While TauCl is relatively impermeable to the cell membrane, studies have 
demonstrated the ability to regulate signalling pathways by acting on receptors 
outside the cell [246]. TauCl can influence the nuclear factor κB (NF-κB) pathways 
of pro-imflammatory mediators. NF-κB is bound by inhibitor κB (IκB) keeping it in 
the cytoplasm [247]. When stimulated, IκB becomes phosphorylated by IκB kinase 
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(IKK) and subsequently ubiquitinated and degraded, releasing NF-κB which 
translocates to the nucleus and upregulates proinflammatory mediators including 
iNOS, tissue necrosis factor α (TNF-α) and cyclooxygenase-2 (COX-2) [247].  TauCl 
inhibits NF-κB translocation to the nucleus, though the exact mechanism in unclear 
[248, 249]. One study suggests that TauCl inhibits IKK, preventing IκB 
phosphorylation [250]. Another study demonstrated oxidation of a Met residue on 
IκB by TauCl, though phosphorylation of serine residues was not inhibited [251]. 
Others demonstrated a reduced DNA binding affinity of NF-κB suggested to be 
caused by the inactivation of the extracellular signal-regulated kinase (ERK) 
pathway [251, 252]. 
TauCl has been shown to increase nuclear translocation of nuclear response 
factor 2 (Nrf2). Nrf2 is bound in the cytoplasm by the protein Keap-1, which when 
oxidised releases Nrf2 for translocation to the nucleus [253], where Nrf2 binds to 
antioxidant response elements and upregulates genes including heme oxygenase-1 
(HO-1), NADPH:quinone oxidoreductase (NQO-1), glutathione peroxidase (GPx), 
peroxiredoxin (Prx), and Trx [254]. TauCl induced a rapid increase in Nrf2 
translocation to the nucleus as well as an increase in cytosolic levels of Nrf2 [255, 
256]. Consequently, increases in heme oxygenase 1 (HO-1) protein and activity 
levels were observed with TauCl treatment of cells [255-257]. Pretreatment of cells 
with TauCl lead to inhibition of cell death by H2O2 [256, 258] and this has been 
attributed to the effects of TauCl on Nrf-2 activation. 
1.4.2.2 MPO in inflammatory pathologies 
HOCl-induced damage to tissue can lead to cellular dysfunction, and hence 
promote disease. MPO and MPO-derived oxidant damage is implicated in numerous 
inflammatory conditions. For example, elevated levels of MPO are found in disease 
samples from patients with cystic fibrosis [259-261], Parkinson’s disease [262], 
multiple sclerosis [263], and Alzheimer’s disease [264-266]. Increases in MPO levels 
are accompanied with biomarkers of HOCl-induced damage including elevated 
levels of 3-Cl-Tyr residues [259] and glutathione sulfonamide [267] in the sputum 
of cystic fibrosis patients; elevated 3-Cl-Tyr in the brain tissue of patients with 
Alzheimer’s disease [264, 268], Parkinson’s disease [269] and multiple sclerosis 
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[263, 270]. MPO and MPO-oxidant damage is also closely correlated in chronic 
kidney disease [271] and rheumatoid arthritis [272].  
In addition, the role of MPO and HOCl-induced oxidative damage in relation to 
cardiovascular disease (CVD) and atherosclerosis has been extensively 
documented. This is of significance as cardiovascular disease is the leading cause of 
death in Australia being the cause of about 30 % of deaths in Australian population 
[273]. As MPO plays a significant role in the development of atherosclerosis, which 
is a major cause of CVD, its contribution to this disease is reviewed in more detail 
below.  
 MPO and atherosclerosis 
Atherosclerosis is an inflammatory disease characterised by the development of 
fatty streaks in the arterial wall, caused by the accumulation and deposition of lipid-
laden macrophages (or foam cells) [274]. As the lesions develop, more foam cells 
accumulate leading to plaque formation, characterised by a fibrous cap with a 
necrotic cell core [274]. MPO has been detected in all stages of atherosclerosis lesion 
development [275], indicating a significant role for MPO in the progression of the 
disease. Numerous markers of MPO-induced oxidative damage have been detected 
in lesions including p-hydroxyphenylacetaldehyde, α-chloro fatty aldehydes, 
unsaturated lysophosphatidylcholine, 3-Cl-Tyr and 5-chloro-uracil [155, 276, 277]. 
Binding of antibodies raised against HOCl-damaged proteins (HOP-1) correlate with 
progression of disease, further implicating MPO as a factor in the progression of the 
disease [278].  
Circulating MPO levels are an independent predictor for presence of coronary 
artery disease with relative plasma concentrations of MPO correlated with severity 
of the disease [279, 280]. In healthy subjects, MPO levels increase the risk of 
cardiovascular disease, though levels could not predict a cardiovascular event [281-
284]. However, MPO levels can predict the incidence of cardiovascular events in 
patients with established coronary artery disease [285-287], and MPO have 
prognostic value for patients presenting with chest pain, with MPO levels a risk 
factor for major cardiovascular events in these patients [288]. Higher than median 
levels of MPO demonstrated a higher all cause mortality in patients who were 
hospitalised after their first myocardial infarction [289]. It should be noted, 
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however, that MPO deficient atherosclerotic mice (ApoE or LDL receptor knockout 
mice) have demonstrated an increase in atherosclerosis [290]. However, in the non-
MPO deficient mice, limited levels of MPO derived biomarkers such as 3-Cl-Tyr are 
observed, suggesting a limited role for MPO in murine atherosclerosis [290]. Mice 
which express human MPO demonstrate a significant increase in lesion size, 
suggesting that the species difference in MPO may be a significant factor [291]. 
Foam cells form when macrophages take up oxidised lipoproteins in an 
uncontrolled manner via interaction with scavenger receptors [274]. An 
MPO/H2O2/Cl- system and reagent HOCl have been shown to oxidize LDL [292, 293]. 
This oxidised LDL is more readily taken up by macrophages [294] and impairs 
cholesterol efflux [295] leading to lipid accumulation and foam cell formation. As 
levels of 3Cl-Tyr are elevated in LDL found in the arterial wall compared to that 
found in circulating LDL, it is suggested that MPO-induced LDL oxidation is 
occurring within the arterial wall [296].  
HOCl is also capable of oxidising high-density lipoprotein (HDL) resulting in 
impaired cholesterol efflux ability [297-301]. The apolipoprotein A-I (apoA-I) 
protein residues are the primary target for HOCl, and there is evidence for oxidation 
of Tyr, Trp and Met residues [124, 298, 302-306]. Loss of Trp residues reduces the 
efflux capacity of HDL [302], and recent data are consistent with the Trp72 residue 
being oxidised by HOCl [303]. Oxidised Trp residues are elevated in atherosclerotic 
lesion, and correlate with increased risk of cardiovascular disease [303]. Selective 
oxidation of the Tyr192 residue of apoA-I is also correlated with impaired 
cholesterol efflux capacity [304], and oxidation of Tyr residues can be mediated by 
a LysCl intermediate [124]. Elevated levels of 3Cl-Tyr and 3-nitro-Tyr are also found 
on HDL of patients with atherosclerosis, compared to healthy subjects, suggesting 
that Tyr oxidation may also play a role [124, 298, 305, 307]. In addition to Tyr and 
Trp, Met residues are oxidised by HOCl, reducing the efflux capacity [306, 307]. 
Furthermore, HOCl exposure to HDL reduces its anti-inflammatory properties by 
reducing the ability to inhibit pro-inflammatory pathways [308, 309], and causes 
the activation NF-κB pathways suggesting HOCl exposure transforms HDL to a more 
pro-inflammatory mediator [309]. 
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Endothelial dysfunction is also considered to be a contributing factor to the 
initiation of atherosclerosis and cardiovascular disease, with endothelial function 
closely related to NO bioavailability [310]. MPO is capable of binding to endothelial 
cells through interactions with the negatively charged glycosaminoglycans and is 
localized to the caveolae [311-313]. The binding of MPO is increased in the presence 
of albumin [312]. Internalisation of the caveloae allows for transcytosis of MPO, 
which is dependent on the albumin binding receptor, to the basement membrane 
where MPO is then localized with fibronectin [311, 312, 314]. The localization of 
MPO to endothelial thus allows for the modulation of NO· availability and 
contributes to endothelial dysfunction.  
MPO has been suggested to induce endothelial dysfunction by the production of 
HOCl, which uncouples eNOS and iNOS, hence perturbing NO production. In both 
isolated enzymes studies and upon treatment of HCAECs, HOCl is reported to 
convert these enzymes from the generation of NO to the production of O2- [242, 
243]. MPO further reduces NO availability by consuming it as a substrate [29, 52]. 
Moreover, HOCl treatment of guinea pig hearts [315] or arterial rings from rats 
[316] or rabbits [317] inhibits the acetylcholine-dependent relaxation of arterial 
rings. VPO, a peroxidase which produces HOCl, is elevated in spontaneously 
hypertensive rats, which exhibit decreased NO availability and lowered response to 
vasodilators, further implicating HOCl in endothelial dysfunction [318].  
Atherosclerotic plaque rupture and the resulting thrombosis is the underlying 
cause of the majority of heart attacks and stroke [319]. MPO may play a role in 
plaque rupture as MPO levels predict infarction risk [288, 320].  Similarly, systemic 
MPO levels are elevated in patients with eroded plaques [321], and monocytes and 
MPO levels are elevated in patients with ruptured plaques [322]. MPO and HOCl-
damaged proteins colocalise in the lesions of patients who have experienced sudden 
cardiac death [323]. Furthermore, HOCl has been shown to induce apoptosis of 
endothelial cells leading to destabilised plaques [324]. MPO release is also thought 
to activate metalloproteins through oxidation of a “cysteine switch” [325], which 
could further destabilise the plaque [326]. 
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 Prevention of MPO damage 
As MPO is a contributing factor to a number of pathologies, particularly 
atherosclerosis, there is considerable interest in the development of therapeutic 
strategies to prevent damage caused by the inappropriate production of oxidants. 
 Inhibition of MPO 
A major limiting factor in hypohalous acid production by MPO is the availability 
of H2O2 to form Compound I. The concentration of available H2O2 is primarily 
dependent on the presence of enzymes, such as GPx, catalase and Prxs, which 
compete with peroxidases for H2O2 [2]. Inhibition of NADPH oxidases, which 
produce O2•-, and hence H2O2 by dismutation, can also limit H2O2 concentrations 
[327].  A common inhibitor of NADPH oxidases is diphenylene iodonium chloride, 
which prevents the production of O2•- in neutrophils, reducing their effectiveness in 
bacteria cell killing [328, 329].  
Many agents can inhibit MPO, LPO and EPO in a non-specific manner [330]. 
Heme poisons, such as cyanide and suicide substrates such as hydrazines and 
hydrazides, can very effectively inhibit peroxidases by heme destruction [330]. 
However, due to their toxicity and lack of specificity, they are not appropriate for 
MPO inhibition in a therapeutic setting. 
As heme poisons have high toxicity, there has been interest in development of 
more specific MPO inhibitors. Novel 2-thioxanthine compounds have recently been 
developed, which have demonstrated ability to inhibit HOCl formation by MPO by 
initially reacting with Compound I, forming a radical that then covalently binds to 
the heme group of MPO causing inactivation [331]. Hydrogen sulfide can reversibly 
bind to the iron in the heme group of MPO at physiological levels, reducing H2O2 
consumption by MPO [332]. Hydroxymates have been shown to be specific toward 
MPO in neutrophils, and reversibly bind to the active site cavity of MPO, inhibiting 
access to the heme moiety inhibiting MPO activity [333]. Ceruloplasmin is capable 
of binding MPO in serum and reducing it from Compound I to Compound II [334]. 
The presence of ceruloplasmin has been suggested to inhibit the recovery of the 
native MPO, keeping as in the Compound II form, inhibiting the production of HOCl 
[334].  However, another study suggested that the binding of ceruloplasmin may not 
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be completely inhibiting the halogenation cycle, instead the binding promotes the 
formation of HOSCN instead of HOCl [335].  
Hypohalous acid production by peroxidases can be competitively inhibited by 
other substrates that react readily with Compounds I and II [336, 337], though this 
is limited by the necessity for high concentrations of substrate to effectively 
compete with the halogenation cycle. Acetominophen has been shown to inhibit 
total oxidant production by MPO, at plasma levels achieved using typical therapeutic 
doses of the drug [20, 338, 339]. However the initial rate of HOCl production was 
enhanced, due to the recycling of Compounds II and III [20].  
Nitroxides have been shown to prevent oxidative damage by acting as effective 
radical scavengers [340, 341]. However, they can also act as substrates for MPO, 
leading to accumulation of Compound II [340]. While Compound II can be recycled 
by O2  [340]. 
Nitroxides, particularly 4-amino-2,2,6,6-tetramethylpiperidin-1-yloxyl, are capable 
of preventing Met oxidation by MPO/H2O2/Cl-  systems, using both purified MPO and 
activated neutrophils [342], however nitroxides can be rapidly reduced by 
biological reductants [339]. Substitution with longer alkyl chains protect the 
nitroxide from reduction, allowing more effective inhibition of MPO [339]. 
Poor peroxidase substrates can inhibit the production of hypohalous acids at low 
physiological concentrations by trapping the enzyme as Compound II. Trp is one 
such substrate, which is readily oxidised by Compound I, though reacts very slowly 
with Compound II [15]. This results in accumulation of Compound II, and hence 
inhibition of HOCl production [343]. However, in the presence of O2•-, Compound II 
is recycled quickly, resulting in poor inhibition [43, 336]. Extracellularly, SOD may 
be able to counter this, but as SOD levels intracellularly are low, SOD may be unable 
to effectively remove the O2•- to inhibit MPO turnover [2]. Substrates such as 
hydroquinone [344] and amascrine [345] can stimulate the production of 
Compound III, inhibiting the halogenation cycle, but Compound III is also recycled 
effectively by O2•- [38]. 
MPO inhibition may lead to a decrease in oxidation damage, and prevention or 
inhibition of disease, however, the enzyme is important in the immune system for 
the role it plays in killing invading pathogens and preventing infection [194, 195]. 
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An alternative method for preventing MPO-related damage may be to remove excess 
oxidant from the sites of inflammation before the damage can occur. 
 Endogenous antioxidant enzyme systems 
Within cells, there are numerous enzymatic systems that control redox 
homeostasis, with many containing redox active Cys or Sec sites. A number of these 
systems scavenge oxidants, including MPO-derived species, before they can cause 
major detrimental effects on cells. These include GPx, the Trx system and Prxs [98, 
101, 346-350]. Other enzymes can reverse oxidative damage caused by cells by 
reducing the oxidised products. Examples of these are methionine sulfoxide 
reductase (Msr) [351-355], which reduce MetSO residues, and glutathione 
reductase (GSR), glutaredoxin and Trx, which are all capable of reducing disulfides 
[356-360].  
 SOD and catalase 
SOD and catalase are metalloproteins responsible for the removal of O2- and 
H2O2 respectively. SODs contain a reactive metal centre, either Cu or Mn, which 
catalyses the dismutation of O2- to form H2O2 [361-363]. While H2O2 is still an 
oxidant capable of damaging cellular components, it is significantly less reactive 
compared to O2-, and so this is considered to be beneficial. Catalase contains 4 heme 
centres and removes H2O2 via two stages, the first is an initial reaction with one 
equivalent of H2O2 to form an oxyferryl heme, followed by a second reaction with 
H2O2 to produce O2 and the native catalase [364-367]. Together, they may work to 
keep the relative level of reactive oxidants in the cell at a manageable level.  
 Glutathione peroxidase 
GPxs were the first identified seleno enzyme, having a selenocysteine at the 
active site [368]. They play an important regulatory role in the redox state of cells 
[369]. GPx enzymes are capable of reducing H2O2 and other peroxides in a catalytic 
cycle (Figure 1.5) [346]. The mechanism involves oxidation of the selenol active site 
to a selenenic acid by peroxides [370], which in turn is reduced by two GSH 
molecules via a selenosulfide intermediate, with the products being the reduced 
enzyme and GSSG [346]. The removal of H2O2 from the cellular environment by such 
mechanisms limits the capacity for MPO to produce HOCl and other oxidants. 
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Figure 1.5 - Catalytic cycle of GPx – adapted from [370] 
 Thioredoxin reductase and thioredoxin 
Thioredoxin reductases (TrxR) are dimeric selenoenzymes containing redox 
active selenocysteines at the active site [371, 372]. TrxRs show direct antioxidant 
activity through reaction with a wide range of oxidative substrates including H2O2, 
ONOOH and HOSCN, with TrxR being subsequently reduced by NADPH [98, 347, 
348]. This system is essential to cells, and lack of it is embryonically lethal [373-
375]. The effectiveness of the TrxR system is due to the presence of selenium-
containing amino acids at the active site. Loss of the Sec residue reduces the capacity 
of the enzymes to act as antioxidants [376-379], with substitution of Sec with Cys 
significantly reducing the catalytic potential of TrxR [379, 380]. 
Trxs are small proteins that are capable of reducing disulfide bonds in the cell 
with the activity arising from the presence of redox active Cys residues at the active 
site (Figure 1.6)[356, 357]. The active site typically consists of a Trp-Cys-Gly-Pro-
Cys motif [381]. In its reduced form, the active site consists of two thiols. When in 
the presence of a protein disulfide, the protein is reduced, and the Cys residues of 
the Trx active site form a disulfide bond. This occurs through a mixed disulfide 
intermediate [381, 382].  
 
Figure 1.6 - The Trx catalytic system – adapted from [356] 
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Oxidised Trx is reduced to its active form by TrxR. Mice overexpressing Trx are 
more resistant to oxidative stress and have a greater life span than wild type mice 
[383]. Trx is found in higher concentrations in the plasma of people with diseases 
linked to increased oxidative stress including human immunodeficiency virus, 
hepatitis C virus and some cancers [384-389]. This enzyme plays essential roles in 
the reduction of oxidative species, as well as reducing other important enzymes 
such as the peroxiredoxins, glutathione reductases and methionine reductases 
(Figure 1.7) [390, 391]. The Trx system is also capable of removing nitrosyl 
modifications from proteins, though its oxidised form is capable of nitrosylating 
proteins [392].  
Trx play significant roles in signalling pathways involved in the response to a 
variety of stresses including virus infection, UV-irradiation, H2O2 and ischemia-
reperfusion injury [393-396]. Reduced Trx inhibits apoptosis through interactions 
with apoptosis signal-regulating kinase (ASK) [397]. Trx can also promote the DNA 
binding capabilities of NF-κB via a direct interaction [394]. It enhances DNA binding 
capabilities of activator protein-1 through interactions with redox factor 1. It also 
interacts with other cofactors such as hypoxia inducible factor 1 and thioredoxin 
interacting protein [398]. Hence, Trx plays a role in cell redox status through direct 
scavenging, reversal of oxidative damage and cell signalling pathways. 
 Peroxiredoxins 
 
Figure 1.7 – Prx and Msr enzyme systems use the thioredoxin system as electron 
donors to reduce H2O2 and MetSO – adapted from [356] 
Prxs are small enzymes that use the Trx system as an electron donor to reduce 
peroxides [102]. They are capable of detoxifying H2O2, ONOOH and other peroxides 
(Figure 1.7) [101, 349, 350]. The rate constant for the reaction with ONOOH (k = 7 x 
107 M−1 s−1) is 5 times faster than that of GPx [399]. The mechanism of action is 
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similar to that described for GPx, except that the reactive residue is a Cys, rather 
than Sec. Prx silencing increases oxidative stress in breast cancer cells [400]. Prx 
knock out mice develop anemia, have an increased incidence of tumours [401, 402], 
lower life spans and increased protein oxidation [403]. The loss of Prxs does not 
appear to be compensated for by increases in other antioxidant enzymes [404]. 
Thus, Prxs, in conjunction with the Trx system, contribute to antioxidant defense of 
the cell by maintaining oxidant levels. 
Prxs may play a role in H2O2 signalling in cells, as H2O2 regulates a number of 
signalling cascades including platelet growth factors and tumor necrosis factors, 
which can be influenced by Prxs [403, 405-409]. Prxs can be inactivated by 
hyperoxidation of the active site Cys [103-105], though this only occurs when all 
factors of the catalytic cycle are present [105]. The inactivation of Prxs is reversible 
in the presence of sulfiredoxins [105, 410]. The inactivation of Prxs allows for the 
build-up of H2O2 in cell, which can then mediate cell signalling via other pathways 
[411, 412].  
 Methionine sulfoxide reductase 
Msr are Trx dependent enzymes that repair oxidative damage in cells [413-416]. 
The Msr family of enzymes reduces methionine sulfoxide back to Met, hence 
repairing oxidative damage (Figure 1.7). Msrs have either 2 Cys residues or a 
Sec/Cys pair at the active site and reduce MetSO via a sulfenic acid intermediate, 
with subsequent formation of an intermolecular disufide bond [351-355]. Msrs is 
then reduced by the Trx system [417]. However, some isoforms of Msr lack the 
second resolving Cys and are reduced by a free thiol or seleno group [417-420]. Msrs 
prefer to reduce oxidised methionine residues on unfolded proteins [413], 
suggesting a role in reducing the impact of oxidative stress on the protein folding 
process. Overexpression of Msr reduces oxidative stress levels in cells [414-416]. 
Msr levels decrease with age [421, 422] and inflammatory diseases such as 
Alzheimer’s disease [423]. Hence, Msrs may play a critical role maintaining cellular 
function and the redox homeostasis in cells. 
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 Glutathione reductase 
GSR is a dimeric flavin-containing enzyme with sub-units of 50 kDa [359, 424, 
425]. The primary function of this enzyme is to reduce GSSG to GSH by catalysis of 
the reaction with NADPH (Figure 1.8) [358-360]. It achieves this by funnelling 
electrons from NADPH through the FAD domain to the Cys residues present in the 
GSSG binding site [426]. GSSG is reduced by GSR via disulfide exchange mechanisms 
with active site Cys residues [427]. This allows for catalytic oxidant scavenging by 
GSH, where GSH reacts with numerous oxidants to produce GSSG, which can then be 
reduced by the action of GSR. By maintaining GSH in a reduced state in cells, GSRs 
play a role in antioxidant defence of cells.  
 
Figure 1.8 – GSR uses NADPH as an electron donor in order to reduce GSSG to GSH 
– adpated from [427] 
 Low molecular mass scavengers 
In addition to a number of enzymatic oxidant detoxification systems, low 
molecular mass antioxidants such as ascorbate have been shown to scavenge MPO-
derived oxidants and protect cells from oxidative damage [428-430]. Ascorbic acid 
has been shown to protect Lys and Trp residues of the LDL protein from oxidation 
by HOCl [429]. Ascorbic acid offers protection of Cys from HOCl and N-chloramine 
oxidation, and displays an ability to reverse N-chloramine formation on LDL protein 
[428, 429]. Ascorbate can also prevent HOCl- and N-chloramine induced apoptosis 
[223, 431, 432], but as thiols are still consumed with ascorbate treatment, this 
protection may not be due to scavenging of HOCl. However, it has been shown that 
ascorbate, at levels achieved in plasma in human supplementation studies, is unable 
to compete kinetically with other targets of HOCl, particularly proteins and amino 
acids [87].  
Low molecular mass thiol compounds are also potent scavengers for MPO-
derived oxidants, and are a major target for HOCl and N-chloramines in the cellular 
environment. Cys has been shown to reduce and reverse HOCl oxidative damage to 
 34 
cells [429] and protect mononuclear leukocytes from inactivation by HOCl [430]. 
GSH reacts with HOCl and other activated oxygen species to form the oxidised 
species GSSG or a sulfonamide [433, 434] in a sacrificial manner to protect cell 
proteins [225]. Differing GSH levels in HMDMs from donors correlate to 
susceptibility of HOCl-induced toxicity [228]. GSH loss in HOCl-treated red blood 
cells occurs before loss of protein thiol residues, indicating a protective effect [226] 
and its presence significantly increases the ability of bacteria to survive treatment 
with HOCl [435].  
Other low molecular mass compounds also demonstrate potential as HOCl 
scavengers. Bilirubin, a product of heme degradation, inhibited N-chloramine 
formation in plasma after exposure to the MPO/H2O2/Cl- system, and reduced levels 
of oxidative stress markers [436]. Probucol protects endothelial cells and aortic 
rings from HOCl-induced inhibition of endothelial relaxation, though as the rate 
constants for the reaction with HOCl are low (~ 102 M-1 s-1) it is unlikely to be due to 
direct scavenging of HOCl [437]. MitoQ, a mitochondrially targeted antioxidant, is 
able to protect against HOCl-induced mitochondrial dysfunction, and hence cell 
death [438]. 
 Selenium compounds as antioxidants 
Selenium compounds have gained increasing interest as potential catalytic 
oxidant scavengers in vivo [90, 439-443]. This is primarily due to the rapid reactions 
with various biological oxidants, which occur at higher rates than the analogous 
sulfur compounds [90, 98, 439], and subsequent recycling by biological reductants 
like GSH [444, 445]. The increased reactivity of selenium compounds is primarily 
attributed to the increased nucleophilicity of selenium compared to sulfur, as well 
as the lowered pKa of selenols compared to thiols [446, 447]. As the ability of 
selenium compounds to act as antioxidants is a focus for this Thesis, the reactions 
of various selenium compounds with both one- and two-electron oxidants are 
discussed below. 
 Ebselen and derivatives 
Ebselen is a benzisoselenazolone that has been used to treat inflammatory 
disorders, due to its capability to act as a GPx mimetic [448]. It has been shown to 
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have low toxicity as the selenium is not bioavailable.  Ebselen has been shown to be 
capable of scavenging both one-electron oxidants, such as the peroxyl radical 
CCl3OO·- with a rate constant for the reaction of 2.9 x 108 M-1 s-1 [449], and the two 
electron oxidants ONOOH [450] and H2O2 [451] with second order rate constants of 
2.0 x 106 M-1 s-1 and 4.8 M-1 s-1 respectively [450, 452] (Figure 1.9). The mechanism 
is thought to involve oxidation to the selenoxide, which is then reduced by two GSH 
molecules to reform ebselen [450]. In the second mechanism, it is thought that 
ebselen reacts with two GSH molecules, via a selenosulfide, to produce the selenol, 
which can then be oxidised to form the selenenic acid. The selenenic acid can 
eliminate water to reform ebselen, or react directly with GSH to form the 
selenosulfide [448, 453, 454]. 
 
Figure 1.9– Catalytic cycles of ebselen – adapted from [454] 
Numerous studies have looked at derivatives of ebselen in order to try to 
improve the efficacy of the GPx mimetic cycle [440-442]. Substitution of the phenyl 
group bound to the N demonstrated that for ideal GPx mimetic activity, the group 
bound needed to have a balance between promoting Se…N interaction to stabilise 
the selenol, without making the Se-N bond too strong reducing the rate at which 
oxidants could react with the selenium centre [440, 441]. Addition of amide groups 
to the benzyl ring in the position next to where Se is bound could increase the GPx 
mimetic activity via Se...O interactions [442].  
Derivatives of ebselen have also been designed as multifunctional drugs [455, 
456]. Substitution of methoxy groups to the selenazolone ring, and a benzyl 
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muscle disease,
165
 a degeneration of muscle fibre in livestock, Keshan disease, a wasting 
and enlargement of the heart tissue, Kaschin-Beck disease, a disabling joint disorder and 
Kwashiorkor, a protein malnutrition disorder.
166
 
 
As a consequence of discovering the importance of selenoproteins, much research has 
been directed towards the development of organic sele ides as GPx and catalase 
mimetics. The benzisoselenazolone ebselen 161 is the most well known and researched of 
these. Ebselen is an anti-inflammatory compound that has been shown to catalyze the 
same reactions as GPx; it has also been shown to have very low toxicity due to the 
selenium not being bioavailable.
167
 Depending on the ROS scavenged ebselen has been 
shown to possess two different in vivo catalytic cycles.  
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Scheme 3.2 The catalytic cycles of ebselen 161. 
 
For the ROS peroxynitrite for example, the selenide 161 is simply oxidized to the 
selenoxide 162, before being reduced by two equivalents of glutathione (GSH) to reform 
the active compound 161. For ROS such as hydrogen peroxide the mechanism is more 
complex. In this case ebselen 161 is thought to react with two equivalents of GSH to give 
the selenol 164 via the selenosulfide 163. The selenol 164 then reacts with peroxide to 
give a seleninic acid, which eliminates water to reform ebselen (Scheme 3.2).
143a
 
 
Other examples of selenium-containing GPx mimetics inclu e the water-soluble amino 
acid selenomethionine 165 and the synthetic phenylaminoethyl selenide 167. Both 
Ebselen 
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piperidine structure instead of the phenyl group maintains the GPx mimetic activity 
of ebselen, though allows for additional cholinesterase inhibition [455]. Similarly, 
substitution of the phenyl group an alkyl chain linked tacrine demonstrated dual 
function as a cholinesterase inhibitor and GPx mimetic [456]. This dual function as 
antioxidant and cholinesterase inhibitor may be beneficial in Alzheimers disease 
where both oxidative stress and cholinesterase activity can contribute to disease 
[455, 456].  
 Selenomethionine 
Selenomethione (SeMet) is a selenoether analogous to Met, where a Se atom 
replaces the sulfur. It is capable of reacting with the MPO-derived oxidants HOCl and 
HOBr with second order rate constants of 3.2 x 108 and 1.4 x 107 M-1 s-1 respectively 
[90]. The rate constants for these reactions are approximately 10 times greater than 
those reported for Met and similar to those reported for GSH [90]. HOSCN is also 
capable of reacting with SeMet with a rate constant of 2.8 x 103 M-1 s-1 [98], whereas 
it is unreactive towards Met [92].  
SeMet has demonstrated rapid reactivity with numerous other one- and two-
electron oxidants. SeMet reacts with hydroxyl radicals with a rate constant of 1.4 x 
1010 M-1 s-1 [457], which is comparable to reaction rates of Met [458] and thiols such 
as Cys [459] and GSH [460], with these sulfur species reacting with rate constants in 
the range of 1.4 x 1010 – 4 x 1010 M-1 s-1. SeMet is capable of reacting with ONOOH, 
with a rate constants of 2.4 x 103 M-1 s-1 [461]. The rate constants for reactions of 
SeMet with oxidants are some of the fastest reported for these oxidants in vivo and 
suggest SeMet would be a competitive target. As such, SeMet is able to protect 
dihydrorhodamine [462] and super-coiled plasmid DNA [463] from ONOOH 
mediated oxidation.  
SeMet has been shown to form selenomethionine selenoxide (SeMetO) upon 
reaction with H2O2 [464], ONOOH [465, 466] and by the enzymatic action of flavin 
containing monooxygenases [464]. This is analogous to the formation of MetSO 
upon oxidation of Met. One-electron oxidation of SeMet (in the presence of O2) also 
yields SeMetO via the radical cation SeMet+ [457], however, MetSO is only a minor 
product under these conditions, with other radicals forming higher abundance 
products [458, 467-469]. SeMet+, and the analogous species Met+, are stabilised by 
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a 3-electron bond between the Se or S and the N or O of the amino acid moiety, or 
interaction with the Se or S of a nearby parent compound [457, 470, 471]. SeMet+ 
and Met+ can then react with O2 to form the corresponding SeMetO or MetSO [457, 
472]. The higher yield of SeMetO compared to SeMetO is attributed to the increased 
stability observed for SeMet+, which has a lifetime 300 times greater than that 
observed for Met+[457, 470, 471]. The increased stability is primarily thought to be 
due to the presence of Se as opposed to S, though pH dependent effects are also 
observed [457].  
SeMetO can be reduced to reform SeMet in the presence GSH (Figure 1.10) [465, 
473]. Cys, ascorbate and methimazole can also achieve the reduction of SeMetO to 
SeMet [445]. Antioxidant enzymes such as Trx are also capable of reducing SeMetO 
[474]. It has been shown that the protective effects of SeMet, as well as other 
selenium-containing antioxidants, can be significantly increased in the presence of 
GSH [465]. 
 
Figure 1.10 – Catalytic cycle of selenomethionine – adapted from [444] 
SeMet can be non-selectively incorporated into proteins in place of Met residues 
[475]. In a cell-free synthesis system in the absence of Met in the cell culture media, 
95% of Met residues were replaced with SeMet in the human c-Ha-Ras protein 
[475]. However, under normal conditions, SeMet incorporation does not occur to 
this extent. The substitution of Met for SeMet can affect protein structure and 
function, with SeMet substituted amyloid proteins showing decreased ability to 
form fibrils and lowered toxicity [476]. However, it is unclear whether this is due to 
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an antioxidant effect provided by SeMet incorporation or by some other means 
[476].  
 Selenols 
Selenols are compounds which contain the functional group R-Se-H. The 
reactions of selenols are difficult to study due to their rapid reaction with 
atmospheric oxygen and subsequent diselenide formation. As such, most 
experiments discussed here were performed under N2 to minimise the contribution 
of auto-oxidation, even though this does not necessarily reflect in vivo conditions. 
The rates of reaction between selenols and other MPO-derived oxidants have not 
yet been determined, though it would be expected that they would be faster than for 
GSH which reacts with HOCl and HOBr with second order rate constants of ~108 and 
~107 M-1 s-1 respectively [90]. Rate constants for the reaction of HOSCN with Sec and 
derivatives (Sec-methyl ester, selenocystamine and 3-selenopropionic acid) were 
determined to be in the range of 1.2 – 5.8 x 106 M-1 s-1 [98]. These rate constants are 
at least 10-fold greater than those reported for the corresponding thiol compounds 
(k = 7.7 x 104 – 1.6 x 105 M-1 s-1) [92]. Rate constants for the reaction between HOSCN 
and selenium substituted GSH (GSeH) and the peptide Gly-Sec-Gly were determined 
to be 1.7 x 106 M-1 s-1, compared to 2.5 x 104 M-1 s-1 for GSH [98].  
GPx contains a Sec residue at the active site, which is capable of reacting with 
oxidants including H2O2 [346], ONOOH [477, 478] and HOSCN [98, 348]. The rate 
constant for these reactions have been shown to be in the range 105 – 107 M-1 s-1 [98, 
477]. These values were higher than calculated for free selenocysteine with H2O2, 
with this attributed to hydrogen bonding interactions between the GPx protein 
structure and H2O2 [479].  
The reaction of selenols with 2-electron oxidants is proposed to initially result 
in the formation of a selenenic acid, analogous to thiol oxidation. These selenenic 
acid intermediates then rapidly react with selenols or thiols to result in diselenide 
or mixed disulfide-selenide species [480, 481]. Selenenic acid species have not been 
reported for low molecular mass species in aqueous solution, though they have been 
described in organic solvents [482]. A selenenic acid intermediate formed at the GPx 
active site after oxidation has been trapped using dimedone [370]. It has been 
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proposed that the protein structure stabilises this selenenic acid, which 
demonstrated stability in the presence of both oxidising and reducing agents [370].  
Sec residues also react rapidly with one-electron oxidants. Sec and GSeH react 
with the phenoxyl radical formed on N-acetyl-Tyr-amide with rate constants of 8 x 
108 and 5 x 108 M-1 s-1 [483]. The rate constant for this oxidation of Sec is ~3 orders 
of magnitude greater than that reported for Cys (k = 6 x 105 M-1 s-1) [483]. Sec and 
GSeH also reacted with insulin bound Tyr radicals with rate constants of 1.6 x 108 
and 4 x 106 M-1 s-1 [483]. The lower rate of reaction of GSeH was attributed to steric 
considerations due to its increased size, though it still reacted significantly faster 
than GSH (k = 1 x 104 M-1 s-1) [483]. 
One-electron oxidation of Sec residues results in the formation of selenyl 
radicals, analogous to thiyl radicals. However, selenyl radicals have a lower 
reduction potential than thiyl radicals [484]. Thiyl radicals quickly abstract 
hydrogen from nearby carbon centres, propagating radical damage [480, 485]. 
Selenyl radicals are more stable and are less likely to undergo hydrogen abstraction, 
and primarily undergo radical recombination reactions, preventing the propagation 
of damage [480]. The increased stability of selenyl radicals is proposed to be 
protective and may partially explain the use of Sec residues in enzymes such as GPx 
as opposed to Cys [480]. 
 Other seleno compounds 
Novel compounds that incorporate selenium in a cyclic carbohydrate structure 
also show potential as MPO-derived oxidant scavengers [439]. 1,5-Anhydro-5-
seleno-L-gulitol (SeGul) has been shown to have a second order rate constant for 
reaction with HOCl of ~ 107 M-1s-1 [439]. A similar compound, 1,4-anhydro-4-
seleno-D-talitol (SeTal) also shows promise as an MPO-derived oxidant scavenger, 
reacting with HOCl, HOBr and HOSCN with rate constants of 1 x 108, 1.5 x 107 and ~ 
1 x 102 M-1 s-1 respectively [486]. Consistent with other selenium species, these 
selenium species react faster than their sulfur analogues [90, 486]. These cyclic 
selenides have been shown to protect human serum albumin from oxidative damage 
induced by HOCl [439, 486]. A related cyclic selenide, trans-3,4-
dihydroxyselenolane, exhibits GPx like activity, being oxidised by H2O2 followed by 
reduction by thiols groups such as GSH [487].  
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Selenoethers with the general structure of Se(CH2CH2X)2, where X is either OH, 
CO2- or NH3+, have GPx mimetic properties, catalysing the reaction between H2O2 and 
GSH [443]. They also react very rapidly with one-electron oxidants such as the 
model peroxyl radical CCl3O2 (k = 1 x 108 – 4.2 x 108 M-1 s-1) [443]. Pyrazole 
conjugated selenoethers also demonstrate significant radical scavenging ability, 
reacting with HO and CCl3O2 with rate constants of 1.4 x 1010 M-1 s-1 and 7.8 x 108 
M-1 s-1 respectively [488]. 
Diselenides also react rapidly with radicals, with selenocystamine reacting with 
HO with a rate constant of 8.1 x 109 M-1 s-1 [489] and (SeCH2CH2COOH)2 reacting 
with CCl3O2 with a  rate constant of 2.7 x 108 M-1 s-1 [490].  Direct reactions between 
diselenides and two-electron oxidants have not been studied extensively. However, 
some have demonstrated GPx activity, with these reacting catalytically with H2O2 
and ONOOH in the presence of GSH or enzymatic reduction systems [491, 492]. 
Selenocystine is reduced by GSH or Trx forming the selenol, which then reacts 
rapidly with oxidants to reform the diselenide, resulting in catalytic scavenging 
[491, 492]. A novel diselenide nicotinamide derivative, and GSeSeG (selenium 
substituted GSSG) have also demonstrated this GPx mimetic ability in the presence 
of GSH [493]. Ebselen is also capable of reacting in this manner, though it is the Se-
N bond that is reduced by GSH and Trx, as opposed to a diselenide bond [448].  
 Endogenous selenium levels and selenium supplementation 
 Dietary selenium and the risk of disease 
In the light of the above data, there is considerable interest in the biological 
activity of selenium and optimal dietary selenium levels. Selenium is an essential 
micronutrient, typically found in human plasma at concentrations of 70 – 140 µg L-
1 with a recommended daily intake of 55 – 70 µg per day [494]. Deficiency in 
selenium intake (< 20 µg per day) is known to have detrimental health 
consequences, with low selenium levels correlating with numerous diseases. 
Selenium levels have been shown to inversely correlate with instances of cancer, 
with incidences of prostrate [495, 496], bladder, lung [497] and laryngeal cancers 
[497] being reduced with higher levels of plasma selenium. Low selenium levels 
correlate with increased markers of oxidative stress in the plasma of sepsis patients 
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[498].  Selenium levels in plasma have been shown to correlate inversely with 
instances of coronary artery disease, myocardial infarction and death from 
cardiovascular disease [499, 500]. Furthermore, supplementation of selenium in 
patients with low selenium levels reduced plasma lipid levels [501]. In contrast, 
where selenium levels were much higher (with a mean of 125.6 ng mL-1), no 
correlation was observed between selenium levels and cardiovascular disease risk 
factors [502]. Furthermore, high selenium levels were correlated with elevated lipid 
levels [503] and hypertension [504], which are both risk factors for cardiovascular 
disease. These data suggest that selenium supplementation may only be effective in 
patients where base levels of selenium are low.  
The observation that selenium supplementation may only be effective in low-
baseline selenium level patients is backed up by observations from the NPC [505] 
and SELECT [506] trials. Both these trials aimed to reduce incidence of cancer by 
supplementation of selenium, and in the SELECT trial Vitamin E was also 
supplemented. The NPC trial demonstrated that patients with lower (though 
nutritionally sufficient) selenium levels (< 123 ng mL-1) showed a decrease in lung 
and prostate cancer incidences [496, 507]. This effect was not observed in the 
SELECT trial, though the mean baseline selenium levels were much higher in this 
study (135 in SELECT vs 114 in NPC) [505, 506].  
 Actions of selenium in biological systems 
While selenium supplementation may not demonstrate efficacy in preventing 
incidence of disease states in people with adequate selenium intake, many studies 
have shown a therapeutic potential of Se compounds in disease models. Selenium 
has been proposed to exert its effects in 3 ways including induction of reactive 
oxygen species (ROS) in cancer cells, upregulation of antioxidant enzymes in the 
selenoproteome and by direct scavenging of oxidants.  
Treatment with sodium selenite can induce the formation of ROS in a number of 
different cell types [508-514]. Selenodiglutathione [514] and selenocystamine [515, 
516], which readily react with thiols such as GSH to produce selenolates are also 
capable of producing ROS [514]. O2  production is thought to be the cause of the 
observed selenium-induced apoptosis, with SOD overexpression inhibiting this 
apoptosis [517]. Methylated selenium species such as methylselenocysteine 
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(MeSeCys) and SeMet are much less toxic, though also have demonstrated capacity 
to induce ROS formation [513, 518, 519], and this is attributed to the formation of 
methylselenolate after metabolism of MeSeCys and SeMet by methioninases [513]. 
Cancer cells are believed to be much more susceptible to selenium induced ROS 
formation than normal cells; this has been demonstrated using selenite and 
selenocystine in patient matched pairs of cancerous and normal prostate cells [520], 
fibroblasts [515] and malignant and benign mesothelioma cells [521]. In each case, 
the cancerous cells were more susceptible to selenium supplementation and this has 
been attributed to a higher level of oxidative stress already occurring in the cancer 
cells, which is then exacerbated in the presence of selenium. Furthermore, inhibition 
of TrxR with auranofin and ethaselen made cancer cells more sensitive to selenium-
induced apoptosis [522, 523], further implicating increased levels of ROS as the 
cause of apoptosis. 
Selenium supplementation results in an upregulation of selenium containing 
enzymes, including GPx, TrxR and other selenoproteins [524-526]. Selenite 
supplementation enhanced GPx expression in rat cardiomyocytes, human lung 
cancer cells [527], and HCAECs [528]. SeMet was also capable of increasing GPx 
expression in the rat cardiomyocytes [529] as well as human trophoblasts [530, 
531], but not HCAECs [532]. This increase in GPx activity protected cells from 
peroxide induced oxidative damage and reduced lipid peroxidation in a hypoxia-
reoxygenation model [529]. Upregulation of selenoenymes by supplementation of 
trophoblasts with SeMet decreased oxidative stress induced by addition of H2O2, as 
well as mitochondrial oxidative stress induced by addition of antimycin [530, 531]. 
Rats given selenite, selenocystine or SeMet in their diet also demonstrated an 
increase in GPx activity in blood and tissue samples [524]. Selenite supplementation 
in rats resulted in a small increase in GPx activity, which improved cardiac outcomes 
in an ischaemia reperfusion model [525, 526].  Low selenium levels have been 
shown to correlate with incomplete GPx expression and an increased risk of 
myocardial infarction [499, 533, 534], and it has been suggested that selenium 
supplementation could reduce this risk [466]. Patients supplemented with selenite 
demonstrated an increased GPx expression when their baseline selenium levels 
were less than 90 ng mL-1 [535], which is postulated to be protective in the context 
of heart disease. 
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TrxR can also be upregulated by supplementation with selenium compounds. 
Selenite supplementation increased TrxR expression in HUVECs, and led to 
increased viability on peroxide exposure [528]. Selenite supplementation in rats 
also demonstrated an increase in TrxR level at low doses [536]. However, at higher 
doses, whilst there was an initial increase in TrxR levels, a subsequent decline in 
levels was observed [525, 526]. MeSeCys and methylselenic acid supplementation 
demonstrated no effects on TrxR levels in the same study [537].  
 Selenium supplementation in disease 
As discussed above, numerous selenium compounds exhibit GPx mimetic 
activity, catalysing the reaction of H2O2 and other oxidants with GSH. This direct 
scavenging of oxidants appears to have multiple beneficial effects in vitro and in vivo, 
particularly when GPx is absent or downregulated. The presence of (additional) 
SeMet, MeSeCys and selenocystamine can protect erythrocytes from lipid 
peroxidation and hemolysis [538]. SeMet also protects J774A.1 murine macrophage 
cells from peroxide damage [474].  The Trx system can also increase the efficacy of 
SeMet [474], and has also been shown to enhance the scavenging potential of 
selenocystamine, ebselen and diselenoglutathione [491, 492].  
Selenium containing compounds have demonstrated particular efficacy in 
models of atherosclerosis. A GPx/ApoE double knock-out mouse model has been 
developed, and these animals quickly develop atherosclerotic lesions [539, 540]. 
Supplementation with ebselen decreases lesion size, and decreases inflammation 
and oxidative stress, and is postulated to achieve this by boosting antioxidant 
defences [539-541]. Ebselen also prevented diabetes related kidney and retina 
nephropathy observed in this model [539, 542, 543]. Diphenyldiselenide has been 
shown to reduce lesion size in an LDL receptor knockout model of atherosclerosis 
[544]. Selenocystamine-coated stents have also been reported to have improved 
bio-compatibility compared to bare metal stents, reducing platelet aggregation, 
smooth muscle proliferation, which is thought to be due to antioxidant activity of 
the selenocystamine [545]. 
While selenium supplementation does not appear to reduce the incidence of 
disease if patients are not selenium deficient, selenium containing compounds have 
demonstrated efficacy in models of disease where oxidative stress plays a major role 
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in the pathogenesis, such as atherosclerosis.  Furthermore, research has 
demonstrated that toxicity of selenium is mostly related to selenolate metabolites 
[519], and toxicity can be reduced by supplementation with different forms of 
selenium [546]. Therefore, there is potential for the development of selenium 
containing compounds that may act as antioxidants to reduce or prevent disease.  
 Hypothesis and aims 
Overall, it is clear from the data above that MPO produces strong oxidants that 
are designed to kill invading pathogens. However, excessive or misplaced 
production of these oxidants has been associated with the development of 
numerous diseases, including atherosclerosis. As sulfur and selenium compounds, 
and enzymes containing these residues show great potential as catalytic 
antioxidants due to their fast reaction kinetics it is proposed that they may be able 
to attenuate damage caused by MPO-derived oxidants, such as HOCl and N-
chloramines. While the rate constants for the reaction of selenium compounds with 
HOCl and other hypohalous acids have been determined recently [90, 98], the 
products of these reactions have not been fully characterised. Furthermore, the rate 
constants for the reaction with N-chloramines are yet to be determined. 
The ability for facile recycling of oxidised selenium compounds suggests a 
potential for a catalytic reduction of MPO-derived oxidants. However, the 
mechanisms and rate constants for the reduction of selenoxides by thiols have not 
been determined. Furthermore, antioxidant enzymes with reactive Cys and Sec 
residues may also be capable of reducing HOCl, N-chloramines and selenoxides, 
though this has yet to be examined. 
The hypothesis for this project is therefore that thiol and seleno compounds and 
related enzymes may modulate oxidative damage induced by myeloperoxidase and 
related peroxidases during inflammation, by acting as catalytic agents and as such 
will be able to modulate the development of disease.  
The proposed studies will address the following specific aims: 
1. Examination of the kinetics and mechanisms of reaction of HOCl and related 
species with thiol and seleno compounds. 
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2. Identification of potential repair / recycling mechanism(s) of low-
molecular-mass compounds. 
3. Determining whether thiol and seleno-dependent enzymes also behave as 
catalytic protective systems. 
4. Examination of the efficacy of these compounds and enzymes in protecting 
cells from oxidant damage. 
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2 Materials and Methods 
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 General Information 
This Chapter contains details of the general Materials and Methods used 
throughout this Thesis. 
Nanopure water, referred to as H2O, is water filtered through a four-stage Milli Q 
system (Millipore-Water, Lane Cove, NSW, Australia). Solutions were prepared in pH 
7.4 0.1 M sodium phosphate buffer (preparation detailed in Section 2.3.1.1) unless 
otherwise stated. The pH of solutions was determined using a Radiometer Analytical 
PHM220 pH meter with pHC2401 probe (Radiometer Analytical, Villeurbanne Cedex, 
France), calibrated with pH 4, 7 and 10 standards (Radiometer Analytical). 
All centrifugation was performed on an Eppendorf Refrigerated Micro Centrifuge 
(Model 5215R, Eppendorf, Hamburg, Germany), unless otherwise stated. 
 Materials 
Reagent Supplier 
Acetic acid, glacial Merck Pty Ltd (Vic, Australia) 
N-α-acetyl-L-histidine (His) Sigma-Aldrich (Castle Hill, NSW, Australia) 
N-α-acetyl-L-lysine (Lys) Sigma-Aldrich (Castle Hill, NSW, Australia) 
N-acetylselenomethionine (NASM) Gift from Dr. Lara Malins and Prof. Richard 
Payne (School of Chemistry, University of 
Sydney, Sydney) 
Acetone Merck Pty Ltd (Vic, Australia) 
Acetonitrile Merck Pty Ltd (Vic, Australia) 
Allophycocyanin-conjugated annexin 
V 
BD Biosciences, Sydney, NSW, Australia 
1,4-anhydro-4-seleno-L-talitol 
(SeTal) 
Gift from Prof. Carl Schiesser (School of 
Chemistry and Bio21 Molecular Science 
and Biotechnology Institute, University of 
Melbourne) 
Auranofin Sigma-Aldrich (Castle Hill, NSW, Australia 
Bovine serum albumin, essentially 
fatty acid free (BSA) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Chelex 100 resin BioRad Laboratories, Inc. (Hercules, CS, 
USA) 
CompleteMini protease inhibitor 
cocktail tablet 
Roche (Mannheim, Germany) 
L-Cysteine (Cys) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Deuterium oxide (D2O) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Dimethylformamide (DMF) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Dimethylsulfone Sigma-Aldrich (Castle Hill, NSW, Australia) 
Dimethylsulfoxide (DMSO) Sigma-Aldrich (Castle Hill, NSW, Australia) 
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Reagent Supplier 
Disodium hydrogen orthophosphate 
dodecahydrate 
Ajax FineChem, Ltd. (Sydney, NSW, 
Australia) 
5,5’-dithiobis(2-nitrobenzoic acid) 
(DTNB) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Dithiothreitol (DTT) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Dulbecco’s modiﬁed Eagle’s medium 
(DMEM) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Ethidium bromide (EtBr) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich (Castle Hill, NSW, Australia 
N-ethylmaleimide (NEM) Sigma Chemical Co. (Castle Hill, NSW, 
Australia) 
Fetal calf serum (FCS) Invitrogen (Eugene, OR, USA) 
Formaldehyde, 37 % Biotechnology 
Grade 
Amresco (Solon, OH, USA) 
Formic acid, > 96% ACS reagent Sigma-Aldrich (Castle Hill, NSW, Australia) 
L-Glutamine Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glutathione (GSH) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glutathione peroxidase, from bovine 
erythrocytes (GPx) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glutathione reductase from Baker’s 
yeast (GR) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glutathione, oxidised approx 98% 
(GSSG) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glyceraldehyde 3-phosphate (GAP) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Glycine (Gly) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Hank’s balanced buffer solution 
(HBSS) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Hydrogen peroxide, 30% (w/w) 
(H2O2) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
5-Iodoacetamidofluorescein (IAF) Invitrogen (Mount Waverley, VIC, 
Australia) 
2-mercaptoethanol Sigma-Aldrich (Castle Hill, NSW, Australia 
Methane sulfonic acid (MSA), 4 M 
containing 0.2 % w/v tryptamine 
Sigma-Aldrich (Castle Hill, NSW, Australia 
Methanol Merck Pty Ltd (Vic, Australia) 
L-Methionine (Met) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Methionine Sulfoxide Reductase A 
(Human Recombinant) (MSRA) 
ProSpec Protein Specialists (East 
Brunswick, NJ, USA) 
Methionine Sulfoxide Reductase B2 
(Human Recombinant) (MSRB2) 
ProSpec Protein Specialists (East 
Brunswick, NJ, USA) 
Methylselenocysteine hydrochloride 
(MeSeCys) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Myeloperoxidase (MPO) Planta Natural Products (Wein, Austria) 
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Reagent Supplier 
Nicotinamide adenine dinucleotide 
(NADH) 
Roche (Mannheim, Germany) 
Nicotinamide adenine dinucleotide 
(oxidised) (NAD+) 
Roche (Mannheim, Germany) 
Nicotinamide adenine dinucleotide 
phosphate (NADPH) 
Roche (Mannheim, Germany) 
Nitrogen Coregas (Yennora, NSW, Australia) 
Phorbol 12-myristrate 13-acetate 
(PMA) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Phthaldialdehyde reagent 
(Incomplete) (OPA) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
PolyMorph Prep Axis-Shield PoC AS (Oslo, Norway) 
Propidium iodide (PI) BD Biosciences, Sydney, NSW, Australia 
Red cell hypotonic lysis buffer Sigma-Aldrich (Castle Hill, NSW, Australia) 
Seleno-bispropionic acid (SeProp) Gift from Prof. K. Indira Priyadarsini 
(Radiation and Photochemistry Division, 
Bhabha Atomic Research Centre, Bombay, 
India) 
Selenocystamine dihydrochloride 
(SeCysta) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Selenomethionine (SeMet) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Silver nitrate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium acetate trihydrate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium carbonate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium chloride (NaCl) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium deoxycholate Sigma-Aldrich (Castle Hill, NSW, Australia 
Sodium dihydrogen orthophosphate 
monohydrate 
Merck Pty Ltd (Vic, Australia) 
Sodium hydroxide (NaOH) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium hypochlorite, 12.5 % w/v 
(HOCl) 
Ajax FineChem, Ltd. (Sydney, NSW, 
Australia) 
Sodium iodide Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium pyrophosphate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium pyruvate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Sodium thiosulfate Sigma-Aldrich (Castle Hill, NSW, Australia) 
Taurine (Tau) Sigma-Aldrich (Castle Hill, NSW, Australia) 
3,3’,5,5’-tetramethylbenzidine (TMB) Sigma-Aldrich (Castle Hill, NSW, Australia) 
ThioGlo-1 reagent Berry and Associates (Dexter, MI, USA) 
Thioredoxin 1, human (Trx) IMCO (Stockholm, Sweden) 
Thioredoxin reductase, rat (TrxR) IMCO (Stockholm, Sweden) 
Trichloroacetic acid (TCA) Sigma-Aldrich (Castle Hill, NSW, Australia) 
Trifluoroacetic acid (sequencing 
grade) (TFA) 
Sigma-Aldrich (Castle Hill, NSW, Australia) 
Triton X-100 Sigma-Aldrich (Castle Hill, NSW, Australia) 
Trypan blue Sigma-Aldrich (Castle Hill, NSW, Australia) 
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 Methods 
 Preparation of buffers 
2.3.1.1 0.1 M Phosphate buffer pH 7.4 
A 0.1 M sodium phosphate pH 7.4 buffer was prepared as previously described 
[547]. Solutions of 0.1 M monobasic orthophosphate and 0.1 M dibasic orthophosphate 
were prepared in H2O. Trace transition metal ions were removed by the addition of 
washed Chelex resin, followed by stirring for 1 h. The Chelex resin was removed by 
vacuum filtration. The monobasic solution was then added to the dibasic solution while 
stirring, until the pH was 7.4. 
 Preparation of oxidant species 
2.3.2.1 Reagent HOCl 
HOCl was diluted from a stock solution of sodium hypochlorite (17 % (w/v)) to 10 
mM in H2O, and then further diluted to the desired concentration in phosphate buffer. 
The concentration of the stock sodium hypochlorite solution was assessed by optical 
absorbance at 292 nm at pH 11, achieved by dilution into 0.1 M NaOH, using the 
absorbance co-efficient of OCl-,  = 350 M-1cm-1 [82]. 
2.3.2.2 Reagent H2O2 
H2O2 was diluted from a stock solution (30 % (w/w)) to 10 mM in water. H2O2 stock 
concentration was determined by optical absorbance at 240 nm of diluted stock 
samples in water using the absorbance co-efficient of H2O2,  = 43.6 M-1cm-1 [548]. 
2.3.2.3 Amino acid N-chloramine formation 
N-Chloramines were formed on reaction of HOCl with amine groups, including free 
amino acids, side chains of peptides (e.g. Lys, His) and the N-terminus of proteins [53, 
58].  
𝑅𝑁𝐻2 +𝐻𝑂𝐶𝑙 → 𝑅𝑁𝐻𝐶𝑙 + 𝐻2𝑂 Reaction 2.1  
A series of model N-chloramines was prepared by reaction of Tau, Gly and N-α-
acetyllysine (10 mM) by mixing with HOCl (2 mM), which yielded approximately 2 mM 
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N-chloramine solution. Final N-chloramine concentrations were determined using the 
TNB method (Section 2.3.3.1) prior to use.  
2.3.2.4 Protein N-chloramine formation 
Bovine serum albumin (BSA; 1 mg mL-1, 15 µM) was incubated with equal volumes 
of HOCl solution (0.5 mM) for 5 min. Protein N-chloramine concentrations were 
determined by the TNB method (Section 2.3.3.1) and the solution diluted to give the 
desired concentration of N-chloramines. 
2.3.2.5 Myeloperoxidase system 
MPO catalyses the reaction of H2O2 and (pseudo)-halides, Cl-, Br- and SCN-, to form 
the hypohalous acids, HOCl, HOBr and HOSCN respectively (e.g. Reaction 2.2) [24]. MPO 
(2 µM) was incubated with Cl- (100 mM) and Tau (10 mM) at 37°C for 10 min before 
addition of H2O2 (50 µM) to initiate HOCl production. Samples were further incubated 
for 30 min, then the concentration of TauCl (from Reaction 2.3) was determined using 
TMB (Section 2.3.3.2). Under these conditions approximately 50 µM HOCl, and 
subsequently TauCl, was formed. Tau was included as it traps HOCl after production as 
TauCl, a longer-lived oxidant, making it easier to detect [549]. Tau is physiologically 
relevant as neutrophils contain up 20 - 50 mM Tau [550], which is released upon 
activation and quickly chlorinated [551, 552].  
𝐻2𝑂2 + 𝐶𝑙
− + 𝐻+  
𝑀𝑃𝑂
→   𝐻𝑂𝐶𝑙 + 𝐻2𝑂 
 
Reaction 2.2  
𝑇𝑎𝑢𝑁𝐻2 +𝐻𝑂𝐶𝑙 → 𝑇𝑎𝑢𝑁𝐻𝐶𝑙 + 𝐻2𝑂   Reaction 2.3 
2.3.2.6 Isolation of neutrophils and formation of neutrophil-derived oxidants 
Neutrophils were isolated immediately after collection of blood into EDTA-coated 
tubes (10.0 mL BD Vacutainer, BD biosciences, Sydney, NSW, Australia) from healthy 
volunteers with informed consent and local ethical approval (Sydney South West Area 
Health Service, Protocols X09-0013 and X-12-0375) in accordance with the Declaration 
of Helsinki (2000) of the World Medical Association, as described previously [553]. 
Neutrophils were isolated using a Polymorphprep density-gradient method. 5 mL of 
whole blood was layered over 5 mL Polymorphprep and centrifuged at 510 g at 21 °C 
for 35 min with maximum acceleration and the deceleration set to 0 to ensure slow 
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braking in an Allegra X-15R Centrifuge (Beckman Coulter). This separated out the 
plasma, mononuclear cells, neutrophils and the red blood cells (Figure 2.1). The plasma 
and mononuclear cell layers were removed, and the neutrophils collected and 
transferred into clean Falcon tubes. 
 
Figure 2.1 – Separation of layers observed after whole blood is layered onto 
Polymorphprep and centrifuged. 
Osmolality was restored by addition of 1.5 mL saline solution (0.45% NaCl). The 
volume was increased 12 mL with saline solution (0.9% NaCl), and mixed by inversion 
to wash neutrophils. Neutrophils were pelleted by centrifugation at 400 g for 10 min 
at 21 °C, with maximum acceleration and deceleration. The majority of supernatant 
was removed, leaving 1 mL in the tube. The pellets were resuspended in 2 mL red cell 
lysis buffer (Product number: R7757, Sigma-Aldrich, Castle Hill, NSW, Australia) and 
incubated for 15 min in the dark to remove any residual red blood cell contamination.  
The volume in tubes was then 12 mL with HBSS, and cells were re-pelleted by 
centrifugation at 400 g for 10 min at 21 °C. If any red cells remained in the pellet, as 
judged by its colour, the red cell lysis step was repeated. The supernatant was then 
removed and the neutrophils washed by resuspension in 12 mL HBSS and mixed by 
inversion. The neutrophils were then pelleted by centrifugation at 400 g for 10 min, 
the supernatant was removed and neutrophils resuspended in 2 mL HBSS for counting. 
Cell number and viability was assessed by trypan blue dye exclusion. The 
neutrophil suspension (10 µL) was mixed with equal volumes of trypan blue dye and 
mixed by aspiration. 10 µL of mixture was pipetted into a haemocytometer chamber 
and cells counted under a microscope. Cells that did not take up the dye were counted 
as viable. 
Neutrophils (2 x 106 cells mL-1) were incubated at 37 °C for 10 min, before addition 
of phorbol 12-myristate 13-acetate (PMA; 0.1 µg mL-1) to induce neutrophil activation. 
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The cells were then incubated for 30 min at 21 C with gentle agitation to ensure that 
the cells remained in suspension. Under these conditions, approximately 50 µM of 
reactive species were produced, as measured by the TMB assay (Section 2.3.3.2). 
 Assays 
2.3.3.1 TNB 
5-thio-2-nitrobenozic acid (TNB), a bright yellow thiol species, reacts with N-
chloramines (and other oxidants), to form the colourless disulfide 5,5’-thiobis(2-
nitrobenzoic acid) (DTNB) [554] (Reaction 2.4).  
2𝑅𝑆𝐻 + 𝑅𝑁𝐻𝐶𝑙 → 𝑅𝑆𝑆𝑅 + 𝑅𝑁𝐻3
+ + 𝐶𝑙−   Reaction 2.4  
The TNB reagent was prepared by alkaline hydrolysis of DTNB (2.5 mg) by NaOH 
in H2O (5 mL; 50 mM) and incubated in the dark for 5 min. This stock solution was then 
diluted 1 : 40 in phosphate buffer (0.1 M, pH 7.4), to give a yellow working solution 
with an absorbance at 412 nm of between 0.5 – 0.7 absorbance units. The working 
solution (950 µL) was mixed with oxidant solution (50 µL, 20 - 100 µM) and incubated 
in the dark for 15 min. The optical absorbance of the solution was measured at 412 nm, 
and the concentration of remaining TNB was determined using the extinction 
coefficient ε = 14150 cm-1 [555]. The concentration of the oxidant was determined by 
the difference between TNB concentration in control and oxidant treated samples, 
based on a 2 : 1 TNB to oxidant stoichiometric ratio. 
2.3.3.2 TMB 
N-chloramines and HOCl, in the presence of iodide ions (I-), rapidly react with the 
colourless 3,3’,5,5’-tetramethylbenzidine (TMB) to form a blue  oxidised product [549]. 
I- catalyses the oxidation of TMB via reaction with N-chloramines or HOCl to form 
hypoiodous acid (HOI), which is then the reactive species that oxidises TMB [549] 
(Reaction 2.5 – 2.7). 
𝑅𝑁𝐻𝐶𝑙 + 𝐻+ + 𝐼− → 𝑅𝑁𝐻2 + 𝐼𝐶𝑙 Reaction 2.5  
𝐼𝐶𝑙 + 𝐻2𝑂 → 𝐻𝑂𝐼 + 𝐻𝐶𝑙 Reaction 2.6  
𝐻𝑂𝐼 + 𝑅′𝐻2  → 𝑅
′ + 𝐼− + 𝐻+ + 𝐻2𝑂 Reaction 2.7 
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The developing reagent was prepared by dissolving 4.8 mg of 3,3’,5,5’-
tetramethylbenzidine (TMB; 20 mM) in dimethylformamide followed by the addition 
of sodium acetate buffer (9 mL, 0.44 M, pH 5.4) and sodium iodide solution (50 µL of 2 
mM). The developing reagent was prepared immediately prior to addition to the 
standards and samples to avoid any artifactual autoxidation of TMB.  
The TMB assay was used to determine oxidant concentration after sulfur and 
selenium compounds were used as scavengers of MPO-derived and neutrophil-derived 
oxidant species produced by systems described above. SeMet, SeTal and Met (0 – 50 
µM) were incubated with either the isolated MPO system or neutrophil system (final 
volume 50 µL). After 30 min, the remaining oxidant was quantified by addition of TMB 
developing reagent (50 µL) followed by a 5 min incubation period. The absorbance was 
measured at 645 nm on a Benchmark Plus microplate reader (BioRad). The oxidant 
concentration was assessed by comparison to a standard curve constructed from 
standards of TauCl (0 – 100 µM).  
2.3.3.3 ThioGlo-1 assay 
ThioGlo-1 is a malemide derived florescent dye used to determine thiol levels in 
biological samples [547]. The ThioGlo-1 reagent specifically reacts with free thiols of 
Cys residues forming a fluorescent product. ThioGlo reagent (2.6 mM) was dissolved 
in acetonitrile and stored in the dark at 4 °C before a working solution was prepared 
by dilution 1 : 100 in phosphate buffer (0.1 M, pH 7.4) immediately prior to use. ThioGlo 
working solution (50 µL) was added to sample or standard (50 µL; 0 – 5 µM thiol) in a 
96-well tissue culture plate and incubated for 10 min in the dark. Fluorescence was 
then measured at λex= 360 nm λem= 530 nm on an M2e plate reader (Molecular 
Devices). The thiol concentration was determined by comparison to a standard curve 
prepared using GSH (0 – 5 µM). 
2.3.3.4 Bicinchoninic acid (BCA) protein assay 
The BCA assay determines protein levels by measurement of the reduction of Cu2+ 
to Cu+ by peptide residues. Cu+ is then chelated by the bicinchoninic acid to form a 
complex that strongly absorbs at 562 nm [556]. Absorbance at 562 nm is proportional 
to protein content. A working solution was prepared by mixing Pierce BCA Protein 
Assay Solution A (Thermo Scientific, Rochford, IL, USA) with CuSO4 (4 % (w/v)) in a 50 
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: 1 ratio. Working solution (200 µL) was then added to protein samples (25 µL) and 
standards (25 µL; 0.1 – 1 mg mL-1) in a 96-well cell culture plate. Solutions were mixed 
by gentle shaking, followed by incubation at 60 °C for 10 min. The absorbance at 562 
nm was measured on an M2e plate reader (Molecular Devices), and protein 
concentration determined by comparison to a standard curve prepared using BSA. 
 Enzymatic reduction assays 
2.3.4.1 Glutathione reductase 
GSR reduces GSSG to GSH using NADPH as a reducing equivalent [557]. GSSG is 
formed when GSH is exposed to oxidants including N-chloramines and selenoxides 
[192, 445]. The rate of GSSG removal, by GSR can be determined by monitoring the 
concentration of NADPH in the presence of GSR and GSH (Reaction 2.8 – 2.9). 
𝑅𝑁𝐻𝐶𝑙 + 2𝐺𝑆𝐻 → 𝑅𝑁𝐻2 +  𝐺𝑆𝑆𝐺 + 𝐻
+ Reaction 2.8  
𝑁𝐴𝐷𝑃𝐻 + 𝐺𝑆𝑆𝐺
𝐺𝑆𝑅
→  𝑁𝐴𝐷𝑃+ + 2𝐺𝑆𝐻 Reaction 2.9  
Commercially available GSR comes in a solution containing DTT to stabilise the 
enzyme, which needs to be removed prior to assay as it can interfere by removing 
oxidants independently of GSR. DTT was removed from the stock solution by passing 
the GSR through a PD-10 column using phosphate buffer (0.1 M, pH 7.4) to elute the 
protein. The GSR concentration was then determined using the BCA assay (Section 
2.3.3.4).  
An Applied Photophysics SX.20MV stopped flow system was used to monitor the 
loss of NADPH upon addition of oxidants to the GSR system in the presence or absence 
of SeMet or SeTal. NADPH (500 µM), GSR (25 nM) and GSH (400 µM) was mixed in the 
stopped flow apparatus with SeMetO, SeTalO or N-chloramine (200 µM). N-Chloramine 
reduction experiments were also performed in the presence of SeMet or SeTal (20 or 
200 µM). The absorbance at 340 nm, corresponding to loss of NADPH, was monitored 
over 60 s. A linear slope was fitted to the initial fast decrease in absorbance, from 2 – 
12 seconds, where maximum enzymatic activity was observed.  
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2.3.4.2 Thioredoxin based systems 
TrxR is capable of reducing oxidants, including H2O2 [528] and HOSCN [348], and 
disulfides [390] using NADPH as a reducing equivalent. Trx reduces protein disulfides 
using TrxR and NADPH as the reducing system [390]. In turn Trx can also reduce 
enzymes including Msrs [417, 420], which reduce MetSO, and GPx [348], which reduces 
H2O2. As NADPH is the reductant used by all of these systems, the rate of enzymatic 
removal of oxidants can be assessed using the loss of NADPH determined by its optical 
absorbance at 340 nm. 
The ability of TrxR to reduce oxidants was assessed by incubating 700 µM NADPH 
and 25 nM TrxR before addition of 200 µM selenoxide or N-chloramine in the presence 
or absence of 1.5 µM Trx. N-Chloramine reduction experiments were performed in the 
presence and absence of SeMet or SeTal (20 or 200 µM).  This Trx system was also used 
to assess the ability of MsrA, MsrB2 and GPx to remove oxidants. In this case, MsrA (95 
nM), MsrB2 (0.25 µM) or GPx (1.5 µM) were incubated with NADPH (700 µM), TrxR 
(25 nM) and Trx (1.5 µM) prior to the addition of 200 µM oxidant, with N-chloramine 
experiments also performed in the presence or absence of SeMet or SeTal (20 or 200 
µM). The absorbance at 340 nm, reflecting the NADPH concentration, was measured 
every 30 s for 2 h on M2e plate reader (Molecular Devices). A straight line was fitted to 
a plot of time vs. [NADPH] to determine rate of NADPH consumption.  
2.3.4.3 Reduction of oxidants by cell lysates 
The enzymatic removal of oxidants was examined using cell lysates, for a more 
physiological representation of enzyme ratio and concentrations present in vivo. 
Auranofin, which binds to Sec residues to inhibit selenoproteins [558], was used as an 
inhibitor of TrxR to enable determination of TrxR’s contribution, as well as the 
contribution of downstream enzymes, on oxidant removal. 
J774A.1 cells (106 cells) were lysed in 3 mL ice-cold H2O and incubated on ice for 15 
min to maximise lysis. Protein levels in the lysates were determined by BCA assay 
(Section 2.3.3.4), with this adjusted to 1 mg protein mL-1. Lysate (50 µg protein) was 
incubated with NADPH (500 µM) in the presence or absence of auranofin (25 nM) for 
15 min, and then SeMetO, SeTalO, N-chloramine or insulin (200 µM) was then added 
and absorbance at 340 nm monitored for 2 h. N-Chloramine experiments were also 
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performed in the presence or absence of SeMet or SeTal (20 or 200 µM). The rate of 
NADPH consumption was determined by fitting a straight line to the resulting NADPH 
vs time plot. 
 HPLC methods 
Buffers were made as specified in each method, and then vacuum filtered using a 
hydrophilic polypropylene 0.2 µm membrane filter (Pall, MI, USA) before use. Samples 
were filtered through 0.2 µm NanoSep centrifugal devices (Pall, MI, USA) before being 
transfered to HPLC vials with 200 µL glass inserts. Samples were kept in the 
autosampler at 4 °C until injection onto the column. 
2.3.5.1 HPLC instrumentation 
A Shimadzu Nexera system, consisting of binary pumps (LC30AD), degasser (DGU-
20A5R), autosampler (SIL30AC) and column oven (CTO-20A), was used to perform 
HPLC experiments. UV-vis detection was performed with a photodiode array (SPD-
M20A). Fluorescence measurements were performed with a fluorescence detector 
(RF-20AXS). 
2.3.5.2 SeMet and SeMetO 
Separation of SeMet, SeMetO, GSH and GSSG was achieved by injection of 20 µl of 
each sample onto a Beckman Ultrasphere ODS column (5 µM , 4.6 x 250 mm), at 40 °C 
as previously described [464]. The mobile phase consisted of acetonitrile (1 % (v/v)) 
adjusted to pH 2.5 with trifluoroacetic acid (TFA) (TFA < 0.05% (v/v)). An isocratic 
elution method was employed with a flow rate of 1 ml min-1. SeMetO eluted at 3.2 min 
and SeMet eluted at 8.6 min, as determined by their UV absorbance.  A photodiode 
array (PDA) detector was used (Shimadzu SPD-M20A) and quantification of peak areas 
was performed at 220 nm. SeMetO standards were produced as described in Section 
2.3.7.1. 
2.3.5.3 SeTal and SeTalO 
Separation of SeTal and SeTalO was achieved by injecting 20 µL of sample onto a 
Zorbax carbohydrate column from Agilent, USA (5 µm, 4.6 x 150 mm) at 35 C with an 
isocratic elution using a flow rate of 1 mL min-1. SeTal and SeTalO were eluted using 
acetonitrile (75 % (v/v)) in H2O with TFA (0.005% (v/v)) for 8 min, followed by a 
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washing step whereby the H2O content was increased to 75% over 1 min, held for 3.5 
min, before decreasing back to 25% water over 1 min, and re-equilibration for 2.5 min. 
SeTal and SeTalO eluted at 2.7 min and 4.4 min respectively. SeTal and SeTalO were 
quantified by their UV absorbance at 220 nm using a PDA detector (Shimadzu SPD-
M20A). SeTalO standards were produced as described in Section 2.3.7.1. 
2.3.5.4 Selenoxides in the presence of NADPH 
The methods described above were unsuitable for separating selenoxides and 
selenoethers when NADPH was present in the samples, due to coelution of NADPH 
derived peaks with other peaks of interest. As such, a different HPLC method was 
developed as described below. 
20 µL samples from enzymatic reduction assays (Section 2.3.4) were injected onto 
an Agilent Zorbax 300SCX column (5 µm, 4.6 x 250 mm) at 30 °C. An isocratic elution 
was performed using a mobile phase of NaH2PO4 (0.01 M, pH 4.8) with a flow rate of 1 
mL min-1. SeMet eluted at 3.9 min, SeMetO eluted at 4.4 min, SeTal eluted at 3.4 min 
and SeTalO eluted at 3.7 min under these conditions. Samples were detected and 
quantified using their absorbance at 220 nm using a PDA detector (Shimadzu SPD-
M20A). 
2.3.5.5 Hydrolysis of protein using methane sulfonic acid (MSA) 
MSA hydrolysis was employed to digest proteins to their component amino acids, 
allowing investigation of oxidative changes to these residues [547]. The MSA method 
was chosen to digest the protein samples, as there is less destruction of MetSO and 
tryptophan products, unlike other methods such as HCl hydrolysis [547]. 
Protein samples (200 µL; 1 mg mL-1) contained in glass hydrolysis vials were 
delipidated then precipitated by addition of TCA (25 µL, 50% (w/v)) and deoxycholate 
(25 µL 0.3 % (w/v)) and incubated for 5 min on ice. Samples were pelleted by 
centrifugation at 7500 g at 4 °C for 10 min. Samples were washed twice with ice-cold 
acetone with the protein pelleted by centrifugation (as above) between washes. 
Acetone was removed and the samples were dried under a gentle stream of nitrogen. 
Samples were then resuspended in MSA (150 µL, 4 M) containing tryptamine (0.2 % 
(w/v)), and the hydrolysis vials placed in Pico-tag vessels. The Pico-tag vessels were 
evacuated using a vacuum pump and flushed with nitrogen three times, before a final 
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evacuation and incubation overnight in an oven at 110 °C. The samples were then 
allowed to cool to 21 °C before being neutralised with freshly prepared NaOH (150 µL; 
4 M) solution. Samples were filtered using 0.2 µm NanoSep centrifugal devices (Pall, 
MI, USA), centrifuged for 2 min at 9300 g, and 40 µL of each sample was transferred to 
a HPLC vial with insert for analysis. 
Standards were prepared by dilution from stock amino acid standards for protein 
hydrolysates (Product number A9781, Sigma Aldrich, St Louis, MI, USA) to 0 - 12.5 µM. 
MetSO (0 – 12.5 µM) was prepared in water and added to the mixed standard. 
Standards (40 µL) were transferred to HPLC vials and analysed. 
Samples were derivatized immediately before injection onto the column in the 
autosampler by the addition of 20 µL ortho-phthalaldehyde (OPA) (995 µL OPA 
reagent, 5 µL 2-mercaptoethanol) with 3 mixing cycles and a 1 min incubation, prior to 
injection of 6 µL of the final mixture onto a Shimadzu ShimPack XR ODS column (2.2 
µm, 4.6 x 100 mm) and eluted with a binary gradient method. Buffer A consists of 
sodium acetate (50 mM; pH 5.3), tetrahydrofuran (THF) (2.5 % (v/v)) and methanol 
(20 % (v/v)) in H2O and Buffer B consists of sodium acetate (50 mM; pH 5.3), THF (2.5 
% (v/v)) and methanol (80 % (v/v)) in H2O. The flow rate was set to 1.2 mL min-1, and 
the initial concentration of buffer B was 0%. The concentration of buffer B was 
increased to 25 % over 6 min, before 1 min at 25 % buffer B and increasing to 62 % 
buffer B over 30 sec which was then held for 2.5 min, before increasing to 100 % buffer 
B over two min and holding for 1 min. The concentration of B was then reduced to 0 % 
over the next 30 s and held there for 3.5 min to re-equilibrate the column. The detection 
of derivatised amino acids was achieved by measuring the fluorescence (λex= 340 nm, 
λem= 440 nm) using a Shimadzu RF-AXS20 fluorescence detector. Figure 2.2 shows a 
sample chromatogram depicting observed retention time and peak shape for the amino 
acids standards.  
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Figure 2.2 – Typical chromatogram observed for amino acid separation using OPA 
derivatisation. Trace shows a 50 pmol standard. 
 Mass spectrometry 
Samples to be analysed by mass spectrometry were prepared in H2O before dilution 
with an equal volume of formic acid (0.2% (v/v)) in methanol. The acidified sample 
was analysed by direct injection on a Thermo Finnigan LCQ Deca XP Max Plus ion trap 
mass spectrometer. The analysis was performed in the positive-ion mode, with the 
electrospray needle held at 4500 V. Nitrogen, the sheath gas, was held at 10 units. The 
collision gas was helium. The temperature of the heated capillary was 275 °C. For 
MS/MS studies the normalized collision energy was set at 35%. Mass values were 
scanned between 100 – 500 m/z and spectra were produced by the average of 50 scans. 
QualBrowser (Version 1.4, ThermoElectron, Rochford, IL, USA) was used to analyse 
spectra. Simulations were obtained from QualBrowser with Gaussian outputs, with a 
0.4 Da resolution and full width and half maximum (FWHM) valleys. 
 NMR spectroscopy 
Samples to be analysed were dried overnight in a rotational vacuum concentrator 
(Christ, Osterode am Harz, Germany), before being dissolved in D2O. A Varian VNMRS 
500 MHz instrument (Bruker, MA, USA) was used to collect NMR data. The machine 
was controlled and analysis performed in VNMR Walkup (Version 6.1, Bruker, MA, 
USA). Spectra were collected at 25 °C. 1H NMR spectra were recorded with a relaxation 
delay of 0.01 seconds and a pulse of 60 degrees with an average of 256 scans. 13C 
experiments were performed with 1H de-coupling with a relaxation delay of 0.01 
seconds and a pulse of 45 degrees and spectra produced from the average of 1024 
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scans. HHCOSY experiments were performed with a relaxation delay of 2.0 scans and 
spectra produced from the average of 512 scans. HSQCAD experiments were 
performed with 1H de-coupling with a relaxation delay of 1.5 seconds and spectra 
produced from the average of 512 scans. Peaks were reported as the ppm shift from 
the residual H2O peak set to 4.74 ppm.  
2.3.7.1 Preparation and quantification of selenoxides 
Selenoxides were formed on selenomethionine, 1,4-anhydro-4-seleno-L-talitol, N-
acetylselenomethionine, methylselenocysteine and seleno-bispropionic acid. Parent 
selenoethers (2 mM) were dissolved in water and mixed with either HOCl or H2O2 (1 
mM in H2O).  
SeMetO and SeTalO concentrations were quantified for use as standards in HPLC 
experiments. SeMetO and SeTalO were produced as above, and then dried overnight in 
a rotational vacuum concentrator (Christ, Osterode am Harz, Germany). SeMetO and 
SeTalO were dissolved in D2O (500 µL) and the 1H NMR spectrum obtained using a 
Varian VNMRS 500 MHz instrument. Dimethyl sulfone (100 µL, 5.3 µM) was added as 
quantification standard, and the 1H NMR spectrum collected again. The concentration 
of selenoxides was calculated by comparison of peak areas of the dimethyl sulfone (δ = 
3.153 ppm, 6H) and product (SeMetO: δ = 2.80 ppm, 3H and δ = 2.71 ppm, 3H; SeTalO: 
δ = 4.74 ppm, 3H). 
 Kinetic analysis 
Kinetics experiments were carried out using an Applied Photophysics SX.20MV 
stopped flow system maintained at 22 °C using a thermostatted water bath. The 
detection system consisted of an ozone-producing Xe light source (150 W; Osram 
GmbH, Munich, Germany) with wavelength selection achieved using a single 
monochromator (slit width, 0.5 mm; bandwidth, ±1.2 nm) and photomultiplier 
detection. The system was controlled by a personal computer running Pro-Data SX 
(version 2.2.12; Applied Photophysics). 
Spectral data from 200 to 310 nm were obtained in a point-by-point manner by 
acquiring kinetic traces at 10-nm intervals with the photomultiplier over this 
wavelength region. Second-order rate constants were obtained by global analysis of 
the kinetic traces using second order models with  > 240 nm using ProKIV (Applied 
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Photophysics, Version 1.0.1.4). Rates were confirmed using pseudo-first order analysis 
at appropriate wavelengths. 
2.3.8.1 First and second order reactions 
The rates for first and second order rate laws can be expressed as Equation 2.1 for 
first order reactions, and Equation 2.2 for second order reactions. 
−
𝛿[𝐴]
𝛿𝑡
= 𝑘[𝐴]𝑎 Equation 2.1 
−
𝛿[𝐴]
𝛿𝑡
= 𝑘[𝐴]𝑎[𝐵]𝑏 Equation 2.2 
Integration of these rate laws give rise to Equation 2.3 and Equation 2.4, for first 
and second order plots respectively, where [A] is the concentration of reactant A at 
time = t, and [A]0 is the initial concentration of reactant A.  
ln[𝐴] = ln[𝐴]0 −  𝑘𝑡 Equation 2.3 
1
[𝐴]
=  
1
[𝐴]0
+ 𝑘𝑡 Equation 2.4 
Based on these equations, if a plot of ln[A] vs time graph is linear, the reaction 
follows first order kinetics. If a plot of 1/[A] vs time graph is linear, the reaction follows 
second order kinetics. As concentration is proportional to absorbance, absorbance data 
can be used to determine whether the reaction follows first or second order kinetics. 
2.3.8.2 Global wavelength analysis 
Global wavelength analysis uses mathematical modelling to determine second 
order rate constants from spectral kinetic data.  It monitors the change in absorbance 
across numerous wavelengths, and can correlate these changes to the contribution of 
changes in the concentrations of reactants and products simultaneously. Based on this, 
the model can determine rate constants from each wavelength, and determine an 
average across the entire range.  
This method has significant advantages over pseudo-first order analysis. Under 
first order conditions, the concentration of [A] is assumed to be constant throughout 
the reaction but the global analysis is capable of accounting for the changes in [A]. The 
wavelengths used in pseudo-first order analysis need to be selected so that the 
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detected absorbance arises primarily from one species, whereas global wavelength 
analysis can account for a contribution from multiple species at the same wavelength. 
Global wavelength analysis can also handle more complex models, unlike pseudo-first 
order analysis which assumes an A + B  C model.  
2.3.8.3 Pseudo-first order analysis 
Second order bimolecular reactions, characterised by Reaction 2.10, have kinetics 
that can be described by the rate law in Equation 2.5. 
𝐴 + 𝐵 → 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 Reaction 2.10 
𝑅𝑎𝑡𝑒 = 𝑘2[𝐴][𝐵] Equation 2.5 
where [A] and [B] are the concentrations of the reactants and k2 is the second order 
rate constant for the reaction. When [A] >> [B], it can be assumed that [A] does not 
significantly change over the course of the reaction, and hence [A] can be considered 
constant. The rate can also be expressed as the change in [B] over time. This can be 
represented by Equation 2.6 
−
𝛿[𝐵]
𝛿𝑡
=  𝑘𝑜𝑏𝑠[𝐵] Equation 2.6 
where 
𝑘𝑜𝑏𝑠 = 𝑘2[𝐴] Equation 2.7 
Integration of Equation 2.7 gives When [B] is kept constant, and initial [A] is varied, 
this allows the plotting of the observed rate constant against the initial [A], and the 
second order rate constant can be determined by the gradient of the slope. Single 
exponential functions were fitted to kinetic traces to give kobs for each concentration of 
A, using ProData Viewer (Applied Photophysics, Version 4.2.12), which were 
subsequently used to determine the observed rate constant., and allows the 
determination of kobs from the absorbance vs. time plots. The absorbance vs time plots 
are used as the absorbance at a given wavelength is proportional to concentration. 
[𝐵] = [𝐵]0𝑒
−𝑘𝑜𝑏𝑠𝑡  Equation 2.8 
When [B] is kept constant, and initial [A] is varied, this allows the plotting of the 
observed rate constant against the initial [A], and the second order rate constant can 
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be determined by the gradient of the slope. Single exponential functions were fitted to 
kinetic traces to give kobs for each concentration of A, using ProData Viewer (Applied 
Photophysics, Version 4.2.12), which were subsequently used to determine the 
observed rate constant.  
 Cell culture 
J774A.1 cells (A.T.C.C. TIB-67) were cultured in Dulbecco’s modiﬁed Eagle’s 
medium (DMEM) supplemented with fetal calf serum (FCS; 10% (v/v)) and L-
glutamine (2 mM), in 175 cm2 flasks under sterile conditions in an atmosphere of 
humidified 5% CO2, at 37 °C. When the cells had reached confluency, they were 
passaged by first washing twice in warm (37 °C) DMEM, followed by scraping into 
media (10 mL). 2 mL of cell suspension was added to each new flask and volume made 
up to 25 mL with DMEM. Cells reached confluency 2-3 days after splitting. 
2.3.9.1 Oxidant treatment of cells 
Confluent flasks of J774A.1 cells were washed twice with warm (37 °C) DMEM 
before scraping into media (10 mL). Cell number and viability were assessed by trypan 
blue dye exclusion. The cell suspension (10 µL) was mixed with equal volumes of 
trypan blue dye and mixed by aspiration. The resulting mixture (10 µL) was pipetted 
into haemocytometer chamber and cells counted under a microscope. Cells that did not 
take up the dye were counted as viable. Cell suspensions were adjusted to 1 x 106 cell 
mL-1 and cells plated at a density of 0.5 x 106 cells per well in 12-well plates, and 
allowed to adhere overnight in an atmosphere of humidified 5 % CO2, at 37 °C. Cells 
were washed twice with warm (37 °C) HBSS, with various concentrations of SeMet or 
SeTal (0 – 50 µM) added to the HBSS, prior to addition of HOCl or TauCl (100 or 200 
µM) for 20 min or 2 h. Cells were then assessed for changes in viability and function as 
described in sections below (Section 2.3.10. to 2.3.9.3). 
2.3.9.2 GADPH activity 
GAPDH is a thiol-dependent cellular enzyme that is critical for glycolysis, and is 
known to be inactivated when cells are treated with HOCl, HOSCN and N-chloramines 
[229, 245]. GAPDH converts glyceraldehyde 3-phosphate (GAP) to 1,3-
bisphosphateglycerate (BPG), reducing NAD+ to NADH in the process [230] (Reaction 
2.11). 
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𝐺𝐴𝑃 + 𝑁𝐴𝐷+
𝐺𝐴𝑃𝐷𝐻
→     𝐵𝑃𝐺 + 𝑁𝐴𝐷𝐻 Reaction 2.11 
J774A.1 cells were prepared and treated as described in Section 2.3.9.1, before 
washing with warm HBSS and lysis in 600 µL ice cold H2O, and centrifuged at 5900 g 
for 5 min at 4 °C to remove any cellular debris. 20 µL of each sample was mixed with 
120 µL of pyrophosphate buffer (28.5 mM sodium pyrophosphate, 38 mM sodium 
phosphate buffer, pH 7.4) and 60 µL of NAD+/GAP solution (1.2 mM GAP, 2.5 mM NAD+) 
in a 96-well plate. The absorbance increase at 340 nm, corresponding to the increase 
in the concentration of NADH, was measured over 10 min using a M2e plate reader 
(Molecular Devices). Enzyme activity was determined by the rate of change in 
absorbance of the resulting time vs absorbance graph. 
2.3.9.3 LDH assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that converts pyruvate to 
lactate by consuming NADH and forming NAD+ (Reaction 2.12). LDH activity can be 
measured by the change in NADH concentration, measured by the change in 
absorbance at 340 nm. The release of LDH from the cytosol into cell media reflects cell 
lysis and can be used as a measure of cell viability [559]. 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝑁𝐴𝐷𝐻 
𝐿𝐷𝐻
→   𝐿𝑎𝑐𝑡𝑎𝑡𝑒 + 𝑁𝐴𝐷+ Reaction 2.12 
J774A.1 cells were plated at a density of 0.5 x 106 cells per well in 12-well plates, 
and allowed to adhere overnight in an atmosphere of humidified 5 % CO2, at 37 °C. Cells 
were washed twice with warm (37 °C) HBSS, then HBSS was added with or without 
SeMet or SeTal (0 – 50 µM) and incubated for 2 h. The cell media was then collected, 
and remaining cells washed with warm (37 °C) HBSS, before lysis using 600 µL cold 
H2O and incubation on ice for 15 min. The protein content was measured by BCA assay 
(Section 2.3.3.4). Media or lysate samples (50 µL) were mixed with NADH (375 µM) 
and sodium pyruvate (2.88 mM) in a total volume of 200 µL, and the absorbance at 340 
nm was monitored over 15 min using an M2e plate reader (Molecular Devices).  The 
rate of change in NADH concentration was determined by fitting a linear slope to the 
Abs vs time plot, which was then normalised to protein concentration. Viability was 
assessed as LDH activity in the lysate over the total LDH activity in both media and 
lysate and expressed as a percentage of untreated control. 
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2.3.9.4 Ethidium bromide release assay 
Ethidium bromide (EtBr) interchelates with DNA causing an increase in 
fluorescence. DNA release from intact cells into the cellular media can be quantified by 
EtBr fluorescence and used as a measure of cell viability [560]. 
Neutrophils (2 x 106 cells) were incubated in HBSS in the presence of SeMet or SeTal 
(0, 25 or 50 µM) at 37 °C for 10 min, before centrifugation (13000 g for 5 min at 4 °C) 
to pellet cells. The cell media was removed and cells resuspended in 500 µL H2O and 
lysed by addition of Triton-X solution (50 µL, 0.2 % (v/v)). EtBr (25 µM) was added to 
both the lysate and media samples and incubated for 5 min, before fluorescence was 
measured (λex = 360 nm, λem= 580 nm) using an M2e plate reader (Molecular Devices). 
Viability was determined by measuring the fluorescence in the lysate sample as a 
percentage of total fluorescence (media + lysate).  
2.3.9.5 IAF labelling of reversibly oxidised thiols 
Oxidation of thiols can result in the formation of various reversible oxidation 
products including disulfides and sulfenic acids, and also non-reversible products such 
as sulfonic acids [2]. MPO-derived oxidants are known to deplete cell thiols [225] and 
cause inactivation of thiol-dependant proteins [245]. If the modifications are 
reversible, then the cell could potentially recover from the oxidative insult. The effect 
of SeMet and SeTal on the formation of reversible thiol modification in cells exposed to 
HOCl or TauCl was assessed using the fluorescent probe 5-iodoacetamide fluorescein 
(IAF).  
J774A.1 cells were prepared and treated as outlined in Section 2.3.9.1, before 
washing in warm (37 °C) HBSS and lysis in a buffer containing HEPES (35 mM), Triton 
X (0.1 % (v/v)), Roche complete protease inhibitor (1x) and N-ethylmaleimide (NEM; 
100 mM). Lysates were centrifuged at 8000 g for 5 min, at 4 °C to remove any insoluble 
cell debris. Excess NEM was removed by filtering the resulting supernatant through a 
10 kDa molecular mass cut-off filter (Amicon, 5 min at 9300 g) twice with washing 
using 200 µL phosphate buffer (0.1 M, pH 7.4). Protein concentrations were 
determined by BCA assay (Section 2.3.3.4) and samples adjusted to 1 mg protein  
mL-1. DTT (1 M) was added to samples to reduce any reversibly oxidised thiols prior to 
addition of IAF (100 µM) and incubation for 10 min in the dark. Excess IAF and salts 
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were removed by addition of 10 % (w/v) TCA to the incubation mixture for 10 min on 
ice to precipitate the protein, before pelleting the protein by centrifugation at 5900 g 
for 5 min, at 4 °C. The supernatant was then removed and protein pellet washed with 
ice-cold 80% (v/v) acetone, before centrifugation at 5900 g for a further 5 min, at 4 oC. 
The acetone was then removed and samples air-dried at 22 °C. Samples were then 
resuspended in 20 µL BioRad NuPage reagent (13 µL H2O, 5 µL NuPAGE LDS sample 
buffer (4X), 2 µL Reducing agent (10X)) for electrophoresis. 
Samples were loaded onto 4-12% tris-acetate gels, and separated at 200 V for 1 h 
in the dark. NuPAGE MOPS SDS running buffer was used as the buffer. Gels were then 
removed and the lower 1 cm of the gel cut off to prevent residual IAF diffusion through 
the gel. Gels were rinsed in water and scanned for fluoresence using a BioRad FX Plus 
Pharox Molecular Imager (λex= 495 nm, λem= 520 nm). Gels were stained for total 
protein levels using either a silver stain [561] or Coomassie blue stain [562]. 
Gels for silver staining were initially placed in solution containing 50 % (v/v) 
methanol and 10 % (v/v) acetic acid in H2O for 30 min to fix the gel, thereby minimising 
protein diffusion and smearing of the bands. Gels were subsequently washed with 5% 
(v/v) methanol for 15 min, followed by washing 3 times with H2O for 5 min. The gels 
were then soaked in a solution containing sodium thiosulfate (0.02 % (w/v)) in H2O to 
sensitise the gel. The gel was then washed with H2O before soaking in silver nitrate 
solution (0.2 % (w/v)) in H2O for 25 min. Excess silver was removed by washing with 
H2O for 5 min and the gels were then developed by soaking in a solution containing 
sodium carbonate (3 % (w/v)), formaldehyde (0.02 % (v/v)) and sodium thiosulfate 
(0.0004 % (w/v)) in H2O. The developing solution was removed when a desired level 
of staining was achieved, and an EDTA solution (1.4 % (w/v)) in H2O was added to stop 
further colour development. Gels were imaged using a UMax PowerLook 1120 gel 
scanner and densitometry using in ImageJ software. 
Gels for Coomassie staining were placed in a staining solution containing 
Coomassie R-250 ((0.1 % (w/v)), ethanol (40 % (v/v)), acetic acid (10% (v/v)) in H2O 
and heated in a Panasonic NN-S548WA microwave oven at high power, loosely covered 
for 1 min, followed by gentle agitation on an orbital shaker for 15 min. The gels were 
then rinsed with H2O prior to destaining in a destain solution (ethanol (10 % (v/v)), 
acetic acid (7.5 % (v/v)) in H2O and heated in a microwave oven at high power, loosely 
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covered for 1 min. The gels were then incubated overnight in fresh destain solution 
prior to imaging using a UMax PowerLook 1120 gel scanner. Densitometry was 
performed using ImageJ software. 
 Flow cytometry 
Apoptotic and necrotic cell death was determined by dual staining with 
allophycocyanin-conjugated annexin V (annexin V-APC) and propidium iodide (PI) 
[563]. Annexin V-APC binds to the phosphatidyl serine that is exposed on the cell 
surface when cells undergo apoptosis [564]. PI is taken up by necrotic cells and binds 
to DNA fragments [565]. 
The J774A.1 cells were plated and treated as described in Section 2.3.9.1 before 
removal from the 12-well plate and transfer to flow cytometry tubes. Cells were spun 
down at 2000 g for 5 min in an Allegra X-15R Centrifuge (Beckman Coulter) to pellet 
cells. Cells were then washed twice with warm (37 °C) HBSS, with 5 min spins (as 
above) to pellet cells between washes. The cells were then resuspended in a master 
mix of Annexin V-APC and PI stains (100 µL, 5 µg mL-1) in HBSS and incubated in an 
atmosphere of humidified 5% CO2, at 37 °C for 15 min. HBSS (400 µL) was added to the 
samples, before placing on ice until analysis. Flow cytometry was performed on a BD 
FACSVerse machine (BD Biosciences, Australia) with fluorescence measurement of 
Annexin V-APC (λex= 650 nm, λem= 661 nm) and PI  (λex= 493 nm, λem= 636 nm). Viable 
cells were determined to be Annexin V and PI negative (Figure 2.3 – lower left 
quadrant). Annexin-V positive cells were determined to be apoptotic (Figure 2.3 – 
lower right quadrant), and PI positive cells were determined to be necrotic (Figure 2.3 
– upper quadrants). 
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Figure 2.3 – Typical flow cytometry plot obtained for control cells with annexin V-APC 
and propidium iodide dual staining 
 Statistical analysis 
Data are reported as the mean ± standard deviation from three or more 
independent experiments, unless otherwise stated. Statistical analyses were 
performed in GraphPad Prism v6.0 (GraphPad Software, San Diego, USA), with p < 0.05 
taken as significant. Statistical and post-hoc tests are detailed in relevant Figure 
legends.  
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3 Reaction of selenium compounds with MPO-derived oxidants 
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 Introduction 
Neutrophils, via the action of released MPO in the presence of H2O2 and Cl-, produce 
HOCl together with other strong oxidants in order to destroy invading pathogens as 
part of the innate immune system. However, when oxidants are produced in excess or 
inappropriately, they are capable of causing damage to host cells and are believed to 
play a role in disease initiation and progression [2].  
Major targets for the reaction of HOCl in the cellular environment are free thiol 
groups, such as the Cys residue of GSH, or thioethers such as Met residues [88]. The 
reaction between HOCl and sulfur residues are some of the fastest reported biological 
reactions with second order rate constants in the order of 107 - 108 M-1 s-1 [86, 90].  
HOCl is also known to react with amine groups, such as those on free amino acids, 
amino acid side chain (e.g. Lys, His) and N-terminal amino acids, to form N-
chloramines, with rate constants ca. 105 M-1 s-1 for alpha amino acids [53, 55, 58, 145, 
554]. N-Chloramines are also capable of inducing oxidation reactions in a similar 
manner to HOCl, though they are more specific to sulfur residues [181].  Second order 
rate constants for the reaction of N-chloramines with thiols and thioethers are in the 
range of 102 – 103 M-1 s-1 [136, 192]. N-Chloramines have demonstrated potential to 
inactivate thiol-dependent enzymes, such as GAPDH and creatine kinase (CK) [245]. 
The higher specificity of N-chloramines for thiol sites results in a lower concentration 
required for GAPDH and CK inactivation compared to HOCl. They also have a 
demonstrated ability to induce apoptosis and cell death [136, 223, 224]. As N-
chloramines have higher stability and reduced reactivity compared to HOCl, they are 
capable of diffusing away from their site of formation and may propagate oxidative 
damage at remote sites [87, 181, 566]. However, the stability and reactivity of N-
chloramines is dependent on structure, with primary N-chloramines more stable than 
those formed on other sites such as the imidazole ring of His [134, 136, 179, 181, 192]. 
Oxidation of Met residues results in the formation of MetSO as a primary product 
[467]. Dehydromethionine is also formed in a lower yield when Met is oxidised by HOCl 
and N-chloramines [115]. It has been suggested that Met oxidation may play a role in 
antioxidant defence, as exposed Met residues are preferentially oxidised over other 
functionally important sites, hence preserving enzymatic function [110, 567, 568]. 
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Oxidation of Met can also lead to inactivation of enzymes, with α1-antiproteinase 
activity being inhibited when exposed to HOCl or N-chloramines [113, 181]. 
Organic selenium compounds have been shown to react with peroxides, 
hypohalous acids and ONOOH [90, 98, 439, 454, 461, 486, 569]. This process is 
significantly faster for SeMet than Met, with second order rate constants for the 
reaction with HOCl > 108 M-1 s-1 [90]. Similarly, other selenoethers react with HOCl and 
HOSCN at a faster rate than the sulfur analogues [90, 98, 439]. These higher rate 
constants have been attributed to the increased nucleophilicity of selenium compared 
to sulfur [570]. Analogous to Met oxidation, SeMet is oxidised by ONOOH, H2O2 and 
flavin-containing monooxygenases to form the selenoxide, SeMetO [461, 464, 474, 
571].  
The increased reactivity of selenium compounds towards MPO-derived oxidants 
suggests that they may be competitive in vivo targets for oxidation. The ability of 
selenium compounds to react with MPO-derived oxidants before these oxidants can 
cause damage to cells and cellular components may have therapeutic benefit in 
inflammatory conditions. 
 Aims 
The aim of the studies presented in this Chapter was to investigate the reactions 
between MPO-derived oxidants, specifically N-chloramines, with the selenoethers, 
SeMet and SeTal (structures shown in Figure 3.1). Reaction products were determined 
by HPLC, mass spectrometry and NMR spectroscopy, and second order rate constants 
were determined using stopped flow methods.  
 
Figure 3.1 - Molecular structures of a) SeMet and b) SeTal 
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 Results 
 Sulfur and selenium compounds scavenge MPO-derived oxidants 
As previous studies have shown that SeMet, SeTal and Met react with the MPO-
derived oxidants HOCl and HOSCN [90, 98, 439], the ability of these compounds to 
remove oxidants produced enzymatically by the MPO system was investigated. The 
efficacy of SeMet, SeTal and Met in scavenging oxidants generated by the MPO/H2O2/Cl- 
system or freshly isolated neutrophils was assessed by the TMB assay in the presence 
of excess Tau [549]. Tau was present in a large excess (10 mM) to scavenge HOCl, 
resulting in the formation of the more stable TauCl, which facilitates accurate oxidant 
measurement [549]. The TMB assay was used as it reacts specifically with HOCl and 
TauCl, and will not react with the other oxidants present in the system (e.g. H2O2) or 
the selenoxides that may be formed as products. 
3.3.1.1 Isolated MPO/H2O2/Cl- 
Myeloperoxidase (2 µM) was incubated with Cl- (100 mM), Tau (10 mM) and SeMet, 
SeTal or Met (0 – 100 µM) for 10 min at 37 °C. H2O2 (50 µM) was added to initiate the 
production of HOCl by MPO, and allowed to incubate for 30 min at 21 °C. On completion 
of the incubation period, the concentration of MPO-derived oxidants was assessed 
using the TMB assay, and quantified by comparison to a standard curve generated 
using known amounts of TauCl.  
The MPO/H2O2/Cl- system produced approximately 50 µM TauCl over 30 min 
following the addition of H2O2, as assessed by the TMB assay, consistent with complete 
conversion of H2O2 to HOCl.  Addition of 12.5 µM SeMet to the MPO/H2O2/Cl- system 
prior to the addition of H2O2 caused a 25 % decrease in the presence of TauCl compared 
to the absence of SeMet (Figure 3.2). Increasing the concentration of SeMet 
demonstrated a further decrease in remaining oxidant levels. After addition of 50 µM 
SeMet, essentially no TauCl was observed after the 30 min incubation. Similarly, 
addition of increasing concentrations of SeTal and Met demonstrated a dose-
dependent decrease in the remaining oxidant concentration (Figure 3.2). The decrease 
in oxidant concentration occurred with a 1 : 1 ratio of scavenger to oxidant removed, 
with a linear decrease and essentially all oxidant removed at 50 µM of Met and SeTal. 
IC50 values were determined by a non-linear fit (log(inhibitor) vs normalised response 
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– variable slope) to TMB scavenging data in GraphPad Prism and are reported in Table 
3.1. No significant differences were observed in the scavenging ability of the various 
compounds SeMet, SeTal and Met under these conditions, which may reflect the long 
(30 min) incubation time employed. 
 
Figure 3.2 – SeMet, SeTal and Met scavenge oxidants produced by the MPO/H2O2/Cl- 
system 
HOCl and TauCl (ca. 50 µM oxidant over 30 min) were produced by adding H2O2 (50 µM) 
to MPO (2 µM) in the presence of Cl- (100 mM), Tau (10 mM) and Met , SeMet  or 
SeTal  (0 – 100 µM). The remaining oxidant concentration after 30 min was 
quantified using the TMB assay. Met, SeMet and SeTal dose dependently decreased the 
concentration of TauCl present 30 min after addition of H2O2. * represents a significant 
(p < 0.05) decrease in remaining TauCl from the 0 µM scavenger control based on one-
way ANOVA with Dunnett’s post-hoc test.  
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Table 3.1 – IC50 values (µM) for the scavenging of MPO-derived oxidants by sulfur and 
selenium compounds.  
IC50 values were determined by using a non-linear fit (log(inhibitor) vs normalised 
response – variable slope) to TMB scavenging data using GraphPad Prism 6.0. Values are 
expressed as IC50 ± 95% confidence interval.  
 Oxidant Met SeMet SeTal 
MPOa 19 ± 7 22 ± 3 19 ± 2 
Neutrophilsb 23 ± 4 25 ± 4 29 ± 3 
a MPO system: MPO (2 µM) / H2O2 (50 µM) / Cl- (100 mM) 
b Neutrophils (2 x 106 cells mL-1) stimulated with PMA (0.1 µg mL-1) for 30 min at 21 
C 
3.3.1.2 Neutrophil viability 
Neutrophils are a potent source of MPO in the circulation, therefore the ability of 
Met, SeMet and SeTal to scavenge oxidants produced by neutrophils was assessed. 
Initially, experiments were performed to assess the toxicity of Met, SeMet and SeTal to 
ensure any reduction in oxidant production was not due to neutrophil death. 
Neutrophil viability on exposure to Met, SeMet and SeTal was assessed by measuring 
DNA release using an EtBr assay. Neutrophils (2 x 106 cells mL-1) were incubated for 
30 min at 37 °C in the presence of Met, SeMet or SeTal (25 or 100 µM), before examining 
DNA release from the cells as a marker of lysis by measuring changes in EtBr 
fluorescence. No changes in neutrophil viability were observed with Met, SeMet or 
SeTal compared to control neutrophils in the absence of these compounds (Figure 3.3).  
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Figure 3.3 – Neutrophil viability is not affected by incubation with Met, SeMet and 
SeTal. 
Neutrophils (2 x 106 cell mL-1) were incubated for 30 min at 37 °C in the presence of 0 
(black bar), 25 µM (no stripe) or 100 µM (striped) SeMet (white bars), SeTal (dark grey 
bars) or Met (light grey bars). Neutrophil viability was not affected by presence of these 
compounds under the conditions employed as measured by DNA release using EtBr. No 
significant difference was observed relative to control based on one-way ANOVA with 
Dunnett’s post-hoc test. Data are reported as the mean ± SD from 3 independent 
experiments. 
3.3.1.3 Neutrophil derived oxidants 
As SeMet, SeTal and Met demonstrated no toxicity for neutrophils under these 
conditions, the ability of each compound to remove oxidants formed by neutrophils 
activated by PMA stimulation (0.1 µg mL-1) was assessed using the TMB assay. Freshly 
isolated neutrophils (2 x 106 cell mL-1) were incubated in warm (37 °C) HBSS in the 
presence of Met, SeMet or SeTal (0 – 100 µM) for 10 min. Neutrophils were stimulated 
by addition of PMA (0.1 µg mL-1), and incubated for a further 30 min. Under these 
conditions, approximately 50 µM oxidant was formed as assessed by the TMB assay. 
The major TMB oxidising species was assumed to be TauCl, as neutrophils release up 
to 20 mM Tau upon activation, which reacts with HOCl formed by the action of MPO. 
After 30 min, the remaining oxidant was assessed using the TMB assay, and quantified 
by comparison to a standard curve prepared using TauCl. 
Addition of SeMet, SeTal or Met to the neutrophil suspension prior to activation 
with PMA resulted in a decrease in the formation of TauCl (Figure 3.4). The 
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concentration of remaining oxidant decreased in a dose-dependent manner with 
increasing concentrations of SeMet, SeTal and Met. A significant difference in 
remaining oxidant relative to the system without added scavenger was achieved with 
addition of 25 µM scavenger. Essentially no oxidant was detected when 62.5 µM SeMet, 
SeTal and Met was present in the incubation mixture. This represents a near 1 : 1 
stoichiometric scavenging of oxidant produced, similar to that observed in the 
MPO/H2O2/Cl- system. IC50 values were determined by a non-linear fit (log(inhibitor) 
vs normalised response – variable slope) to TMB scavenging data in GraphPad Prism 
and are reported in Table 3.1. No significant differences were observed in the 
scavenging efficacy between the compounds examined under these conditions.  
 
Figure 3.4 - SeMet, SeTal and Met scavenge oxidants produced by activated neutrophils. 
HOCl and subsequently TauCl, (ca. 50 µM oxidant over 30 min) was produced by 
stimulating neutrophils (2 x 106 cells mL-1) with PMA (0.1 µg mL-1) in the presence Met 
, SeMet  or SeTal  (0 – 100 µM). The remaining oxidant concentration after 
30 min was quantified by the TMB assay. Met, SeMet and SeTal dose dependently 
decreased the concentration of TauCl present 30 min after activation of neutrophils. * 
represents a significant (p < 0.05) decrease in remaining TauCl from 0 µM scavenger 
control based on one-way ANOVA with Dunnett’s post-hoc test. Data are reported as the 
mean ± SD from 3 independent experiments. 
 
 Reaction kinetics of oxidation of SeMet and SeTal by N-chloramines 
The above data show that Met, SeMet and SeTal can effectively remove N-
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in a more complex system, these compounds would need to have favourable reaction 
kinetics in order to scavenge oxidants before they react with endogenous species. 
Second order rate constants for the reaction between N-chloramines and Met have 
previously been reported [192], and were therefore not examined in this study. 
However, the rate constants for the reaction of a variety of model N-chloramines with 
SeMet and SeTal were determined.  
Second order rate constants for the reaction between SeMet, SeTal and model N-
chloramines, derived from Tau, N-α-acetyllysine and glycine were determined using 
stopped-flow methods. N-Chloramines (125 µM) and SeMet or SeTal (0.5 – 2.5 mM) 
were mixed in the stopped-flow apparatus and kinetic traces recorded for the spectral 
region between 240 - 310 nm in 10 nm steps.  
SeMet and SeTal both absorb in the 200 - 300 nm region and sample spectra are 
shown in Figure 3.5. N-Chloramines are also detectable by UV absorbance and have a 
maximum absorbance at ca. 250 nm (Figure 3.5c) [554]. Absorbance decreases were 
observed in the 250 – 290 nm region when each N-chloramine was mixed with SeMet 
or SeTal (Figure 3.6), which is attributed to N-chloramine loss. In experiments with 
SeTal, absorbance decreases were observed between 250 – 300 nm, though at 240 nm 
an increase in absorbance was observed, possibly due to the formation of a selenoxide 
(SeTalO).  
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Figure 3.5 – Initial spectra recorded for SeMet, SeTal and TauCl 
The UV-vis absorbance spectra were collected at 10 nm steps between 240 – 310 nm for 
use as fixed spectra in global wavelength analysis. Spectra are a) SeMet (1 mM), b) SeTal 
(1 mM) and c) TauCl (250 µM) phosphate buffer (in 0.1 M pH 7.4) at 22 °C. Data are 
representative of three independent experiments.  
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Figure 3.6 – UV absorbance changes over time and at different wavelengths when TauCl 
(125 µM) was mixed with SeMet (500 µM) or SeTal (500 µM) 
Spectral absorbance changes observed over time between 240 – 310 nm recorded at 10 
nm intervals for reaction mixtures containing TauCl (125 µM) and a) SeMet (500 µM) or 
c) SeTal (500 µM) at 22 °C and pH 7.4. For clarity, selected spectra are shown at intervals 
of 2 s for SeMet and 10 s for SeTal. The direction of absorbance change is indicated by the 
arrows. b and d) show the typical changes in absorbance over time b) for SeMet at 250 
nm and d) SeTal at 270 nm. Data are representative of three independent experiments. 
Rate constants were determined by global wavelength analysis in ProKIV (Applied 
Photophyscis) using a simple “N-chloramines + scavenger  Product” second order 
mechanism and are reported in Table 3.2. Fixed spectra of the reactants (250 µM N-
chloramine; 1 mM SeMet or SeTal Figure 3.5) were used to aid analysis and allow for 
the determination of extinction coefficients by the analysis program. Kinetic analysis 
of data was performed between 240 – 310 nm as below 240 nm limited absorbance 
changes were observed. This was due to strong absorbance ( > 1 Abs unit), which 
affects the linearity of the response and yields less accurate data. The second order rate 
constants determined are reported in Table 3.2. The rate constants determined are 
some of the fastest known for N-chloramine reactions, with the rate constants SeMet 
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being greater than the analogous Met, and the thiol antioxidant GSH [192]. Similarly, 
the rate constants for SeTal are comparable to those reported for GSH [192]. 
Table 3.2 – Second order rate constants for the reaction between SeMet and SeTal and 
model N-chloramines 
Second order rate constants determined by global wavelength analysis (with 95% 
confidence limits) at pH 7.4 (0.1 M phosphate buffer) and 22 °C for the reactions of SeMet 
and SeTal with the N-chloramines formed on Tau, N-α-acetyl-lysine and Gly. Values in 
brackets are second order rate constants determined by pseudo-first order analysis of the 
data, and are included as a comparison of the data analysis methods. 
 
N-Chloramine 
k2 (M-1 s-1) 
SeMet SeTal 
TauCl  
817 ± 20 
(890 ± 50) 
115 ± 4 
(108 ± 3) 
LysCl 
3430 ± 70 
(4600 ± 450) 
683 ± 14 
(670 ± 60) 
GlyCl 
2250 ± 40 
(2460 ± 170) 
430 ± 7 
(400 ± 30) 
Second order rate constants were confirmed using pseudo-first order analysis at 
250 nm for SeMet reactions and 270 nm for SeTal reactions. 250 nm was selected for 
SeMet, as 250 nm is the maximum for N-chloramine absorbance, therefore changes at 
this wavelength should be primarily due to N-chloramine loss. However, absorbance 
changes at 250 nm for SeTal experiments were complicated by contributions from 
SeTal, and therefore, absorbance changes at 270 nm were used for pseudo first order 
analysis. The observed rate constant, kobs, was determined by fitting exponential curves 
to absorbance vs time plots. Second order rate constants were then derived from the 
gradient of the line of a [SeMet] or [SeTal] vs kobs plot, and are reported in Table 3.2. 
The second order rate constants determined in both analyses agree well with one 
another (Table 3.2), though the rate constant determined by global analysis is 
considered to be the more accurate reflection of the rate constant. This is because the 
global analysis uses data from multiple wavelengths and accounts for the change in 
concentration of reagents as the reaction progresses, whereas the pseudo first order 
analysis requires the assumption that scavenger concentration are constant during the 
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course of the reaction. As a result of these considerations, there should be less error in 
the global analysis rate constant, compared to the pseudo first order analysis, making 
the determination more reliable.  
 
Figure 3.7 – Pseudo first order plots for reaction between SeMet and SeTal and N-
chloramines 
N-chloramine (125 µM) (TauCl (circle), LysCl (triangle) or GlyCl (square)) was mixed 
with a) SeMet or b) SeTal (0.5 – 2.5 mM) and the absorbance change monitored at 250 
nm for SeMet and 270 nm for SeTal. Exponential decay plots were fitted to the resulting 
kinetic traces to determine the observed rate constant for the reaction, kobs. The gradients 
of these linear fits provide the rate constant and are reported in the paratheneses in Table 
3.2. Data represent mean ± SD from three independent experiments. Where not visible 
error bars are hidden by symbol.  
 Characterisation of selenomethionine oxidation products 
In the previous section, data have been presented which are consistent with SeMet 
reacting rapidly with MPO-derived oxidants, however, the products of the reaction of 
SeMet with HOCl and N-chloramines have not been characterised. Previous studies 
have demonstrated that reaction of SeMet with H2O2 and ONOOH gives rise to SeMetO, 
which has been previously characterised [461, 464, 571]. Initial studies focussed on 
the products formed when HOCl and N-chloramines react with SeMet. 
3.3.3.1 Mass spectrometry 
SeMet (500 µM) in H2O was mixed with HOCl or H2O2 (400 µM) and incubated at 22 
°C for 5 min. The resulting solutions were mixed in equal volumes with 0.02% (v/v) 
formic acid in methanol and analysed by mass spectrometry. H2O was used for the 
experiments, rather than the phosphate buffer used in the kinetic studies, to minimise 
contamination of the mass spectrometer with buffer salts.  
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Selenium occurs naturally in multiple different isotopes with 80Se being the most 
abundant (49.6 %), 78Se the second most abundant (23.8 %), followed by 76Se, 82Se, 77Se 
and 74Se (9.4 %, 8.7 %, 7.6 % and 0.9 % respectively) [572]. This natural abundance 
gives rise to a characteristic mass spectrum for compounds containing selenium, with 
peak areas proportional to the abundance of each isotope. This isotope ratio can be 
observed in the simulated mass spectra for SeMet shown in Figure 3.8b. 
The parent SeMet species, [SeMet+H]+, was observed in all samples at m/z 198.1 
(the 80Se isotope) with the expected pattern for Se from m/z 192.4 – 201.2 (Figure 
3.8a,c,e). Peaks reported are those for the 80Se isotope, which is the most abundant 
isotope of selenium. Isotope ratios correspond with the expected patterns, and this was 
confirmed by computer modelling (Figure 3.8b). 
Treatment of the samples with H2O2 and HOCl would be expected to yield a 
selenoxide, on the basis of literature data [571]. However, no peak was detected at m/z 
214.0, which would be the expected mass of the singly charged selenoxide species 
[SeMetO+H]+ (Figure 3.8d demonstrates the expected ions for this species based on 
simulation).  This ion may not be seen under the conditions employed due to poor 
ionisation of the SeMetO species. However, upon treatment of SeMet with HOCl, new 
peaks were detected at m/z 196.3 and 218.2 (80Se peak, with the expected isotope 
patterns), which corresponds to a loss of 2 mass units or a gain of 20 mass units 
respectively compared to the parent ion [SeMet+H]+ at m/z 198.1. These mass changes 
are consistent with the loss of H2 to form dehydroselenomethionine ions as either H+ 
or Na+ adducts, [DeHSeMet+H]+ and [DeHSeMet+Na]+ respectively (supported by 
computer modelling in Figure 3.8f).  
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Figure 3.8 – Distribution of ions detected by mass spectrometry when SeMet was 
treated with HOCl or H2O2 with supporting computer simulation. 
Species detected by mass spectroscopy on reaction of SeMet (500 µM) with HOCl or H2O2 
(400 µM). Samples were mixed in a 1 : 1 ratio with 0.02% (v/v) formic acid in methanol 
before analysis by mass spectrometry. a) Parent SeMet (250 µM). c) SeMet (250 µM) 
treated with 200 µM H2O2. e) SeMet (250 µM) treated with 200 µM HOCl. b, d and f) show 
computer simulation of b) the parent ion of SeMet, d) the H-adduct of SeMetO and f) the 
H- and Na-adducts of dehydroselenomethionine. Neither of the experimental spectra 
show the expected ion pattern for SeMetO at m/z 214.0 for 80Se as seen in the computer 
simulation d). H2O2 only shows ions which correspond to ions from SeMet as seen in the 
model c). HOCl treatment gives rise to ions that are m/z 2 less than the parent SeMet (m/z 
196.3), and are consistent with the dehydroselenomethionine hydrogen adduct, 
[DeHSeMet+H]+. The peaks centred around m/z 218.2 are consistent with the Na adduct 
of dehydroselenomethionine, [DeHSeMet+Na]+. f) shows a computer simulation of equal 
concentrations of [DeHSeMet+H]+ and [DeHSeMet+Na]+. Simulations were produced 
using QualBrowser by inputting empirical formulae with Gaussian outputs with a 0.4 Da 
resolution and full width half maximum valleys. 
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MS/MS fragmentation spectra of the m/z 196.3 and 218.2 ions yielded major 
fragment ions at m/z 167.9 and 189.9 (Figure 3.9), corresponding to a loss of 28 mass 
units. This fragmentation pattern has been previously described for 
dehydromethionine and is attributed to loss of C2H2 [115]. The difference in fragment 
masses of 22 mass units after fragmentation suggests that the m/z 196.3 and 218.2 ions 
are the same species present as either the H+ or Na+ adduct. Thus, the peaks at m/z 
167.9 and 189.9 are attributed to the ions [DeHSeMet+H-C2H2]+ and [DeHSeMet+Na-
C2H2]+ respectively. 
 
Figure 3.9 – MS/MS fragmentation pattern of m/z 196.3 and m/z 218.2 peaks for SeMet 
treated with HOCl. 
SeMet (250 µM) treated with HOCl (200 µM) and mixed in a 1 : 1 ratio with 0.02% (v/v) 
formic acid in methanol before analysis by mass spectrometry. MS/MS analysis was 
performed on ions at a) m/z 196.3 and b) m/z 218.1. A loss of 28 mass units was observed 
for both species, and attributed to loss of C2H2 giving rise to ions [DeHSeMet+H-C2H2]+ and 
[DeHSeMet+Na-C2H2]+ respectively. 
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3.3.3.2 NMR 
Although SeMetO was not observed in the mass spectrometry experiments using 
the conditions employed in this study, oxidation of SeMet by H2O2 has been previously 
demonstrated to produce SeMetO [464, 571]. Therefore, SeMet was treated with H2O2 
and the resulting products were analysed by NMR. SeMet (5 mg, 25 µmoles) in H2O was 
reacted with equimolar concentrations of H2O2 or HOCl for 15 min at 22 °C. The 
samples were then dried overnight using a rotational vacuum concentrator (Christ, 
Osterode am Harz, Germany). The resulting white solid was dissolved in 600 µL D2O 
and analysed by NMR.  
Reaction of SeMet with H2O2 resulted in a product consistent with 1H NMR 
spectroscopy data previously reported for SeMetO [464]. The spectra demonstrate the 
formation of two products, which are attributed to SeMetO, and hydrated SeMetO as 
previously described [464], and chemical shifts and splitting are reported in Table 3.3. 
Peaks consistent with SeMetO were the only product peaks observed. However, 
residual signals from the parent SeMet compound were present at 1.893, 2.00-2.16, 
2.48-2.56 and 2.73 ppm, as well as overlapping with a SeMetO signal at 3.70 ppm. 
Table 3.3 – 13C NMR chemical shifts for selenoxide formed on reaction of SeMet with 
H2O2 
 SeMetO SeMetO.H2O 
Environment ppm Splitting H ppm Splitting H 
A 2.564 s 3 2.654 s 3 
B 2.82 - 3.16 Multiplet 2 3.52 - 3.66 Multiplet 2 
C 2.20 – 2.26 q 2 2.36 – 2.44 Multiplet 2 
D 4.18 - 4.22 t 1 ~3.704 obscured 1 
SeMet (5 mg, 25 µmol) was also treated an equimolar concentration of HOCl and 
the product of the reaction analysed by 1H NMR spectroscopy (Figure 3.11). The most 
intense signals detected corresponded to SeMetO proton environments with ppm and 
relative integral areas the same as that observed for H2O2 treated SeMet (Figure 3.10). 
As a result, the primary product of HOCl treatment of SeMet was therefore assigned to 
the selenoxide, SeMetO. However, HOCl treated SeMet also gave rise to small 1H NMR 
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signals at 3.75, 4.11 and 4.42 ppm which could not be attributed to either parent SeMet 
or SeMetO, and were not observed with H2O2 treatment. This suggests the formation of 
a secondary product, potentially dehydroselenomethionine, though due to low 
intensity and poor resolution of these peaks, this could not be confirmed from these 
data. However, this is consistent with the mass spectrometry data that suggest HOCl 
can lead to formation of dehydroselenomethione, whereas H2O2 cannot.  
 88 
 
Figure 3.10 – 1H NMR spectra of SeMet treated with H2O2 
SeMet (5 mg; 25 µmol) dissolved in water was mixed with equimolar H2O2, dried overnight 
and redissolved in D2O (600 µL) was analysed by 1H NMR spectroscopy. Chemical shifts 
are reported using the residual H2O peak as a reference (∂ = 4.64 ppm). Product signals 
are consistent with those previous reported for SeMetO. The conversion to SeMetO was 
incomplete with residual parent peaks observed in the spectra.  
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Figure 3.11– 1H NMR spectra of SeMet treated with HOCl 
SeMet (5 mg; 25 µmol) dissolved in water was mixed with equimolar HOCl, dried 
overnight and redissolved in D2O (600 µL) and analysed by 1H NMR spectroscopy. 
Chemical shifts are reported relative to the residual H2O peak set to 4.64 ppm. The largest 
signals are consistent with the formation of SeMetO.  Peaks at 3.75, 4.11 and 4.42 ppm 
attributed to minor product, possibly dehydroselenomethionine. 
3.3.3.3 Standardisation of SeMetO for HPLC 
1H NMR spectroscopy was used as a method of quantifying the selenoxide 
standards for use in HPLC. As the relative peak areas in 1H NMR spectra correlate to 
the number of protons in the environment, the concentration of products can be 
determined by comparison to a known concentration of an internal standard.  
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SeMetO was produced by the reaction of SeMet (25 µmol) with an equimolar 
concentration of H2O2, which was incubated for 15 min, before it was divided into 2 
aliquots and dried overnight in a rotational vacuum concentrator (Christ, Osterode am 
Harz, Germany). One aliquot of the resulting white solid was dissolved in 600 µL D2O, 
before addition of the internal standard dimethyl sulfone (DMSO2) (5.3 µM). The 1H 
NMR spectra were collected (Varian VNMRS 500 MHz) (Figure 3.10), and the 
concentration of SeMetO determined by comparison of dimethyl sulfone peaks (∂ = 
3.15 ppm, 6H) to SeMetO peaks (∂ = 2.80 ppm, 3H; ∂ = 2.71 ppm, 3H). The calculated 
concentration for SeMetO was 15 mM, giving a SeMetO recovery of ~85 %. As peaks 
consistent with unreacted SeMet in the sample were observed, the low recovery may 
be attributed to unreacted parent SeMet. 
 Selenoxide formation upon exposure of SeMet to HOCl and N-chloramines 
The NMR data presented in the previous section suggests that the major oxidation 
product generated when SeMet reacts with HOCl is SeMetO. An HPLC method was used 
to enable quantification of SeMetO formation upon exposure of SeMet to HOCl and 
other MPO-derived species, including N-chloramines. 
3.3.4.1 HPLC method development 
Initial studies employed an HPLC method that has previously been used in the 
literature [445], which uses a Beckman Ultrasphere ODS column with an isocratic 
elution using 0.1 % ACN made to pH 2.5 with TFA as a mobile phase. Under these 
conditions, SeMetO eluted close to the solvent front at 3.2 min. However, a peak was 
observed in all samples at 3 min that was attributed to the phosphate buffer salts in the 
samples. Furthermore, a negative peak was observed immediately after the SeMetO 
peak, which is also believed to buffer-derived. The SeMetO peak eluted between these 
two features of the chromatogram, and whilst separation was not ideal, the peak was 
resolved from the buffer peaks. As this made integration of SeMetO difficult, attempts 
to optimise the separation of SeMetO from SeMet using different HPLC methods and 
columns were performed. 
Numerous buffer compositions and columns were attempted in order to better 
resolve SeMetO. The columns attempted are detailed in Table 3.4, and were selected 
based on the varied properties of the stationary phases. The buffer solutions conditions 
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tested comprised of an isocratic run with a flow rate of 1 mL min-1 consisting of varying 
concentrations of ACN in H2O made to pH 2.5 with TFA.  The concentrations of ACN 
used were 0, 0.1, 1, 10, 50 or 100 % ACN v/v, to assess whether varying concentrations 
of organic components in the mobile phase could affect retention times. The range of 
conditions used has very little difference in SeMetO peak position, which generally 
eluted either with the solvent front or immediately after the solvent front. As these 
attempts to increase retention of SeMetO on different columns were unsuccessful, the 
original HPLC method described in Section 2.3.5.2 was used for further analysis. 
Table 3.4 – Columns used in HPLC method development for SeMet oxidation 
experiments. 
Column details 
Ultrasphere ODS, 5 µm, 4.6 x 250 mm, Beckman 
Hypercarb PGC, 5 µm, 2.1 x 100 mm ThermoScientific 
Supelcosil LC-NH2, 5 µm, 4.6 x 250 mm, Supelco 
Viva C18, 5 µm, 4.6 x 250 mm, ResTek 
Synergi Polar RP 80A, 4 µm, 4.6 x 250 mm, Phenomenex 
Zorbax ODS, 5 µm, 4.6 x 250 mm, Agilent 
Kinetex C18 100A, 2.6 µm, 100 x 2.1 mm, Phenomenex 
3.3.4.2 Quantification of SeMetO formation 
Oxidation of SeMet to SeMetO by HOCl, TauCl and BSA-Cl was assessed by HPLC, as 
described in Section 2.3.5.2. SeMetO standards were prepared by mixing SeMet with 
H2O2 and standardised using NMR with dimethylsulfone as an internal standard as 
described in Section 3.3.3.3. SeMet (160 µM) was mixed with each oxidant (0 – 320 µM) 
and allowed to react for 15 min at 22 °C before filtering and analysis by HPLC (Figure 
3.12). With HOCl, a decrease in the SeMet peak (8.6 min) was observed when 40 µM 
oxidant was added to SeMet (160 µM). This corresponded with an increase in the 
SeMetO peak (3.2 min) area. With increasing oxidant concentrations, further decreases 
in the SeMet peak area were observed, with corresponding increases in the SeMetO 
peak (Figure 3.12). 
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Figure 3.12 – Representative chromatograms of SeMet exposed to 0 - 200 µM HOCl 
SeMet (160 µM) was mixed with 0 µM (unbroken line), 120 µM (dashed line) or 200 µM 
(dotted line) HOCl and subsequently analysed by HPLC. A dose dependent decrease in the 
parent SeMet peak area (8.6 min) with a concomitant increase in the SeMetO peak area 
(3.2 min) was observed with increasing oxidant concentration.  
Upon quantification, an initial decrease of 36 µM SeMet was observed with the 
addition of 40 µM HOCl (Figure 3.13a). This corresponded to an increase of 30 µM 
SeMetO (Figure 3.13b). With each subsequent addition of 40 µM SeMet, a similar ratio 
of SeMet was consumed with corresponding SeMetO increase. With an excess of HOCl 
(200 µM) added, essentially all the SeMet was consumed and a maximum SeMetO 
concentration of 128 µM was detected. When HOCl was in greater excess over SeMet 
(> 200 µM), decreases in the SeMetO concentration were observed, though these 
changes were not statistically significant from the concentration observed at 200 µM 
HOCl. A similar dose-dependent decrease in SeMet concentrations was observed in the 
corresponding experiments with TauCl where an increase in the formation of SeMetO 
was also seen (Figure 3.13c,d). In this case, essentially all SeMet was consumed with 
addition of 200 µM TauCl. A loss of SeMetO was not observed when a molar excess 
TauCl was added to SeMet, in contrast to experiments with HOCl (Figure 3.13d). A 
lower conversion of SeMet to SeMetO was seen with BSA-Cl (0 – 320 µM) (Figure 
3.13e,f), which was prepared by mixing BSA (1 mg mL-1) with HOCl (0.5 mM) for 5 min 
and adjusted to 320 µM as assessed by the TNB assay, prior to reaction with SeMet (160 
µM). In the case of BSA-Cl (Figure 3.13e,f), approximately 20 µM SeMet was consumed 
for every 40 µM BSA-Cl added. SeMet was essentially completely consumed upon 
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addition of 320 µM BSA-Cl, and this corresponded to the maximum amount of SeMetO 
observed.  The percentage conversions of SeMet to SeMetO were calculated by the ratio 
of the maximum SeMetO observed to the concentration of SeMet consumed, giving 
values of 80%, 84% and 86% for HOCl, TauCl and BSA-Cl respectively. The highest 
yields of SeMetO were observed with HOCl and TauCl when the oxidants were in slight 
excess (200 µM) of SeMet, whereas the maximum conversion of SeMet to SeMetO was 
observed when BSA-Cl was present with a 2-fold excess of SeMet. 
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Figure 3.13 – Conversion of SeMet to SeMetO by HOCl, TauCl and BSA-Cl 
SeMet (160 µM) was mixed with a,b) HOCl, c,d) TauCl or e,f) BSA-Cl (0 – 320 µM) and 
incubated for 15 min at 22 °C before analysis by HPLC. a,c,e) show a dose-dependent 
decrease in SeMet concentration upon addition of increasing concentrations of each 
oxidant. b,d,f) show a corresponding increase in the SeMetO concentration. * indicates 
significant difference from control (0 µM oxidant) based on one-way ANOVA with 
Dunnett’s post-hoc test. Data represent the mean ± SD from 5 independent experiments. 
 Characterisation of further oxidation products of SeMetO 
As SeMetO formation was decreased with higher excesses of HOCl, preliminary 
experiments investigating further oxidation products of SeMetO with HOCl were 
performed. As a similar decrease in SeMetO was not observed with TauCl or BSA-Cl, 
only higher excesses of HOCl were investigated. 
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SeMet (200 µM) was incubated with HOCl (0 – 0.8 mM) for 15 min and the resulting 
products of the reactions were analysed by HPLC using a Beckman Ultrasphere ODS 
column with a 0.1 % ACN made to pH 2.5 with TFA as the mobile phase. Addition of an 
increasing concentration of HOCl to SeMet lead to a dose-dependent decrease in the 
concentration of SeMetO (Figure 3.14). Under these conditions, increases in 2 
unidentified peaks were observed (#1 3.1 min, #2 10.2 min). The higher 
concentrations of HOCl (600 – 800 µM) led to decreases in the size of peak #1, whereas 
the #2 peak size was more consistent, with a maximum at 1x HOCl, with a subsequent 
decrease at 2x, with no further changes with increasing concentration.  
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Figure 3.14 – SeMetO reacts with HOCl to form additional products 
SeMet (200 µM) was mixed with HOCl (0 – 0.8 mM) and the products analysed by HPLC. 
Traces show SeMet treated with a) 1 x, b) 2 x, c) 3 x or d) 4 x molar excess of HOCl. 2 
unidentified peaks were observed in the HPLC traces at 3.1 min and 10.2 min. A dose-
dependent decrease of SeMetO was observed with increasing HOCl. Initially the peak at 
3.1 min increased, followed by a decrease with increasing HOCl. The peak at 10.2 min was 
increased at 1 x excess of HOCl, followed by a decrease at 2 x molar excess and stayi 
consistent with 3 – 4 x excess. 
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The differences observed between HOCl and H2O2 treated SeMet samples in the 
mass spectrometry and NMR data, and the unidentified peaks in the HPLC traces after 
excess HOCl treatment suggested that HOCl could give rise to additional products to 
H2O2, potentially by further reaction with SeMetO. As HOCl is also reactive with the 
amine group, whereas this is not a favourable site for reaction with H2O2, the reaction 
of SeMetO with HOCl was monitored by UV-vis spectroscopy, to assess potential N-
chloramine formation and decay. N-Chloramines typically absorb at 250 nm [554], 
therefore changes in absorbance in this region as the reaction progresses may indicate 
N-chloramine formation. SeMetO (500 µM) formed by reaction of SeMet (1 mM) with 
excess concentrations of H2O2 (2.5 mM) was mixed with HOCl (2 mM) using a stopped-
flow instrument, and the change in absorbance measured, between 200 and 300 nm 
with 5 nm steps for 30 s (Figure 3.15). An initial increase in absorbance was observed 
over the first 6 s in the range between 250 - 280 nm as demonstrated at 260 nm (Figure 
3.15 a), before a subsequent decrease in absorbance. This is potentially due to the 
formation of N-chloramines and subsequent rapid decay. Absorbance changes 
consistent with 2 phases were also observed in the 200 – 235 and 290 – 300 nm ranges, 
with an initial fast increase in absorbance, followed by a slower further increase in 
absorbance as demonstrated by absorbance changes at 290 and 225 nm (Figure 3.15 
b,c). This is likely due to the formation of the final products that may be further 
oxidation of the selenium centre forming a selenone analogous to MetSO oxidation 
[88], or aldehyde formation due to N-chloramine decay [86]. As the data is preliminary 
and the mechanism is not well characterised, kinetic analysis to determine rate 
constants cannot be performed. However, from these data presented, the observed rate 
constant was determined to be 0.582 for the intial reaction of SeMetO and HOCl. This 
gives an estimated rate constant of 5.82 x 105 M-1 s-1, which is in the same order of 
magnitude as the formation of other chloramines [60].  
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Figure 3.15 – Absorbance vs time traces when pre-formed SeMetO was mixed with 
HOCl at 260, 290 and 225 nm.  
SeMetO (250 µM) and HOCl (500 µM) were mixed in stopped flow apparatus and 
absorbance changes between 200 and 300 nm were monitored for 30 seconds. 
Absorbance vs time plots are shown for a) 260 nm, b) 290 nm and c) 225 nm. 2 phase 
kinetics were observed, at each wavelength with a fast initial phase followed by a slow 
second phase.  
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 SeTal oxidation products 
The data presented in the previous section demonstrate that HOCl and N-
chloramines react with SeMet to form a selenoxide, though with HOCl there is also 
evidence for the formation of further oxidation products. As SeTal is a selenoether that 
is also capable of reacting rapidly with MPO-derived oxidants including HOCl [486], 
selenoxides are a likely product of this reaction. However, the products of these 
reactions have not yet been characterised upon exposure of SeTal to HOCl and N-
chloramines. Experiments were therefore undertaken to characterise potential 
products, using mass spectrometry and NMR spectroscopy, and to quantify the 
conversion of SeTal to these products in each case. 
3.3.6.1 Mass spectrometry 
Initial mass spectrometry studies with SeTal were undertaken with SeTal (250 µM) 
in a solution containing methanol (50 % (v/v)) and formic acid (0.01 % (v/v)). 
However, no signal was detected at around m/z 229 which is the expected mass for 
ions of the H-adduct of SeTal, [SeTal+H]+. This is attributed to a low extent of ionisation 
of SeTal due to the absence of facile protonation sites. Thus, further experiments were 
undertaken in the presence of NaCl (500 µM) with the expectation that the 
[80SeTal+Na]+ ion might be detected at m/z 251.3, as reported previously [486]. As 
anticipated, a group of peaks centred at m/z 251.3 (Figure 3.16a), attributed to 
[80SeTal+Na]+, were detected, with the expected isotope ratios for selenium 
(demonstrated by computer simulation in Figure 3.16b). However, additional peaks 
were detected at m/z 255.0, 257.0 and 259.0. These are attributed to Na adducts of 
contaminants, as they are also observed with NaCl in the absence of SeTal (Figure 
3.16e). 
Following detection of the parent [80SeTal+Na]+ ion, HOCl oxidation of SeTal was 
investigated by taking SeTal in H2O (500 µM) and mixing with HOCl (400 µM), before 
incubating at 21 °C for 5 min. The resulting solution was mixed in equal volumes with 
0.02% (v/v) formic acid in methanol and analysed by mass spectrometry. NaCl was not 
added to the samples in this case as the HOCl solution contains high levels of NaCl. The 
major product peak detected was characterised by an increase of 16 mass units at m/z 
267.2 (Figure 3.16c) when compared to the parent Na+ adduct ion, with this attributed 
to [80SeTalO+Na]+ (demonstrated by a computer model in Figure 3.16d). Weak signals 
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corresponding to that of the H+ adduct product [80SeTalO+H]+ were also detected at 
m/z 245.3, but these were partially obscured by residual parent [SeTal+Na]+ peaks.  
In order to further characterise the SeTal product and determine the site of oxygen 
incorporation, MS/MS studies of the [80SeTalO+Na]+ ion were undertaken. This gave 
rise to numerous fragments (Figure 3.17). The major fragment, m/z 248.9, 
corresponded to a loss of 18 mass units, consistent with loss of water from the 
[80SeTalO+Na]+ ion. Two subsequent losses of 30 mass units to give ions with m/z 218.8 
and 188.8, are both consistent subsequent elimination of two CH2O groups from 
[80SeTalO+Na-H2O]+. A final loss of 26 mass units to give the fragment at m/z 162.8 is 
consistent with C2H2 loss. The suggested structures of these ions and fragmentation 
mechanism are presented in Figure 3.18. 
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Figure 3.16 – Mass spectra of SeTal and the proposed oxidation product SeTalO 
a) SeTal (500 µM) and NaCl (500 µM) were mixed with an equal volume of formic acid 
(0.02 % (v/v)) in methanol and analysed by mass spectrometry. The peak at m/z 251.3 
corresponds to [80SeTal+Na]+ ion as shown by a simulation in b), with the surrounding 
peaks consistent with the Se isotope pattern. The peaks at m/z 255.0, 257.0 and 259.0 are 
due to NaCl present in sample, and are observed in e) NaCl (500 µM) control. b) SeTal in 
H2O (500 µM) was mixed with HOCl (400 µM) and incubated at 22 °C for 5 min and then 
mixed in equal volumes with formic acid (0.02 % (v/v)) in methanol and analysed by mass 
spectrometry. The peak at m/z 267.2 represents a mass increase of 16 mass units from 
the parent [80SeTal+Na]+ ion consistent with selenoxide formation with the major ion 
attributed to [80SeTalO+Na]+ as shown by a computer simuution in d). Simulations were 
produced using QualBrowser by inputting empirical formulae with Gaussian outputs with 
a 0.4 Da resolution and full width half maximum valleys. 
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Figure 3.17 – MS/MS fragmentation pattern of the m/z 267.2 ion attributed to 
[SeTalO+Na]+ 
SeTal in H2O (500 µM) was mixed with HOCl (400 µM) and incubated at 21 °C for 5 min, 
prior to mixing with equal volumes of 0.02% (v/v) formic acid in methanol and analysis 
by mass spectrometry. MS/MS was performed on the ion with m/z 267.2 that is assigned 
to [SeTalO+Na]+, and gives rise to ions with m/z 247.8, consistent with loss of water 
[SeTalO+Na-H2O]+. Peaks at 218.8 and 188.8 correspond to losses of 30 mass units, 
consistent with 2 subsequent losses of CH2O, [SeTalO+Na-H2O-CH2O]+, and [SeTalO+Na-
H2O-(CH2O)2]+ respectively. The peak at m/z 162.8 represents a further loss of 28 mass 
units consistent with loss of C2H2, [SeTalO+Na-H2O-(CH2O)2-C2H2]+. Proposed structures 
are shown in Figure 3.18. 
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Figure 3.18 – Proposed fragmentation pattern of SeTalO 
Figure shows the proposed fragments observed in Figure 3.17 arising from MS/MS 
analysis of the peak at 267.2 when SeTal is treated with HOCl.  
3.3.6.2 NMR spectroscopy 
The data presented in the previous section are consistent with the addition of an 
oxygen atom to the SeTal structure. As such, the proposed product was tentatively 
assigned as a selenoxide (Figure 3.18). NMR spectroscopy studies were performed in 
order to fully characterise the proposed species. SeTal (5 mg, 22 µmoles) in H2O was 
reacted with equimolar concentrations of HOCl for 15 min at 22 °C. Samples were dried 
overnight using a rotational vacuum concentrator (Christ, Osterodeam Harz, 
Germany). The resulting white solid was dissolved in 600 µL D2O and analysed by 1H 
NMR spectroscopy, as well as acquisition of the NMR spectra of the parent SeTal 
compound. The spectra for SeTal agree with previous results, and peaks are assigned 
in Figure 3.19 and Figure 3.20 
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Figure 3.19 – 1H NMR spectrum for SeTal 
SeTal (5 mg) was dissolved in 600 µL D2O and the 1H NMR spectrum collected. Chemicals 
shifts are reported relative to the residual H2O peak which was set to 4.64 ppm. 
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Figure 3.20 – 13C NMR spectrum for SeTal 
SeTal (5 mg) was dissolved in 600 µL D2O and the 13C NMR spectrum collected. Chemical 
shifts reported as relative ppm. 
The 13C NMR spectrum for the oxidised SeTal sample showed a total of 12 product 
carbon environments for SeTalO, all with similar intensity signals (Figure 3.21). This 
suggests the formation of two products on exposure of SeTal to HOCl, as SeTal only 
contains 6 carbons. As addition of an oxygen to the selenium centre can form either R 
or S isomers of the selenoxide (Figure 3.22), this is consistent with the formation of 
SeTalO. The 13C peaks were assigned after analysis of the COSY and HSQCAD spectra, 
though relative ppm is reported here for ease of explanation. All 12 peaks can be 
attributed to products (Table 3.5), as they are shifted from the parent compound peaks 
(Figure 3.20), particularly those at lower ppm values, which are closer to the selenium 
centre. For example, carbon A shifts from 26.6 ppm in the parent SeTal to 55.6 and 51.5 
ppm in the R and S isomers respectively. The shift in ppm is consistent with the 
shielding caused by addition of oxygen to the selenium centre. As the intensities of all 
peaks are similar, this suggests the products are formed in almost equal ratios. 
A	
B	
C	
D	
E	
F	
AB	C	 D	 E	F	
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Figure 3.21 – 13C NMR spectra for SeTal treated with HOCl 
SeTal (5 mg; 22 µmoles) was dissolved in water, mixed with equimolar HOCl, dried 
overnight and redissolved in 600 µL D2O before analysis by 13C NMR spectroscopy. 
Chemical shifts are reported as relative ppm. Two species with similar concentrations 
were detected, and determined to be isomers of SeTalO. Peak assignment is given in Table 
3.5 
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Table 3.5 – 13C NMR chemical shifts for selenoxide formed on reaction of SeTal with 
HOCl. 
 
 
 
 
 
 
Figure 3.22 – R and S stereoisomers of SeTalO 
The 1H NMR spectrum shows 13 peaks, which corresponds to each isomer 
containing 7 proton environments, with the peak at a chemical shift of 4.74 being an 
overlapping signal for a proton environment in both isomers (Figure 3.23).  The 
relative peak integral area supports this, with an integration value consistent with 2 
protons being present. The peak identities are reported in Table 3.6, and were assigned 
using COSY analysis, which are discussed later. The product peaks are shifted 
downfield from their parent counterparts (Figure 3.19). For example, the protons in 
environment B in both R and S isomers give rise to a signal at 4.74 ppm, compared to 
4.34 in the parent SeTal spectrum. The down field shift is consistent with shielding 
observed by the addition of an electronegative atom such as oxygen. 
Environment R S 
A 55.571 51.497 
B 76.725 76.725 
C 78.679 78.478 
D 76.073 62.889 
E 70.928 72.184 
F 67.722 66.793 
A 
B C 
D 
E 
F 
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Figure 3.23 – 1H NMR spectrum for SeTal treated with HOCl 
SeTal (5 mg; 22 µmoles) dissolved in water, mixed with equimolar HOCl, dried overnight 
and redissolved in 600 µL D2O before analysis by 1H NMR spectroscopy. Chemical shifts 
are reported as ppm relative to the residual H2O peak set to 4.64 ppm. Two species with 
similar concentrations were observed, and determined to be isomers of SeTalO. Proton 
environment and J-coupling constants are assigned in Table 3.6. 
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Table 3.6 - 1H NMR chemical shifts for selenoxide formed on reaction of SeTal with 
HOCl. 
Chirality R S 
Environment ppm Splitting H ppm Splitting H 
A1 3.71 d; J = 4 1 3.25 d; J = 14 1 
A2 2.79 dd; J = 14, 4 1 2.87 dd; J= 14 1 
B 4.74 obscured 1 4.74 Obscured 1 
C 4.13 dd; J = 12, 4 1 4.45 dd; J = 11, 3 1 
D 3.32 dd J = 11, 4 1 3.36 dd; J = 9 1 
E 4.10 obscured 1 4.08 obscured 1 
F 3.72 dq; J= 70, 12, 4 2 3.76 dq; J = 13, 3 2 
 
Heteronuclear single quantum coherence experiments (HSQCAD) correlate carbon 
centres with coupled protons. Signals are observed in the 2D spectrum where the 
proton signal (across the top) is bound to the carbon (down the left) (Figure 3.24), and 
allows for the determination of which protons are bound to which carbon centres. The 
correlation for the proton signals bound to carbon A are outlined as an example. The 
HSQCAD spectra demonstrated a significant shift in 2 protons bound to the carbon A in 
the R isomer at chemical shifts of 2.79 and 3.71, and a similar though smaller shift 
between protons bound to carbon A in the S isomer at 2.87 and 3.25. A large shift in 
proton environments suggests that one proton from the pair has become significantly 
shielded compared to the other. This is consistent with the addition of oxygen on an 
adjacent atom.   
A1, A2 
B C 
D 
E 
F 
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Figure 3.24 – HSQCAD spectra for SeTalO treated with HOCl 
SeTal (5 mg; 22 µmoles) dissolved in water was mixed with equimolar HOCl, dried 
overnight and redissolved in 600 µL D2O was analysed by HSQCAD NMR. Peaks reported 
as ppm relative to the residual H2O peak set to 4.64 ppm. 
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The formation of a selenoxide would result in the addition of oxygen to the Se atom 
in SeTal, giving rise to chirality around the Se.  As SeTal is cyclic in structure, the 
formation of R and S isomers of SeTalO (structures in Figure 3.22) would be expected 
to differentially shield protons above and below the plane of the ring. Assuming that 
the Se atom is above the plane of the ring structure due to steric considerations, the R 
isomer, where the oxygen is bound in plane with the ring, would be expected to shield 
the protons axial to the ring. In the S isomer, where the oxygen is out of plane with the 
ring, smaller shifts would be expected due to lower shielding. Hence, the protons 
observed with the more significant shifts are attributed to the R isomer.  
Homonuclear correlation spectroscopy (HHCOSY) correlates spin-coupled protons. 
Signals are observed in the 2D spectrum where 2 proton environments are spin-
coupled (Figure 3.25). Therefore signals off the diagonal indicate protons that are on 
adjacent carbons. This allows for the determination of proton environments that are 
adjacent to one another, and the assignation of peaks. Protons coupling with the peak 
at 4.74 is outlined as an example. As this represents an overlapping proton 
environment from both the R and S isomer, it appears to be coupled to 6 other proton 
environments. From the HSQCAD spectrum, the signals at 2.79 and 3.71 ppm represent 
protons bound to carbon A in the R isomer, and signals at 2.87 and 3.25 ppm represent 
the protons from the S isomer. Therefore the signals at 4.13 and 4.45 ppm must 
represent the protons from position C. The further down field proton is assigned to the 
S isomer, due to the greater effect of the oxygen being above the ring. The proton 
assignation was confirmed using J-coupling values and splitting patterns observed in 
the 1H spectrum, where these values could be determined.  Once the 1H spectrum was 
assigned, analysis of the HSQCAD spectrum (Figure 3.24) allowed for the carbon 
centres to be assigned (Table 3.5). 
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Figure 3.25 – HHCOSY spectra for SeTalO treated with HOCl 
SeTal (5 mg; 22 µmoles) dissolved in water was mixed with equimolar HOCl, dried 
overnight and redissolved in 600 µL D2O was analysed by HHCOSY NMR. Peaks are 
reported as ppm relative to the residual H2O peak set to 4.64 ppm.  
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3.3.6.3 Standard quantification for HPLC 
1H NMR spectroscopy was used a method of quantifying the selenoxide standard 
for use in HPLC.  SeTal was produced by the reaction of SeTal (22 µmol) with equimolar 
concentration of HOCl for 15 min. The sample was divided into 2 aliquots and dried 
overnight in a rotational vacuum concentrator (Christ, Osterodeam Harz, Germany). 
One aliquot of the resulting white solid was dissolved in 600 µL D2O, before addition of 
the internal standard dimethyl sulfone (DMSO2) (5.3 µM). The 1H NMR spectra was 
collected (Varian VNMRS 500 MHz), and the concentration of SeTal determined by 
comparison of dimethyl sulfone peaks (∂ = 3.15 ppm, 6H) to SeTalO peaks (∂ = 4.74, 2H 
– 1H from the R and S isomer each). The concentration of SeTalO recovered was 
determined to be 15 mM, which represents a ~ 96 % recovery of SeTalO. 
 Selenoxide formation upon exposure of SeTal to HOCl and N-chloramines 
The mass spectrometry and NMR data demonstrated formation of SeTalO upon 
addition of HOCl to SeTal, however, the stoichiometry for this reaction could not be 
determined from these experiments. As such, an HPLC method was developed in order 
to quantify the conversion of SeTal to SeTalO upon addition of HOCl and model N-
chloramines.  
3.3.7.1 HPLC method development 
Initially SeTal oxidation experiments were attempted using the same buffer and 
column conditions as those reported for SeMet oxidation experiments (Section 3.3.3.1). 
However, the SeTalO species was not retained by the column very efficiently and eluted 
immediately after the solvent front. As a result, a carbohydrate specific column was 
sourced and found to give excellent separation of SeTal and SeTalO. The method is 
described in Section 2.3.5.3, and example chromatograms can be seen in Figure 3.26.  
3.3.7.2 Quantification of SeTalO formation 
Oxidation of SeTal to SeTalO by HOCl, TauCl and BSA-Cl was assessed using the 
HPLC method as optimised above. SeTalO standards were prepared by exposing SeTal 
to HOCl and were standardised by 1H NMR spectroscopy using an internal standard of 
dimethylsulfone as described in Section 3.3.7. SeTal (160 µM) was mixed with HOCl, 
TauCl or BSA-Cl (0 – 320 µM) and allowed to react for 15 min at 22 °C before filtering 
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and analysis by HPLC (Figure 3.26). Addition of 40 µM of oxidant caused a decrease in 
area of the SeTal peak. The decrease was concentration dependent with smaller areas 
observed with higher concentrations of oxidant added. The decreases in SeTal area 
corresponded with an increase in the area for the SeTalO peak. 
 
Figure 3.26 – Representative chromatograms of SeTal exposed to 0 - 200 µM HOCl 
SeTal (160 µM) was mixed with HOCl (0 µM (unbroken line), 120 µM (dashed line) or 200 
µM (dotted line)) and analysed by HPLC. A dose-dependent decrease in the parent SeTal 
peak area (2.7 min) was observed, with a concomitant increase in the SeTalO peak area 
(4.4 min).  
An initial loss of 40 µM SeTal was observed with addition of 40 µM HOCl to 160 µM 
SeTal, with a corresponding (40 µM) increase in the SeTalO concentration (Figure 
3.27a,b). As the concentration of HOCl increased, further dose-dependent decreases of 
SeTal were observed until SeTal was completely consumed at a concentration of 200 
µM HOCl. This corresponded to increases in SeTalO, which reached a maximum 
concentration (151 µM) after addition of 200 µM HOCl. TauCl addition resulted in a 
similar trend with SeTal totally consumed at 200 µM TauCl, which corresponded to a 
maximum SeTalO yield of 153 µM (Figure 3.27c,d). HOCl and TauCl consumed SeTal in 
a ratio that was very close to 1 : 1, with concentrations of SeTalO observed very similar 
to the concentrations of SeTal consumed. Maximum conversion of SeTal to SeTalO was 
achieved with 200 µM HOCl or TauCl with a 94% and 96% conversion respectively. 
BSA-Cl addition exhibited a dose-dependent decrease in SeTal concentration with a 
corresponding SeTalO increase, however, BSA-Cl did not completely consume SeTal 
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until a 2 : 1 BSA-Cl to SeTal molar ratio was reached, with a maximum conversion to 
SeTalO of 91% (145 µM) (Figure 3.27e,f).   
 
Figure 3.27 – Oxidation of SeTal to SeTalO by HOCl, TauCl and BSA-Cl 
SeTal (160 µM) was mixed a,b) HOCl, c,d) TauCl or e,f) BSA-Cl (with 0 – 320 µM) and 
incubated for 15 min at 22 °C before analysis by HPLC. a,c,e) show dose-dependent 
decrease in SeTal upon addition of increasing concentration of each oxidant. b,d,f) show 
a corresponding increase in SeTalO concentration. * indicates significant difference from 
control (0 µM oxidant) based on one-way ANOVA with Dunnett’s post-hoc test. Data 
represent the mean ± SD from 3 independent experiments. 
 Discussion 
The studies reported in this Chapter examined the reaction between the 
selenoethers, SeMet and SeTal, and oxidants derived from neutrophils, primarily HOCl 
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and N-chloramines. It has been shown that SeMet and SeTal rapidly scavenge oxidants 
produced by MPO/H2O2/Cl- and neutrophils, and that the primary oxidation product 
formed upon reaction with HOCl, TauCl and BSA-Cl was the respective selenoxide.  
Met, SeMet and SeTal were capable of reducing concentrations of TauCl present in 
samples 30 min after initiation of HOCl formation by either an isolated MPO-system or 
neutrophils. This suggests that SeMet and SeTal may be scavenging HOCl directly 
before TauCl formation, as the rate constants for this reaction are 108 M-1 s-1 [90] for 
both species, compared to 105 M-1 s-1 for N-chloramine formation [60]. Alternatively, 
this may be occurring by direct scavenging of H2O2 by Met, SeMet and SeTal, reducing 
the total HOCl and hence TauCl formation, as selenoethers are known to react with 
H2O2 [454, 464, 569, 571]. However the reaction kinetics for the reaction of Met and 
H2O2 are slow (reported as 13.95 M-1 h-1 (3.9 x 10-3 M-1 s-1) at pH 4.5) [573], and while 
rate constants for SeMet and SeTal with H2O2 have not been determined, the rate 
constants for H2O2 oxidation of similar selenoethers are in the range of 10 - 102 M-1 s-1 
[569]. As MPO has favourable kinetics for the consumption of H2O2 [24], it is reasonable 
to suggest that HOCl is being produced under these conditions. Alternatively, if SeMet 
and SeTal do not react directly with HOCl, they may be scavenging TauCl after its 
formation prior to assay with TMB. 
SeMet is known to be oxidised to SeMetO by H2O2, ONOOH and flavin containing 
monooxygenases [461, 464, 571]. The primary oxidation product detected in the 
current study when SeMet and SeTal were oxidised by HOCl, TauCl and BSA-Cl was the 
respective selenoxide, SeMetO or SeTalO. The stoichiometry of the reaction for SeTal is 
very close to a 1 : 1 reaction of HOCl and TauCl with SeTal, with SeMet occuring less 
efficiently with ca. 85 % of SeMet being converted to SeMetO. HOCl oxidation of SeMet 
also gave rise to a small amount of a second product, which is proposed to be 
dehydroselenomethionine on the basis of mass spectrometry results. This is analogous 
to the formation of dehydromethionine upon oxidation of Met by HOCl and N-
chloramines [115]. In the current study, dehydroselenomethionine was not detected 
when SeMet was oxidised by H2O2. With only 85 % conversion SeMetO upon exposure 
of SeMet to HOCl or N- chloramines, formation of dehydroselenomethionine may 
account for some of the “missing” SeMet that does not form SeMetO. While the 
concentrations of dehydroselenomethione formed were not quantified in this study, it 
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may be possible quantify dehydroselenomethionine concentrations via the use of an 
iodine assay, as dehydromethionine has been detected via reaction with iodide to form 
iodine at low pH, or by a HPLC method [115]. 
Alternatively, the formation of selenones may be occuring, analogous with sulfone 
formation on Met. Oxidation of MetSO leads to the formation of methionine sulfone, 
though the reaction occurs slowly [88]. While selenone formation may be possible, 
direct evidence for the formation of the selenone has not been reported.  The data 
presented in this Chapter do not appear to indicate selenone formation. 
Reaction of excess HOCl with SeMet resulted in a loss of SeMetO, suggesting 
potential further reactions. Initial studies demonstrated that SeMetO treated with HOCl 
showed a loss of SeMetO that was not observed with H2O2. This decrease in SeMetO 
corresponded to an increase in unidentified peaks detected by HPLC. UV-vis data 
collected on stopped flow instrumentation demonstrated an initial increase at ca. 250 
nm followed by a rapid decrease in intensity. As reactivity was not observed with H2O2 
and the absorbance changes occur around 250 nm, which is the region where N-
chloramines absorb, it suggests that the further reactivity of SeMetO with HOCl is 
mediated through chlorine chemistry at the amine site. Furthermore, SeTalO did not 
exhibit reactivity with HOCl, further implicating reaction via the amine site.  
N-Chloramine formation may be more significant for reaction of SeMetO and HOCl 
than for SeMet, though chloramine formation on SeMet has not been assessed. Whilst 
N-chloramines are known to be generated on amino acids with rate constants of ca. 105 
M-1 s-1 for α-amino acid, and HOCl reacts with SeMet at a rate of 108 M-1 s-1, indicating 
that formation of SeMetO is kinetically favourable [60, 90]. Furthermore, N-
chloramines are capable of oxidising SeMet to SeMetO, so it is conceivable that any N-
chloramines formed on SeMet would react with a second SeMet to form SeMetO. 
However, in the case of SeMetO, oxidation of SeMetO to the selenone is likely to be 
significantly slower than SeMetO formation, if the chemistry is similar to sulfur 
chemistry. This may mean that the N-chloramine formation becomes more favourable 
once initial oxidation of the selenium centre to the selenoxide has occurred. The decay 
of the N-chloramine, observed at ~ 260 nm, could be due to formation of an aldehyde 
species, consistent with other N-chloramines [86], which may account for the 
unidentified peaks in the HPLC trace. 
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The [SeMetO+H]+ formed from SeMetO was not detected by mass spectrometry 
under the conditions used in this study, though the 1H NMR data confirm formation of 
SeMetO. Gamelgaard has previously detected SeMetO at m/z 214 for [80SeMetO+H]+, 
when SeMet was treated with H2O2 and then subsequently exposed to microwaves 
[571]. This is potentially due to microwave induced homolysis of H2O2 forming HO• 
radicals (as previously suggested [574]), which may induce the formation of 
dehydroselenomethionine. Gamelgaard also detected peaks at m/z 196.3 (as observed 
in the current study), which was attributed to [SeMetO+H-H2O]+, suggesting a loss of 
water after ionisation. The ions detected in the current study at m/z 196.3 have been 
attributed to the formation of dehydroselenomethonine, as they were only detected in 
HOCl treated samples. If the source of the m/z 196.3 ion was due to the loss of water 
from SeMetO, these ions should also be detected in H2O2 treated SeMet. 
The data obtained in the current study suggest that selenium compounds react 
more rapidly with N-chloramines than the analogous sulfur compounds. The second 
order rate constants for SeMet determined in this study (k2 = (0.8 – 3.4) x 103 M-1 s-1) 
are at least ten times greater than those previously reported for Met (k2 = (0.4 – 2.0) x 
102 M-1 s-1) [192]. This is consistent with data for other MPO-derived oxidants, HOCl, 
HOSCN and HOBr, for both SeMet and SeTal and their respective sulfur analogues [90, 
98].  
N-chloramines formed in a biological setting are reported to display a selectivity 
for thiols, which can lead to protein inactivation if the targeted thiol is part of the active 
site of an enzyme [245]. GSH, a major intracellular thiol antioxidant, would be expected 
to be a major target of N-chloramines in vivo, with second order rate constants in the 
range of (1.1 – 2.6) x 102 M-1 s-1 [192], which are some of the fastest reported for N-
chloramines. This reactivity is similar to that reported for various peroxides, which 
have been shown to preferentially oxidise SeMet in the presence of the thiol- and 
thioether-containing targets GSH and Met [474]. As the reaction of N-chloramines and 
SeTal has similar rate constants to that of GSH, and SeMet rate constants are ca. 10 
greater than GSH, it suggests that selenoethers should provide a potential target for N-
chloramine reactions in vivo, providing that they are present in sufficient 
concentration.  
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 Conclusions 
The data in this Chapter demonstrate that SeMet and SeTal are capable of reacting 
rapidly with HOCl and model N-chloramines (Figure 3.28). The primary products of 
these reactions are selenoxides, which have been characterised here by mass 
spectrometry and NMR spectroscopy. The second order rate constants for these 
reactions determined in these studies suggest that SeMet and SeTal will be competitive 
in vivo targets for the oxidants. The following Chapter investigates potential 
subsequent reactions that may be mediated by selenoxides.  
 
Figure 3.28 – SeMet and SeTal react with MPO-derived chlorinating oxidants to 
produce selenoxides. 
 120 
4 Reduction of selenoxides by thiols 
 121 
 Introduction 
Selenoxides are the major product formed when selenoethers are oxidised by 
peroxides and MPO-derived oxidants [444, 464]. Selenoxides can be subsequently 
reduced by thiols [444, 445]. Thiol-containing compounds, including GSH, are capable of 
reducing SeMetO to SeMet, forming a disulfide (Reaction 4.1). Ascorbate is also capable 
of reducing SeMetO, though this process is significantly slower than for thiols [445]. 
𝑆𝑒𝑀𝑒𝑡𝑂 + 2𝑅𝑆𝐻 → 𝑆𝑒𝑀𝑒𝑡 + 𝑅𝑆𝑆𝑅 + 𝐻2𝑂 Reaction 4.1  
One electron reduction of SeMetO has also been demonstrated through pulse 
radiolysis studies [473]. The reduction is very fast with hydrated electrons, occurring 
with a rate constant near the diffusion limit (k = 1010 M-1s-1), and with k = 5.9 x 108 M-1s-
1 and 3.5 x 107 M-1s-1 for the one electron reductants CO2•- and (CH3)2C•OH respectively 
[473]. The rate of one electron reduction is enhanced by a nitrogen-selenium non-
covalent interaction [473]. 
The facile reduction of selenoxides has given rise to the hypothesis that selenium 
compounds may be able to catalytically scavenge oxidants in vivo. Numerous 
selenoethers and other selenocompounds have been described as GPx mimetics, with 
ebselen being one of the first described [441, 443, 490, 569, 575]. These GPx mimetics 
catalyse the reaction between GSH and H2O2 or other oxidants, which may be lead to a 
decrease in oxidative damage.  
SeMet and SeTal can react rapidly with MPO-derived oxidants to produce the 
corresponding selenoxides [90, 486]. In order for SeMet and SeTal to act as catalytic 
oxidant scavengers, the reduction of the selenoxides must also be a favourable and rapid 
reaction, otherwise a build-up of selenoxide would occur, and inhibit the catalytic cycle.  
This Chapter explores the reaction rate constants and mechanisms of selenoxide 
reduction in order to determine the feasibility of the proposed catalytic scavenging cycle 
in biological systems.  
 Aims 
The aim of the studies presented in this chapter was to assess and quantify the ability 
of thiols to reduce selenoxides formed on SeMet (and related selenoethers) and SeTal. 
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This was achieved by monitoring the concentration of reaction products after thiols 
were mixed with selenoxides, and by determining the rate constants and mechanisms of 
these reactions. 
 Results 
 Selenoxides oxidise thiols 
Previous studies have demonstrated that SeMetO is reduced by thiols, including GSH, 
forming SeMet and GSSG [444, 445]. It was therefore hypothesised that GSH should be 
capable of reducing other selenoxides, including SeTalO and an analogue of SeMetO, 
methylselenocysteine selenoxide (MSCO). In order to assess this hypothesis, the loss of 
thiols upon reaction of various selenoxides with GSH was examined using the ThioGlo 
assay to monitor thiol concentration. SeMetO, SeTalO or MSCO (0 – 1 µM) were added to 
GSH (4 µM) and incubated for 10 min at 22 °C. Remaining thiol levels were determined 
by the ThioGlo assay (Figure 4.1).   
Initial experiments examined the loss of thiols upon SeMetO addition (Figure 4.1 a). 
Addition of 0.2 µM SeMetO to 4 µM GSH resulted in a loss of approximately 0.4 µM GSH. 
Further addition of SeMetO dose-dependently decreased the GSH concentration with the 
maximum addition of 1 µM SeMetO decreasing the GSH concentration by 2 µM. This 
represents a 2 : 1 stoichiometry of the reaction of GSH and SeMetO, which is consistent 
with previous reports [444, 445]. Similar experiments were performed with SeTalO and 
MSCO. Addition of these selenoxides also resulted in a dose-dependent decrease in GSH 
concentration. The observed stoichiometry was 2 : 1: for GSH to selenoxide added.  
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Figure 4.1 – Concentration of GSH remaining after selenoxide addition 
a) SeMetO, b) SeTalO or c) MSCO (0 – 1 µM) was added to GSH (4 µM) and incubated for 
10 min at 22 °C. Remaining thiol levels were determined by ThioGlo assay. Thiol levels dose-
dependently decreased upon addition of selenoxides in all cases. * represents a significant 
decrease (p < 0.05) in thiol concentration compared to control (0 µM selenoxide) based on 
one-way ANOVA with a Tukey’s post-hoc test. Data represent mean ± SD of three 
independent experiments. 
 GSH reduces selenoxides 
The above data indicate that selenoxides are capable of consuming GSH, consistent 
with previous reports of selenoxide reduction by thiols [444, 445]. As SeTalO also caused 
a decrease in thiol levels upon addition to GSH, it was anticipated that the reduction of 
the SeTalO was also occurring. In order to assess these hypotheses, products of the 
reaction between SeMetO and SeTalO with GSH were assessed by HPLC. 
4.3.2.1 Reduction of SeMetO 
Initial experiments assessed the ability of GSH to reduce SeMetO, formed by reaction 
of SeMet (3.2 mM) with HOCl (1.6 mM).  An excess of SeMet was used in order to 
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minimise the formation of products other than SeMetO. Preformed SeMetO (1.6 mM) 
was mixed with GSH (0 – 3.2 mM) and incubated for 10 min at 22 °C before a 10-fold 
dilution into H2O and analysis by HPLC. 
Addition of 0.4 mM GSH caused a decrease in the peak area of SeMetO, with a 
corresponding increase in the SeMet peak area (Figure 4.2). Furthermore a peak for 
GSSG was observed, and no GSH peak was observed, suggesting complete conversion of 
GSH to GSSG on reaction with SeMetO. Upon addition of increasing GSH concentrations, 
further decreases in SeMetO peak size were observed, with increases in the peak area 
for both SeMet and GSSG. 
 
Figure 4.2 – Representative chromatograms of SeMetO (1.6 mM) exposed to GSH (0 – 3.2 
mM) 
SeMetO (1.6 mM) was mixed with 0 (unbroken line), 1.2 mM (dashed line) or 3.2 mM (dot-
dashed line) GSH and incubated for 10 min at 22 °C, prior to 1 in 10 dilution into H2O and 
HPLC analysis with UV detection at 230 nm. A dose-dependent decrease of SeMetO was 
observed with increasing GSH, and this corresponded to an increase in SeMet and GSSG 
concentrations. Arrows indicate direction of peak change observed with increasing GSH 
concentration. 
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Upon quantification (Figure 4.3), a dose-dependent decrease of SeMetO was 
observed with increasing GSH concentration. Approximately 0.2 mM SeMetO was 
reduced for every 0.4 mM GSH added to SeMetO. This corresponded with an equal 
increase in SeMet and GSSG, of about 0.2 mM each for every 0.4 mM GSH added. These 
data are consistent with the reduction of SeMetO to SeMet by GSH, with the expected 
stoichiometry observed as described in Reaction 4.2. 
𝑆𝑒𝑀𝑒𝑡𝑂 + 2𝐺𝑆𝐻 → 𝑆𝑒𝑀𝑒𝑡 + 𝐺𝑆𝑆𝐺 + 𝐻2𝑂 Reaction 4.2  
 
Figure 4.3 – GSH (0 – 3.2 mM) reduces SeMetO (1.6 mM) forming SeMet and GSSG 
SeMetO (1.6 mM), formed by the reaction of SeMet and HOCl, was mixed with GSH (0 – 3.2 
mM) and incubated for 10 min before 1 in 10 dilution into H2O and analysis by HPLC. 
Species measured were a) SeMetO, b) SeMet and c) GSSG. A dose dependent decrease in 
SeMetO was observed with increasing GSH concentration, which corresponded with a 
stoichiometric increase in SeMet and GSSG formation. * represents a significant difference 
(p < 0.05) from control (0 mM GSH) based on one-way ANOVA with a Tukey’s post-hoc test. 
Data represent mean ± SD of three independent experiments. 
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4.3.2.2 Reduction of SeTalO 
The ability of GSH to reduce SeTalO was also assessed using HPLC analysis. SeTalO 
(1.6 mM), formed by the reaction of SeTal (3.2 mM) and HOCl (1.6 mM), was mixed with 
GSH (0 – 3.2 mM) and incubated for 10 min at 22 °C, before a 10-folddilution into H2O 
and analysis by HPLC. 
Addition of GSH (0 – 3.2 mM) to SeTalO (1.6 mM) resulted in a decrease in peak area 
for SeTalO, which corresponded to an increase in the peak area for SeTal (Figure 4.4). 
However, as the HPLC conditions used for the separation of SeTal and SeTalO were 
different to those employed for the separation of SeMet and SeMetO, no peak 
corresponding to GSSG or GSH was observed. It is thought that these species were 
eluting with the solvent front. Higher concentrations of GSH caused a greater decrease 
in SeTalO peak area, with a corresponding increase in SeTal peak area. 
 
Figure 4.4 – Representative chromatograms of SeTalO (1.6 mM) exposed to GSH (0 – 3.2 
mM) 
SeTalO (1.6 mM) was mixed with 0 (unbroken line), 1.2 mM (dashed line) or 3.2 mM (dotted 
line) GSH and incubated for 10 min at 22 °C, prior to 1 in 10 dilution into H2O and HPLC 
analysis with UV detection at 230 nm. A dose-dependent decrease of SeTalO was observed 
with increasing GSH, and this corresponded to an increase in SeTal. Arrows indicate 
direction of peak change observed with increasing GSH concentration. 
Analogous to SeMetO reduction, a dose-dependent decrease in SeTalO concentration 
was observed with increasing GSH concentrations (Figure 4.5). Addition of 40 µM GSH 
gave a 20 µM decrease in SeTalO, with a corresponding 20 µM increase in SeTal 
concentrations. The stoichiometry would be expected to be the same as the reaction of 
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SeMetO with GSH (Reaction 4.2). However, due to limitations with the HPLC method, 
GSSG concentrations could not be determined as they eluted with the solvent front.  
 
Figure 4.5 – GSH (0 – 3.2 mM) reduces SeTalO (1.6 mM) forming SeTal 
SeTalO (1.6 mM), formed by the reaction of SeTal (3.2 mM) and HOCl (1.6 mM), was mixed 
with GSH (0 – 3.2 mM) and incubated for 10 min before 1 in 10 dilution into H2O and 
analysis by HPLC with UV detection at 230 nm. Species measured were a) SeTalO and b) 
SeTal. A dose-dependent decrease in SeTalO was observed with increasing GSH 
concentration, which corresponded to an equal increase in SeTal formation. * represents a 
significant difference (p < 0.05) from control (0 mM GSH) based on one-way ANOVA with a 
Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments. 
 Determination of rate constants for selenoxide reduction by thiols 
As the above data indicate that GSH is capable of reducing SeMetO and SeTalO to the 
corresponding selenoethers SeMet and SeTal, in biological systems there is a potential 
for a catalytic reduction cycle where SeMet and SeTal could consume multiple 
equivalents of oxidant. However, for this to be biologically relevant, the reduction 
kinetics would need to be rapid for efficient selenoxide removal. In order to investigate 
this in more detail, stopped flow kinetic analysis was used to determine the kinetics of 
the reactions between selenoxides and thiols. 
Initially reduction of SeMetO and most biologically relevant thiol, GSH, was 
attempted. However, the reaction of SeMetO with GSH led to complex kinetics, which 
were difficult to analyse due to overlap of the selenoxide and thiol absorbance spectra 
(Section 4.3.3.4). As a result, the aromatic thiol, TNB, which absorbs at 412 nm, was used 
as a model thiol to investigate the reduction kinetics of selenoxides in an attempt to 
simplify the observed kinetic data. 
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4.3.3.1 Reduction of SeMetO and SeTalO by TNB 
TNB, which has a yellow colour, can react with oxidants to form the colourless 
disulfide DTNB [555]. As TNB and DTNB have distinguishable peak absorbance (TNB = 
412 nm; DTNB = 324 nm) [555] that do not overlap with the absorbances of selenoxides 
(200 – 300 nm), TNB presented an ideal model thiol to explore the kinetics and 
mechanisms of selenoxide reduction.  
SeMetO or SeTalO (5 µM) and TNB (25 – 125 µM) were mixed in the stopped flow 
apparatus and the absorbance monitored at 412 nm (loss of TNB, i.e. thiol consumption) 
and 324 nm (increase in DTNB product, i.e. disulfide formation). Decreases in 
absorbance over time were observed at 412 nm, consistent with a consumption of TNB, 
whilst concomitant increases in absorbance were observed at 324 nm, consistent with 
DTNB formation.  
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Figure 4.6 – Representative figures demonstrating the change in absorbance at a,c) 412 
nm or b,d) 324 nm after a,b) SeMetO (5 µM) or c,d) SeTalO (5 µM) was mixed with TNB 
(25 µM) monitored by stopped flow apparatus 
a,b) SeMetO (5 µM) or c,d) SeTalO (5 µM) was mixed with TNB (25 µM) by stopped flow 
apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the absorbance at a,c) 412 and 
b,d) 324 nm was monitored over time. In both cases, a loss in absorbance was observed at 
412 nm, indicating TNB consumption. Concomitantly, an increase in absorbance was 
observed at 324 nm, indicating DTNB formation. 
First-order (t vs. ln(Abs)) and second-order (t vs. 1/Abs) analysis of the absorbance 
data at 412 nm obtained when SeMetO or SeTalO were mixed with TNB yielded the 
graphs in Figure 4.7. For both SeMetO and SeTalO a linear first-order plot was observed, 
and the second-order plots were non-linear. The linearity of the first-order plots 
indicates a first order (or, more likely, a pseudo first-order) mechanism is occurring.  
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Figure 4.7 – First- and second-order plots for the reaction between a,b) SeMetO (5 µM) 
or c,d) SeTalO (5 µM) and TNB (25 µM) based on absorbance data obtained at 412 nm 
SeMetO (5 µM) or SeTalO (5 µM) was mixed with TNB (25 µM) by stopped flow apparatus 
in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the absorbance at 412 nm was monitored 
over time. The absorbance data obtained was then analysed by either a,c) first-order 
conditions (ln(Abs) vs time) or b,d) second-order conditions (1/Abs vs time). For both 
SeMetO and SeTalO, the ln(Abs) vs time plots were observed to be linear, indicating first-
order reaction mechanisms are occurring. 
The stoichiometry of the reaction of thiols and selenoxides indicate that for every 
one mole of selenoxide reduced, 2 moles of thiols will be consumed. Based on this, the 
reaction may be occurring via one of two mechanisms.  One potential mechanism is a 
one-step process where 2 thiol groups meet and react with the selenoxide at the same 
time. This would result in a kinetic profile demonstrating a second-order reaction with 
respect to thiols. However, a second-order reaction with respect to thiols was not 
observed (Figure 4.7).   
Alternatively, the reaction may be a two-step process where one thiol group reacts 
with the selenoxide to form a seleno-sulfide intermediate, with the rate constant for this 
step designated as k1. This intermediate could then react with a second thiol group to 
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produce the disulfide and selenoether, with the rate constant for this step designated as 
k2 (Figure 4.8). Kinetic models demonstrate that in such a 2-step system where the k1 > 
k2 (for modelling purposes a 10-fold increase of k1 over k2 was used), the thiol 
concentration [RSH] decreases exponentially and the first-order plot is linear (Figure 
4.9). k1 can then be determined from the gradient of the pseudo first-order plot. 
However, if k2 > k1, 2-phase kinetics will be observed for [RSH]. This gives a non-linear 
first-order plot, and a single exponential decay does not fit to the data well.  
 
Figure 4.8 – Proposed two-step mechanism of selenoxide reduction by thiols 
Initial reaction of selenoxides (A) with thiols is proposed to lead to the formation of a 
seleno-sulfide intermediate (B). The rate constant for the initial reaction is designated as 
k1. A second thiol then reacts with the intermediate with a rate constant k2, producing a 
selenoether (C), disulfide (D) and water (E) as products. 
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Figure 4.9 – Computational models showing reaction profile for the proposed two-step 
mechanism 
a) shows computational model (black line) of the reaction (A + RSH  C + RSH  D + E + 
F) where concentration of RSH is set to 5 M, representing a ten-fold excess of the 
concentration of A, set to 0.5 M. The rate constant for the k2 was set to 10 and k1 was set to 
1. The simulation was run for 1000 points, with the theoretical concentrations of A and 
RSH calculated at 0.001 s intervals. An exponential decay function was fitted to the data 
obtained for concentrations of RSH (white line). c) shows the same model (black line), with 
k2 set to 1 and k1 set to 10, with the exponential fit (white line). The concentration of RSH 
obtained in a) was plotted as ln[RSH] vs time in b). The concentration of RSH obtained in 
c) was plotted as ln[RSH] vs time in d). When k2 > k1 first-order conditions are observed, 
with concentration data fitting to single exponential curve, and ln[RSH] vs time plots 
linear. When k2 < k1, first-order mechanisms are not observed. Computational models were 
performed in Mechanism-Based Kinetics Simulator available at 
(http://www.stolaf.edu/depts/chemistry/courses/toolkits/126/js/kinetics/). Exponential 
fits were performed in Prism v6.  
As first-order kinetics were observed when SeMetO and SeTalO were mixed with 
TNB, based on the linearity of the first-order plots and good fits to single exponential 
decays, this suggests that the rate limiting step in this reaction is k1, based on kinetic 
modelling. The second step, k2, is not observed, which is consistent with the model. As 
the kinetics are following a first-order mechanism, the rate constant for the reaction can 
be determined from the gradient of a plot of the initial concentration of TNB against the 
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observed rate constant (kobs) for the condition. The kobs values were determined by 
fitting a single exponential curve to absorbance data in ProData Viewer (Applied 
Photophysics). The determined second-order rate constants for the reduction of SeMetO 
and SeTalO by TNB were k1 = (3.8 ± 0.1) x 104 and k1 = (4.9 ± 0.2) x 103 M-1 s-1 respectively 
(Figure 4.10). 
 
Figure 4.10 – Pseudo-first order plots for the reduction of a) SeMetO and b) SeTalO by 
TNB 
SeMetO (5 µM) or SeTalO (5 µM) was mixed with increasing concentrations of TNB (25 - 
125 µM) by stopped flow apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the 
absorbance at 412 nm was monitored over 60 s. The observed rate constant, kobs, for each 
condition was determined from the absorbance vs time plots using single exponential 
fitting in ProData Viewer software (Applied Photophysics). kobs  was plotted against the 
initial TNB concentration for a) SeMetO or b) SeTalO, and the second order rate constants 
determined from the gradients of these plots. Data represent mean ± SD of three 
independent experiments. 
The rate of DTNB production was also measured from the absorbance changes at 324 
nm by the same pseudo first-order method. The observed rate constants at 412 nm and 
324 nm were very similar, and points overlay one another in the pseudo first-order 
analysis plots of 412 and 324 nm data. The rate of DTNB production observed was not 
significantly different to the rate at which TNB was being consumed, with k1 = (3.8 ± 0.1) 
x 104 M-1 s-1 for SeMetO and (4.8 ± 0.2) x 103 M-1 s-1 for SeTalO. This supports the 
mechanism proposed where a rate-limiting intermediate formation occurs followed by 
a fast second step where the disulfide is formed.  
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Figure 4.11 – kobs determined from data measured at 324 nm (open circles) and 412 nm 
(closed circles) when SeMetO (5 µM) was mixed with increasing concentration of TNB 
(25 – 125 µM) 
SeMetO (5 µM) was mixed with increasing concentrations of TNB (25 - 125 µM) by stopped 
flow apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the absorbance at 412 or 
324 nm was monitored over 60 s. The observed rate constant, kobs, for the reaction at 412 
nm (closed circles) or 324 nm (open circles) was determined from the absorbance vs time 
plots using single exponential fitting in ProData Viewer software (Applied Photophysics). 
kobs  was plotted against initial TNB concentration for SeMetO, and the second order rate 
constant determined from the gradients of these plots. Data represent mean ± SD of three 
independent experiments. 
4.3.3.2 Reduction of other selenoxides by TNB 
The rate constant determined for the reduction of SeMetO by TNB was an order of 
magnitude greater than that for SeTalO. It was thought that this may be due to effects of 
the surrounding molecular environment of the selenoxide moiety, with the amine group 
of SeMetO potentially interacting with the selenium, and increasing the rate at which the 
reaction occurs as seen in one-electron reduction of SeMetO [473]. In order to examine 
this possibility, the rate constants for the reaction of TNB with various selenoxides with 
structures related to SeMetO were determined. 
The selenoxides were chosen based on chemical structures similar to that of SeMetO 
with the amine group either hindered or absent (Figure 4.12).  Se-Methyl selenocysteine 
selenoxide is also an α-amino acid with one carbon less in the side chain than SeMetO 
and therefore the nitrogen and selenium atoms should not be able to interact due to 
steric considerations. N-acetylselenomethionine selenoxide has the amine group of 
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SeMetO blocked by an N-acetyl group. SePropO keeps the carboxyl group the same 
distance from the Se atom, though the amine group is removed.  
 
Figure 4.12 – Structures of model selenoxides used in the determination of the 
mechanisms and kinetics of selenoxide reduction by thiols. 
MSCO, NASMO or SePropO (5 µM) were mixed with increasing concentrations of TNB 
(25 – 125 µM) and absorbance changes monitored at 412 and 324 nm (Figure 4.13). 
Upon mixing, a time dependent decrease in absorbance was observed at 412 nm, 
corresponding to consumption of TNB. At the same time, an increase in absorbance at 
324 nm was observed, corresponding to formation of DTNB. Absorbance data at 412 nm 
was used to plot both first- (ln(Abs) vs time) and second-order (1/Abs vs time) plots. 
The first-order plots for MSCO, NASMO and SePropO were observed to be linear, 
confirming the mechanism is likely to be the same as that observed in the reduction of 
SeMetO and SeTalO by TNB. 
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Figure 4.13 – Changes in absorbance at 412 nm over time and the corresponding first-
order analysis plots (lnAbs vs time) for the reactions of MSCO, NASMO and SPO with TNB 
a) MSCO (5 µM), b) NASMO (5 µM) or c) SePropO (5 µM) were mixed with TNB (25 µM) by 
stopped flow apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the absorbance at 
412 nm was monitored over time. Absorbance data were plotted as ln(Abs) vs time for d) 
MSCO, e) NASMO or f) SePropO in order to determine the order of reaction. The ln(Abs) vs 
time plots for MSCO, NASMO and SPO were all linear, and therefore the reaction with TNB 
follows a first-order mechanism. 
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As a first-order (or pseudo first-order) mechanism was observed, second order rate 
constants were determined by pseudo first-order analysis. The observed rate constants 
(kobs) for each condition were determined by fitting exponential curves to the 
absorbance vs time data for each sample (Figure 4.14). Second-order rate constants for 
the reaction of MSCO, NASMO and SePropO with TNB were then determined by plotting 
kobs against initial TNB concentration. The rate constants were determined to be k1 = 
(4.4 ± 0.3) x 103, k1 = (1.2 ± 0.04) x 103 and k1 = (1.3 ± 0.03) x 103 M-1 s-1 for MSCO, NASMO 
and SePropO respectively. The rate constant for the formation of DTNB was also 
calculated from absorbance data at 324 nm, and the rate constants obtained were not 
significantly different from those determined at 412 nm (Table 4.1).  Interestingly, all 
these selenoxides gave rate constants about 10-fold lower than those determined for 
SeMetO, supporting the hypothesis that the presence of an amine group may contribute 
to the facile reduction of SeMetO.  
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Figure 4.14 – Pseudo first-order plots for the reaction of a) MSCO, b) NASMO and c) 
SePropO with TNB 
MSCO (5 µM), NASMO (5 µM) or SePropO (5 µM) was mixed with increasing concentrations 
of TNB (25 - 125 µM) by stopped flow apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 
°C and the absorbance at 412 nm was monitored over time. The observed rate constant, 
kobs, for each condition was determined from the absorbance vs time plots using single 
exponential fitting in ProData Viewer software (Applied Photophysics). kobs  was plotted 
against initial TNB concentration for a) MSCO, b) NASMO or c) SPO and the second-order 
rate constants determined from the gradient of these plots. Data represent mean ± SD of 
three independent experiments. 
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Table 4.1 – Second-order rate constants for the reduction of selenoxides by TNB 
 k1 / M-1 s-1 
Selenoxide -d[TNB]/dt  +d[DTNB]/dt 
SeMetO (3.8 ± 0.1) x 104 (3.8 ± 0.1) x 104 
SeTalO (4.9 ± 0.2) x 103 (4.8 ± 0.2) x 103 
MSCO (4.4 ± 0.3) x 103 (4.9 ± 0.6) x 103 
NASMO (1.2 ± 0.04) x 103 (1.2 ± 0.1) x 103 
SePropO (1.3 ± 0.03) x 103 (1.3 ± 0.06) x 103 
4.3.3.3 Contribution of amine group to rate constant 
SeMetO has a rate constant for reduction by TNB that is about 10 times higher than 
the other selenoxides measured (Table 4.1). This is proposed to be due to the amine 
group present in the structure, as nitrogen and selenium non-bonding interactions have 
been shown to have effects on redox properties of compounds [473]. Thus, experiments 
were performed examining the reduction of NASMO and MSCO by TNB in phosphate 
buffer (pH 7.4, 0.1 M) supplemented with Gly (10 mM) to investigate whether the 
presence of an extramolecular amine group could effect the rate of reduction.  
MSCO, NASMO and TNB were prepared using a phosphate buffer (pH 7.4, 0.1 M) 
containing Gly (10 mM). The rate of reaction between selenoxides and TNB was assessed 
by stopped flow as described above. Absorbance changes consistent with the loss of TNB 
and formation of DTNB were observed. Second-order rate constants were determined 
from the data by plotting kobs against TNB concentration (Figure 4.15). Linear regression 
analysis yielded the second-order rate constants shown in Table 4.2. These rate 
constants were higher than those measured in the absence of Gly, and a statistical 
comparison of the slope (Prism v6 – unpaired t-test) indicated that there was a 
significant 2-fold increase in k1 for NASMO in the presence of Gly. The small increase in 
k1 determined for MSCO in the presence of Gly was not significantly different to the k1 
determined in the absence of Gly.  
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These results initially appear inconsistent. However, the rate constant for the 
reduction of MSCO by TNB is already elevated compared to NASMO in the absence of Gly. 
This may arise from the fact that MSCO already contains a free amine group, that though 
unlikely to interact intramolecularly, may interact intermolecularly with the Se centre. 
Therefore, the addition of excess in the form of Gly may not have as dramatic an impact 
compared to the NASMO, which has no free amine. The increased rate constant for 
NASMO suggests that extramolecular amine groups may interact favourably with 
selenoxides to facilitate their reduction by thiols, but this effect is not as profound as that 
of an intramolecular Se…N interaction.  
 
Figure 4.15 – Plots of kobs values measured by stopped flow at 412 nm after a) NASMO 
(5 µM) or b) MSCO (5 µM) was mixed with increasing TNB (25 – 125 µM) with (open 
symbol) or without (closed symbol) Gly (10 mM) in buffer 
a) NASMO (5 µM) or b) MSCO (5 µM) was mixed with increasing concentrations of TNB (25 
- 125 µM) by stopped flow apparatus in phosphate buffer (pH 7.4, 0.1 M) with (closed 
symbol) or without (open symbol) Gly (10 mM) at 22 °C and the absorbance at 412 nm was 
monitored over time. The observed rate constant, kobs, for each condition was determined 
from the absorbance vs time plots using single exponential fitting in ProData Viewer 
software (Applied Photophysics). kobs  was plotted against initial TNB concentration for a) 
NASMO or b) MSCO and the second order rate constants determined from the gradient of 
these plots. Data represent mean ± SD of three independent experiments. 
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Table 4.2 – Comparison of second order rate constants determined for the reaction of 
NASMO and MSCO in the presence or absence of Gly (10 mM) 
Selenoxide k1  / M-1 s-1 k1 in presence of 
10 mM Gly / M-1 s-1 
MSCO (4.4 ± 0.3) x 103 (5.0 ± 0.3) x 103 
NASMO (1.2 ± 0.04) x 103 (2.5 ± 0.2) x 103 
 Reduction of selenoxides by GSH 
In the previous section, TNB was used as a reductant to simplify the kinetics of 
selenoxide reduction compared to that for GSH. However, TNB is an aromatic thiol that 
may not be a representative model for reduction of selenoxides by biologically relevant 
thiols. Thus, the reduction of selenoxides by the endogenous thiol GSH was examined 
using stopped flow.  
SeMetO, SeTalO, NASMO, MSCO or SePropO (125 µM) and GSH (0.5 – 2.5 mM) were 
mixed in the stopped flow apparatus and absorbance monitored between 200 – 310 nm 
in 10 nm steps. Upon mixing, increases in absorbance were observed across the 
spectrum with a maximum increase at around 280 nm (Figure 4.13a). This is likely to 
correspond to the formation of GSSG, as disulfide bonds are known to exhibit absorbance 
maxima in the region of 250-300 nm, depending on structure [576, 577]. 
SeTalO, MSCO, NASMO and SePropO demonstrated pseudo first-order kinetics upon 
reaction with GSH. This is demonstrated by the linear first-order plots of the absorbance 
vs time data at 270 nm (Figure 4.16c). The data observed at 270 nm shows a single 
exponential increase, however due to the small absorbance changes and fluctuations in 
light source, the data are not completely smooth. As the kinetics demonstrated pseudo 
first-order kinetics the same mechanism as exhibited for reduction by TNB was used for 
rate constant determination in ProKIV. The spectra of the reactants were measured at 
known concentrations and fixed for the analysis procedure in order to simplify the 
global analysis by decreasing the number of unknown fitting parameters. The second-
order rate constants that were determined from these fits and reported in Table 4.3, and 
were confirmed by pseudo first-order analysis at 270 nm.  
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Figure 4.16 – Spectral kinetics, absorbance change at 270 nm and first-order plot for the 
reaction between SeTalO and GSH 
SeTalO (125 µM) was mixed with GSH (0.5 mM) in phosphate buffer (pH 7.4, 0.1 M) at 22 
°C by stopped flow apparatus. a) shows the absorbance changes over 0.75 s monitored at 
wavelengths between 240 - 300 nm at 10 nm steps.  b) shows the  absorbance change at 
270 nm over time after mixing. The absorbance data from b) were analysed for first-order 
behaviour by plotting as ln(Abs) vs time. As the ln(Abs) vs time is linear, the reaction follows 
a first-order mechanism. 
Table 4.3 - Second order rate constant determined for the reduction of selenoxides with 
GSH 
Selenoxide k1 / M-1 s-1  
SeTalO (3.4 ± 0.3) x 103 
MSCO (2.5 ± 0.4) x 104 
NASMO (1.3 ± 0.2) x 103  
SePropO (4.6 ± 0.6) x 102 
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SeMetO showed more complex reaction kinetics with GSH than the other 
selenoxides. The data obtained for TNB suggest that the mechanism is likely to be 
occurring via a two-step reduction. The kinetic data for SeMetO reduction by GSH shows 
two phases, as demonstrated by the change in absorbance over time data at 240 nm 
(Figure 4.17). The data show an initial fast decrease in absorbance followed by a slower 
increase in absorbance. This suggests that the initial reaction of the selenoxide, k1, and 
the subsequent reaction of the selenosulfide intermediate, k2, occur on timescales that 
allow for both to be observed. Thus, it is proposed that the same mechanism is occurring 
for the TNB reduction, but in the case of SeMetO reduction by GSH, the first step, k1, is 
occurring significantly faster than the second step, k2, and therefore the two phases are 
observed.  
 
Figure 4.17 - Spectral kinetics and absorbance at 240 nm for the reaction between 
SeMetO and GSH. 
SeMetO (125 µM) was mixed with GSH (0.5 mM) in phosphate buffer (pH 7.4, 0.1 M) at 22 
°C by stopped flow apparatus and a) shows the absorbance changes over 0.2 s monitored 
at wavelengths between 240 – 300 nm at 10 nm steps.  b) shows the change in absorbance 
at 240 nm after mixing SeMetO and GSH. In this plot, two-phase kinetics are observed with 
an initial rapid drop in absorbance, followed by an increase in absorbance. 
Based on these assumptions, a kinetic model based on the mechanism in Figure 4.8 
was used for global wavelength analysis. Initial analysis using this model was unable to 
converge to the data due to too many unknown parameters. In order to assist with the 
fitting, pseudo first-order analysis of the fast initial decrease, k1, was performed at 240 
nm. This gave a second-order rate constant of 1.2 x 105 M-1 s-1 (Figure 4.18). The value of 
k1 was then fixed in the global analysis fitting using the above model. This resulted in 
good convergence of the model, and led to the determination of second-order rate 
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constant for the reaction of the selenosulfide intermediate with GSH, k2, as 1.5 x 104 M-1 
s-1. 
 
Figure 4.18 - Plots of kobs values for initial absorbance decrease measured by stopped 
flow at 240 nm SeMetO (125 µM) was mixed with increasing GSH (0.5 – 2.5 mM)  
SeMetO (125 µM) was mixed with increasing concentrations of GSH (0.5 – 2.5 mM) by 
stopped flow apparatus in phosphate buffer (pH 7.4, 0.1 M) at 22 °C and the absorbance at 
240 nm was monitored over time. The observed rate constant for the initial decrease in 
absorbance, kobs, for each condition was determined from the absorbance vs time plots 
using single exponential fitting in ProData Viewer software (Applied Photophysics). kobs  
was plotted against initial GSH concentration and the second order rate constants 
determined from the gradient of this plot. Data represent mean ± SD of three independent 
experiments. 
 Reduction of selenoxides by DTT 
Reduction of selenoxides by dithiothreitol (DTT) was investigated as it was thought 
that the presence of a second thiol group could increase the rate of the second step k2, 
particularly for SeMetO reduction through intramolecular interactions. It was 
anticipated that the initial step, k1, would then become the rate limiting step, thereby 
resulting in only one phase being detected in the absorbance changes, and hence 
simplifing the determination of k1. 
SeMetO, SeTalO, NASMO, MSCO or SePropO (125 µM) and DTT (0.5 – 2.5 mM) 
were mixed in the stopped flow apparatus and the absorbance was monitored between 
200 – 310 nm in 10 nm steps. Upon mixing, increases in absorbance were observed with 
a maximum around 280 nm (Figure 4.15a). This likely corresponds to disulfide 
formation as these show maxima in this region due to the S-S bond [577]. Decreases in 
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absorbance were observed at wavelengths < 240 nm, which is potentially due to loss of 
the selenoxide. 
The change in absorbance at 270 nm was plotted in both first- and second-order 
plots in order to determine the appropriate reaction mechanism. First-order plots for 
SeTalO, NASMO and SePropO were linear (Figure 4.19), whereas the data for SeMetO 
and MSCO did not fit to either first- or second-order kinetic analysis (Figure 4.20).  
As the first-order plots for SeTalO, NASMO and SePropO were linear, the mechanism 
was determined to be a pseudo-first order kinetic mechanism. Global wavelength 
analysis of the data was performed in ProKIV with a a model reflecting the proposed 
mechanism in Figure 4.8. This mechanism is identical to that for the TNB reduction of 
selenoxides where only a rate limiting initial reaction, k1, with one thiol is observed. The 
spectra of the reactants were measured at known concentrations and fixed for the 
analysis procedure in order to simplify the global analysis by decreasing the number of 
unknown fitting parameters. Second order rate constants were confirmed by pseudo-
first order analysis of absorbance vs time data at 270 nm. Again, while the single 
exponential increase is observed at 270 nm (Figure 4.19b), the data are not smooth due 
to small absorbance changes and fluctuations in the light source. 
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Figure 4.19 – Spectral kinetics, absorbance change at 270 nm and first-order plot for the 
reaction between SeTalO and DTT  
SeTalO (125 µM) was mixed with DTT (0.5 mM) in phosphate buffer (pH 7.4, 0.1 M) at 22 
°C by stopped flow apparatus. a) shows the absorbance changes over time monitored at 
wavelengths between 240 – 300 nm at 10 nm steps.  b) shows absorbance change at 270 
nm over time after mixing. The absorbance data from b) were analysed for first-order 
behaviour by plotting as ln(Abs) vs time; as the ln(Abs) vs time is linear, the reaction follows 
a first-order mechanism. 
Table 4.4 – Second order rate constants determined for the reduction of selected 
selenoxides with DTT 
Selenoxide k2 / M-1 s-1  
SeTalO (3.0 ± 0.3) x 103 
NASMO (2.3 ± 0.3) x 104 
SePropO (7.3 ± 1) x 102  
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The absorbance data obtained at 270 nm when SeMetO or MSCO was mixed with DTT 
were analysed by both first-order (ln(Abs) vs time) or second-order (1/Abs vs time) 
analysis plots (Figure 4.20c and d respectively), in an attempt to determine the reaction 
mechanism. However, as neither of these plots were linear, it was concluded that the 
reduction of SeMetO and MSCO by DTT does not follow either first- or second-order 
mechanisms.  
 
Figure 4.20 - Spectral kinetics, absorbance change at 270 nm and kinetic analysis for the 
reaction between SeMetO and DTT  
SeMetO (125 µM) was mixed with DTT (0.5 mM) in phosphate buffer (pH 7.4, 0.1 M) at 22 
°C by stopped flow apparatus and a) shows the absorbance changes over 0.5 s monitored 
at wavelengths between 240 – 300 nm at 10 nm steps.  b) shows absorbance changes 
measured at 270 nm over time after mixing. The absorbance data from b) were analysed 
for first-order behaviour by plotting c) ln(Abs) vs time., or  second order behaviour by 
plotting d) 1 / Abs vs time. As neither of these plots are linear, the reaction does not appear 
to follow either first- or second-order mechanisms.  
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A number of potential models for the reaction were considered, but none of these 
yielded satisfactory fits to the data in ProKIV. Models attempted included; 
 Se=O + RSH  Intermediate 
 Se=O + RSH  Intermediate + RSH  Se + RSSR 
 Se=O + RSH  Intermediate Se + RSSR 
 Se=O + RSH  Intermediate A Intermediate B 
The observed complex kinetics are proposed to be due to the initial formation of a 
seleno-sulfide intermediate as proposed in Figure 4.8 for TNB that can then react via a 
number of different pathways. Once formed, the intermediate can then react with 
another DTT thiol, either intramolecularly or extramolecularly. Alternatively, two of the 
selenosulfide intermediates may react with one another, either at the selenosulfide 
bond, or at the free thiol on DTT.  As the kinetic data were complex, definitive rate 
constants could not be determined from these data. However, the data suggest that the 
reduction occurs with a rate constant that is in the same order of magnitude as TNB 
reduction of selenoxide, due to the similar time frames of the absorbance changes.  
 Discussion 
The data in this Chapter demonstrate that selenoxides are capable of reacting with 
thiols, producing disulfides and reforming the parent selenoether compound. The 
mechanism of these reactions were examined and have been proposed to occur via a 
selenosulfide intermediate. The rate constants for these reactions have also been 
defined in this Chapter and are summarised in Table 4.5. 
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Table 4.5 – Second-order rate constants determined for the reaction between 
selenoxides and various model low molecular mass thiol compounds 
 Second order rate constants determined for the reaction 
between selenoxides and thiols / M-1 s-1 
 TNB  DTT GSH 
SeMetO 3.8 x 104 - k1 1.2 x 105 
k2 1.5 x 104 
SeTalO 4.9 x 103 3.0 x 103 3.4 x 103 
MSCO 4.4 x 103 - 2.5 x 104 
NASMO 1.2 x 103 2.3 x 104 1.3 x 103 
SePropO 1.3 x 103 7.3 x 102 4.6 x 102 
 
GSH was capable of reducing SeMetO as has been previously described [444, 445]. 
The products of the reaction between GSH and SeMetO were SeMet and GSSG.  The 
stoichiometry observed was a 2 : 1 ratio of thiol consumed to selenoxide reduced. The 
reaction between SeTalO and GSH occurred with the same stoichiometry, with 1 mol 
SeTalO consumed and 1 mole of SeTal recovered for every 2 moles of GSH added. It is 
reasonable to assume that the reaction would occur via the same mechanism as the 
reduction of SeMetO, resulting in the formation of GSSG as a product. However, this was 
unable to be measured due to limitations with the HPLC method employed to separate 
SeTal and SeTalO. This could be measured with further development of HPLC methods, 
or using a fluorescent labelling approach to label GSSG, which was though it was 
considered beyond the scope of this project. 
The stopped flow data show that TNB and DTT are also capable of reacting with 
selenoxides. A decrease in the TNB concentration and concomitant increase in the DTNB 
concentration was observed by optical absorbance at 412 and 324 nm respectively. With 
DTT, the likely product will be the disulfide based on the absorbance increases observed 
around 290 nm, which correspond to the region of disulfide absorbance [576, 577]. The 
 150 
proposed mechanism is a two-step process, where the initial step is the reaction of the 
selenoxide and a thiol to form a selenosulfide intermediate. This species could then be 
reduced by reaction with a second thiol, eliminating water and forming the selenoether 
and disulfide. 
The two-phase reduction mechanism was most clearly observed for the reduction of 
SeMetO with GSH. At 240 nm, an initial rapid decrease in absorbance is observed, which 
is proposed to be the initial reaction, followed by a slower increase in absorbance, which 
is proposed to be due to the second step. The data obtained for the other selenoxide 
reactions with thiols are also consistent with this mechanism, assuming that the second 
step has a rate constant (k2) significantly greater than the rate constant for the first step 
(k1). Data obtained for the reduction of SeMetO by GSH suggest that the rate constant for 
the second thiol reaction (k2) is in the order of  
104 M-1 s-1. If this rate constant holds for the other selenoxide species and with TNB as 
the thiol, this value is an order of magnitude greater than that measured for the first thiol 
reaction. This would give rise to kinetic traces that appear first order, as described in 
Section 4.3.3.1. 
A selenosulfide species has been proposed as the intermediate formed after the 
reaction with the first thiol. However, studies to characterise this product were not 
performed, though thermodynamic modelling may provide further evidence to support 
this as a viable mechanism. A similar selenosulfide has been proposed as an intermediate 
formed when MsrB reduces MetSO [354, 446, 578]. In the case of the MsrB reaction, the 
selenol of the active site SeCys attacks the sulfur residue of MetSO, forming a Se-S-OH 
structure. The resolving Cys residue then reacts with the Se, forming an Se-S bond on 
MsrB, and Met and H2O act as leaving groups [354, 446, 578]. This mechanism is similar 
to the one proposed in this Chapter.  
Selenosulfide species are known to react with thiols to produce disulfides and selenol 
species as products [579]. It is this disulfide exchange mechanism that gives enzymes 
like TrxR its reducing capability [446]. Previously, the rate constants between low 
molecular mass thiol and selenosulfide species (DTT and hemi-selenocystine) have been 
extrapolated from experimental data based on thermodynamic calculations and 
determined to be ~ 10 M-1 s-1 [579]. Similar selenosulfide reactions take place during 
the enzymatic cycles of the Msr family (described above) and TrxR, where disulfide or 
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selenosulfide exchange reactions occur in order to reduce the oxidised substrates [379, 
446, 580, 581]. Analysis of the reaction of the Sec catalytic domain of TrxR with active 
thioredoxin gives rate constants of up to 107 -108 M-1 min-1 [379, 581]. The higher rate 
constant observed with the enzymatic system likely reflects the positive influence of the 
surrounding protein structure. 
In the current studies, the rate constants determined for further reaction of the 
selenosulfide intermediate are ~ 104 M-1 s-1, based on the rate determined for the second 
step of SeMetO reaction with GSH. This is significantly greater than that calculated for 
the hemi-selenocysteine and DTT reaction [579], however in this latter case, the 
selenosulfide intermediate is proposed to still be bound to the –OH group. The presence 
of the electronegative oxygen atom bound to the Se centre may contribute to the 
electrophilicity of the Se atom by withdrawing electrons. This would lead to a more rapid 
nucleophilic reaction of the second thiol. 
SeMetO consistently had the highest rate constant for reaction with thiols out of the 
selenoxides tested, and was about an order of magnitude greater than the other 
selenoxides examined. This is attributed to a non-bonding interaction between the 
selenoxide moiety and the free amine, which is present on SeMetO, but not in the other 
structures excluding MeSeCys. However, as MeSeCys has one carbon less in the side-
chain, steric considerations would mean that the amine group is unable to interact 
strongly with the selenoxide moiety.  
In Chapter 3, it was demonstrated that oxidation of SeMet in particular may give rise 
to other products, with a major secondary product being dehydroselenomethionine 
(Section 3.3.3). In this Chapter, the ability for thiols to reduce selenoxides was 
investigated to establish the potential for a catalytic scavenging cycle. If the products of 
the initial oxidation of SeMet is not SeMetO, there is potential for the proposed cycle to 
be disrupted. However, if the other products are also capable of being reduced by thiols, 
the catalytic cycle may still have potential. In the case of dehydroselenomethione, it is 
likely that a reduction by GSH will occur, as dehydromethionine is reduced by GSH to 
give methionine [117], and ebselen, a selenocompound containing a Se-N bond like 
dehydroselenomethionine, also reacts with GSH [454].  
As amine interactions appear to have a positive effect on the selenoxide reduction 
rate constant, experiments were undertaken with Gly supplemented phosphate buffer 
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(10 mM). An increase in reduction rate was observed with NASMO, though no increase 
in rate was observed for MSCO. As MSCO already contains an amine group, it is proposed 
that the increase in extramolecular amine concentration had minimal effect on the rate 
constant. The increased NASMO reduction rates suggest that amine groups are indeed 
playing a role in the selenoxide reduction. However, the addition of Gly to the buffer did 
not increase the rate constant for NASMO reduction to that observed for SeMetO. This is 
likely due to the fact that interaction with the intramolecular amine group is more 
favourable for entropic reasons in SeMetO, compared to the extramolecular amine of Gly 
for NASMO.  
Interaction of the amine group with the Se atom of SeMet has been shown to facilitate 
the one-electron reduction of SeMetO [473]. A three-electron bond between the Se and 
N atoms forms upon reaction with a hydrated electron, based on transient absorbance 
changes, and the rate constant determined for this reaction is 1.2 x 1010 M-1 s-1 [473]. In 
contrast, the reduction of the sulfur analogue MetSO by the hydrated electron occurs 
with a significantly lower rate constant of k = 2 x 108 M-1 s-1 [582]. It is proposed that the 
Se-N three-electron bond stabilises the intermediate, allowing for reduction to SeMet, 
and this stabilisation does not occur with MetSO [473]. Similarly, the same intermediate 
is proposed to facilitate the one-electron oxidation of SeMet to SeMetO, with stabilisation 
of the intermediate increasing the rate of one-electron oxidation compared to Met [457, 
470, 471]. 
The rate constants determined for the reduction of selenoxides by GSH are 
comparable to, or greater than, the rate constants determined in Chapter 3 for the 
oxidation of SeMet and SeTal by a variety of N-chloramines to form the selenoxides. The 
rapid reduction observed for selenoxides suggests that GSH will be capable of reducing 
selenoxides in vivo, potentially giving rise to a catalytic scavenging cycle of N-
chloramines. The rate constants suggest that a build-up of selenoxide would not occur, 
given sufficient thiol concentration, thereby providing rapid turnover of the 
selenoethers and allowing selenium compounds to further react with oxidants.  
The main products of these proposed catalytic reactions appear to be the disulfides, 
particularly GSSG. Numerous enzymes in the body are capable of reducing disulfides, 
thus providing a regeneration of the reducing equivalents to keep the catalytic cycle 
active. Furthermore, many of these enzymes contain either a thiol or selenol at the active 
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site. The rapid reaction of selenoxides with thiols, and production of disulfide products 
like GSSG, may lead to the potential of endogenous antioxidant defence systems to 
interact with selenium compounds in order to reduce oxidative damage. This hypothesis 
is explored further in Chapter 5.  
 Conclusions 
SeMetO and SeTalO are readily reduced by GSH and other thiol compounds to reform 
SeMet and SeTal and disulfide species. The reduction is proposed to happen in a two-
step mechanism, via a selenosulfide intermediate. The rate constants for these reactions 
have been defined and are summarised in Table 4.5. The facile reduction of SeMetO and 
SeTalO by GSH highlights the potential for a catalytic oxidant scavenging cycle in vivo, 
that may provide therapeutic benefit in inflammatory conditions.  
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5 Reduction of selenoxides and N-chloramines by redox enzymes 
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 Introduction 
Exposure to MPO-derived oxidants can lead to conformational and functional 
changes of proteins within the cellular environment [106]. In order to combat oxidative 
stress the cell uses a variety of redox systems that either detoxify oxidant species, such 
as GPx [583], or reduce oxidation products, such as TrxR, Trx [357] and Msrs [584]. 
TrxR is a selenoprotein whose primary function is to reduce protein disulfide 
bonds, like those formed on oxidised Trx [585]. It achieves this via the formation of 
intermolecular selenosulfide bonds, which are then reduced by a resolving Cys residue, 
forming an intramolecular Se-S bond [372]. TrxR uses NADPH as an electron donor to 
reduce the Se-S formed on oxidised TrxR [372, 585]. TrxR has also demonstrated 
ability to reduce MPO-derived oxidants, particularly HOSCN (Figure 5.1) [348].  
 
Figure 5.1 – TrxR uses NADPH as a reducing equivalent to detoxify oxidants such as 
HOSCN 
Trx is one of the primary disulfide reductase enzymes present in cells. It reduces 
disulfides formed on proteins through disulfide exchange processes, forming an 
intermolecular disulfide bond on Trx [357]. This disulfide can then be reduced by TrxR, 
regenerating Trx [357]. While TrxR is the primary reductant for Trx, GSH can also 
perform this role when TrxR is inhibited or down-regulated [586]. Trx participates in 
antioxidant defence through multiple roles, including reduction of the Prxs, which are 
redox proteins responsible for detoxification of peroxide species (Figure 5.2) [102]. 
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Figure 5.2 – Trx is capable of reducing a wide variety of substrates such as protein 
disulfides, peroxides, diselenides and SeMetO. Oxidised Trx is then subsequently 
oxidised by TrxR using NADPH. 
The Trx system has been shown to interact with numerous selenium compounds. 
It is capable of reducing selenite [587], as well as organic selenium species, such as 
diselenides, selenodiglutathione [588] and selenocystine [492]. The interaction of the 
Trx system and selenocysteine or ebselen enhances the removal of peroxides [379, 
589, 590] and ONOOH [591]. The Trx system has also been shown to reduce SeMetO to 
SeMet and catalytically remove protein hydroperoxides [474]. 
Msrs reduce MetSO residues to Met (Figure 5.3) [109, 592]. Msrs are stereospecific 
with MsrA reducing S stereoisomers of MetSO, and MsrB reducing the R stereoisomer 
[593, 594]. MsrA is capable of reducing both free and peptide bound MetSO, though it 
shows a preference for peptide bound residues [109]. MsrB almost exclusively reduces 
peptide bound MetSO [109], demonstrating a specificity for unfolded protein residues 
[413]. The presence of Msrs suggests that Met oxidation may play a protective role 
maintaining protein function under oxidising conditions in vivo [110, 567]. 
 
Figure 5.3 – Msrs are capable of reducing MetSO, and are subsequently reduced by the 
NADPH/TrxR/Trx system 
GPx is a selenoprotein that detoxifies H2O2 and lipid peroxides (Figure 5.4) [583]. 
The peroxides oxidise the catalytic Sec residue, forming a seleninic acid (RSeOH) group 
[370], which is then reduced by 2 equivalents of GSH to reduce the protein and form 
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GSSG [583]. While GSH is the primary reductant for GPx, the Trx system is also capable 
of donating electrons to reduce the enzyme [595].  
 
Figure 5.4 – GPx is capable of using either the NADPH/GSR/GSH system or 
NADPH/TrxR/Trx system to reduce H2O2  
GSR is a thiol dependent enzyme that is responsible for the reduction of GSSG to 
GSH (Figure 5.5) [557]. GSH is a key antioxidant in cellular systems and reacts with a 
variety of oxidants, including N-chloramines [192] and selenoxides [444], to form 
GSSG. GSSG is then recycled back to GSH by the action of GSR [557]. GSR achieves 
reduction of GSSG by disulfide exchange reactions [427]. 
 
Figure 5.5 – GSR catalyses the reaction between GSSG and NADPH to form GSH 
These enzymes use NADPH as a reducing equivalent to reduce their substrates. 
HOCl and N-chloramines can react directly with NADPH, though the reaction of N-
chloramines is quite slow (~1 M-1 s-1) [63, 138, 139]. This reaction forms a 
chlorohydrin species in a reaction that can not be reversed by the cells enzymatic 
NADPH recycling enzymes such as GAPDH, and the production of this enzyme is toxic 
to cells [63, 138, 139].  
These enzymatic systems all play a role in the maintenance of redox homeostasis in 
the cell. The key feature consistent throughout these systems is the presence of a thiol 
or selenol at the active redox site of the enzyme that takes part in the reaction with 
oxidants in order to detoxify them. As N-chloramines have demonstrated reactivity 
with thiols [192], it was expected that they should also react with enzymes containing 
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a Cys active site. HOCl is capable of reacting with selenols, including the Sec active site 
of GPx, with higher rate constants than analogous thiol compounds [98]. In addition, N-
chloramines retain the oxidising power of HOCl in relation to thiols, and so N-
chloramines also have the potential to react with selenols. Furthermore, given that 
selenoxides also react with thiol groups [444, 445], there may be the potential for these 
enzymes to reduce selenoxides. 
 Aims 
Given that many redox enzymes contain either a thiol or selenol at their active site, 
it was hypothesised that the cellular antioxidant enzymes should be able to react with, 
and hence reduce, selenoxides and N-chloramines. The aim of the studies presented in 
this Chapter was therefore to determine the ability of redox enzymes to reduce 
selenoxides and N-chloramines.  
 Results 
 Reduction of selenoxides 
5.3.1.1 Thioredoxin reductase and thioredoxin 
Trx and TrxR are capable of reducing a wide variety of substrates including 
peroxides [379, 589, 590], disulfides [357] and numerous selenium species [491, 492, 
587]. They have previously been shown to reduce SeMetO [474]. Initial experiments 
aimed to confirm the ability of the Trx system to reduce SeMetO, and assess the ability 
of this system to reduce SeTalO, as proposed in Figure 5.6. 
 
Figure 5.6 – Proposed mechanism for the reduction of SeMetO and SeTalO by 
NADPH/TrxR/Trx. The selenoxides may be reduced by either the TrxR or Trx in this 
system. 
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The ability of TrxR to reduce SeMetO and SeTalO was investigated by both HPLC 
and the spectrophotometric consumption of NADPH. NADPH (700 µM) and TrxR (25 
nM) with or without Trx (1.5 µM) were incubated together for 5 min before addition of 
SeMetO or SeTalO (200 µM) in phosphate buffer (0.1 M, pH 7.4) at 22 °C. Insulin (200 
µM) was also added to the NADPH/TrxR/Trx system as a positive control, as it is a 
native substrate for Trx. The concentration of NADPH and TrxR were selected based 
on previously published results [474]. TrxR uses NADPH as a reducing agent, therefore 
the amount of NADPH consumed should be equal to the amount of substrate reduced. 
NADPH concentrations were monitored by optical absorbance at 340 nm (Figure 5.8a). 
The rate of reduction was determined by fitting the initial (25 min) linear section of the 
[NADPH] vs time graph (Figure 5.8b).  
It should be noted that the starting concentration of NADPH in these assays was 
observed to be about 540 µM, in contrast to the 700 µM NADPH that was added. The 
reported NADPH concentrations were determined based on the absorbance coefficient 
at 340 nm (ε = 6300 cm-1 M-1). However, based on the UV-vis absorbance spectra 
obtained for NADPH (50 µM (based on mass)) (Figure 5.7), it is suspected that some 
impurities were present, as the calculated concentrations of NADPH were 28 and 37 
µM based on extinction coefficients at 340 and 260 nm respectively. The increase in 
apparent concentration using the extinction coefficient at 260 nm is likely to be due to 
auto-oxidation of NADPH to NADP+, which would also contribute to absorbance at 260 
nm. This discrepancy caused an underestimation of the initial starting concentration of 
NADPH as solutions were prepared assuming the total mass of the sample was NADPH. 
This may also affect the interpretation of total NADPH consumption, potentially 
underestimating the concentrations of NADPH consumed, therefore introducing 
greater error that should be considered when calculating the stoichiometry between 
NADPH and substrate.  
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Figure 5.7 – UV-vis spectrum of NADPH 
NADPH (50 µM (based on mass)) was prepared in phosphate buffer (0.1 M, pH 7.4) and 
the UV-vis spectrum between 200 and 400 nm at 22 °C was measured. Absorbance values 
at 340 nm and 260 nm were 0.177 and 0.528 absorbance units respectively.  
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Figure 5.8 – Change in NADPH concentration over 25 min after SeMetO and SeTalO 
were added to NADPH, TrxR and Trx. 
SeMetO, SeTalO or insulin (200 µM) was added to NADPH (700 µM) and TrxR (25 nM) in 
the c,d) presence or a,b) absence of Trx (1.5 µM) and the absorbance monitored for 45 
min at 340 nm. a, b) show typical [NADPH] vs time plots obtained for the control (solid) 
or when 200 µM SeMetO (dashed), SeTalO (dotted) and insulin (dot-dashed) were added 
to a) NADPH/TrxR and c) NADPH/TrxR/Trx. SeMetO increased the rate at which NADPH 
is consumed compared to the control (NADPH/TrxR) though SeTalO does not. b, d) The 
rate of NADPH consumption was determined by fitting a straight line to the data 
represented in a, c). Data in a,c) are representative of 3 independent experiments. Data 
in b,d) represent mean ± SD from 3 independent experiments. * indicates significant 
difference (p < 0.05) from control based on one-way ANOVA with Tukey’s post-hoc test. 
A small time dependent decrease of 6 ± 2 nM s-1 in the control sample (700 µM + 25 
nM TrxR) was observed and was attributed to the slow auto-oxidation of NADPH. 
Addition of SeTalO did not produce any further significant increase in the rate of 
NADPH consumption over the control, with an observed NADPH loss rate of 8 ± 6 nM 
s-1, suggesting that TrxR is unable to reduce SeTalO. SeMetO increased the rate at which 
NADPH was consumed to 42 ± 6 nM s-1, which is consistent with a previous report on 
TrxR reducing SeMetO [474]. Total NADPH consumption reflected the differences in 
the rate of NADPH consumed by each sample, with SeMetO demonstrating a significant 
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increase in total NADPH consumed compared to control samples, whereas no 
significant difference was observed for SeTalO (Figure 5.9).  
 
Figure 5.9 – Total NADPH consumed after SeMetO, SeTalO or insulin was added to 
NADPH and a) TrxR with or without b) Trx  
SeMetO (200 µM), SeTalO (200 µM) or insulin (200 µM) was added to NADPH (700 µM) 
(control bars) and TrxR (25 nM) and in the b) presence and a) absence Trx (1.5 µM) and 
the absorbance monitored for 45 min at 340 nm. The difference in NADPH concentration 
immediately after the addition of SeMetO, SeTalO or insulin and 45 min afterward was 
determined by absorbance at 340 nm. Addition of SeMetO or insulin caused an increase 
in NADPH consumption over control, though addition of SeTalO did not. Data represent 
mean ± SD from 3 independent experiments. * represents a significant difference (p < 
0.05) from control based on one-way ANOVA with Tukey’s post-hoc test..  
The above data indicate that TrxR is capable of reducing SeMetO, and previous 
studies suggest that the presence of Trx should increase the rate of SeMetO reduction 
[474]. If Trx is increasing the rate of selenoxide reduction, an increase in rate of NADPH 
consumption would be expected over that observed for NADPH/TrxR. Similar to the 
TrxR data, a small time dependent decrease in NADPH was observed in control samples 
of 6 ± 2 nM s-1 (NADPH/TrxR/Trx), and upon addition of SeTalO there was no 
significant effect on the rate of change of absorbance with a decrease of 8 ± 1 nM  
s-1 observed (Figure 5.8c,d). SeMetO increased the rate of NADPH consumption to 42 ± 
4 nM s-1, which is not significantly different to the rate observed with NADPH/TrxR. 
Again, total NADPH consumption demonstrated the same trend, with SeMetO 
consuming a significantly greater amount of NADPH than observed in control samples, 
though SeTalO did not (Figure 5.9b). 
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As there was no increase in reduction on addition of Trx, insulin was included as a 
positive control to ensure Trx activity could be observed. An increase in rate of NADPH 
consumption to 12 ± 1 µM s-1 was observed over NADPH/TrxR samples, though this 
change was not significantly different (Figure 5.8). However, over the course of 45 min, 
addition of insulin caused a consumption of the NADPH of 14 ± 7 µM compared to the 
control samples where only of 3 ± 1 µM was consumed (Figure 5.9b).  
As NADPH was being consumed by the TrxR and Trx systems after SeMetO addition, 
HPLC methods were used to determine whether reduction of SeMetO was occurring 
with a corresponding increase in SeMet (Section 2.3.5.4). Samples were incubated for 
2 h before removal of the proteins by centrifugal filtering through 10 kDa molecular 
mass cut-off filters. The concentrations of selenoxide and parent selenoether were 
determined by UV-Vis detection of peaks at 220 nm, and the concentrations of SeMet 
and SeMetO determined by comparison with standard curves generated using 
authentic materials (Section 2.3.7.1) (Figure 5.10). After 2 h SeMetO (200 µM) had been 
completely reduced, with a corresponding increase in SeMet concentration. In 
analogous experiments with SeTalO (200 µM), no change in SeTalO or SeTal 
concentration was observed after 2 h, consistent with the NADPH data monitored at 
340 nm. The levels of SeMet, SeMetO, SeTal and SeTalO were the same whether Trx was 
present or samples contained TrxR alone, demonstrating that TrxR is capable of 
reducing SeMetO to SeMet, though is unable to reduce SeTalO. These data suggest that 
Trx did not contribute any additional reduction potential to the system. 
There is a discrepancy between the amount of NADPH consumed by the TrxR and 
Trx (Figure 5.9) and the concentration of SeMetO reduced (Figure 5.10), though here 
this is partially explained by the fact that NADPH concentrations were monitored over 
45 min, compared to the 2 h when SeMet and SeMetO levels were assessed by HPLC. 
However, by extrapolating the 45 min data, an underestimation of NADPH 
consumption compared to the 200 µM expected consumption, based on the amount of 
SeMetO reduced, still occurs. This is thought to be related to issues that caused an 
underestimation of the starting concentration of NADPH, discussed earlier in this 
section. 
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Figure 5.10 – Concentration of selenoxides reduced and selenoether recovered after 
selenoxides are incubated with NADPH and TrxR with or without Trx. 
SeMetO or SeTalO (200 µM) was added to NADPH (700 µM) and TrxR (25 nM) in the 
presence or absence of Trx (1.5 µM) and incubated for 2 h before analysis by HPLC. a) 
shows the concentration of selenoxide reduced and b) shows recovery of the respective 
selenoether. NADPH/TrxR (black) and NADPH/TrxR/Trx (white) were both able to 
reduce SeMetO (200 µM), with a full recovery of SeMet. No changes were observed for 
SeTalO. Data represent the mean ± SD from 3 independent experiments. 
5.3.1.2 Glutathione peroxidase 
GPx, an enzyme with the primary function of removing H2O2, contains an active site 
thiol that may be capable of reducing selenoxides [583]. GPx can use the Trx system, 
and ultimately NADPH, as a reducing equivalent [595]. The ability of GPx to reduce 
selenoxides was assessed by UV-vis spectroscopy and HPLC analysis (Figure 5.11). 
 
Figure 5.11 – Proposed mechanism for the reduction of SeMetO and SeTalO by 
NADPH/TrxR/Trx/GPx. The selenoxides may be reduced by the TrxR, Trx or GPx in 
this system. 
The loss of NADPH was monitored after SeMetO, SeTalO or H2O2 (200 µM) was 
added to NADPH (700 µM), TrxR (25 nM), Trx (1.5 µM) and GPx (1.5 µM) (Figure 5.12). 
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The rate of NADPH loss was determined by fitting the initial (25 min) linear section of 
the [NADPH] vs time graph (Figure 5.12a). The loss NADPH occurred at 5 ± 0.3 nM s-1 
in control samples (NADPH + TrxR + Trx + GPx). No change in the rate of NADPH 
consumption was observed when SeTalO was added to samples with NADPH being 
consumed at a rate of 3 ± 1 nM s-1. NADPH consumption increased to 32 ± 4 nM s-1 upon 
the addition of SeMetO. This increase was not significantly different to that obtained 
with NADPH and TrxR alone (Figure 5.8).  
 
Figure 5.12 – Change in NADPH concentration over time when SeMetO, SeTalO or H2O2 
were added to the GPx system. 
SeMetO, SeTalO or H2O2 (200 µM) was added to NADPH (700 µM) + TrxR (25 nM), Trx 
(1.5 µM) and GPx (1.5 µM) and the absorbance monitored for 2 h at 340 nm. a) show 
typical [NADPH] vs time obtained for the control (NADPH/TrxR/Trx/GPx) (solid) or when 
SeMetO (dashed), SeTalO (dotted) or H2O2 (dot-dashed) were added to the 
NADPH/TrxR/Trx/GPx system. SeMetO increases the rate at which NADPH is consumed 
compared to the control though SeTalO does not. b) The rate of NADPH consumption was 
determined by fitting a straight line to the initial 25 min represented in a). Data represent 
mean ± SD from 3 independent experiments. * indicates significant difference (p < 0.05) 
from control based on one-way ANOVA with Tukey’s post-hoc test. 
H2O2 is a substrate for GPx and was included as a positive control. An increase to 11 
± 4 nM s-1 of NADPH consumption was observed with H2O2 addition, though this was 
not statistically significant compared to NADPH/TrxR/Trx/GPx control samples. 
However, over the course of 2 h, a significantly higher amount of NADPH was 
consumed by H2O2 samples, with a total of 81 ± 30 µM NADPH consumed, compared to 
control samples with 37 ± 8 µM NADPH consumed (Figure 5.13). Total NADPH 
consumption upon addition of SeMetO and SeTalO reflected the trend observed in the 
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rate of NADPH consumption, with SeMetO consuming a significantly greater amount of 
NADPH than the NADPH/TrxR/Trx/GPx alone, though SeTalO did not.  
 
Figure 5.13  - Total NADPH consumed after H2O2, SeMetO or SeTalO was added to GPx 
system 
H2O2, SeMetO or SeTalO (200 µM) was added to NADPH (700 µM), TrxR (25 nM), Trx (1.5 
µM) and GPx (1.5 µM) and the absorbance monitored for 2 h at 340 nm. The difference in 
NADPH concentration from addition of H2O2 and 2 h post addition was determined by 
absorbance at 340 nm. H2O2 and SeMetO caused an increase in total NADPH consumed 
over control, whereas SeTalO did not. Data represent mean ± SD from 3 independent 
experiments. * indicates significant difference (p < 0.05) from control based on one-way 
ANOVA with Dunnett’s post-hoc test. 
As NADPH consumption increased with SeMetO addition, this suggested that 
reduction of SeMetO was occuring. SeMet and SeMetO levels were therefore assessed 
by HPLC with UV-vis detection at 220 nm to determine whether SeMetO reduction was 
occuring. Samples were incubated for 2 h before removal of the proteins by filtering 
through 10 kDa molecular mass cut-off filters and the concentrations of selenoxide and 
parent selenoether were quantified as described in Section 2.3.5.4. Similar to the Trx 
system, complete reduction of SeMetO to SeMet was observed after 2 h, but no change 
was observed for SeTalO (Figure 5.14). There is also a difference between the 
concentration of NADPH consumed (Figure 5.13) and the amount of SeMetO reduced 
(Figure 5.14), potentially due to the underestimation of NADPH concentrations based 
on the extinction co-efficient. 
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Figure 5.14 – Concentrations of selenoxides and selenoethers following 2 h incubation 
of SeMetO and SeTalO with the GPx system. 
SeMetO or SeTalO (200 µM) was added to NADPH (700 µM), TrxR (25 nM), Trx (1.5 µM) 
and GPx (1.5 µM) and incubated for 2 h before analysis by HPLC. a) shows concentration 
of selenoxide reduced and b) shows recovery of the respective selenoether. The GPx system 
was able to reduce the SeMetO (200 µM), with a full recovery of SeMet. No changes were 
observed for SeTalO. Data represent mean ± SD from 3 independent experiments. Error 
bars may not be visible due to small error measured. 
In summary, addition of SeMetO to the NADPH/TrxR/Trx/GPx system 
demonstrated a consumption of NADPH as measured by optical absorbance at 340 nm. 
This corresponded with a decrease in levels of SeMetO and increase in levels of SeMet 
2 hours after SeMetO addition as assessed by HPLC. However, NADPH consumption, or 
reduction of SeTalO levels were not observed upon addition of SeTalO to the 
NADPH/TrxR/Trx/GPx system. 
5.3.1.3 Methionine sulfoxide reductases 
Msrs are enzymes that specifically reduce MetSO residues [109, 592]. As they 
contain Cys and Sec residues at the active site, there may also be potential for reaction 
with selenoxides [109, 592]. Furthermore, due to the structural similarity of SeMetO 
and MetSO, there is potential for Msrs to reduce SeMetO in particular (Figure 5.15).   
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Figure 5.15 – Proposed mechanism for the reduction of SeMetO and SeTalO by 
NADPH/TrxR/Trx/Msrs. The selenoxides may be reduced by either the TrxR, Trx or 
Msrs in this system. 
The loss of NADPH was monitored after SeMetO, SeTalO or MetSO (200 µM) was 
added to NADPH (700 µM), TrxR (25 nM), Trx (1.5 µM) and MsrA (95 nM) or MsrB2 
(0.25 µM) (Figure 5.16). These concentrations of Msr were chosen as they represent 
one unit of enzyme activity according to the manufacturer’s data sheet. A decrease of 4 
± 1 nM s-1 was observed in control samples without addition of selenoxides. Addition 
of SeMetO (200 µM) increased the rate of NADPH consumption to 51 ± 16 and 51 ± 14 
nM s-1 for MsrA and MsrB2 respectively. A slight increase in the NADPH consumption 
rate was observed with MetSO addition to 8 ± 3 nM s-1 for MsrA and 10 ± 4 nM s-1 for 
MsrB2, but this was not a significant increase. It is likely that the small observed change 
with MetSO is because although Msrs are capable of reducing free MetSO, peptide 
bound MetSO is a more favourable substrate [109]. SeTalO addition did not affect the 
rate of NADPH consumption with an NADPH consumption rate of 9 ± 5 and 9 ± 8 nM s-
1 for MsrA and MsrB2 respectively, suggesting no reduction was occurring. As with the 
other enzyme systems (Figure 5.8 and Figure 5.12), total NADPH consumption 
reflected the differences in the inital rates of NADPH consumption, with SeMetO 
causing a significant increase in total NADPH consumed compared to control, where 
SeTalO does not (Figure 5.17). 
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Figure 5.16 – Change in NADPH concentration over time after SeMetO, SeTalO or MetSO 
were added to Msr systems 
SeMetO, SeTalO or MetSO (200 µM) was added to NADPH (700 µM) + TrxR (25 nM), Trx 
(1.5 µM) and MsrA (95 nM) or MsrB2 (0.25 µM) and the absorbance monitored for 2 h 
min at 340 nm. Graphs show typical [NADPH] vs time obtained of the control (solid) or 
when 200 µM SeMetO (dashed), SeTalO (dotted) and MetSO (dot-dashed) were added to 
the a) MsrA or c) MsrB2 system. The rate of NADPH consumption was determined by 
fitting a straight line to the initial 25 min represented in a and c). SeMetO increases the 
rate at which NADPH is consumed compared to the control though SeTalO does not. b, d) 
The rate of NADPH consumption was determined by fitting a straight line to the data 
represented in a, c). Data represent mean ± SD from 3 independent experiments. * 
indicates significant difference (p < 0.05) from control based on one-way ANOVA with 
Tukey’s post-hoc test. 
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Figure 5.17 – Total NADPH consumed 2 h after SeMetO or SeTalO addition to NADPH, 
TrxR, Trx and MsrA or MsrB 
SeMetO or SeTalO (200 µM) was added to NADPH (700 µM) + TrxR (25 nM), Trx (1.5 µM) 
and a) MsrA (95 nM) or b) MsrB2 (0.25 µM) and the absorbance monitored for 2 h at 340 
nm. NADPH consumed was determined by the difference in NADPH concentration from 
the initial reading to 2 h after selenoxide addition. Addition of SeMetO caused a 
significantly greater consumption of NADPH compared to control, whereas SeTalO 
addition did not.  Data represent mean ± SD from 3 independent experiments. * indicates 
significant difference (p < 0.05) from control based on one-way ANOVA with Tukey’s post-
hoc test. 
As NADPH consumption was observed with SeMetO addition, it was anticipated 
that there should be a loss of SeMetO with a corresponding increase in SeMet. SeMet 
and SeMetO levels were measured after 2 h by HPLC. Samples were incubated for 2 h 
before removal of enzymes by filtering through a 10 kDa molecular mass cut-off filters 
and the concentrations of selenoxide and parent selenoether were analysed by HPLC 
with UV detection, and quantification performed as in Section 2.3.5.4. Similar to the 
data obtained from the NADPH/TrxR/Trx system (Figure 5.10), after 2 h complete 
reduction of SeMetO to SeMet was observed, and no change was observed with SeTalO 
(Figure 5.18). Again, a difference in NADPH consumed and selenoxide reduced is 
observed, which is believed to be related to the measurement of NADPH concentration 
discussed in Section 5.3.1.1. 
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Figure 5.18 – Concentrations of selenoxides and selenoethers following 2 h incubation 
of SeMetO and SeTalO with the Msr systems 
SeMetO or SeTalO (200 µM) was added to NADPH (700 µM), TrxR (25 nM), Trx (5 µM) 
and MsrA (95 nM) (black bars) or MsrB2 (0.25 µM) (white bars) and incubated for 2 h 
before analysis by HPLC. a) shows the concentration of selenoxide reduced and b) shows 
the recovery of  corresponding selenoether. The Msr systems were able to reduce the 200 
µM SeMetO, with a full recovery of SeMet. No changes were observed for SeTalO. Data 
represent mean ± SD from 3 independent experiments.  
In summary, addition of SeMetO to NADPH/TrxR/Trx/MsrA or MsrB2 resulted in 
the loss of NADPH as measured by optical absorbance at 340 nm, with a decrease in 
SeMetO observed with a concomitant increase in SeMet concentrations, as measured 
by HPLC. SeTalO had no effect when added to these antioxidant enzyme systems. 
5.3.1.4 Glutathione reductase 
Selenoxides react with GSH to form GSSG as demonstrated in Chapter 4. GSSG 
should then be reduced by GSR at the expense of NADPH [557]. The ability of the GSR 
system to reduce SeMetO and SeTalO was monitored by NADPH consumption as 
assessed by optical absorbance at 340 nm.   
 
Figure 5.19 – Proposed reaction mechanism for the reduction of selenoxides by the 
NADPH/GSR.GSH system, with the formation of GSSG by reaction of selenoxides with 
GSH. 
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NADPH (500 µM), GSR (25 nM) and GSH (400 µM) was mixed with either SeMetO 
or SeTalO (200 µM) in phosphate buffer (0.1 M, pH 7.4) at 22 °C by stopped flow 
apparatus. Consumption of NADPH was monitored by UV-vis absorbance at 340 nm 
over 1 min (Figure 5.20). It should be noted that the concentration of NADPH was 
required to be lowered as initial experiments performed with 700 µM NADPH, 
consistent with other experiments in this Chapter, resulted in the UV-Vis detector 
attached to the stopped flow apparatus being saturated. Upon addition of selenoxides, 
an increase in the rate of NADPH consumption was observed over 1 min. The maximum 
rate of NADPH consumption was determined by fitting a linear slope to the UV-vis data, 
and this was assumed to correspond to the rate of selenoxide removal from the system. 
The rate of NADPH consumption was 7.4 ± 1 µM s-1 upon mixing the GSR system with 
SeMetO, and 6.7 ± 0.3 µM s-1 with SeTalO addition. Total NADPH consumption upon 
SeMetO or SeTalO addition is also consistent with the reduction of selenoxides. The loss 
of NADPH concentration suggests that the NADPH/GSR/GSH system reduced both 
SeMetO and SeTalO.  
 
Figure 5.20 - Change in NADPH concentration over time after SeMetO or SeTalO was 
added to the GSR system. 
SeMetO or SeTalO (200 µM) was mixed by stopped flow apparatus with NADPH (500 µM), 
GSR (25 nM) and GSH (400 µM) and the absorbance monitored for 1 min at 340 nm. a) 
shows typical [NADPH] vs time data obtained when 200 µM SeMetO (dashed), SeTalO 
(dotted) were mixed with the GSR system. Both SeMetO and SeTalO induced a steady 
decrease in NADPH concentration. b) The rate of NADPH consumption was determined 
by fitting a straight line to the initial 10 s of data represented in a). Data represent mean 
± SD from 3 independent experiments.  
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Figure 5.21 – Total NADPH consumed following addition for SeMetO or SeTalO to 
NADPH, GSH and GSR after 1 min 
SeMetO or SeTalO (200 µM) was added to NADPH (500 µM), GSR (25 nM) and GSH (400 
µM) and the absorbance monitored for 1 min at 340 nm. NADPH consumed was 
determined by the difference in NADPH concentration from the initial reading to 1 min 
after selenoxide addition. Addition of SeMetO and SeTalO both demonstrated an equal 
consumption of NADPH. 
As NADPH consumption was observed that suggested a reduction of selenoxides 
via GSSG formation, an HPLC method was used to determine the concentrations of 
selenoethers and selenoxides after incubation of selenoxides with the 
NADPH/GSR/GSH system (Section 2.3.5.4). After addition of SeMetO to the GSR system, 
no SeMetO remained in the samples after 10 min, corresponding to a consumption of 
200 µM SeMetO. An increase of 200 µM SeMet levels was observed at the same time 
point, demonstrating that the GSR system was capable of reducing SeMetO to SeMet.  A 
difference between the total NADPH consumed (Figure 5.21) and the concentration of 
SeMet recovered (Figure 5.22) was observed, with this thought to be due to issues with 
NADPH concentration determination discussed in Section 5.3.1.1. Unfortunately, due 
to interference by components of the GSR system, similar experiments to give the 
concentrations of SeTal and SeTalO could not be determined. 
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Figure 5.22 – Concentration of SeMetO reduced and SeMet recovered after SeMetO was 
added to the NADPH/GSR/GSH system 
SeMetO (200 µM) was added to NADPH (500 µM), GSR (25 nM) and GSH (400 µM) and 
incubated for 10 min, before the SeMetO and SeMet concentrations were determined by 
HPLC. A decrease in SeMetO concentration of 200 µM was observed, which corresponded 
to an increase in SeMet of 200 µM. Data represent mean ± SD from 3 independent 
experiments. 
In summary, TrxR was capable of reducing SeMetO and the addition of additional 
enzymes to the TrxR system, i.e. Trx and GPx or Msr, did not result in an increase in the 
rate of NADPH consumption. The TrxR system was unable to reduce SeTalO, and 
addition of other enzymes did not allow for reduction to occur. The NADPH/GSR/GSH 
system however, was capable of reducing both SeMetO and SeTalO, which occurred 
much more rapidly than the TrxR reduction of SeMetO.  
 Redox enzymes reducing N-chloramines 
N-Chloramines have previously been reported to react with thiol groups [192], and 
selenols are generally more reactive towards oxidants and therefore should be capable 
of reacting with N-chloramines [90, 98]. As redox enzymes often have either a thiol or 
selenol active site, they should be able to react with N-chloramines. This reaction 
should lead to oxidation of the redox enzyme and reduction of N-chloramine. These 
enzymes therefore may be able to protect cells against oxidative damage via direct 
antioxidant capacity toward N-chloramines. Furthermore, TrxR and GSR have 
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demonstrated ability to reduce selenoxides, and as selenoethers rapidly scavenge N-
chloramines, this may lead to enhanced oxidant removal. 
5.3.2.1 Thioredoxin reductase 
TrxR and Trx can detoxify peroxides, ONOOH and HOSCN, via reaction with active 
site SeCys and Cys respectively [348, 591]. As they are capable of removing these 
oxidants, their ability to reduce N-chloramines was investigated. In the presence of 
ebselen and selenocystamine the rate of peroxide removal by the Trx system is 
enhanced [492], and as TrxR and Trx has demonstrated the ability to reduce SeMetO 
[474], the presence of selenium compounds may further enhance oxidant removal 
(Figure 5.23). 
 
Figure 5.23 – Potential reactions occurring when N-chloramines are added to 
NADPH/TrxR/Trx/SeMet or SeTal. N-Chloramines may react directly with NADPH, or 
with TrxR, or Trx, or with SeMet and SeTal to form selenoxides which are subsequently 
reduced by TrxR and Trx.  
The ability of TrxR to reduce model N-chloramines, TauCl, LysCl and GlyCl, was 
investigated by HPLC and the rate of NADPH consumption. NADPH (700 µM) and TrxR 
(25 nM) were incubated together for 5 min before addition of N-chloramine (200 µM). 
NADPH concentrations were monitored by optical absorbance at 340 nm (Figure 5.24). 
Only the UV-vis data for TauCl is shown, as comparable data is obtained with LysCl and 
GlyCl addition. The rate of NADPH consumption was determined by fitting a line to the 
initial (25 min) linear section of the [NADPH] vs time graph (Figure 5.25). 
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A rate of loss of NADPH of 104 ± 2 nM s-1 was observed when TauCl was added to 
NADPH alone. This is attributed to the direct reaction of TauCl with NADPH. The 
NADPH consumption rate increased to 111 ± 4 nM s-1 in the presence of TrxR, however 
this increase was not statistically significant. The presence of SeMet or SeTal (20 µM) 
reduced the rate of NADPH consumption to 92 ± 5 and 91 ± 6 nM s-1 respectively. 
Increasing the concentration of SeMet (200 µM) further reduced the rate of NADPH 
loss to 50 ± 7 nM s-1, whereas with SeTal (200 µM) the NADPH consumption rate was 
reduced to 18 ± 4 nM s-1. The reduction in the rate of NADPH consumption is attributed 
to the formation of selenoxides upon N-chloramine addition, with higher 
concentrations of SeMet or SeTal leading to a further reduction in NADPH consumption 
rate as more selenoxide is formed. As the TrxR system is capable of reducing SeMetO, 
but not SeTalO (Section 5.3.1.1), the rate of NADPH consumption is further reduced by 
the formation of SeTalO. The rates of NADPH loss was very similar to that observed in 
the presence of the selenoxides, consistent with the rapid generation of the selenoxide, 
which is then reduced by the Trx system (Figure 5.8). 
The UV-vis vs time data monitored at 340 nm for LysCl and GlyCl were very similar 
to that obtained for TauCl (Figure 5.24) and the rate of NADPH consumption was 
determined by fitting to the NADPH concentration over time data obtained for the 10 
min following N-chloramine addition (Figure 5.25). The rates of NADPH loss in control 
samples were higher for LysCl and GlyCl, 211 ± 13 and 184 ± 12 nM s-1 respectively, 
than for TauCl. As with TauCl, no significant difference in the rates of NADPH 
consumption were seen in the presence of TrxR compared to the control for LysCl or 
GlyCl, with rates of 203 ± 11 and 179 ± 13 nM s-1 respectively. Small decreases in the 
NADPH consumption rate were observed with SeMet (20 µM) and SeTal (20 µM), 
though this change was not significant for either LysCl (182 ± 16 and 174 ± 13 nM s-1 
respectively) or GlyCl (154 ± 12 and 154 ± 9 nM s-1 respectively). At higher 
concentrations, SeMet (200 µM) and SeTal (200 µM) significantly reduced the rate of 
NADPH consumption to 44 ± 6 and 28 ± 7 nM s-1 respectively upon LysCl addition, and 
42 ± 4 and 16 ± 9 nM s-1 for GlyCl addition. These rates of NADPH consumption are 
similar to those observed in the reduction experiments with pre-prepared selenoxides 
(Figure 5.8). 
 177 
 
Figure 5.24 – Loss of NADPH over time when TauCl is added to NADPH ± TrxR ± SeMet 
or SeTal. 
UV-vis absorbance at 340 nm was monitored after addition of TauCl to samples 
containing NADPH, TrxR with or without SeMet and SeTal. a) TauCl (200 µM) was added 
to NADPH (700 µM) in the a) presence (dotted line) or absence (solid) of TrxR (25 nM). 
b,c) TauCl (200 µM) was added to NADPH (700 µM) and TrxR (25 nM) in the presence of 
20 µM (dashed line) or 200 µM (dot-dashed line) b) SeMet or c) SeTal. Addition of TauCl 
caused a time dependent decrease in NADPH, which was inhibited by the presence of 
SeMet and SeTal. Data are representative of 3 independent experiments. 
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Figure 5.25 - Rate of NADPH consumption when N-chloramines were added to NADPH 
in the presence of TrxR and SeMet or SeTal 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysCl (200 µM) or c) GlyCl (200 µM), were added to samples of NADPH (700 µM) ± TrxR 
(25 nM) (black bars) ± SeMet or SeTal (20 µM (white bars) or 200 µM (grey bars)). The 
rate of NADPH consumption was determined by fitting a straight line to the data 
obtained. The presence of N-chloramines caused a high rate of loss of NADPH that was 
decreased by the presence of SeMet and SeTal in a concentration-dependent manner. 
Data represent mean ± SD from 3 independent experiments. * indicates significant 
difference (p < 0.05) from control based on one-way ANOVA with Tukey’s post-hoc test. 
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In addition to examining the initial rate of NADPH loss, the total amount of NADPH 
consumed 2 h after the addition of N-chloramines was assessed (Figure 5.26). A total 
decrease of 150 ± 5 µM NADPH was observed 2 h after addition of TauCl (200 µM), with 
140 ± 6 and 149 ± 4 µM being consumed upon LysCl (200 µM) or GlyCl (200 µM) 
addition respectively. However, the NADPH consumption may be underestimated due 
to issues with NADPH concentration measurement, as discussed in Section 5.3.1.1, and 
it should be noted that these numbers do not account for the loss of NADPH due to 
autooxidation. The presence of TrxR did not significantly increase the total NADPH 
consumed upon N-chloramine addition, nor did the presence of lower concentration of 
SeMet or SeTal (20 µM). A slight decrease in the total NADPH consumed was observed 
in the presence of higher concentrations of SeMet (200 µM) upon TauCl and GlyCl 
addition, though this was not significant, and probably reflects the ability of 
NADPH/TrxR to reduce SeMetO though at a lower rate than N-chloramines (Figure 
5.8). The presence of SeTal (200 µM) significantly reduced the total NADPH 
consumption upon addition of N-chloramines, consistent with the inability of 
NADPH/TrxR to reduce SeTalO (Figure 5.8). 
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Figure 5.26 - Total NADPH consumed 2 h after N-chloramines were added to NADPH 
in the presence of TrxR and SeMet or SeTal 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysC (200 µM)l or c) GlyCl (200 µM), were added to samples of NADPH (700 µM) ± TrxR 
(25 nM) (black bars) ± SeMet or SeTal (20 µM (white bars) or 200 µM (grey bars)). 
NADPH consumed was determined by the difference in NADPH concentration from the 
initial reading to 2 h after N-chloramine addition. The addition of N-chloramines caused 
consumption of NADPH. There was a slight decrease in NADPH consumption when SeMet 
(200  µM) was present, though this was not significant. Significantly less NADPH was 
consumed when SeTal (200 µM) was present for each N-chloramine. Data represent mean 
± SD from 3 independent experiments. * indicates significant difference (p < 0.05) from 
control based on one-way ANOVA with Tukey’s post-hoc test. 
As the rate consumption of NADPH in the presence of TrxR was significantly 
decreased in the presence of SeMet (200 µM) or SeTal (200 µM), it was proposed that 
SeMet and SeTal were scavenging the N-chloramines to form the respective 
selenoxides. The selenoxides are then the species that are reduced by the NADPH/TrxR 
system rather than the N-chloramines themselves. In order to investigate this possible 
interpretation of the data further, the levels of SeMet, SeTal, SeMetO and SeTalO were 
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assessed by HPLC with UV detection at 20 min and 2 h after TauCl addition (Figure 
5.27). 
NADPH (700 µM) and TrxR (25 nM) were incubated with SeMet (200 µM) or SeTal 
(200 µM) for 5 min before addition of TauCl (200 µM). The proteins were removed by 
filtering through 10 kDa molecular mass cut-off filters after incubation for 20 min or 2 
h after N-chloramine addition. The concentration of SeMet and SeTal and the 
corresponding selenoxides was then determined by HPLC (Section 2.3.5.4). 
SeMetO and SeTalO were the primary species present 20 min after TauCl addition 
to the samples with 164 ± 8 µM SeMetO and 175 ± 6 µM SeTalO present, compared to 
56 ± 25 µM SeMet and 19 ± 7 µM SeTal. After 2 h, in SeMet samples, the majority of the 
SeMetO had been reduced with only 12 ± 13 µM remaining. This corresponded to a 
recovery of SeMet with a final concentration of 173 ± 10 µM. The concentrations of 
SeTal and SeTalO remained unchanged between the time points, with 23 ± 16 and 174 
± 10 µM measured at 2 h for SeTal and SeTalO respectively, consistent with the 
NADPH/TrxR system being unable to reduce SeTalO. These concentrations better 
reflect the concentration of NADPH consumed in previous experiments (Figure 5.26) 
compared with the experiments with selenoxide alone, as discussed in Section 5.3.1.1, 
though it should be noted that total NADPH consumption may be underestimated due 
to autoxidation of NADPH. 
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Figure 5.27 – Concentrations of SeMet, SeMetO, SeTal and SeTalO after TauCl was 
added to NADPH, TrxR and SeMet or SeTal. 
NADPH (700 µM) and TrxR (25 nM) were incubated with a) SeMet (200 µM) or b) SeTal 
(200 µM) for 5 min before addition of TauCl (200 µM). The concentrations of a) SeMet 
(black bars) and SeMetO (white bars) or b) SeTal (black bars) and SeTalO (white bars) 
were determined by HPLC at 20 mins or 2 h after addition of TauCl. At 20 min SeMetO 
and SeTalO were the primary species present. After 2 h SeMetO had been reduced, but no 
change was observed for SeTalO. Data represent mean ± SD from 3 independent 
experiments.  
In summary, a decrease in the rate of NADPH consumption was observed when N-
chloramines were added to NADPH in the presence of Trx, however this rate was not 
significantly different from NADPH alone. The presence of SeMet and SeTal reduced 
the rate at which NADPH was consumed when N-chloramines were added to 
NADPH/TrxR. This is attributed to the rapid formation of selenoxides, followed by 
subsequent reduction of SeMetO, though SeTalO could not be reduced by this system 
(consistent with Section 5.3.1.1). This was confirmed by HPLC studies which showed 
that high levels of selenoxides were present 20 mins after N-chloramine addition for 
both SeMetO and SeTalO, and SeMetO levels were decreased at 2 hours with a 
concurrent increase in SeMet, whereas no changes were observed in SeTalO 
concentrations. 
5.3.2.2 Thioredoxin 
N-Chloramines, TauCl, LysCl or GlyCl, (200 µM) were added to NADPH (700 µM), 
TrxR (25 nM) and Trx (1.5 µM) with or without SeMet or SeTal (20 or 200 µM) and the 
absorbance at 340 nm was monitored for 2 h. The rate of NADPH consumption, and 
hence N-chloramine reduction, was determined by fitting a straight line to the linear 
portion (10 min) of the NADPH concentration vs. time plots (Figure 5.28). 
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There was an increase in the rate of NADPH consumption from 104 ± 2 nM s-1 in the 
NADPH controls to 116 ± 6 nM s-1 when TauCl (200 µM) was added to 
NADPH/TrxR/Trx (Figure 5.28a). However, the increase over NADPH/TrxR was not 
significant. There were no significant increase in NADPH consumption over NADPH 
alone when LysCl or GlyCl were added to NADPH/TrxR/Trx, with rates of 204 ± 5 and 
183 ± 17 nM s-1 observed (Figure 5.28b,c).  
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Figure 5.28 – Rate of NADPH consumption when N-chloramines were added to the  
NADPH/TrxR/Trx system with SeMet or SeTal 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysCl (200 µM) or c) GlyCl (200 µM), were added to samples of NADPH (700 µM) ± TrxR 
(25 nM) ± Trx (1.5 µM) (black bars) ± SeMet or SeTal (20 µM (white bars) or 200 µM (grey 
bars)). The rate of NADPH consumption was determined by fitting a straight line to the 
data obtained. The presence of both TrxR and Trx increased the rate at which NADPH was 
consumed when TauCl was added to the system. TrxR and Trx had no effect on NADPH 
consumption rates when LysCl or GlyCl was added. N-Chloramines caused a rapid rate of 
consumption of NADPH which could be inhibited by the presence of SeMet and SeTal. Data 
represent mean ± SD from 3 independent experiments. # indicates significant difference 
(p < 0.05) from NADPH alone, and * indicates significant difference (p < 0.05) from 
NADPH.TrxR.Trx based on one-way ANOVA with Tukey’s post-hoc test. 
The presence of SeMet (20 µM) and SeTal (20 µM) significantly decreased the 
NADPH consumption rate to 92 ± 1 and 96 ± 5 nM s-1 respectively when TauCl was 
added to the Trx system. Small decreases in the NADPH consumption rates were also 
observed when LysCl and GlyCl were added to the TrxR system in the presence of 
SeMet or SeTal (20 µM) to 178 ± 16 and 176 ± 10 nM s-1 with LysCl (200 µM) addition 
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and 157 ±11 and 161 ±19 with GlyCl (200 µM) addition (Figure 5.28b,c). As for TauCl, 
these rates were not significantly different from the rate of NADPH consumption either 
alone or in the presence of TrxR and Trx. The presence of higher concentrations of 
SeMet (200 µM) in the NADPH/TrxR/Trx system reduced the NADPH consumption 
rate further to 46 ± 3, 43 ± 5 and 45 ± 3 nM s-1 for TauCl, LysCl and GlyCl respectively. 
These rates are similar to those observed when 200 µM SeMetO was added to 
NADPH/TrxR/Trx system (Figure 5.9). The presence of SeTal (200 µM) reduced the 
NADPH consumption rate to 19 ± 4, 23 ± 6 and 18 ± 3 nM s-1 for TauCl, LysCl and GlyCl 
respectively. 
In addition to examining the initial rate of NADPH loss, the total amount of NADPH 
consumed 2 h after the addition of N-chloramines was assessed (Figure 5.29). Total 
losses of 161 ± 18, 143 ± 22 and 161 ± 18  µM NADPH were observed 2 h after the 
addition of TauCl, LysCl or GlyCl to NADPH/TrxR/Trx respectively. As for the 
NADPH/TrxR system (Figure 5.26), this was less than the 1 : 1 ratio as expected. The 
presence of SeMet (20 µM) or SeTal (20 µM) did not have an affect on total NADPH 
consumed, but the presence of higher concentrations of SeMet (200 µM) demonstrated 
a decrease in total NADPH consumed to 117 ± 14, 118 ± 10 and 120 ± 8 µM upon 
addition of TauCl, LysCl and GlyCl respectively, though this was not significantly 
different to NADPH/TrxR/Trx alone. The presence of SeTal (200 µM) significantly 
reduced the total NADPH consumed by the system as seen with the NADPH TrxR 
system (Figure 5.26), and reflects the inability of NADPH/TrxR/Trx to reduce SeTalO. 
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Figure 5.29 - Total NADPH consumed 2 h after N-chloramines were added to NADPH 
in the presence of TrxR, Trx and SeMet or SeTal 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysCl (200 µM) or c) GlyCl (200 µM), were added to samples of NADPH (700 µM), TrxR 
(25 nM) (black bars) and Trx (1.5 µM) ± SeMet or SeTal (20 µM (white bars) or 200 µM 
(grey bars)). NADPH consumed was determined by the difference in NADPH 
concentration from the initial reading to 2 h after N-chloramine addition. The addition 
of N-chloramines caused consumption of NADPH. Less NADPH was consumed when SeMet 
(200  µM) was present, though this was not significant. Significantly less NADPH was 
consumed when SeTal (200 µM) was present in each case. Data represent mean ± SD from 
3 independent experiments. * indicates significant difference (p < 0.05) from control 
based on one-way ANOVA with Tukey’s post-hoc test. 
In light of the above data, it was proposed that N-chloramines were reacting with 
N-chloramines to form selenoxides, which are then reduced by the NADPH/TrxR/Trx 
system. As such, the levels of selenoxides, SeMetO and SeTalO, and parent selenoethers, 
SeMet and SeTal, were measured by HPLC (Section 2.3.5.4) with UV-vis detection at 
incubation times of 20 min and 2 h after the addition of TauCl (200 µM) to NADPH (700 
µM), TrxR (25 nM) and Trx (1.5 µM) (Figure 5.30). After 20 min, the selenoxides were 
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the major species present at 165 ± 8 µM and 175 ± 7 µM of SeMetO and SeTalO detected 
respectively, with the corresponding SeMet and SeTal concentrations being 52 ± 30 
and 21 ± 7 µM respectively. After 2 h, the majority of SeMetO had been reduced to 
SeMet with 12 ± 13 µM SeMetO and 170 ± 10 µM SeMet detected. No significant changes 
were observed in the concentration of SeTal and SeTalO after 2 h compared to 20 min, 
with 21 ± 14 and 174 ± 10 µM SeTal and SeTalO measured at 2 h respectively.  
 
Figure 5.30 – Concentrations of SeMet, SeMetO, SeTal and SeTalO after TauCl was 
added to NADPH, TrxR, Trx and SeMet or SeTal 
NADPH (700 µM) TrxR (25 nM) and Trx (1.5 µM) were incubated with 200 µM a) SeMet 
or b) SeTal for 5 min before addition of TauCl (200 µM). The concentrations of a) SeMet 
(black bars) and SeMetO (white bars) or b) SeTal (black bars) and SeTalO (white bars) 
were determined by HPLC at 20 mins or 2 h after addition of TauCl. After 20 min SeMetO 
and SeTalO were the primary species present. After 2 h, the concentration of SeMetO had 
been reduced, whilst no change was observed for SeTalO. Data represent mean ± SD from 
3 independent experiments.  
A decrease in NADPH was observed when N-chloramines were added to NADPH in 
the presence of TrxR and Trx. The rate of NADPH consumption was only increased 
when TauCl was added to NADPH/TrxR/Trx. The presence of SeMet and SeTal reduced 
the rate at which NADPH was consumed when N-chloramines was added to 
NADPH/TrxR/Trx. As with NADPH and TrxR alone, this was attributed to the rapid 
formation of selenoxides, with reduction of SeMetO levels observed after 2 h. 
5.3.2.3 GPx 
GPx is capable of reducing peroxides, via reaction of the peroxide with the active 
site Sec [583]. As HOCl has demonstrated reactivity with SeCys residues [98], N-
chloramines are also likely to react with this site, thus GPx may be capable of reacting 
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with and reducing N-chloramines. The ability of GPx to reduce N-chloramines, and the 
interactions with SeMet and SeTal were assessed (Figure 5.31). 
 
Figure 5.31 – Potential routes of N-chloramine consumption when exposed to 
NADPH/TrxR/Trx/GPx/SeMet or SeTal 
The N-chloramines, TauCl, LysCl and GlyCl (200 µM), were added to NADPH (700 
µM), TrxR (25 nM), Trx (1.5 µM) and GPx (1.5 µM) with or without SeMet or SeTal (20 
µM or 200 µM). The changes in absorbance at 340 nm were monitored for 2 h (Figure 
5.32), and the rate of NADPH consumption was determined by the fitting of a straight 
line to the initial 25 min of the resulting NADPH concentration vs time plots (Figure 
5.33).  
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Figure 5.32 – Plots of the NADPH concentration over time after TauCl was added to the 
GPx system in the presence or absence of SeMet and SeTal. 
UV-vis absorbance was monitored at 340 nm after addition of TauCl to samples 
containing NADPH, TrxR, Trx and GPx with or without SeMet and SeTal. a) TauCl (200 
µM) was added to NADPH (700 µM) in the a) presence (dotted line) or absence (solid) of 
the TrxR (25 nM), Trx (1.5 µM) and GPx (1.5 µM). b,c) TauCl (200 µM) was added to the 
GPx system in the presence of 20 µM (dashed line) or 200 µM (dot-dashed line) b) SeMet 
or c) SeTal. Addition of TauCl caused a time dependent decrease in NADPH concentration 
and the rate of this decreased by presence of SeMet and SeTal. Data are representative of 
3 independent experiments. 
The addition of N-chloramines causes a loss of NADPH in control samples of 106 ± 
18, 186 ± 36, and 164 ± 27 nM s-1 after addition of TauCl, LysCl and GlyCl respectively 
(Figure 5.33). The presence of the TrxR/Trx/GPx did not have an effect on the rate of 
NADPH consumption upon N-chloramine addition with rates of NADPH consumption 
of 112 ± 15, 170 ± 30 and 170 ± 26 nM s-1 observed upon addition of TauCl, LysCl and 
GlyCl to NADPH/TrxR/Trx/GPx respectively. The presence of SeMet (20 µM) lowered 
the rate of NADPH consumption to 93 ± 19, 126 ± 30 and 137 ± 20 nM s-1 for TauCl, 
LysCl and GlyCl respectively, and 20 µM SeTal lowered the rates to 91 ± 9, 142 ± 35 and 
134 ± 11 nM s-1, though none of these changes were not significantly different to 
NADPH alone and the NADPH/TrxR/Trx system (Figure 5.28). The presence of SeMet 
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(200 µM) significantly reduced the rate of NADPH consumption for all N-chloramines, 
to 61 ± 20, 56 ± 30 and 69 ± 16 nM s-1 for TauCl, LysCl and GlyCl respectively. The 
presence of SeTal (200 µM) demonstrated a greater reduction in NADPH consumption 
rate for all N-chloramines, to 17 ± 10, 7 ± 9 and 18 ± 9 nM s-1 for TauCl, LysCl and GlyCl 
respectively. The rates of NADPH consumption in the presence of SeMet (200 µM) and 
SeTal (200 µM) are similar to those observed when SeMetO (200 µM) or SeTalO (200 
µM) are added to the GPx system (Figure 5.12). 
In addition to examining the initial rate of NADPH loss, the total amount of NADPH 
consumed 2 h after the addition of N-chloramines was assessed (Figure 5.34). Addition 
of TauCl, GlyCl of LysCl (200 µM) to NADPH/TrxR/Trx/GPx caused a decrease of 145 ± 
6, 147 ± 12 and 159 ± 6 µM NADPH respectively. Again, this is less than what might be 
expected, and could be related to NADPH concentration determination. The presence 
of SeMet (20 µM) or SeTal (20 µM) did not significantly affect the total NADPH 
consumed by the system. The presence of 200 µM SeMet and SeTal significantly 
reduced the total NADPH consumed, reflecting the lower reduction rate of SeMetO and 
the inability of the system to reduce SeTalO (Section 5.3.1.2).  
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Figure 5.33 – NADPH consumption rates when N-chloramines are added to the GPx 
system in the presence or absence of SeMet and SeTal. 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysCl (200 µM) or c) GlyCl (200 µM), were added to samples of NADPH (700 µM) ± TrxR 
(25 nM) ± Trx (1.5 µM) ± GPx (1.5 µM) ± SeMet or SeTal (20 µM (white bars) or 200 µM 
(grey bars)). The rate of NADPH consumption was determined by fitting a straight line to 
the initial 25 min if the data obtained. Addition of TauCl caused a time dependent 
decrease in NADPH concentration and this rate was decreased by presence of SeMet and 
SeTal. Data represent mean ± SD from 3 independent experiments. * indicates significant 
difference (p < 0.05) from control based on one-way ANOVA with Tukey’s post-hoc test. 
N
A
D
P
H
N
A
D
P
H
.T
rx
R
.T
rx
.G
P
x
Se
M
et
Se
Ta
l
0.00
0.05
0.10
0.15
N
A
D
P
H
 c
o
n
s
u
m
e
d
/ 
µ
M
s
-1
a)
*
*
NADPH.TrxR.Trx.GPx
N
A
D
P
H
N
A
D
P
H
.T
rx
R
.T
rx
.G
P
x
Se
M
et
Se
Ta
l
0.00
0.05
0.10
0.15
0.20
0.25
N
A
D
P
H
 c
o
n
s
u
m
e
d
/ 
µ
M
s
-1
b)
*
*
NADPH.TrxR.Trx.GPx
N
A
D
P
H
N
A
D
P
H
.T
rx
R
.T
rx
.G
P
x
S
eM
et
Se
Ta
l
0.00
0.05
0.10
0.15
0.20
0.25
N
A
D
P
H
 c
o
n
s
u
m
e
d
/ 
µ
M
s
-1
c)
*
*
NADPH.TrxR.Trx.GPx
 192 
 
Figure 5.34 - Total NADPH consumed 2 h after N-chloramines were added to NADPH 
in the presence of TrxR, Trx, GPx and SeMet or SeTal 
The UV-vis absorbance of NADPH at 340 nm was monitored after a) TauCl (200 µM), b) 
LysCl (200 µM) or c) GlyCl (200 µM), were added to samples of NADPH (700 µM) ± TrxR 
(25 nM) ± Trx (1.5 µM) ± GPx (1.5 µM) ± SeMet or SeTal (20 µM (white bars) or 200 µM 
(grey bars)). The amount of NADPH consumed was determined by the difference in 
NADPH concentration from the initial reading to 2 h after N-chloramine addition. The 
addition of N-chloramines caused consumption of NADPH. Significantly less NADPH was 
consumed when SeMet (200  µM) or SeTal (200  µM) was present. Data represent mean ± 
SD from 3 independent experiments. * indicates significant difference (p < 0.05) from 
control based on one-way ANOVA with Tukey’s post-hoc test. 
The concentrations of SeMet and SeTal and their respective selenoxides were 
assessed by HPLC with UV-vis detection after incubation for 2 h of NADPH (700 µM), 
TrxR (25 nM), Trx (1.5 µM), GPx (1.5 µM) and SeMet (200 µM) or SeTal (200 µM) with 
TauCl (200 µM) (Figure 5.35). The primary species present after 2 h incubation for the 
SeMet containing samples was SeMet at a concentration of 160 ± 12 µM, and SeMetO at 
a concentration of 18 ± 10 µM. At the same time point, the primary species in the SeTal 
containing samples was SeTalO present at 157 ± 11 µM, with SeTal present at 18 ± 5 
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µM. This is consistent with results with the TrxR and Trx samples (Section 5.3.2.1 and 
5.3.2.2), demonstrating formation of SeMetO and SeTalO, with subsequent enzymatic 
reduction of SeMetO but not SeTalO. 
 
Figure 5.35 – Concentrations of SeMet, SeMetO, SeTal and SeTalO 2 h after TauCl was 
added to the GPx system in the presence of SeMet or SeTal. 
NADPH (700 µM), TrxR (25 nM), Trx (1.5 µM) and GPx (1.5 µM) were incubated with a) 
SeMet (200 µM) or b) SeTal (200 µM) for 5 min before addition of TauCl (200 µM). After 
2 h, SeMet was the major species present in SeMet samples, and SeTalO was the major 
species present in SeTal samples. Data represent mean ± SD from 3 independent 
experiments.  
A decrease in NADPH was observed when N-chloramines were added to NADPH in 
the presence of TrxR, Trx and GPx, however, no increase in rates were observed 
compared to NADPH alone. The presence of SeMet and SeTal reduced the rate at which 
NADPH was consumed when N-chloramines were added to NADPH/TrxR/Trx/GPx. 
This is attributed to the rapid formation of selenoxides upon addition of N-
chloramines, followed by slower reduction of SeMetO but not SeTalO. 
5.3.2.4 Methionine sulfoxide reductases 
The active sites of Msrs contain either a Cys, in the case of MsrA, or Sec, in the case 
of MsrB2 [109, 592]. As many other thiol and seleno enzymes demonstrate ability to 
reduce oxidants via reaction with active site thiol and selenol active sites, Msrs may 
also have some reductase ability. NADPH consumption was monitored by UV-vis 
spectroscopy at 340 nm when TauCl was added to NADPH/TrxR/Trx/MsrA or MsrB2. 
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TauCl (200 µM) was added to NADPH (700 µM), TrxR (25 nM), Trx (1.5 µM) and 
MsrA (95 nM) or MsrB (0.25 µM). The change in absorbance at 340 nm was monitored 
for 2 h. The rate of NADPH consumption was determined by fitting a straight line to the 
initial 25 min to the NADPH vs time plot. A time dependent decrease in NADPH was 
observed upon the addition of TauCl to the Msr systems, yielding a decrease of 94 ± 16 
and 87 ± 10 nM s-1 in NADPH for the MsrA and MsrB2 systems respectively (Figure 
5.36). These changes represent a slight decrease in NADPH consumption rate 
compared to previous systems examined, though this was not statistically significant 
from NADPH alone (104 ± 2 nM s-1), or the Trx system (116 ± 6 nM s-1) (Section 5.3.2.2). 
Similarly, no difference was observed in the total NADPH consumed by the system 
(Figure 5.37), though total NADPH consumption measured was lower than the 
concentration of TauCl added, which may be due to the underestimation of NADPH 
concentrations, discussed in Section 5.3.1.1. This may reflect the inability of the Msrs 
to increase the rate of TauCl removal. Due to limited supply of the Msr enzymes, the 
analogous experiments were not performed with LysCl and GlyCl, or N-chloramines 
scavenging by these enzyme systems in the presence of SeMet and SeTal. However, it 
is anticipated based on previous data presented that the same trend of decreased 
NADPH consumption in the presence of SeMet and SeTal would occur, as the presence 
of Msr was unable to increase NADPH consumption over that observed for TrxR in the 
presence of preformed SeMetO or SeTalO. 
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Figure 5.36 - NADPH consumption rates when N-chloramines are added to the Msr 
system. 
The UV-vis absorbance of NADPH at 340 nm was monitored after TauCl (200 µM) was 
added to NADPH (700 µM) ± TrxR (25 nM) ± Trx (1.5 µM) ± MsrA (95 nM) or MsrB2 (0.25 
µM). The rate of NADPH consumption was determined by fitting a straight line to the data 
obtained. N-Chloramine addition caused a loss of NADPH, and no change was observed 
with the addition of Msrs. Data represent mean ± SD from 3 independent experiments. No 
significant difference (p < 0.05) was observed from control based on one-way ANOVA with 
Tukey’s post-hoc test. 
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Figure 5.37 – Total NADPH consumed after addition of TauCl to NADPH in the presence 
or absence of TrxR, Trx and MsrA or MsrB 
The UV-vis absorbance of NADPH at 340 nm was monitored after TauCl (200 µM) was 
added to NADPH (700 µM) ± TrxR (25 nM) ± Trx (1.5 µM) ± MsrA (95 nM) or MsrB2 (0.25 
µM). NADPH consumed was determined by the difference in NADPH concentration from 
the initial reading to 2 h after N-chloramine addition. N-Chloramine addition caused a 
loss of NADPH, and no change was observed with the addition of Msrs. Data represent 
mean ± SD from 3 independent experiments. No significant difference (p < 0.05) was 
observed from control based on one-way ANOVA with Tukey’s post-hoc test. 
 Reduction of N-chloramines by GSR 
N-Chloramines are capable of reacting with GSH to form GSSG [192], which can in 
turn be reduced by GSR at the expense of NADPH. Therefore, the GSR system should be 
able to detoxify N-chloramines. As SeMet and SeTal react more quickly with N-
chloramines (Chapter 3), and in turn form selenoxides that react with GSH to form 
GSSG (Chapter 4), SeMet and SeTal may be able to increase the rate at which the GSR 
system can detoxify N-chloramines. In order to test this hypothesis, NADPH 
consumption was monsitored by UV-vis absorbance at 340 nm after N-chloramines 
were added to NADPH/GSR/GSH in the presence and absence of SeMet or SeTal.  
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Figure 5.38 – Potential routes of N-chloramine consumption upon addition to 
NADPH/GSR/GSH/SeMet or SeTal 
N-Chloramines (200 µM) were mixed with NADPH (500 µM), GSR (25 nM) and GSH 
(400 µM) in the presence and absence of SeMet or SeTal (20 or 200 µM) using stopped 
flow apparatus and the absorbance at 340 nm monitored over 1 min (Figure 5.39). A 
short lag phase in NADPH consumption was observed, which is attributed to the time 
taken to form GSSG upon addition of oxidant, which is then reduced by GSR. A decrease 
in NADPH concentration was observed under all conditions. The rate of NADPH 
consumption was determined by fitting a linear slope to UV-vis data between 2 – 10 s 
after mixing (Figure 5.40).  
 
Figure 5.39 – Concentration of NADPH over time after TauCl was added to the GSR 
system in the presence and absence of SeMet. 
TauCl (200 µM) was mixed with NADPH (500 µM), GSR (25 nM) and GSH (400 µM) using 
stopped flow apparatus in the presence or absence of SeMet (20 or 200 µM). The NADPH 
concentration, based on absorbance at 340 nm, was monitored for 1 min. The NADPH 
concentration decreased over time after addition of TauCl consistent with the GSR system 
detoxifying TauCl. 
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Addition of TauCl, LysCl and GlyCl (Figure 5.40 a, b and c respectively) showed a 
decrease in NADPH concentrations at a rate of 6.3 ± 0.2, 7.8 ± 0.2 and 6.9 ± 0.1 µM s-1 
respectively. Inclusion of lower concentrations of SeMet (20 µM) or SeTal (20 µM) did 
not significantly effect the rate of NADPH consumption, with NADPH consumption 
rates of 6.4 ± 0.02, 7.9 ± 0.4 and 7.1 ± 0.1 µM s-1 when TauCl, LysCl or GlyCl was added 
to NADPH/GSR/GSH/SeMet (20 µM) respectively, and 6.0 ± 0.3, 7.4 ± 0.2 and 6.7 ± 0.4 
µM s-1 when added to NADPH/GSR/GSH/SeTal (20 µM). When higher concentrations 
of SeMet (200 µM) was present with the GSR system, the rate NADPH consumption was 
significantly increased to 7.1 ± 0.2 µM s-1 upon addition of TauCl. A trend towards an 
increase in rate was observed with SeTal (200 µM) and TauCl addition though this 
change was not statistically significant, with an observed NADPH consumption rate of 
6.6 ± 0.2 µM s-1. A slight increase in the rate of NADPH consumption was observed in 
the presence of SeMet (200 µM) or SeTal (200 µM) when GlyCl was added, with rates 
of 7.5 ± 0.3 and 7.0 ± 0.3 µM s-1, but again this was not statistically significant. The 
inclusion of SeMet (200 µM) and SeTal (200 µM) did not appear to have any effect on 
the rate of NADPH consumption when LysCl was added to NAPDH/GSR/GSH in the 
presence or absence of these compounds, with NADPH consumption rates of 8.1 ± 0.3 
and 7.8 ± 0.5 µM s-1. The rate of NADPH consumption by these N-chloramines is most 
likely a reflection of the rate at which these species react with GSH to form GSSG. 
However, the NADPH consumption rate may also be being limited by the rate at which 
GSR can reduce GSSG. 
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Figure 5.40 – Rate of NADPH consumption after N-chloramines were added to the GSR 
system in the presence and absence of SeMet or SeTal. 
N-Chloramines, a) TauCl, b) LysCl, or c) GlyCl, (200 µM), were mixed with NADPH (500 
µM), GSR (25 nM) and GSH (400 µM) by stopped flow apparatus in the presence or 
absence (black bars) of SeMet or SeTal (20 (white bars) or 200 µM (grey bars)). NADPH 
concentration, based on absorbance at 340 nm, was monitored for 1 min and the rate of 
NADPH consumption determined by fitting a linear slope to the slope observed 2 – 10 s 
after mixing. Addition of N-chloramine caused a decrease in NADPH concentration. 200 
µM SeMet increased the rate of TauCl scavenging. No significant difference was observed 
with any other N-chloramine or SeMet or SeTal concentration. Data represent mean ± SD 
from 3 independent experiments. * indicates significant difference (p < 0.05) from control 
based on one-way ANOVA with Tukey’s post-hoc test. 
In addition to examining the initial rate of NADPH loss, the total amount of NADPH 
consumed 2 h after the addition of N-chloramines was assessed (Figure 5.41). A loss of 
172 ± 5, 183 ± 10 and 183 ± 12 µM NADPH was observed 2 h after addition of TauCl, 
LysCl or GlyCl to NADPH/GSR/GSH, respectively. These values were lower than 
expected, and attributed to possible impurities in the NADPH, discussed in Section 
5.3.1.1. The presence of SeMet (200 µM) demonstrated a very small decrease in total 
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NADPH consumed compared to the NADPH/GSR/GSH system alone, though this was 
not statistically significant. The presence of SeTal (20 or 200 µM) reduced the total 
NADPH consumed upon addition of TauCl (200 µM) compared to the NADPH/GSR/GSH 
system alone, to 157 ± 2 and 155 ± 4 respectively. The total NADPH consumed upon 
addition of GlyCl was also reduced by SeTal (200 µM) to 155 ± 9. The total NADPH 
consumed upon addition of LysCl to the system containing SeTal was also reduced, 
though this was not significant.   
 
Figure 5.41 – Total NADPH consumption after N-chloramines were added to the GSR 
system in the presence and absence of SeMet or SeTal. 
N-Chloramines, a) TauCl, b) LysCl, or c) GlyCl, (200 µM), were mixed with NADPH (500 
µM), GSR (25 nM) and GSH (400 µM) by stopped flow apparatus in the presence or 
absence (black bars) of SeMet or SeTal (20 (white bars) or 200 µM (grey bars)). NADPH 
concentration, monitored at 340 nm, was measured for 1 min and the total of NADPH 
consumption determined by difference of initial and final absorbance observed. The 
addition of N-chloramine caused a decrease in NADPH concentration. The presence of 
SeMet did not affect the total NADPH consumed. SeTal reduced total NADPH consumption 
upon addition of TauCl, and reduced NADPH consumption at 200 µM upon addition of 
GlyCl. The presence of SeTal did not have an affect with LysCl. Data represent mean ± SD 
from 3 independent experiments. * indicates significant difference (p < 0.05) from control 
based on one-way ANOVA with Tukey’s post-hoc test. 
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In parallel with the NADPH consumption experiments, the concentrations of SeMet 
and SeMetO were assessed by HPLC (Section 2.3.5.4) 10 min after 200 µM TauCl, LysCl 
and GlyCl were added to NADPH (500 µM), GSR (25 nM), GSH (400 µM) and SeMet (200 
µM). For each N-chloramine, approximately 200 µM SeMet was observed in the 
samples (Figure 5.42). No SeMetO was observed in any of the samples after 10 min. 
This is consistent with the formation of GSSG upon addition of N-chloramines, either 
via selenoxide formation or direct reaction with GSH. The total SeMetO reduced 
appears to be greater than the amount of NADPH consumed, and this may be due to 
difficulties with NADPH concentration measurement (see Section 5.3.1.1). 
Unfortunately, due to interferences in the chromatogram, SeTal and SeTalO levels 
could not be assessed.  
 
Figure 5.42 – Concentrations of SeMet recovered after N-chloramines were added to 
the GSR system in the presence of SeMet.  
TauCl, LysCl and GlyCl (200 µM) were added to NADPH (500 µM), GSR (25 nM), GSH (400 
µM) and SeMet (200 µM). The concentration of SeMet was determined after 10 min 
incubation by HPLC. SeMet (200 µM) was observed in each sample. Data represent mean 
± SD from 3 independent experiments. 
In summary, the addition of N-chloramines to NADPH/GSH/GSR induced a rapid 
decrease in NADPH concentration. The presence of 200 µM SeMet increased the rate of 
reduction observed, and a trend to increase was observed when TauCl or GlyCl was 
added in the presence of SeTal. The proposed mechanism is an initial rapid reaction of 
N-chloramines with SeMet or SeTal to form selenoxides, which then react with GSH to 
form GSSG and subsequent reduction by GSR. This is in contrast to the TrxR system, 
with coupled enzymes, where a reduction in the NADPH consumption rate occurs with 
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the presence of SeMet or SeTal. This is likely due to the reduced rate of selenoxide 
reduction by the TrxR system compared to the GSR system. 
 Reduction by J774A.1 cell lysates 
As the TrxR and GSR systems demonstrated ability to reduce selenoxides and N-
chloramines in isolated experiments, their ability to reduce these oxidants in a cell 
lysate system was investigated. Lysates of J774A.1 cells were prepared by lysing 6 x 
106 cells in 3 mL ice-cold H2O and incubating on ice for 15 min. Lysates were 
centrifuged to remove cellular debris, and the supernatant collected. The protein level 
was assessed by BCA assay and adjusted to 1 mg protein mL-1. 
5.3.4.1 Selenoxides 
Lysates (50 µg protein) were incubated with NADPH (500 µM) for 5 min before 
addition of SeMetO, SeTalO or insulin (200 µM). These experiments were performed in 
the presence or absence of auranofin (2.5 µM), as auranofin binds to Sec residues 
inhibiting the function of selenoenzymes, with TrxR being a major target [558]. The 
addition of auranofin should allow the contribution of the TrxR/Trx system to the 
overall rate and extent of NADPH loss to be determined. The concentrations of protein 
in lysates and auranofin used in this study are similar to those used previously [596, 
597]. The absorbance of NADPH at 340 nm was monitored for 2 h after the addition of 
selenoxide or the positive control insulin (Figure 5.43). Rates of NADPH consumption 
were determined by fitting a straight line to the initial 25 min of the NADPH vs time 
plot (Figure 5.43).  
A decrease of 3 ± 0.4 nM s-1 of NADPH concentration was observed in control 
samples (50 µg lysate and 500 µM NADPH) (Figure 5.43). Addition of SeMetO (200 µM) 
and SeTalO (200 µM) did not significantly affect the rate of NADPH consumption 
compared to the control, with NADPH consumption rates of 3 ± 0.5 and 3 ± 0.2 nM s-1 
respectively. Auranofin had no effect on in the rate of NADPH consumption in either 
the control (NADPH and lysate alone at 3 ± 0.4 nM s-1) or when SeMetO and SeTalO was 
added, with rates of 3 ± 0.4 and 3 ± 0.5 nM s-1. Insulin (200 µM) was included as a 
positive control for TrxR/Trx activity and increased the rate of NADPH consumption 
over the control to 5 ± 0.4 nM s-1. Treatment of lysates with auranofin slightly 
decreased the rate of insulin reduction to 4 ± 0.5 nM s-1, though this was not a 
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significant difference. These data suggest that cell lysates under these conditions are 
unable to reduce selenoxides, or that the major NADPH consuming reaction are not 
mediated by the TrxR/Trx system. 
 
Figure 5.43 – NADPH consumption after selenoxides or insulin were added to cell 
lysates with or without auranofin. 
NADPH concentration over time when cell lysates (50 µg) with added NADPH (500 µM) 
(control represented by solid line) were incubated with SeMetO (200 µM) (dashed line), 
SeTalO (200 µM) (dotted line) or insulin (200 µM) (dot-dashed line) in the a) absence or 
b) presence of auranofin. Rates of NADPH consumption was determined by fitting a 
straight line to the data represented in a and b, and represented in c). Control - black bars; 
SeMetO - white bars; SeTalO  - dark grey bars; and insulin - checked bars. Insulin increases 
the rate of NADPH consumption, however SeMetO and SeTalO did not. Data represent 
mean ± SD from 3 independent experiments. * indicates significant difference (p < 0.05) 
from control based on one-way ANOVA with Tukey’s post-hoc test. 
5.3.4.2 Taurine chloramine 
Lysates (50 µg protein) were then incubated with NADPH (500 µM) with and 
without SeMet or SeTal (20 or 200 µM) for 5 min before addition of TauCl (200 µM). 
This was carried out in the absence (Figure 5.44a,c) or presence (Figure 5.44b,d) of 
auranofin (2.5 µM). The absorbance at 340 nm was monitored for 2 h after the addition 
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of TauCl (Figure 5.44a,b). Rates of NADPH consumption (Figure 5.44c,d) were 
determined by fitting a straight line to the initial 25 min of the NADPH concentration 
vs time plot (Figure 5.44a,b).  
Addition of TauCl to the cell lysate gave rise to an NADPH consumption rate of 26 ± 
0.9 nM s-1 (Figure 5.44c). No significant difference in the NADPH consumption rate 
induced by TauCl was observed when auranofin was pre-incubated with the lysate 
samples with an NADPH consumption rate of 24 ± 3 nM s-1 (Figure 5.44d), which 
suggests that the NADPH consumption is independent of any selenoenzymes, such as 
GPx and TrxR as these should be inhibited by auranofin presence. The presence of 
SeMet (20 µM) or SeTal (20 µM) led to a small decrease in the NADPH consumption to 
21 ± 2 and 22 ± 1 nM s-1, though these changes were not statistically significant. The 
presence of SeMet (200 µM) or SeTal (200 µM) significantly reduced the rate of NADPH 
consumption to 2 ± 0.6 and 5 ± 5 nM s-1. The addition of auranofin to the lysates again 
did not demonstrate an effect on the NADPH consumption rate when lysates were 
exposed to TauCl in the presence of SeMet (200 µM) and SeTal (200 µM). The decrease 
in rate of NADPH consumption is attributed to the formation of selenoxides, inhibiting 
direct consumption of NADPH by TauCl.  
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Figure 5.44 – Rate of NADPH consumption after TauCl was added to cell lysates in the 
presence and absence of SeMet or SeTal 
TauCl (200 µM) was added to cell lysates (50 µg protein) with added NADPH (500 µM) in 
the presence or absence of SeMet or SeTal (20 or 200 µM). The NADPH concentration, 
monitored at 340 nm, was measured for 2 h and the rate of NADPH consumption 
determined by fitting a linear slope to initial 25 min. Addition of TauCl caused a decrease 
in NADPH concentration. SeMet and SeTal decreased the rate of NADPH consumption, 
with statistical significance when 200 µM was present. Data represent mean ± SD from 3 
independent experiments. * indicates significant difference (p < 0.05) from control based 
on one-way ANOVA with Tukey’s post-hoc test. 
5.3.4.3 DTNB 
As the cell lysates appeared to be unable to reduce the selenoxides or N-
chloramines, and auranofin had no effect on insulin reduction, the reduction of DTNB 
was used as an alternative positive control to ensure activity of the TrxR enzymes in 
this system. It has been shown previously that the GSR and Trx systems in cell lysates 
can reduce the colourless DTNB to the yellow TNB, which can be monitored at 412 nm 
[598, 599]. The contribution of DTNB reduction by the Trx system can be inhibited by 
the inclusion of auranofin [598, 599]. 
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Cell lysates (50 µg protein) were incubated with NADPH (500 µM) with or without 
auranofin (2.5 µM) before addition of DTNB (200 µM). The absorbance was monitored 
at 412 nm for 2 h. The rate of absorbance change was determined by fitting a line to 
the absorbance vs time plot after the first 15 min, where the rate of absorbance 
becomes more linear after an initial rapid increase. The change of absorbance occurred 
at a rate of 0.017 ± 0.001 mAbs units s-1 for samples without auranofin. This decreased 
to a rate of 0.009 ± 0.0003 mAbs units s-1 for auranofin treated samples. The ability of 
the lysates to produce TNB suggests that the lysates used were redox active. Inhibition 
of TNB production by auranofin demonstrates that selenium enzymes, presumably 
TrxR, are contributing to TNB formation. However, GPx can also be inhibited by 
auranofin, which can affect levels of GSH. As GSH can react directly with DTNB, this may 
also contribute to the TNB formation. 
 
Figure 5.45 – Change in absorbance at 412 nm after DTNB was added to cell lysates 
with or without auranofin 
DTNB (200 µM) was added to cell lysate (50 µg) with NADPH (500 µM) with or without 
auranofin (2.5 µM). a) shows absorbance over time after DTNB addition to samples with 
(dashed line) or without (solid line) auranofin. b) rates of Abs change observed in samples 
with (black bar) or without (white bar) auranofin. Cell lysates are able to reduce DTNB 
to TNB, which can be inhibited at least in part by auranofin. Data represent mean ± SD 
from 3 independent experiments. * indicates significant difference (p < 0.05) from control 
based on unpaired t-test. 
 Discussion 
The aims of the experiments performed in this Chapter were to determine whether 
endogenous antioxidant defence systems could act as a mechanism for the repair of 
selenoxides, which are the major products formed when SeMet and SeTal react with 
MPO-derived oxidants. If this repair process is taking place, the interaction between 
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SeMet and SeTal and these enzymes may represent a potential catalytic scavenging 
cycle of MPO-derived oxidants in vivo. Furthermore, the ability of these enzymes to 
detoxify N-chloramines in the presence and absence of SeMet and SeTal was examined, 
as thiol and selenium enzymes have demonstrated potential to remove oxidants, 
including peroxides and HOSCN [98, 347, 348]. 
The NADPH/TrxR system is capable of reducing SeMetO, but no reduction of SeTalO 
was observed (Figure 5.10). The inability of TrxR to reduce SeTalO may reflect that 
SeTalO cannot access the active site of TrxR. However this is unlikely, as the active site 
of TrxR protrudes from the body of the enzyme on a flexible tail [372], thus accessibility 
would not be expected to be an issue. It is possible that SeTalO is unable to react with 
the active site Sec, though as SeTalO is capable of reacting with thiols (see Chapter 4 of 
this thesis), and selenols are generally considered to have a greater reduction potential 
than thiols, this explanation also seems unlikely. However, there is no definitive 
experimental evidence for the reaction of SeTalO with a selenol, though this would be 
expected to be thermodynamically favourable, as Sec has a higher reduction potential 
than both GSH and Cys. Thus, it is perhaps more likely that kinetic factors are 
influencing the reaction and that the rate of reaction is too slow to be relevant under 
the conditions employed. If the inability of selenoxides to rapidly react with selenols is 
the cause, it would be anticipated that SeMetO should also be unable to react with the 
selenol active site. If this is the case, the site of reduction of SeMetO in TrxR may be the 
N-terminal Cys-X-X-Cys redox centre [372], which SeTalO may not be able to access 
due to steric considerations. 
Trx, in these experiments, was not observed to increase the rate of SeMetO 
reduction by a NADPH/TrxR/Trx system over that in samples with NADPH/TrxR 
alone. It has previously been reported that addition of Trx can almost double the rate 
at which the NADPH absorbance at 340 nm decreased upon addition of SeMetO [474]. 
However, the previous data were not converted to NADPH consumption rates and 
cannot therefore be directly compared to the data presented in this Chapter. A key 
difference that may account for this discrepancy may be that previously 20 µM Trx 
expressed in E. coli was utilised, compared to 1.5 µM human recombinant Trx used in 
the current study. 1.5 µM Trx was chosen in these experiments as it best represented 
the physiological ratio relative to 25 nM TrxR of Trx : TrxR observed in cells [600]. The 
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increased concentration of Trx used in the studies by Suryo-Rahmanto et al [474] may 
be sufficient to compete with reduction of SeMetO by TrxR, thereby increasing the rate 
of reduction compared to the current studies. 
Trx, MsrA, MsrB2 and GPx were all unable to increase the rate at which NADPH was 
consumed upon addition of SeMetO or SeTalO. This may be due to the reduction of TrxR 
by NADPH being the limiting factor in the reduction cycle, and therefore NADPH 
consumption is not being increased with the addition of coupled enzymatic systems. 
Alternatively, the kinetics of the reaction of SeMetO with TrxR may be greater than that 
observed for the other enzymes, and therefore TrxR preferentially reduces SeMetO 
directly, and no increase in NADPH consumption is observed. However, it may be a 
reflection of the inability of SeMetO and SeTalO to oxidise the active site thiols of these 
other enzymes. This is probably unlikely as the thiols at these sites demonstrate higher 
reactivity with other oxidants compared to free thiols, which have demonstrated 
reactivity with selenoxides. Alternatively, it may be a problem of selenoxides accessing 
the active site, as the active site cysteines are generally buried within protein folds. 
Again, this is probably unlikely as the selenoxides are comparatively small compared 
to disulfides formed on protein structures that are the endogenous targets of these 
enzymes, though other factors such as hydrophilic or hydrophobic interactions, with 
the protein structure may be affecting the accessibility. 
The NADPH/GSR/GSH system was capable of rapidly reducing the SeMetO and 
SeTalO with 200 µM consumed within 1 min. An initial lag phase was observed, and is 
attributed to the initial formation of GSSG, by the reaction of the selenoxides with GSH, 
which is then the species reduced by GSR, which consumes NADPH. A comparison of 
the observed NADPH consumption rates suggests that selenoxides are more likely to 
be reduced by the GSR system over the Trx system. As GSH is present in millimolar 
concentrations in cells [222], compared with much lower levels of enzymes, the GSR 
route of removal is perhaps the most likely mechanism for selenoxide repair in vivo.  
The stoichiometry of the reduction of SeMetO and N-chloramines does not agree 
well between UV-vis experiments and HPLC experiments. The HPLC experiments 
demonstrate near complete reduction of SeMetO, with corresponding recovery of 
SeMet after 2 h, reflecting a total of 200 µM SeMetO reduced. However, the NADPH 
consumed as assessed by the extinction coefficient shows less than 200 µM NADPH 
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consumed, however, the expected ratio would be 1 : 1 for NADPH consumed to SeMetO 
reduced. It is proposed that the NADPH consumption is being underestimated due to 
impurities. It was found that the NADPH absorbance at 340 nm was consistently below 
the expected level based on the mass of NADPH weighed out. This caused an 
underestimation of NADPH concentration both initially and when the total consumed 
was calculated. Further experiments would be required, using a more fully 
characterised NADPH sample, to accurately assess the stoichiometry of the enzymatic 
reductions observed in this Chapter. Consumption of selenoxides or N-chloramines via 
reaction with amino acid residues may be a possible explanation of the lower than 
expected NADPH consumption levels, however, this is unlikely. Selenoxides do not 
appear to react with residues other than Cys based on previous reports [439, 486]. 
While N-chloramines are capable of reacting with other protein residues, a lower than 
1 : 1 stoichiometry of NADPH to N-chloramine is observed where no protein is present, 
and therefore reaction with protein residues cannot fully account for the difference. 
Another possibility is consumption of oxidants by additives in the enzymes solutions, 
as some of these enzyme solutions contain DTT. When DTT was present, it was 
removed by solid-phase extraction, though this process may not have been completely 
efficient. However, this still cannot account for the difference observed when no 
enzymes were present.  
A time-dependent decrease in NADPH concentration was also observed when N-
chloramines were added to NADPH. Chlorinating oxidants, including HOCl, N-
chloramides and N-chloramines, react with NADPH to form a chlorohydrin product [63, 
83, 601-603], though this is a slow process for N-chloramines with second order rate 
constants of about 1 M-1 s-1 [83]. Previous data have shown that this product cannot be 
recycled by GAPDH to reform NADPH [603]. The formation of the chlorinated product 
depletes the NADPH pool making it unavailable for metabolism, thus the formation of 
the chlorinated nucleoside is considered to be toxic [603]. 
Selenium and sulfur enzymes have previously demonstrated capability to reduce 
MPO-derived oxidants [98, 348]. In general, the active site Sec or Cys residue is 
oxidised, to RSeOH or RSOH respectively, and subsequently reduced via selenosulfide 
or disulfide exchange mechanisms. As N-chloramines have been previously shown to 
react with thiols [192], it was expected that they would also demonstrate reactivity 
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with the selenium and sulfur enzymes examined in this study. With the exception of 
TauCl scavenging by TrxR and Trx, no significant increase in NADPH consumption was 
observed over control levels when the various enzyme systems were exposed to N-
chloramines. This may reflect that the rate constants for the reaction of N-chloramines 
with the enzymes are lower than the rate constants for the reaction of the N-
chloramines with NADPH directly. 
There is potential that while no increase in NADPH consumption rates was 
observed, that the presence of the redox enzymes promoted the formation of NADP+, 
via the transfer of electrons through the FAD domain of the proteins. NADP+ is a 
reversible product from which NADPH can be regenerated by the action of enzymes 
such as GAPDH, as opposed to the chlorohydrin product formed by N-chloramine 
reaction with NADPH, which is irreversible [603].  However, no product studies were 
performed and the ratios of NADP+ to the chlorohydrin product were not assessed, so 
further work would be required to demonstrate whether this mechanism is occurring 
in these systems.  
The presence of selenium compounds decreased the rate of NADPH consumption 
when the NADPH/TrxR system and coupled enzymes were exposed to N-chloramines. 
The rate observed was similar to the rate at which the selenoxides induced NADPH 
consumption when added directly to the NADPH/TrxR system. Similarly, cell lysates 
showed a decrease in NADPH consumption in the presence of SeMet and SeTal when 
exposed to TauCl. This is likely to be due to the rapid formation of selenoxides, as SeMet 
and SeTal react with N-chloramines with rate constants that are 3 orders of magnitude 
greater than the reaction with NADPH (Chapter 3 of this thesis; [83]). This is supported 
by the observation of high levels of selenoxides present 20 min after N-chloramine 
addition, which then reduces over the course of 2 h for SeMetO. While the rate of 
oxidant removal by the Trx system in the presence of SeMet and SeTal was reduced, 
the reaction product is likely to be NADP+ and not chlorohydrins, due to transfer of 
electrons through the protein chain, as opposed to chlorination of NADPH by N-
chloramines. As NADP+ is recyclable through the actions of enzymes such as GAPDH, 
and the chlorohydrin product is not, this presumably will result in a better outcome in 
the context of cells. However, studies on NADPH products were not performed, so this 
proposed switch in mechanism could not be confirmed. 
 211 
The NADPH/GSR/GSH system demonstrated a more rapid consumption of NADPH 
upon the addition of LysCl than GlyCl or TauCl. This trend is consistent with the second 
order rate constants determined for the reaction of GSH with these N-chloramines, 
with LysCl having the highest rate constant, followed by GlyCl and TauCl [192]. SeMetO 
and SeTalO have rate constants for reaction with GSH significantly higher than those 
reported for N-chloramines (Table 5.1), however, GSR was not able to remove these 
selenoxides significantly faster than LysCl or GlyCl. Based on the rate constants 
reported for the reaction of LysCl and GlyCl with GSH, and those reported in Chapter 3 
for the reaction with SeMet and SeTal (Table 5.1), it would be expected that in the 
presence of 200 µM SeMet or SeTal, the majority of N-chloramine would be reacting 
with the selenium compounds as opposed to directly with the GSH. At lower 
concentrations of SeMet and SeTal, the direct reaction between the N-chloramines and 
GSH would be favoured. The increased rate of GSSG production would be expected to 
result in an increased rate of NADPH consumption, though this was not observed. This 
may be because LysCl, GlyCl and the selenoxides produce GSSG at a rate that saturates 
the GSR activity.  
The presence of SeMet when the GSR system was exposed to TauCl increased the 
rate of NADPH consumption. This is likely due to the rapid reaction of TauCl with SeMet 
and subsequent reduction, therefore producing GSSG at a faster rate than TauCl alone. 
A significant increase in NADPH consumption rate was not observed when SeTal was 
present, and this may reflect the lower rate of reaction of SeTal with TauCl, as well as 
the slower reduction of SeTalO by GSH.  
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Table 5.1 – Comparison of second order rate constants for the reaction of N-
chloramines and selenoxides with GSH, SeMet and SeTal 
Oxidant kGSH / M-1s-1  kSeMet / M-1s-1 kSeTal/ M-1s-1 
TauCl 115a 820 c 115 c 
LysCl 259a 3400 c 680 c 
GlyCl 228a 2300 c 430 c 
SeMetO 1.5 x 104 b - - 
SeTalO 3.4 x 104 b - - 
a Peskin, A et. al. [192]; b Chapter 4 of this thesis; c Chapter 3 of this thesis 
The ability of other selenium compounds, such as ebselen and selenocystamine, to 
enhance oxidant scavenging has previously been reported, though these function via a 
different mechanism to that discussed here [492, 589, 590]. It is proposed that the 
redox enzymes reduce the diselenides or ebselen to a selenol group, which then rapidly 
reacts with the oxidant to reform the parent compound [492, 589, 590]. Ebselen was 
more effective at oxidant removal in conjunction with the Trx system compared to the 
GSR system [589], while the opposite was observed for SeMet and SeTal. This is 
consistent with the differing mechanism proposed for SeMet and SeTal, where the 
parent species react directly with the oxidant to form selenoxides, followed by 
reduction by the enzymes or GSH to reform the parent compound. 
Cell lysates did not show an increase in NADPH consumption upon addition of 
SeMetO or SeTalO. This suggests that enzymatic systems present in these preparations 
are not recycling the selenoxides efficiently as would be expected by the isolated 
enzyme results when compared to other NADPH consuming reactions. Enzymes such 
as TrxR and Trx, while expressed in this cell line [599], may not be expressed at a high 
enough level to enhance the rate of NADPH consumption when selenoxides are added 
to the lysates. This may also be the case for insulin reduction, where the increase in the 
rate of NADPH consumption upon addition of insulin was not significantly inhibited by 
auranofin as expected. The inability of auranofin to inhibit NADPH consumption in the 
presence of insulin suggests that NADPH consumption is not due to seleno enzymes as 
expected. This is in contrast to the DTNB reduction results which demonstrate that 
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there is some activity of seleno enzymes observed in the lysates as they are capable of 
reducing DTNB to TNB in a manner that is inhibited by the presence of auranofin. Based 
on these results, it cannot be discounted that the selenoxides may be reduced by a 
different mechanism when added to the cell lysates, however, as the concentrations of 
selenoxides were not measured after exposure to the lysates, so it is unclear whether 
this could be the case. 
 Conclusions 
N-Chloramines, MPO-derived oxidants, and selenoxides, the major product formed 
when selenoethers react with MPO-derived oxidants, can be reduced by the 
endogenous antioxidant systems NADPH/TrxR and NADPH/GSR/GSH. Furthermore, 
selenoethers showed the ability to increase NADPH consumption when N-chloramines 
were added to the NADPH/GSR/GSH system, however, SeMet and SeTal reduced the 
rate at which NADPH was consumed after the addition of N-chloramines to the 
NADPH/TrxR system. Together, the endogenous antioxidant defence systems and the 
selenoethers, SeMet and SeTal, may be capable of catalytically removing MPO-derived 
oxidants, preventing oxidative damage and having a therapeutic benefit. 
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6 Selenium compounds modulating MPO-derived oxidant 
damage in cells 
 215 
 Introduction 
Macrophages are a key cell type in the initiation and progression of atherosclerosis 
[274]. They are responsible for the uptake of LDL in the arterial wall with increased 
uptake occurring after LDL is modified by oxidants [294, 301]. The increased LDL 
uptake coupled with impaired cholesterol efflux after macrophages are exposed to 
oxidants induces the formation of foam cells [297, 300]. Accumulation of foam cells is 
the initial event in the development of fatty streaks in the arterial wall, leading to the 
development of atherosclerotic plaques [274]. As such, J774A.1 cells, a murine 
macrophage-like cell line, were chosen for the studies presented in this chapter. 
Exposure of cells to high doses of HOCl, including J774A.1 murine macrophages, 
causes cell death by lysis [221]. The primary cause of lysis is thought to be via 
modifications to membrane proteins, particularly K+ pumps [220], which cause cell 
swelling, or cross linking of membrane proteins causing morphological changes [213, 
219]. Lower doses of HOCl can also cause cell death by apoptosis [222]. HOCl treatment 
has been shown to induce apoptosis in a range of different cell types, with cytochrome 
c release from mitochondria and caspase activation [604-606]. Chloramines are also 
capable of causing apoptosis through caspase activation leading to cell death [607-
609]. 
HOCl and chloramine treatment causes loss of cellular thiols [162, 221, 222, 225]. 
HOCl causes a decrease in GSH and total cellular thiols of J774A.1 cells, with a 
concomitant increase in GSSG [222]. Erythrocytes and endothelial cells treated with 
HOCl also demonstrate a loss of GSH with a corresponding increase in GSSG [221, 225, 
226]. The thiol dependent enzyme glyceraldehyde phosphate dehydrogenase (GAPDH) 
is a specific target of both HOCl and N-chloramines [229]. Exposure of cells to HOCl and 
model chloramines results in thiol loss and a decrease in GAPDH activity [245], with 
the extent of thiol loss and GAPDH inactivation induced by N-chloramines depending 
on cell permeability [135]. While TauCl is efficient at inhibiting isolated GAPDH [245], 
it was unable to affect GAPDH function in HUVECs as it is cell impermeable [135, 246]. 
However, in the presence of other amines, transchlorination can occur, forming 
membrane permeable chloramines that can inhibit GAPDH [135]. Numerous other 
thiol dependent enzymes have been shown to be inhibited on exposure to HOCl and 
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chloramines including creatine kinase, glutathione S-tranferases and membrane 
ATPases [220, 225, 229, 233]. 
HOCl and TauCl also react with other protein residues including Met, Tyr and Trp 
[180]. HOCl and TauCl react with Met residues to form MetSO, which can result in 
enzyme inhibition [111]. HOCl also reacts with Tyr and Trp residues to form 
chlorinated products [120, 121, 129, 296]. Chloramines have been shown to mediate 
Tyr chlorination, though this reaction is slow [121]. These modifications can lead to 
protein inactivation depending on the site of oxidation, as well as protein cross-linking 
and aggregation [40, 106]. HOCl is capable of oxidising Met and Trp residues on 
proteins within cells [220]. 
Selenium-containing compounds rapidly scavenge HOCl and N-chloramines 
forming selenoxides as the major product (dependent on oxidant concentrations), 
which can be then recycled by cellular reductants such as GSH [444, 445] (See also 
Chapters 4 and 5). Thus, antioxidant supplementation with SeMet and SeTal may be an 
effective strategy in reducing oxidative damage to cells exposed to MPO-derived 
oxidants. Selenium compounds can react directly with oxidants, and have also 
demonstrated an ability to upregulate cellular antioxidant enzymes in order to protect 
against oxidative damage [524-526]. Supplementation of trophoblast cells with SeMet 
protected against H2O2 induced damage [531] or oxidative stress induced by the 
disruption of mitochondria with antimycin or rotenone [530]. SeMet has also 
demonstrated efficacy in protecting J774A.1 cells and erythrocytes from H2O2 and t-
butylhydroperoxide induced damage [474, 538].  Isolated protein studies have 
demonstrated SeMet and SeTal are capable of protecting protein residues from 
oxidation by HOCl by acting as a direct antioxidant [439, 486]. However, the use of 
SeMet and SeTal as an antioxidant protecting against MPO-derived oxidants in a 
cellular context has not yet been explored. 
As demonstrated in Chapter 3, SeMet and SeTal react rapidly with HOCl and TauCl 
and may provide a competitive target for oxidants in a cellular context. The data 
presented in Chapters 4 and 5 demonstrate the potential for catalytic scavenging 
cycles, where selenoxides are reduced by endogenous antioxidant systems, leading to 
an enhanced removal of oxidants. Together, these data suggest that SeMet and SeTal 
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may be capable of providing cells with protection against cellular damage caused by 
MPO-derived oxidants. 
 Aims 
This chapter examines a variety of markers of oxidative consequences arising from 
the exposure of J774A.1 cells to HOCl and TauCl, including apoptosis and cell death, 
thiol loss and thiol-dependent enzyme activity, and the oxidation status of amino acid 
residues in the presence or absence of SeMet and SeTal, to assess the ability of these 
compounds to modulate cellular damage.   
 Results 
 Cell viability in the presence of SeMet and SeTal 
Initial studies were performed to examine the viability of J774A.1 cells when 
exposed to SeMet and SeTal in the absence of oxidant treatment, as previous studies 
have shown that SeMet can be toxic under certain conditions [513, 610]. J774A.1 cells 
were plated at a density of 5 x 105 cells mL-1 and exposed to increasing concentrations 
of SeMet or SeTal in HBSS (0 – 200 µM) for 30 min, prior to assessing the viability using 
the LDH assay (Figure 6.1).  No change in viability was observed compared to the 
control (0 µM SeMet or SeTal) with increasing concentrations of selenium compounds. 
This suggests that concentrations of up to 200 µM SeMet and SeTal can be tolerated by 
J774A.1 cells under the conditions employed. 
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Figure 6.1 – J774A.1 cell viability after supplementation with SeMet or SeTal (0 – 200 
µM) 
J774A.1 cells were plated at 5 x 105 cells mL-1 in a 12-well plate and allowed to adhere 
overnight. Cells were washed with warm HBSS before incubation with SeMet or SeTal (0 
– 200 µM) in HBSS for 30 min at 37 °C. Media was collected and cells washed with HBSS 
before lysis in 600 µL H2O. LDH activity in media and lysate samples was measured and 
normalised to protein levels assessed by BCA assay. The viability ratio was determined by 
LDH activity in the lysate over the total LDH activity. No significant difference from 
control (0 µM SeMet or SeTal) was observed based on one-way ANOVA with Tukey’s post-
hoc test. Results are reported as mean ± SD, n = 3.  
 Cellular thiol levels after oxidant treatment 
HOCl and TauCl treatment of cells is known to reduce intracellular thiol levels [162, 
221, 222, 225]. As SeMet and SeTal may provide a competitive target for these oxidants 
in a cellular context, based on results from Chapter 3, supplementation of cells with 
SeMet and SeTal prior to oxidant treatment may be beneficial. The ability of SeMet and 
SeTal to modulate cellular thiol loss was assessed using the ThioGlo-1 assay. 
6.3.2.1 Intact cells 
J774A.1 cells were incubated with SeMet or SeTal (0 - 50 µM) in HBSS for 15 min at 
37 °C before addition of HOCl or TauCl (200 µM) and further incubation for 15 min at 
37 °C. Cells were lysed in 600 µL H2O and thiol levels determined by the ThioGlo-1 
assay. In each case, thiol levels were normalised to protein concentration as assessed 
by the BCA assay. 
Initial studies were performed to determine the effect of SeMet and SeTal (50 µM) 
on cellular thiol levels in the absence of oxidant. A trend towards a decrease in thiol 
levels was observed on incubation of J774A.1 cells with SeMet and SeTal, though this 
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change was not statistically significant, and is potentially due to increase production of 
reactive oxygen species by the cell [513]. Next, experiments to measure thiols after 
cells were exposed to HOCl and TauCl were performed. HOCl treatment of cells reduced 
the thiol levels to 52% of the non-treated control values (Figure 6.2a,c). TauCl 
treatment reduced thiol levels to a similar extent (Figure 6.2b,d).  
Experiments were then performed to determine whether pre-treatment of cells 
with SeMet or SeTal could modulate the levels of thiols after oxidant treatment. 
However, the presence of SeMet (Figure 6.2a) or SeTal (Figure 6.2c) did not 
significantly reduce thiol loss compared to that observed with HOCl alone. Similarly, no 
significant difference was seen between the thiol levels in cells exposed to TauCl alone, 
or TauCl in the presence of SeMet (Figure 6.2b) or SeTal (Figure 6.2d). This may reflect 
the formation of selenoxides following HOCl and TauCl oxidation of SeMet or SeTal, 
which can subsequently react with thiols, as demonstrated in previous Chapters.  
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Figure 6.2– Thiol levels after J774A.1 cells treated with HOCl or TauCl in the presence 
of SeMet or SeTal. 
J774A.1 cells (5 x 105 cells per well) were incubated with SeMet (a,b) or SeTal (c,d) (0 - 50 
µM) in HBSS  for 15 min at 37 °C before addition of HOCl (a,c) or TauCl (b,d) (200 µM) 
and further incubation for 15 min at 37 °C. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars). Cells were lysed in 
600 µL H2O and thiol levels determined by ThioGlo-1 assay, and thiol levels normalised to 
protein assessed by the BCA assay. A decrease in thiol levels was observed with HOCl and 
TauCl treatment. No significant difference was observed in thiol levels between cells 
treated with HOCl or TauCl alone and those treated with HOCl and TauCl in the presence 
of SeMet or SeTal. * indicates significant difference (p < 0.05) from untreated control 
levels based on one-way ANOVA with Tukey’s post-hoc test. Data are reported as mean ± 
SD from 3 independent experiments.  
6.3.2.2 Cell lysates 
SeMet and SeTal did not appear to have an effect on cellular thiol levels when whole 
cells were exposed to oxidants, however, it was unclear how rapidly and to what extent 
the SeMet and SeTal were taken up by the cells. As such, lysate experiments were 
performed in order to determine the effects of oxidants and SeMet and SeTal on thiol 
levels in the absence of an intact cell membrane. 
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J774A.1 cells were lysed in H2O and the lysates adjusted to 1 mg mL-1 protein 
assessed by the BCA assay. The lysates were then supplemented with SeMet or SeTal 
(0 - 25 µM) before addition of HOCl or TauCl and incubation for 15 min at 22 °C. Thiol 
levels were assessed by ThioGlo-1 assay. As the thiols in the lysate samples are 
(presumably) more accessible to oxidants than in intact cells, experiments were 
performed to optimise the level of oxidant added in each case. Lysates were therefore 
incubated with increasing HOCl or TauCl (0 – 200 µM) for 15 minutes, before thiol 
levels were determined by the ThioGlo assay. At 12.5 µM HOCl or TauCl a 92 % loss of 
thiols compared to the non-treated control was observed (Figure 6.3). Experiments 
with higher concentrations of HOCl or TauCl resulted in complete thiol consumption. 
Therefore, 12.5 µM oxidant was used for subsequent experiments. 
The addition of SeMet or SeTal (25 µM) to the lysate in the absence of oxidant did 
not significantly change the thiol levels from that observed in the untreated control 
lysate samples (Figure 6.3). Addition of HOCl or TauCl (12.5 µM) reduced the thiol 
concentration by 92 % compared to the non-treated control samples, and a similar 
extent of thiol loss was seen in the presence of SeTal (Figure 6.3c,d). However, in the 
presence of SeMet (Figure 6.3a,b) a trend towards a further decrease in thiols 
compared to HOCl or TauCl alone was observed, though this was not statistically 
significant. This is attributed to the formation of selenoxides and subsequent reaction 
with residual cellular thiols. The further decrease observed in the SeMet treated 
samples may reflect the increased rate of reaction of SeMet with HOCl or chloramines 
compared to SeTal, resulting in a higher SeMetO yield, causing a greater reduction in 
thiol levels observed. 
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Figure 6.3 - Thiol levels in lysates after HOCl or TauCl treatment in the presence or 
absence of SeMet or SeTal 
J774A.1 cells were lysed in H2O and the lysates adjusted to 1 mg mL-1 protein assessed by 
the BCA assay. Lysates were then supplemented with SeMet or SeTal (0 - 25 µM) before 
addition of HOCl or TauCl (12.5 µM) and incubation for 15 minutes at 22 °C. Non-treated 
lysates and lysates treated with SeMet or SeTal alone (50 µM) were included as control 
samples (black bars).  Thiol levels were assessed by ThioGlo-1 assay. HOCl and TauCl 
decreased the thiol concentration by 92 % of that seen in the non-treated control. No 
significant difference was observed in thiol levels between lysates treated with HOCl or 
TauCl alone and those treated with HOCl and TauCl in the presence of SeMet or SeTal. 
Data represent mean ± SD from 3 independent experiments. * indicates significant 
difference (p < 0.05) from untreated control levels based on one-way ANOVA with Tukey’s 
post-hoc test. 
 Cellular GAPDH activity after oxidant treatment 
As total cellular thiols were reduced by HOCl and TauCl oxidant exposure, the 
activity of the thiol-dependent enzyme GAPDH was examined. GAPDH is a thiol 
dependent enzyme that catalyses the conversion of glyceraldehyde-3-phosphate (GAP) 
to glycerate-1,3-biphosphate (GBP), a step in the glycolysis pathway essential for 
glucose metabolism and energy production [230]. GAPDH has a thiol at the active site 
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and is readily inactivated when cells are treated with HOCl and TauCl [245]. The ability 
of SeMet and SeTal to prevent GAPDH inactivation was therefore assessed.  
J774A.1 cells were incubated with SeMet or SeTal (0- 50 µM) in HBSS for 15 min at 
37 °C before addition of HOCl or TauCl (200 µM) and further incubation for 15 min at 
37 °C. Cells were washed with warm HBSS before lysis in 600 µL H2O and the 
measurement of GAPDH activity. GAPDH activity was measured by the increase in 
NADH concentration after addition of NAD+ and GAP (as assessed by optical absorbance 
at 340 nm) with the values normalised to the protein levels (as assessed by BCA assay). 
Initial experiments examined the effect of SeMet and SeTal (50 µM) on GAPDH 
activity in cells (Figure 6.4).  A decrease in GAPDH activity was observed in the 
presence of SeMet alone, though this was not statistically significant. A slight decrease 
in GAPDH activity in the presence of SeTal was also observed, though this decrease was 
not as large as that observed with SeMet treatment. This compares well to the extent 
of loss in total cellular thiols (Figure 6.2). 
Treatment of cells with HOCl (200 µM) in the absence of SeMet or SeTal resulted in 
a significant decrease in GAPDH activity (Figure 6.4a,c) as previously reported [222]. A 
comparable loss in GAPDH activity was observed on treatment of the cells with TauCl 
(Figure 6.4b,d), in contrast to previous reports with other cell types [135, 246]. In 
general, the presence of SeMet and SeTal did not prevent the loss of GAPDH activity. 
However, a significant increase in GAPDH activity, consistent with prevention of HOCl-
induced damage, was seen on pre-treatment of cells with 10 µM SeMet before addition 
of HOCl  (Figure 6.4a). 
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Figure 6.4 – GAPDH activity after J774A.1 cells were treated with HOCl or TauCl in the 
presence of SeMet or SeTal 
J774A.1 cells (5 x 105 cells per well) were incubated with SeMet (a,b) or SeTal (c,d) in 
HBSS (0- 50 µM) for 15 min at 37 °C before addition of HOCl (a,c) or TauCl (b,d) (200 µM) 
and further incubation for 15 min at 37 °C. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars).  Cells were lysed in 
600 µL H2O and GAPDH activity measured by monitoring the increase of NADH at 340 nm 
after addition of NAD+ and GAP to the lysates, normalised to protein concentration. 
Treatment of cells with HOCl or TauCl reduced GAPDH activity levels. Presence of 10 µM 
SeMet increased GAPDH activity levels back to control, however no effect was seen with 
TauCl treated cells or any other concentration of SeMet or SeTal. Data represent mean ± 
SD from 3 independent experiments. * indicates significant difference (p < 0.05) from 
untreated control levels, and # indicates significant difference from HOCl treated cells in 
the absence of SeMet (p < 0.05) based on one-way ANOVA with Tukey’s post-hoc test. 
 Reversible thiol oxidation 
In general, the data presented above are consistent with a lack of protection of 
thiols by SeMet and SeTal on exposure of macrophages to HOCl or TauCl. However, in 
the experiments reported above, the nature of the oxidised thiol products was not 
examined. Oxidation of thiols by HOCl and TauCl can give rise to numerous oxidation 
products, some of which are irreversible [95]. If HOCl and TauCl react with SeMet or 
SeTal, it would be expected that selenoxide species would be formed. Selenoxides 
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should give rise to disulfides as oxidation products upon reaction with thiols [444, 
445]. As disulfides are reversible oxidation products, the ability of SeMet and SeTal to 
promote reversible thiol oxidation was assessed by using the thiol-specific probe IAF 
after SDS-PAGE to separate cellular proteins. 
J774A.1 cells were incubated with SeMet or SeTal (0- 50 µM) in HBSS for 15 min at 
37 °C before addition of HOCl or TauCl (200 µM) and further incubation for 15 min at 
37 °C. Cells were lysed in the presence of NEM (100 mM) to alkylate any remaining free 
thiols after oxidant exposure. Reversibly oxidised thiols were reduced by addition of 
DTT (1 M), before the subsequent addition of IAF to fluorescently label the newly 
reduced thiol-containing proteins. The IAF labelled proteins were run out on 4-12% 
Tris-acetate gels and the proteins visualised by fluorescence (λex = 495 nm; λem = 520 
nm). Proteins were subsequently stained with Coomassie or silver stain and the 
fluorescent band density normalised to protein loading based on the total protein 
staining of 3 separate protein bands (Figure 6.5). 
Protein loading ratios were determined by densitometric analysis of 3 bands on the 
protein stained gels, with the most intense bands selected for protein loading 
determination. The relative loading of each lane was determined by densitometric 
analysis of the bands, which were averaged before expressing values as protein loading 
relative to the non-treated control for the lane. The ratio of bands within the same lane 
to each other remained consistent across all treatments, suggesting the only difference 
between lanes should be due to protein loading.  However, it is difficult to draw 
conclusions from these data owing to some discrepancies in the amount of protein 
loaded that is reflected in the Coomassie stained gels (Figure 6.5a,c). The inconsistent 
protein loading also made it difficult to attribute differences in IAF fluorescence in 
samples to changes in reversible thiol levels (Figure 6.5b,d).  These difficulties 
stemmed from redissolving the precipitated protein from the wash steps required for 
IAF staining. Further method optimisation to ensure equal protein loading before 
determination of whether SeMet and SeTal can promote irreversible thiol oxidation is 
needed, but was beyond the scope of this thesis. 
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Figure 6.5 – Representative gels showing protein loading and IAF stained reversible 
thiol products 
J774A.1 cells (5 x 105 cells per well) were incubated with a,b) SeMet or c,d) SeTal (0 - 50 
µM) in HBSS for 15 mins at 37 °C before addition of HOCl (200 µM) and further incubation 
for 15 min at 37 °C. Non-treated cells and cells treated with SeMet or SeTal alone (50 µM) 
were included as control samples. Cells were lysed in the presence of NEM and reversible 
thiols were tagged with IAF after DTT reduction. Proteins were run out on a gel and 
scanned for IAF fluorescence (λex = 495 nm; λem = 520 nm) (b,d). Gels were stained for 
protein using Coomassie stain (a,c). A, B and C represent bands chosen for densitometry 
analysis. 
 Oxidation of amino acid residues 
The above data suggest that SeMet and SeTal are ineffective as protective agents for 
cellular thiol loss induced by HOCl and TauCl under the conditions employed in this 
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study. However, Met is another significant target for oxidation by HOCl and TauCl in 
cells [220], which can influence protein function [111, 112]. SeMet and SeTal can 
prevent oxidation of Met residues when isolated proteins are exposed to HOCl [439, 
486]. Thus, the ability of SeMet and SeTal to protect Met and other amino acid residues 
from oxidation on exposure of cells to HOCl or TauCl was assessed using an HPLC 
approach in which the concentration of Met and its oxidation product MetSO were 
quantified after MSA hydrolysis of cellular proteins. 
J774A.1 cells (5 x 105 cells mL-1) were incubated in the presence of SeMet or SeTal 
in HBSS (0 – 50 µM), before addition of HOCl or TauCl (200 µM) and further incubation 
for 15 min. Cells were washed with warm HBSS and lysed in 600 µL H2O, before cellular 
proteins were isolated by precipitation by TCA (50 % (w/v)) prior to digestion into 
component amino acids by MSA hydrolysis as described in Section 2.3.5.5. Amino acids 
were derivatised with OPA and concentrations analysed after separation by HPLC, to 
assess the concentration of Met and the formation of the oxidation product MetSO. The 
results are expressed as pmol of Met or MetSO per pmol of Ile, which is generally 
resistant to oxidation by HOCl and N-chloramines [547]. 
Initially, studies to determine the effect of SeMet or SeTal alone (50 µM) on Met and 
MetSO levels were performed. No significant differences between the levels of Met and 
MetSO in the non-treated controls were observed on treating cells with SeMet or SeTal 
(Figure 6.6). Next, experiments were conducted to determine the effect of HOCl and 
TauCl on Met and MetSO levels. Surprisingly, no significant loss in Met or formation of 
MetSO was observed on exposure of the cells to HOCl, even though Met is a known 
target of HOCl oxidation (Figure 6.6) [86]. Similar results were obtained in the 
analogous experiments with TauCl (Figure 6.7).  
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Figure 6.6 – Met and MetSO levels after J774A.1 cells were exposed to HOCl in the 
presence of SeMet or SeTal 
J774A.1 cells (5 x 105 cells) were treated with HOCl (200 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 15 min. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars).   Cells were washed 
with warm HBSS and lysed in 600 µL H2O, before protein precipitation and MSA 
hydrolysis. Amino acids were derivatised with OPA and concentrations analysed by HPLC. 
Met and MetSO levels are reported relative to Ile. No significant differences were observed 
between treatments based on one-way ANOVA with Tukey’s post-hoc test. Data represent 
mean ± SD from 3 independent experiments. 
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Figure 6.7 – Met and MetSO levels after J774A.1 cells were exposed to TauCl in the 
presence of SeMet or SeTal 
J774A.1 cells (5 x 105 cells) were treated with TauCl (200 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 15 min. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars).   Cells were washed 
with warm HBSS and lysed in 600 µL H2O, before protein precipitation and MSA 
hydrolysis. Amino acids were derivatised with OPA and concentrations analysed by HPLC. 
Met and MetSO levels are reported relative to Ile. No significant differences were observed 
between treatments based on one-way ANOVA with Tukey’s post-hoc test. Data represent 
mean ± SD from 3 independent experiments. 
Met and MetSO levels did not appear to be effected after treatment of intact cells 
with HOCl and TauCl, which may reflect protection by the cell membrane, or 
insufficient concentrations of oxidant. Therefore, as Met are favoured oxidation sites in 
isolated proteins exposed to HOCl and N-chloramines, a lysate model was used to 
determine whether SeMet and SeTal could afford protection from HOCl and TauCl 
induced damage. J77A.1 cells were lysed in H2O and adjusted to 1 mg mL-1 protein 
before incubation with SeMet or SeTal (0 – 50 µM) for 15 min at 22 °C. HOCl or TauCl 
(200 µM) was then added and samples incubated for a further 15 min, before protein 
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precipitation and digestion by MSA. Amino acids were derivatised and analysed by 
HPLC.  
SeMet and SeTal alone (50 µM) did not significantly affect Met or MetSO levels in 
the cell lysate proteins compared to the non-treated control (Figure 6.8). In this case, 
addition of HOCl (200 µM) significantly decreased Met levels (Figure 6.8a,c), with a 
corresponding increase in MetSO levels (Figure 6.8b,d). Increasing concentrations of 
SeMet or SeTal demonstrated a slight trend toward Met protection, with an increase in 
Met and a decrease in MetSO, though this was not statistically significant.  
Addition of TauCl (200 µM) to cell lysates (1 mg protein mL-1) also resulted in a loss 
of Met residues (Figure 6.9 a,c), with a corresponding increase in MetSO (Figure 6.9 
b,d). However, no dose-dependent trend in Met protection was observed in this case. A 
recovery of Met was seen at the highest levels of SeMet or SeTal, though this difference 
was not statistically significant from the level detected with TauCl alone (Figure 6.9). 
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Figure 6.8 - Met and MetSO levels after J774A.1 lysates were exposed to HOCl in the 
presence of SeMet or SeTal. 
J774A.1 cells were lysed in H2O and the lysates adjusted to 1 mg mL-1 protein assessed by 
the BCA assay. Lysates were then supplemented with SeMet or SeTal (0 - 50 µM) before 
addition of HOCl (200 µM) and incubation for 15 min at 22 °C. Non-treated lysates and 
lysates treated with SeMet or SeTal alone (50 µM) were included as control samples 
(black bars).   Protein was precipitated and digested using MSA hydrolysis and amino 
acids derivatised with OPA and separated by HPLC. a,c) Met and b,d) MetSO levels are 
reported relative to Ile concentrations. HOCl treatment decreases levels of Met, with a 
corresponding increase in MetSO. No significant difference was observed in Met or MetSO 
levels between cells treated with HOCl or TauCl alone and those treated with HOCl and 
TauCl in the presence of SeMet or SeTal. Data represent mean ± SD from 3 independent 
experiments. * indicates significant difference (p < 0.05) from untreated control levels 
based on one-way ANOVA with Tukey’s post-hoc test. 
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Figure 6.9 - Met and MetSO levels after J774A.1 lysates were exposed to TauCl in the 
presence of SeMet or SeTal 
J774A.1 cells were lysed in H2O and the lysates adjusted to 1 mg mL-1 protein assessed by 
the BCA assay. Lysates were then supplemented with SeMet or SeTal (0 - 50 µM) before 
addition of TauCl (200 µM) and incubation for 15 min at 22 °C. Non-treated lysates and 
lysates treated with SeMet or SeTal alone (50 µM) were included as control samples 
(black bars).   Protein was precipitated and digested using MSA hydrolysis and amino 
acids derivatised with OPA and separated by HPLC. a,c) Met and b,d) MetSO levels are 
reported relative to Ile concentrations TauCl treatment decreases levels of Met, with a 
corresponding increase in MetSO. No significant difference was observed in Met and 
MetSO levels between cells treated with HOCl or TauCl alone and those treated with HOCl 
and TauCl in the presence of SeMet or SeTal. Data represent mean ± SD from 3 
independent experiments. * indicates significant difference (p < 0.05) from untreated 
control levels based on one-way ANOVA with Tukey’s post-hoc test. 
HOCl and TauCl can also target Tyr, Trp, Lys and His residues, causing an observed 
decrease in the concentration of these amino acid residues when HOCl or TauCl reacts 
with them [86]. The levels of these amino acids were also assessed in these 
experiments, however no changes in their concentrations were observed after oxidant 
treatment (data not shown). 
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 Cell viability after oxidant treatment 
6.3.6.1 Modulation of necrosis observed after 15 min  
Although SeMet and SeTal appear to be ineffective or only weakly protective 
against thiol and Met oxidation on exposure of J774A.1 cells to HOCl and TauCl, it is 
possible that these compounds may act as protective agents via other pathways. It has 
been shown previously that HOCl and TauCl can induce cell death via apoptosis and 
necrosis [219, 222, 606, 607].  It was therefore hypothesised that SeMet and SeTal may 
modulate the pattern of HOCl and TauCl induced cell damage that cause these 
pathways to be activated, and hence preserve cell viability after oxidant exposure.  
Initially, experiments were performed at 15 min post oxidant exposure to examine 
changes in viability observed at the same time point as the oxidative changes examined 
earlier in this Chapter. Cells were preincubated with SeMet or SeTal (0 – 50 µM) for 15 
min, prior to the addition of 200 µM HOCl or TauCl, with a further incubation of 15 min. 
The viability and percentage of necrotic and apoptotic cells were determined by dual 
staining with propidium iodide (PI) and Annexin-V respectively, with analysis by flow 
cytometry (Figure 6.10). As 15 min is too short a time period for apoptosis induction, 
only necrotic cell populations are examined here. 
Annexin-V binds to surface exposed phosphatidyl serine residues, which are 
externalised during the process of cellular apoptosis [564]. Therefore, cells that stain 
positive for Annexin-V are considered to be apoptotic. PI is taken up by necrotic cells 
and interchelates with double-stranded DNA [565].  
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Figure 6.10 – Example flow cytometry plots for control populations and cells treated 
with HOCl and TauCl 
J774A.1 cells (5 x 105 cells) were plated overnight before washing and treatment with b) 
HOCl or c) TauCl (200 µM) in HBSS for 15 min. a) shows HBSS control cells. Cells were 
scraped and pelleted before washing with HBSS and staining with Annexin-V APC and PI 
and subsequent analysis by flow cytometry. Cells in the lower left quadrant were 
considered to be viable, cells in the lower right quadrant were considered apoptotic, and 
cells in the upper quadrants were considered necrotic. TauCl and HOCl treatment induced 
necrosis in J774A.1 cells, however, no apoptotic cell population was observed under these 
conditions. 
Initial studies examined the viability of a control population of cells incubated in 
HBSS in the presence and absence of 50 µM SeMet or SeTal. The J774A.1 control cells 
were 70% viable after the 30 min incubation in HBSS and removal from the tissue 
culture plates. In this case, approximately 30% of cells were in the necrotic population 
(Figure 6.11).  The presence of SeMet or SeTal alone (50 µM) did not significantly affect 
cell viability compared to the non-treated control population, which corresponded 
with the data observed with the LDH assay (Figure 6.1). Upon addition of HOCl, the 
viable cell population decreased to 30% of the total cell population (Figure 6.9a,c). 
There was a corresponding increase in the population of necrotic cells to 70% of the 
total cell population (Figure 6.9b,d). HOCl treatment is known to cause necrosis at high 
concentrations due to chemical changes in the cell membrane [222]. Addition of 
increasing concentrations of SeMet demonstrated a trend toward increasing viability, 
with a corresponding decrease in necrosis, however, the levels of each population were 
not significantly different to cells treated with HOCl alone (Figure 6.11a,b). 
Preincubation with SeTal did not significantly affect the cell viability observed after 
oxidant treatment (Figure 6.11c,d). 
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Figure 6.11 – Viable and necrotic cell populations 15 mins after J774A.1 cells were 
exposed to HOCl in the presence of SeMet or SeTal. 
J774A.1 cells (5 x 105 cells) were treated with HOCl (200 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 15 min. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars).  Cells were pelleted 
and washed with warm HBSS before addition of Annexin-V APC and PI stains. Cell 
populations were counted using flow cytometry. A decrease in the viable cell population 
(a,c) was observed with HOCl treatment, with a corresponding increase in necrosis (b,d). 
No changes were observed with SeMet (a,b) or SeTal (c,d) treatment. Data represent 
mean ± SD from 3 independent experiments. * indicates significant difference (p < 0.05) 
from untreated control levels based on one-way ANOVA with Tukey’s post-hoc test. 
TauCl treatment also decreased the viability of cells with a corresponding increase 
in the necrotic cell population, though these differences were not statistically 
significant after incubation for 15 min (Figure 6.12). Pretreatment of cells with SeMet 
and SeTal prior to oxidant exposure did not have an effect on the distribution of cell 
populations (Figure 6.12). 
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Figure 6.12 - Viable and necrotic cell populations 15 mins after J774A.1 cells were 
exposed to TauCl in the presence of SeMet or SeTal. 
J774A.1 cells (5 x 105 cells) were treated with TauCl (200 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 15 min. Non-treated cells and cells treated with SeMet 
or SeTal alone (50 µM) were included as control samples (black bars).  Cells were pelleted 
and washed with warm HBSS before addition of Annexin-V APC and PI stains. Cell 
populations were counted using flow cytometry. A decrease in the viable cell population 
(a,c) was observed with TauCl treatment, with a corresponding increase in necrosis (b,d). 
No changes were observed with SeMet (a,b) or SeTal (c,d) treatment based on one-way 
ANOVA with Tukey’s post-hoc test. Data represent mean ± SD from 3 independent 
experiments. 
6.3.6.2 Modulation of necrosis observed after 2 h 
As 15 min is too short a time to observe apoptosis as it is regulated by signalling 
pathways, the study was extended to a 2 h incubation before changes in cell viability 
were assessed. The oxidant concentrations were reduced to 100 µM to minimise the 
extent of lysis of the cells as previously reported [222]. 
Initial preliminary experiments were performed to determine the extent of 
apoptosis observed when the cells were exposed to camptothecin (CPT; 25 µM) or 
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staurosporin (5 µM) as positive controls [611, 612]. J774A.1 cells were plated at a 
density of 0.5 x 106 cells per well in 12-well plates, and allowed to adhere overnight in 
an atmosphere of humidified 5 % CO2, at 37 °C. Cells were washed twice with warm 
HBSS, before the addition of 25 µM CTP or 5 µM staurosporin in HBSS and further 
incubation for 2 h. Staurosporin treatment was also performed with a 4 h incubation. 
Cells were then stained with Anexxin-V APC and PI, and the viable, apoptotic and 
necrotic cell populations were assessed by flow cytometry (Figure 6.13). Cells treated 
with these agents demonstrated a decrease in viability with a corresponding increase 
in necrosis (Figure 6.14). However, again no change in the apoptotic cell populations 
were observed (Figure 6.14), with less than 1% of the cell population in the lower right 
quadrant (Figure 6.13). The reason for this discrepancy compared to published data is 
not certain, but may reflect late stage apoptosis, where PI is also taken up, or that 
different, early passage cells were used in the current study [222]. 
 
Figure 6.13 – Flow cytometry plots for J774A.1 treated with CPT and staurosporin and 
stained with Annexin-APC and PI 
J774A.1 cells (5 x 105 cells) were treated with d) CPT (25 µM) for 2 h, or for staurosporin 
(5 µM) for e) 2 h or f) 4 h. a, b, c) represent controls for each condition. Cells were scraped 
and pelleted before being washed with warm HBSS and stained with Annexin-V APC and 
PI stains. Fluorescence was measured using flow cytometry and cells sorted in quadrants 
representing: Lower left – Annexin negative, PI negative; Lower right – Annexin positive, 
PI negative; Upper left – Annexin negative, PI positive; and Upper right – Annexin positive, 
PI positive. 
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Figure 6.14 - Cell viability for J774A.1 cells treated with CPT and staurosporin 
J774A.1 cells (5 x 105 cells) were treated with a) CPT (25 µM) for 2 h, or staurosporin (5 
µM) for b) 2 h or c) 4 h. Black bars represent incubation with HBSS alone, and white bars 
represent staurosporin or CPT treatment.  Cells were scraped and pelleted before being 
washed with warm HBSS and stained with Annexin-V APC and PI stains. Cell populations 
were counted using flow cytometry. All treatments showed a decrease in viability with a 
corresponding increase in necrosis. No change was observed in apoptotic cell populations. 
As n =1, no error bars are present. 
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Experiments to determine the cell viability of a control population of cells in the 
presence and absence of SeMet and SeTal (50 µM) were performed. However, due to a 
lack of Annexin V staining in the positive controls, only necrotic cell populations could 
be assessed. The viability of non-treated control cells was significantly decreased after 
2 h in HBSS when compared to that seen at 15 min, with 30 – 40% cells determined as 
viable (Figure 6.15a,c). The remaining 60-70% of the cell population were found to be 
necrotic (Figure 6.15b,d). This may be related to an increase in susceptibility of the 
cells to damage by mechanical scraping required to lift the cells from the plate into 
suspension for flow cytometry analysis following longer incubation in HBSS. The 
mechanical scraping could not be avoided as J774A.1 cells are trypsin resistant. The 
presence of SeMet and SeTal did not affect the cell populations. However, no further 
loss in cell viability was observed compared to the non-treated control cells on addition 
of either HOCl (Figure 6.15) or TauCl (Figure 6.16) (100 µM) to the J774A.1 cells. Again, 
SeMet and SeTal addition did not affect the cell populations observed in cells treated 
with HOCl (Figure 6.15). This is consistent with the HOCl treated cells, as HOCl did not 
induce cell death over and above that seen in the non-oxidant treated cells. When cells 
were treated with TauCl in the presence of SeMet, a trend towards a further decrease 
in the viable cell population together with an increase in necrotic population was 
observed, though this was not statistically significant (Figure 6.16a,b). This effect was 
not observed in the presence of SeTal. However, it should be noted that there was 
considerable variability in the extent of necrosis seen in the non-oxidant treated cells 
in these experiments, and repetition would be required to confirm this observation. 
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Figure 6.15 - Viable and necrotic cell populations 2 hrs after J774A.1 cells were exposed 
to HOCl in the presence of SeMet or SeTal. 
J774A.1 cells (5 x 105 cells) were treated with HOCl (100 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 2 h. Non-treated cells and cells treated with SeMet or 
SeTal alone (50 µM) were included as control samples (black bars).  Cells were pelleted 
and washed with warm HBSS before addition of Annexin-V APC and PI stains. Cell 
populations were counted using flow cytometry. No changes were observed in the viable 
(a,c) or necrotic (b,d) cell populations with HOCl treatment. No significant changes were 
observed with SeMet (a,b) or SeTal (c,d) treatment compared to HOCl treatment in the 
absence of SeMet or SeTal based on one-way ANOVA with Tukey’s post-hoc test.. Data 
represent mean ± SD from 3 independent experiments. 
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Figure 6.16 – Viable and necrotic cell populations 2 hrs after J774A.1 cells were 
exposed to TauCl in the presence of SeMet or SeTal. 
J774A.1 cells (5 x 105 cells) were treated with TauCl (100 µM) in the presence or absence 
of SeMet or SeTal (0 – 50 µM) for 2 h. Non-treated cells and cells treated with SeMet or 
SeTal alone (50 µM) were included as control samples (black bars).  Cells were pelleted 
and washed with warm HBSS before addition of Annexin-V APC and PI stains. Cell 
populations were counted using flow cytometry. No changes were observed in the viable 
(a,c) or necrotic (b,d) cell populations with TauCl treatment. No significant changes were 
observed with SeMet (a,b) or SeTal (c,d) treatment compared to TauCl treatment in the 
absence of SeMet or SeTal based on one-way ANOVA with Tukey’s post-hoc test.. Data 
represent mean ± SD from 3 independent experiments. 
 Discussion 
Cellular thiols are major targets of HOCl and the levels of protein thiols and GSH are 
reduced when cells are exposed to this oxidant [221, 222, 229].  As expected HOCl 
decreased cellular thiols and decreased GAPDH activity, consistent with previous work 
on murine macrophage-like J774A.1 cells [222]. TauCl, on the other hand, is generally 
reported to be impermeable to cell membranes [135, 229].  TauCl does not induce 
oxidation of cellular thiols or cause inactivation of GAPDH when exposed to endothelial 
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or Jurkat cells, though in the presence of other amines, like Gly or His, transchlorination 
reactions can occur, forming more cell permeable N-chloramines [135, 246]. However, 
TauCl is taken up by the RAW 264.7 murine macrophage cell line [249] and reversible 
oxidation of intracellular cofilin by TauCl in a human lymphoma cell line has been 
reported [609]. Furthermore, TauCl mediated oxidation of Met residues of IκBα 
resulting in loss of NF-κB activity [251]. In this study, J774A.1 cells treated with TauCl 
demonstrated a loss of cellular thiols and a decrease in GAPDH activity, which has not 
been reported with other cell types. This may indicate an increase in permeability of 
J774A.1 cell membranes compared to other cell types, allowing TauCl access to the 
cytosol and hence thiol loss. If this is occuring, it could be demonstrated by assessing 
N-chloramine concentration in media after exposure of cells to TauCl, though this 
experiment was not performed and would not rule out reactivity of TauCl with cell 
membrane components [246]. It is unlikely that transchlorination reactions would be 
occurring in the studies performed in this Chapter, as treatments were performed in 
HBSS, which contains no free amines to undergo these reactions. 
Circulating levels of SeMet in patients who have been supplemented with SeMet 
difficult to demonstrate in vivo, due to rapid metabolism and incorporation into protein 
[613]. SeTal has not previously been used in in vivo studies. The concentration of SeMet 
and SeTal used in this Chapter were selected based on previous supplementation 
studies [474, 513, 529-531, 538], and at a dose at which no effect on viability was 
observed. 
Incubation of SeMet and SeTal with J774A.1 cells in the absence of oxidant 
demonstrated a loss of cellular thiols and a decrease in GAPDH activity, though these 
differences were not statistically significant compared to non-treated control cells. 
Selenium compounds, including SeMet, have previously been shown to increase ROS 
production in cells, which is primarily attributed to the formation of selenolates after 
metabolism of SeMet by methioninases [513]. An increase in ROS due to SeMet and 
SeTal may be causing the decrease in thiol levels observed. Furthermore, reaction of 
SeMet and SeTal with basal levels of ROS, forming selenoxides which then react with 
cellular thiols may also result in a decrease in cellular thiols. 
The presence of SeMet and SeTal did not affect the levels of thiols observed in cells 
after oxidant treatment (Figure 6.2 and Figure 6.3). This is potentially due to the 
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limited scavenging of oxidant, as in this case, the HOCl or TauCl are in excess of SeMet 
and SeTal. SeMet and SeTal have higher rate constants for the reaction with the 
oxidants compared to cellular components, as demonstrated in Chapter 3, so it would 
be expected that SeMet and SeTal are at least partially consuming the HOCl or TauCl. 
The primary product produced by the reaction between SeMet or SeTal and HOCl or 
TauCl would be the respective selenoxides. As demonstrated in Chapter 4, these 
selenoxides can react with GSH and protein thiols, thus depleting cellular thiols. This 
may be why no protection from HOCl or TauCl induced damage is observed when cells 
are supplemented with SeMet and SeTal prior to oxidant addition. Furthermore, the 
presence of SeMet has a non-statistically significant trend to further reduce the 
concentration of thiols in cell lysates exposed to HOCl or TauCl (Figure 6.3). This may 
be reflecting the increased specificity of selenoxides towards thiols compared to HOCl 
and TauCl, which are capable of reacting with other targets.  
In general, the presence of SeMet and SeTal did not modulate GAPDH activity upon 
oxidant exposure to cells (Figure 6.4). This is potentially due to reaction of the active 
site of GAPDH with the selenoxides SeMetO and SeTalO formed upon HOCl or TauCl 
addition, as selenoxides have demonstrated protein thiol reactivity previously [445]. 
The ability of selenoxides to inactivate GAPDH could be assessed using isolated protein 
exposed to SeMet and SeTalO and determining activity. Alternatively, as the cells were 
treated with an excess of HOCl and TauCl over SeMet or SeTal, it may be that the 
concentration of SeMet and SeTal was not high enough to scavenge sufficient HOCl or 
TauCl to inhibit the loss of GAPDH activity.  
Experiments with cells exposed to HOCl (200 µM) in the presence of 10 µM SeMet 
consistently demonstrated an increase in GAPDH activity compared to that seen in the 
absence of SeMet (Figure 6.4a). The protection afforded at 10 µM may be indicative of 
a “sweet spot” of SeMet supplementation, where the SeMet is scavenging enough HOCl 
to prevent GAPDH inactivation, but the levels of SeMetO are not high enough for GAPDH 
to become a target for oxidation by SeMetO. However, more work would be needed in 
order to fully establish whether this is the case.  
HOCl and cell-permeable N-chloramines such as those formed on Gly can induce the 
formation of reversible thiol oxidation products [614]. TauCl is less able to penetrate 
the cell membrane [135] and therefore a lower of level of intracellular reversible thiol 
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products may be expected. However, in the data presented here, no increase in 
reversible thiol products was observed with HOCl or TauCl treatment, which may 
reflect oxidation of other targets, such as reaction with the cellular membrane. 
Furthermore, HOCl and TauCl can oxidise thiol residues to sulfinic and sulfonic acids, 
which are irreversible thiol oxidation products [86]. SeMet and SeTal may react to form 
selenoxides in cells upon HOCl or TauCl addition, which react with thiols to form 
disulfides, with no evidence reported for the formation of sulfenic or sulfonic acids 
[444, 445]. As disulfides are reversible oxidation products, the IAF protocol was 
attempted to assess levels of reversible thiols (Figure 6.5). However, due to issues with 
sample preparation, the results for this approach were inconclusive. 
The lack of significant changes in reversible oxidation products observed in this 
study may be due to the large variation between samples. Protein levels of the sample 
were adjusted prior to reaction of cellular proteins with IAF. However, the pelleting 
and washing stages that are required after IAF addition may have caused loss of 
sample. Furthermore, the purified IAF-containing proteins became very insoluble, 
potentially leading to further variation in protein levels. Thus, in order to obtain more 
consistent results, protein quantification and subsequent adjustment should be 
performed prior to protein separation by SDS-PAGE. 
HOCl and TauCl oxidise amino acid residues on proteins, particularly Met which is 
oxidised to MetSO [106]. Oxidation of Met is postulated to play a protective role in cells 
as they can be repaired by the action of Msrs [351-355]. However, when Met is at the 
active site of proteins, oxidation of Met residues may inactivate the enzyme [615, 616]. 
For example, the oxidation of the active site Met of IκBα by TauCl is proposed to result 
in the inactivation of NF-κB and play a role in the induction of apoptosis [251]. As SeMet 
and SeTal both have second order rate constants greater than that reported for Met for 
reaction with both HOCl [90] and TauCl (Chapter 3), this suggests that the SeMet or 
SeTal should be preferentially oxidised over Met residues, providing their 
concentration is sufficient and localisation in the cellular environment is appropriate. 
In the data presented in this Chapter, HOCl and TauCl were both able to decrease the 
concentration of Met when exposed to cell lysate samples, with a corresponding 
increase in MetSO observed (Figure 6.8 and Figure 6.9). The addition of SeMet and 
SeTal to lysate samples showed a trend toward protection of Met residues when the 
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lysates were exposed to HOCl, though this was not significant. This contrasts with other 
studies that have reported that the presence of selenium compounds prevents Met 
residues from oxidation [439, 486], though these studies used isolated proteins, and a 
higher ratio of selenium compound to oxidant than used in this study. A higher 
concentration of SeMet and SeTal may therefore increase the potential protective 
effects of these compounds on HOCl and TauCl induced damage. 
HOCl and TauCl treated J774A.1 cells showed no loss of Met or increase in MetSO 
(Figure 6.6 and Figure 6.7). This may be due to the oxidant reacting with other species, 
such as thiols, or the lipid bilayer of the cell, with insufficient oxidant remaining to 
oxidise Met residues. Cells also contain Msrs, which are able to reduce MetSO back to 
Met [351-355], which could result in repair of Met oxidation prior to its detection by 
these methods.  
While no significant protection of thiol or Met residues was observed with SeMet 
and SeTal treatment, these residues are not the only targets of HOCl and TauCl in cells. 
Other chemical markers of oxidation that could be assessed include chlorinated 
tyrosine and tryptophan products [106]. These products are particularly important in 
disease settings as they are used as biomarkers of HOCl-mediated damage [119]. 
However, no change in tyrosine or tryptophan residue concentrations was observed in 
these experiments, and therefore the presence of these products was not explored 
further, particularly as they are usually accompanied by significant Met oxidation.  
The cellular toxicity of SeMet and SeTal was assessed using the LDH assay as a 
measure of viability when J774A.1 cells were exposed to SeMet or SeTal (0 – 200 µM) 
(Figure 6.1). Under these conditions, no changes in viability with a 30 min treatment 
time were observed. SeMet, is a major form of dietary selenium and is generally well 
tolerated at low concentrations, although it has been demonstrated to induce apoptosis 
in cells [513, 610]. This is primarily attributed to the metabolites of SeMet, which cause 
an increase in ROS production, which subsequently lead to apoptosis and cell death in 
prostate cancer cell lines [513, 610]. However, at low concentrations of SeMet (3 µM) 
toxicity required the addition of methioninases to induce the formation of 
methylselenolates [513]. The studies in prostate cancer cell lines demonstrated 
apoptosis approximately 48 – 72 hours post SeMet treatment (50 µM) [610], so it is 
possible that toxicity may only be evident after extended incubation times.  
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Exposure of J774A.1 cells to HOCl (200 µM) for 15 min demonstrated an increase 
in necrosis compared to non-treated controls (Figure 6.12). This is consistent with 
previously reported data where significant cell lysis was observed after J774A.1 cells 
were exposed to HOCl under the same conditions employed in this study [222], and 
this has also been demonstrated in other cell types [213, 219, 605]. SeMet and SeTal (0 
– 50 µM) were unable to modulate this increase in necrosis (Figure 6.11). After a more 
prolonged (2 h) exposure to HOCl (100 µM), there was no increase observed in the 
necrotic population of cells compared to the non-treated control in this study, and the 
presence of SeMet or SeTal did not have an effect on cell populations (Figure 6.15). The 
levels of background necrosis observed in non-treated control samples were 
significantly greater (at ~70 %) in this study than reported previously in J774A.1 cells 
(~10 %) [222]. This may reflect differences in the cell populations used in each case, 
with low passage cells used in the current study that may be more susceptible to 
damage by the mechanical scraping that is required to lift the cells into suspension for 
analysis by flow cytometry. Due to the high level of necrotic cells in the non-treated 
controls and large errors, it is difficult to draw conclusions about any changes in cell 
populations that may be occurring. 
No changes in apoptotic cell populations were observed in any of the experiments 
performed in this study (Figure 6.10 and Figure 6.14). This is in contrast to previous 
reports that have demonstrated induction of apoptosis after treatment of cells by HOCl, 
TauCl, CPT and staurosporin [607, 608, 611, 612]. The previous studies used Annexin-
V FITC, whereas this current work used Annexin-V APC. Annexin-V APC was used 
instead of Annexin-V FITC for these studies as the fluorescent profiles of FITC and PI 
overlap, whereas APC and PI do not.  The change should result in less interference 
between the Annexin-V and PI fluorescence that could confound the results. 
Furthermore, Annexin-V requires calcium to be present in the buffer in order to bind 
effectively [617]. Previous work has used binding buffers with increased calcium 
compared to HBSS [222], which may explain why limited Annexin-V binding was being 
observed in this study. However, at least some Annexin-V binding was occurring in 
these experiments (Figure 6.10 and Figure 6.13), but the cell groups that were staining 
positive for Annexin-V were also PI positive and were therefore considered necrotic. 
The lack of a positive control makes it difficult to draw any conclusions about any 
apoptotic cell populations in this study. 
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In summary, SeMet and SeTal demonstrated limited efficacy in modulating 
oxidative damage to murine macrophage-like J774A.1 cells that had been exposed to 
reagent HOCl and TauCl. However, previous studies have demonstrated that SeMet is 
capable of enhancing peptide-bound hydroperoxide detoxification in J774A.1 cells 
[474]. Selenium compounds, including SeMet, are also able to reduce hemolysis of 
erythrocytes and lipid peroxidation induced by H2O2 [538]. Thus, SeMet and SeTal may 
also modulate oxidative damage in ways that have not been assessed in these studies. 
For example, SeMet has demonstrated efficacy in inducing expression of antioxidant 
enzymes including GPx and TrxR [529-531]. The increase in GPx expression was able 
to protect against oxidative damage in a hypoxia-reoxygenation model of damage to 
rat cardiomyocytes [529]. SeMet was also found to induce the upregulation of selenium 
enzymes in trophoblast cells and protect them from H2O2-mediated damage [531] or 
oxidative damage induced by mitochondrial dysfunction [530]. While there was no 
significant cellular protection in J774A.1 cells demonstrated by the assays used in these 
studies, SeMet and SeTal may be effective in reducing oxidative stress in other contexts, 
and by other mechanisms.  
 Conclusions 
SeMet and SeTal showed a limited ability to inhibit the oxidative damage to J774A.1 
cells induced by HOCl and TauCl measured in these studies. However, the majority of 
these changes were assessed only after a very short time frame following oxidative 
insult, and were only assessed using chemical markers of damage. Over longer time 
periods, SeMet and SeTal may provide more significant protection to cellular functions 
such as metabolism, proliferation and differentiation, which were not assessed by the 
methods used in this study.  
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7 General discussion and future directions 
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  General overview 
Neutrophils, through the action of MPO, produce the hypohalous acids, HOCl, 
HOSCN and HOBr in order to destroy invading pathogens [1]. Under physiological 
conditions, approximately 50 % of the H2O2 consumed by MPO goes into the formation 
of HOCl [24], which can further react with amine groups of various biological molecules 
to form the secondary oxidants N-chloramines [53-58]. HOCl and N-chloramines can 
also cause damage to host tissue if produced inappropriately in excessive quantities 
[2]. HOCl will react with most components of cellular systems [86], though the fastest 
reactions reported are those with sulfur residues, particularly thiols, with second-
order rate constants of up to 108 M-1 s-1 [90]. N-Chloramines retain the oxidising and 
chlorinating power of HOCl, however, they display a higher specificity for sulfur 
residues [86, 136, 192]. Thus, the reaction with Met and Cys are some of the fastest 
reported reactions for N-chloramines, with second-order rate constants in the range of 
102 – 103 M-1 s-1 [86, 136, 192]. Antioxidants may be capable of modulating oxidative 
damage caused by MPO-derived oxidants by scavenging these oxidants before they are 
able to react with cellular components causing damage.  
Selenium-containing compounds have garnered interest as potential antioxidants 
to modulate inflammatory damage due to their favourable reaction kinetics [90, 98, 
486]. Selenium-containing compounds have consistently demonstrated higher second 
order rate constants compared to analogous thiol compounds for reactions with 
biological oxidants including HOCl and HOSCN [90, 98, 486]. The increased reactivity 
of selenium compounds has been attributed to the increased nucleophilicity of 
selenium compared to sulfur, and the lowered pKa of selenols compared to thiols [446, 
447]. The increased rate constants suggest that selenium compounds will be 
competitive in vivo targets for oxidants, capable of acting as scavengers to reduce the 
extent of oxidative damage. Furthermore, selenium compounds have been shown to 
give rise to products such as selenoxides that can be reduced by thiols, potentially 
giving rise to catalytic oxidant scavenging cycles [444, 445].  
The studies presented in this Thesis were undertaken to examine the potential of 
the selenoethers SeMet and SeTal to scavenge MPO-derived oxidants, by determining 
the rate constants and products of these reactions, and characterising potential 
reduction pathways of the products in vivo. The potential of these compounds to 
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protect cells from damage caused by exposure to MPO-derived oxidants was also 
assessed.  
 Selenium compounds as catalytic oxidant scavengers 
A key requirement of antioxidants is their ability to kinetically compete with the 
typically more abundant biological targets of oxidants, in order to prevent damage to 
cellular components. In a biological setting, the reaction of the MPO-derived oxidants 
HOCl and N-chloramines with thiols are some of the fastest reported with rate 
constants of >108 M-1 s-1 for the reaction of HOCl with GSH and Cys [90], and 102 – 103 
M-1 s-1 for the corresponding N-chloramine reactions, though these rate constants are 
dependent on the specific N-chloramine [136, 192]. The rate constants for the reaction 
of SeMet and SeTal with HOCl and the other hypohalous acids produced by MPO, HOBr 
and HOSCN, have previously been determined [90, 98], and these rate constants are 
consistently greater than those determined for the analogous sulfur compounds. These 
rate constants are comparable to those determined for the reactions with thiols and 
GSH [90, 98], suggesting that SeMet and SeTal would be able to modulate oxidation 
reactions of HOCl if present at appropriate concentrations. Similarly, the rate constants 
determined for the reaction of SeMet with biologically relevant N-chloramines 
determined in Chapter 3, demonstrate that in each case, the rate constant is 
significantly greater than those determined previously for Met [192]. Furthermore, the 
rate constants for SeMet and SeTal are comparable to those determined for Cys and 
GSH. Again, this suggests that SeMet and SeTal will be a competitive target for N-
chloramines in vivo, if present at appropriate concentrations and locations. 
This study focussed on the use of SeMet and SeTal as scavengers of HOCl and model 
N-chloramines. However, SeMet has demonstrated efficacy as a scavenger of other one- 
and two-electron oxidants. High rate constants for the reaction between SeMet and 
HOBr (k = 1.4 x 107 M-1 s-1) [90], HOSCN (k = 2.8 x 103 M-1 s-1) [98], ONOOH (k = 2.4 x 103 
M-1 s-1) [461] and HO (k = 1.4 x 1010 M-1 s-1) [457] have been reported. SeTal has been 
less extensively studied, but rate constants have been reported for HOBr (k = 1.5 x 107 
M-1 s-1) and HOSCN (k = ~100 M-1 s-1) [90]. The rate constants for SeMet and SeTal 
reactions with 2-electron oxidants are consistently greater than those reported for Met 
[90, 92], and comparable to those reported for Cys [90, 92] (Table 7.1). These data 
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suggest that SeMet and SeTal may be capable of acting as scavengers of multiple species 
of oxidants in vivo, in addition to HOCl and the N-chloramines described in this Thesis.  
Table 7.1 – Second order rate constants for the reactions of SeMet, SeTal, Met and Cys 
with biologically relevant oxidant species.  
 Second order rate constants / M-1 s-1 
 HOCl HOBr HOSCN ONOOH HO 
SeMet 3.2 x 108 a 1.4 x 107 a 2.8 x 103 b 2.4 x 103 c 1.4 x 1010 d 
SeTal 1.0 x 108 e 1.5 x 107 e ~100 e - - 
Met 3.4 x 107 a 3.6 x 106 f Slow g 3.6 x 103 h 2.3 x 1010 i 
Cys 3.6 x 108 a 1.2 x 107 f 7.8 x 104 g 3.8 x 103 h 4 x 1010 j 
a[90]; b[98]; c[461]; d[457]; e[486]; f[61] - Met rate constant determined for N-Ac-Met-
OMe and Cys rate determined for N-Ac-Cys; g[92]; h[618] – determined at 37 °C; i[468] 
; j[459] 
Thiol and selenol containing antioxidant enzymes have also demonstrated efficacy 
in detoxifying oxidants. The primary role of the GPx family (a Sec containing enzyme) 
and the peroxiredoxin family (thiol containing enzymes) is to remove H2O2, but they 
are also capable of removing other oxidants [101, 102, 346, 349, 350, 583]. TrxR is also 
capable of detoxifying ONOOH, H2O2 and the MPO-derived oxidant, HOSCN [98, 347, 
348]. In Chapter 5, the ability of selenium and thiol containing enzymes to remove N-
chloramines was assessed. The NADPH/GSR/GSH system was capable of rapidly 
removing N-chloramines, via the reaction with GSH and formation of GSSG and 
subsequent reduction by GSR. The system was capable of removing LysCl and GlyCl at 
a higher rate than TauCl, and this reflects the relative reactivity of the N-chloramines 
[192]. In contrast, the presence of TrxR was not capable of increasing the rate at which 
NADPH was consumed upon addition of N-chloramines, though the presence of both 
TrxR and Trx increased the rate of NADPH consumption upon TauCl addition. While no 
increase in NADPH consumption was observed, this does not exclude the possibility 
that some amount of the N-chloramines were reacting with the enzymatic systems. 
Direct reaction of N-chloramines with NADPH leads to the formation of a chlorohydrin, 
which is damaging to cells as the reaction cannot be reversed to reform NADPH [63, 
83]. When NADPH is consumed by the enzymatic systems, NADP+ is formed as a 
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product, which, through the action of enzymes of GAPDH, can be recycled to NADPH 
[230]. Therefore, the reduction of N-chloramines by enzymatic systems may have 
potential therapeutic benefit by reducing the amount of chlorinated NADPH. Future 
studies could assess the relative levels of NADP+ to the chlorinated NADPH species 
formed by the addition of N-chloramines to the NADPH/TrxR and related enzyme 
systems to further characterise the potential for these enzymes to react with N-
chloramines. 
The major products formed when SeMet and SeTal are exposed to HOCl and N-
chloramines are the respective selenoxides, SeMetO and SeTalO. The selenoxides form 
in a near 1 : 1 ratio of HOCl or N-chloramine scavenged to selenoxide formed, as 
demonstrated in Chapter 3. As endogenous thiols and redox enzymes can reduce 
selenoxides, as described in Chapters 4 and 5, this gives potential for a catalytic 
scavenging cycle in vivo. This would allow SeMet and SeTal to remove oxidants with a 
greater than 1 : 1 ratio, without the destruction of the seleno compounds. These 
reactions are likely to be of significance as the higher second-order rate constants for 
SeMet and SeTal suggest that these compounds will remove oxidants more rapidly than 
endogenous thiols (Table 7.1). This was observed in GSR experiments, where the 
presence of SeMet increased the rate of NADPH consumption when TauCl was added 
to the NADPH/GSR/GSH system compared to the NADPH/GSR/GSH system in the 
absence of SeMet (Chapter 5). The interaction between selenium compounds and the 
GSR system demonstrated the potential for rapid oxidant detoxification, without 
complete consumption of thiols by selenoxides. This would allow for the continuation 
of the catalytic cycle, without a build up of selenoxides occuring. 
Conversely, SeMet and SeTal in the presence of the NADPH/TrxR and other 
enzymes, Trx, Msrs and GPx, reduced the rate at which NADPH was consumed upon 
addition of N-chloramines. This is in contrast to work demonstrating the ability for 
SeMet to enhance the consumption of peroxides [474]. This may reflect the direct 
oxidation of NADPH by N-chloramines, which does not occur with peroxides [83, 138, 
139]. Alternatively, the decrease in NADPH consumption observed may be due to a 
slower turn over of SeMetO and SeTalO compared to N-chloramines, whereas with 
peroxides this is reversed, with a slow consumption of peroxides and hence an 
observed increase in NADPH consumption. Rahmanto et al demonstrated that addition 
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of SeMet led to an increase in peroxide consumption when H2O2 or t-
butylhydroperoxide were exposed to either the NADPH/TrxR/Trx system or J774A.1 
cells, which was attributed to the catalytic removal of peroxides by SeMet [474]. The 
abilities of other selenium compounds to catalytically interact with the 
NADPH/TrxR/Trx system have been described with diselenides (such as selenocystine 
and Sec substituted GSSG) and other selenium compounds, such as ebselen, with these 
species increasing the rate at which H2O2 and ONOOH is removed [448, 491, 492]. 
While reduction of selenoxides mediated by TrxR is significantly slower than by thiols, 
the TrxR pathway may allow for continued catalytic scavenging of oxidants by SeMet 
and SeTal after cellular thiols are consumed. 
It has been shown that the efficacy of action of selenium compounds as antioxidants 
may be further increased by optimisation of the surrounding chemical environment. 
Selenoethers synthesised by Prabhu et al, with the structure Se(CH2CH2CHX)2 where X 
was either -OH, -COOH or NH3+ groups  demonstrated differing GPx mimetic 
capabilities [443]. In this case, the –COOH substituted selenoether demonstrated the 
highest GPx mimetic ability, followed by –OH then -NH3+ [443]. However, these studies 
did not determine whether the rate limiting step was the oxidation of the selenoether, 
or subsequent repair of the oxidised product, and the differences in GPx activity were 
attributed to the differing stereochemistry between the compounds, with the –COOH 
substituted compound having the most easily accessible Se atom, and the –NH3+ 
substituted compound having the least accessible [443]. Furthermore, it has been 
proposed that weak interaction between the amino acid residues and the Sec residue 
of GPx enhance it’s nucleophilic reactivity by stabilisation of the selenolate [619]. This 
reaction cycle however proceeds through a selenenic acid intermediate before GSH 
reduction, unlike SeMet and SeTal in this study where a selenoxide is formed. 
In Chapter 4, it was demonstrated that the availability of amine groups increased 
the efficiency of selenoxide reduction. Whilst the mechanism was not fully elucidated 
in these studies, it is proposed that the selenium-amine interaction may facilitate a 
more efficient catalytic scavenging cycle. This could be further explored through 
thermodynamic modelling to assess potential interaction between the amine and 
selenium centre. Thus, strategic substitution of functional amine groups into the 
structure of new selenium compounds may allow the production of more effective 
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antioxidant compounds. Furthermore, functionalisation using other moieties may 
produce more targeted antioxidants, for example, a triphenylphosphine group may 
make selenium antioxidants more specific for oxidants produced by the mitochondria, 
due to the attraction of the positive phosphine to the mitochondria. This mitochondrial 
targeting strategy has been shown to be effective for mitoquinone (MitoQ), which links 
ubiquinone to a triphenylphosphine group by a long alkyl chain [620]. MitoQ has been 
shown to protect against hypertension and cardiac hypertrophy, while improving 
endothelial function in spontaneously hypertensive rats [621]. It has also 
demonstrated an ability to reduce macrophage numbers in atherosclerotic plaques 
[622] and prevent HOCl-induced cellular damage [438]. 
 Potential for selenium compounds to modulate oxidative 
damage 
SeMet and SeTal have demonstrated efficacy in protecting isolated proteins against 
oxidative damage upon exposure to HOCl [486]. Incubation of BSA and plasma proteins 
with SeTal and the related selenium-containing carbohydrate, 1,5-anhydro-5-
selenogulitol, prior to exposure to HOCl was able to prevent damage to His, Lys, Met, 
Trp and Tyr residues, and also inhibited 3-Cl-Tyr formation [439, 486].  
In Chapter 6, the ability of SeMet and SeTal to modulate oxidative damage to 
J774A.1 cells upon HOCl or TauCl exposure was assessed using thiol levels and Met 
oxidation as markers of oxidative damage. Exposure of cells or lysates to HOCl or TauCl 
caused a loss of thiols and an oxidation of Met residues, but SeMet and SeTal were 
unable to modulate these changes under the conditions employed. This is in contrast 
to previous reports where the presence of SeMet or SeTal has been shown to protect 
Met residues from oxidation when isolated proteins were exposed to HOCl [439, 486]. 
However, the protection reported by Storkey et al only achieved significance when the 
ratio of selenium compounds to HOCl was greater than 1 : 4, which was the maximum 
ratio used in this study [439, 486]. Future studies could potentially use a higher 
concentration of SeMet and SeTal, which may result in greater protection of protein 
residues when cells are exposed to HOCl and N-chloramines. 
A potential limiting factor in the ability of SeMet and SeTal to scavenge hypohalous 
acids and N-chloramines in vivo is likely to be achieving a high enough concentration 
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in order to compete with other reactions. While no protection was observed in 
experiments measuring the consequences of oxidant exposure to cells in Chapter 6, it 
is unclear how much of the SeMet or SeTal were taken up by the cells. SeMet is known 
to be transported into the cell through Met channels [623], but the  levels of SeTal taken 
up by cells have not been measured. This is an important area for further study, and 
could be done using techniques such ICP-MS [624], or x-ray absorption and 
fluorescence spectroscopy [625] which have been used to speciate selenium 
compounds in biological samples, in order to compare levels of selenium in the media 
to levels in the cytosol after SeMet or SeTal supplementation.  
Kinetic modelling of HOCl reactions in plasma suggests that the primary target for 
HOCl would be protein residues, owing to their abundance, with Met and Cys residues 
being consumed first, followed by reaction with His and Lys residues [87]. The 
modelling demonstrates that GSH, which is present at 2 µM in plasma, and has a 
similarly high rate constant for the reaction with HOCl as SeMet and SeTal, consumes 
less than 1 % of HOCl [87]. However, the reaction with GSH is likely to be more 
significant in a cellular context where cytosolic GSH levels are 5-10 mM [626]. Based 
on these calculations and the rate constants for the reaction of SeMet and SeTal (which 
are similar to GSH (Table 7.1)), concentrations of SeMet and SeTal would need to reach 
a concentration of > 2 µM in plasma in order to make a significant contribution by 
directly scavenging HOCl. These concentrations of SeMet or SeTal may be difficult to 
achieve in plasma, owing to toxicity and factors such as absorption into the circulation 
and subsequent metabolism (in the case of SeMet). Possible toxicity and metabolism of 
SeTal is presently unknown, and should be the focus of future studies. 
Scavenging N-chloramines may be a more feasible mechanism for SeMet and SeTal. 
N-chloramines are longer-lived oxidants in vivo compared to HOCl due to their lower 
reactivity, and these have a greater specificity for sulfur-containing residues [86, 136, 
192]. The increased stability allows for diffusion away from the site of production, 
potentially inducing oxidative damage at other sites [14, 87, 181]. As the studies in 
Chapter 3 show that SeMet and SeTal are capable of rapid reaction with N-chloramines, 
they may be able to repair N-chloramine formation on proteins and hence reduce the 
propagation of oxidative damage away from the site of inflammation. 
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Furthermore, degradation of N-chloramines can lead to formation of N-centred 
radicals [141], which may also propagate HOCl-induced damage, or the formation of 
reactive aldehydes, which can further react to form advanced glycation end products 
[188]; these products are thought to be significant in diseases such as diabetes. 
Carbonyls, as a marker of protein N-chloramine or N-chloramide degradation after 
HOCl treatment, could be measured by assay with 2,4-dinitrophenylhydrazine [137, 
547]. The ability of SeMet and SeTal to repair N-chloramines may lead to a decrease in 
protein carbonyl formation and therapeutic benefit.  
It is also possible that SeMet and SeTal may modulate oxidative damage by other 
mechanisms, such as the upregulation of antioxidant defences and oxidative repair 
enzymes of the selenoproteome [529-531]. SeMet has demonstrated an ability to 
increase the levels of GPx and TrxR in vivo [524, 535], however this effect is dependent 
on baseline selenium levels. In patients with low baseline Se levels, SeMet 
supplementation increased expression of these selenoproteins [535], but this was not 
observed in patients with adequate Se levels. In a cellular context, pre-treatment with 
SeMet in rat cardiomyocytes led to increased viability after ischemia-reperfusion 
treatment [529]. The effect was attributed to the ability of SeMet to mitigate the 
increase in oxidative damage seen with ischemia-reperfusion injury. SeMet pre-
treatment also prevented oxidative damage to trophoblast cells exposed to H2O2 or that 
induced by mitochondrial dysfunction [530, 531]. While no protection was afforded by 
SeMet in the current studies, which examine whether SeMet may protect against cell 
death in J774A.1 cells exposed to HOCl and TauCl, future studies using longer pre-
incubation times may demonstrate protection as a result of SeMet-mediated increases 
in antioxidant defences. The ability of SeTal to upregulate selenoproteins has not yet 
been examined, and should be the focus of future studies. If, like SeMet, SeTal is capable 
of upregulating selenoproteins, this may be another pathway that SeTal could be 
capable of affording protection against oxidant damage. 
 Factors that may affect use of selenium compounds as 
antioxidants in vivo 
Attempts to measure SeMet in human plasma have concluded that the majority of 
SeMet is bound to or incorporated into proteins, as free SeMet levels are below the 
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limits of detection [613]. However, supplementation with SeMet has been shown to 
increase Se levels in circulation with the increase being proportional to the level of 
SeMet being administered [505, 506, 627]. However, the speciation of the selenium 
compounds present in plasma is unclear, with most studies reporting total Se in plasma 
without identifying the chemical nature. In a study [627] where SeMet was 
administered at up to 500 µg per day as SeMet, total circulating Se levels were observed 
to increase with no change of expression of GPx or selenoprotein-P, though it was 
suggested that SeMet makes up 3% of total plasma Se. However, it should be noted that 
the reported increases in observed GPx and selenoprotein-P expression when patients 
are supplemented with SeMet are dependent on the subject’s initial baseline selenium 
levels. Another study [628] showed that less than 0.5% of Se excreted in urine was in 
the form of SeMet when patients were administered the L-SeMet isomer, though when 
they were given DL-SeMet the SeMet concentrations in urine increased to 20 % of total 
Se. This was suggested to be due to the easier metabolism of L-SeMet, as the 
stereochemistry makes this a preferred substrate [628]. This suggests 
supplementation with D-SeMet may be a viable option to increase the plasma 
availability of free SeMet to act as an oxidant scavenger. Similarly to in vivo studies, 
speciation of selenium in cells post-treatment is not performed, though many studies 
have demonstrated increases in SeMet incorporation into protein, or increases in the 
selenoproteome, though these generally doesn’t account for the total selenium studies 
[474, 513, 529-531, 538]. 
The low level of SeMet observed in plasma is likely to be due to either the 
metabolism of SeMet or due to the incorporation of SeMet into protein. SeMet is the 
major source of Se in the body [494], and is used by cells to produce Sec for insertion 
into selenoproteins [623].  SeMet can also be metabolised in the liver producing 
selenosugars, which are subsequently excreted in urine [623]. Alternatively, SeMet can 
be non-selectively incorporated into proteins replacing Met residues, as demonstrated 
by a cell-free synthesis of the human h-Ras protein [475]. When SeMet is incorporated 
into amyloid proteins, the ability of these proteins to form fibrils is reduced, hence 
decreasing toxicity [476]. The incorporation of SeMet may protect against oxidative 
damage, potentially due to the facile reduction of SeMetO, as demonstrated in Chapter 
4.  
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It has been demonstrated that metabolism of SeMet by methioninases increases 
ROS generation in cells, particularly O2-, due to formation of selenolates [513]. This is 
potentially reflected in results from Chapter 6, where a reduction in thiol levels was 
observed in the presence of SeMet and SeTal, though this decrease was not statistically 
significant. The increase in ROS is believed to lead to apoptosis by induction of the p53 
pathway [513, 518, 519], however, no increase in apoptosis was observed in J774A.1 
cells incubated with SeMet in this study. Increases in O2- when J774A.1 cells are 
exposed to SeMet and SeTal could be assessed by electron paramagnetic spectroscopy 
with spin trapping [629], or by assaying O2- production using dihydroethidium and 
product determination by HPLC coupled with mass spectrometry [630]. Furthermore, 
induction of p53 may be occurring in J774A.1 cells at a later time point than that 
assessed in this study (2 h), as apoptosis due to SeMet has been reported after 48 – 72 
h in other cells lines [513, 518, 519]. Further work at extended time points may be 
required in order to more fully elucidate the consequences of SeMet or SeTal 
incubation with the J774A.1 cells. 
SeTal may not face the same limitations as SeMet, which is a primary source of 
selenium in the diet [494], is readily metabolised, and subsequently causes ROS 
formation [513] and is incorporated protein [623]. This may make SeTal a better 
candidate as an antioxidant scavenger by the Se being more available in the circulation, 
as it may not be metabolised to the same extent as SeMet. SeTal, in the conditions used 
in this study, was well tolerated by J774A.1 macrophages; however, bioavailability and 
toxicity have not been extensively examined with SeTal supplementation and should 
be the subject of future studies.  
The studies in Chapter 6 used a macrophage-like murine cell line to assess the 
potential for SeMet and SeTal to modulate cellular damage due to exposure to HOCl or 
TauCl. The study could be extended to assess the benefit of SeMet and SeTal 
supplementation on primary human monocyte-derived macrophages, which would be 
a more relevant cell model for assessing potential production in vivo. Furthermore, 
future studies could assess the benefit of supplementing endothelial cells with SeMet 
and SeTal, as endothelial dysfunction induced by oxidant exposure is implicated in the 
initiation of atherosclerosis [310, 316, 631, 632]. This is significant as HOCl and N-
chloramines activate independent cellular pathways in different cell types [89]. 
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Supplementation with SeMet and SeTal may also be beneficial in other pathologies. 
Supplementation with SeMet or the selenium-containing compound ebselen has been 
reported to protect against alcohol-induced liver injury in rat models [633, 634]. 
Supplementation with SeMet reduces levels of oxidative stress in brains, which may be 
beneficial for neurological disorders such as Alzheimer’s and Parkinson’s disease [476, 
635, 636]. trans-3,4-dihydroxyselenolane (DHS) is a cyclic selenium compound with 
similar chemical structure to SeTal and has been demonstrated to reduce 
indomethacin-induced gastric inflammation [637]. These studies demonstrate that 
selenium supplementation may be used as a potential therapy in numerous disease 
states, potentially by reducing of oxidative stress by acting as a catalytic oxidant 
scavenger as outlined in this thesis. 
 Concluding remarks 
The studies presented in this Thesis highlight the potential for the use of SeMet and 
SeTal as catalytic scavengers of MPO-derived oxidants. It has demonstrated that SeMet 
and SeTal rapidly react with HOCl and N-chloramines in order to form selenoxides, 
which have been chemically characterised. Potential biologically relevant reduction 
pathways of the selenoxides were identified including rapid reduction by the 
endogenous thiol GSH, the rate of which has been determined, as well as through direct 
enzymatic reduction via the activity of TrxR. Taken together, these processes highlight 
the potential for a catalytic scavenging cycle that may modulate oxidative damage in 
vivo. 
However, while SeMet and SeTal demonstrated favourable chemical properties as 
MPO-derived oxidant scavengers, limited modulation of oxidative damage was 
observed when cells were exposed to HOCl and TauCl in the presence of the selenium 
compounds. Given the limitations associated with the treatment conditions and 
methodology used to assess markers of oxidative damage and the cellular viability 
assays examined in this thesis, it is clear that more work is required to more fully 
elucidate how these selenium compounds are metabolised by cells, and whether they 
can protect cells from damage by MPO-derived oxidants. 
The findings in this Thesis contribute significantly to the understanding of the 
mechanisms through which selenoethers may modulate oxidative damage. This may 
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provide insight into how better to design protective agents or antioxidants in the 
future. This has particular relevance for numerous inflammatory pathologies where 
MPO and oxidative damage induced by HOCl and N-chloramines are prevalent, 
including atherosclerosis, a disease that affects ca. 40 % of the Australian population. 
The ability of selenoethers to modulate inflammatory damage therefore has important 
implications for therapeutic application.    
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